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Abstract 
Colorectal cancer is the second most common cause of cancer death in the United 
Kingdom (UK).  At present, surgery remains the cornerstone of its management and is the 
mainstay of curative treatment.  However, surgery for colorectal cancer is associated with 
significant postoperative morbidity and mortality.  These postoperative complications, 
whether classified by their type or severity, are associated with poorer quality of life, 
increased socioeconomic and direct healthcare costs, and poorer oncologic outcomes.  
The stress response to surgery is a neurohormonal and immune response to trauma which 
seeks to stop haemorrhage, prevent infection, and promote healing.  However, an 
inappropriately exaggerated postoperative systemic inflammatory response is now 
understood to be associated with infective complications following surgery for colorectal 
cancer.  It is thought that this may occur through the suppression of the adaptive immune 
system by this overwhelming innate response.  However, it’s effect on the longer term and 
oncologic outcomes is less clear.  In addition, the factors which influence this 
postoperative systemic inflammatory response are unclear.  Furthermore, it remains to be 
determined whether attenuation of the postoperative systemic inflammatory response will 
improve short and long term outcomes following surgery for colorectal cancer. 
The work presented in this thesis further examines the relationship between the 
postoperative systemic inflammatory response, postoperative complications, and long term 
oncologic outcomes following surgery for colorectal cancer.  Several perioperative factors 
which might influence the postoperative systemic inflammatory response are examined.  
Finally, the question as to whether attenuation of the postoperative systemic inflammatory 
response might result in improved outcomes following surgery for colorectal cancer is 
examined. 
The magnitude of the postoperative systemic inflammatory response, in particular, 
exceeding C-reactive protein (CRP) concentrations of 150mg/L on postoperative days 3 or 
4, has been reported to be associated with the development of infective type postoperative 
complications.  Chapter 3 examined the relationship between the postoperative systemic 
inflammatory response and complication severity, reporting that exceeding these CRP 
thresholds was associated with major complications as defined by Clavien Dindo grades 3 
to 5. 
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Although postoperative complications are recognised to have a negative prognostic impact, 
the relationship between the postoperative systemic inflammatory response and long term 
oncologic outcome is less clear.  The results of Chapter 4 suggest that an exaggerated 
postoperative systemic inflammatory response has a negative prognostic impact 
independent of complications following surgery for colorectal cancer. 
There is already some evidence to suggest that patient and operative factors such as the use 
of laparoscopic surgery, body mass index (BMI), comorbid disease, and the presence of 
preoperative systemic inflammation influence the postoperative systemic inflammatory 
response.  Chapters 5 to 11 examined some other important patient and perioperative 
factors which might have an influence on the postoperative systemic inflammatory 
response.   Chapter 5 reported that BMI and visceral obesity measured by preoperative CT 
scans are associated with the magnitude of the postoperative systemic inflammatory 
response and complications in female patients only.  Chapter 6 reported no significant 
association between poorer exercise tolerance, a lower anaerobic threshold as measured by 
cardiopulmonary exercise testing (CPEX), and the magnitude of the postoperative systemic 
inflammatory response in a small number of patients.   Chapter 7 reported no association 
between the formation of a temporary defunctioning stoma (at the time of anterior 
resection for rectal cancer), and the magnitude of the postoperative systemic inflammatory 
response.  Chapter 8 reported that operation duration is not directly associated with the 
postoperative systemic inflammatory response, instead suggesting that the surgical 
approach is more important.  Chapter 9 reported no association between perioperative 
blood transfusion and the magnitude of the postoperative systemic inflammatory response, 
but did find a significant association between preoperative inflammation and anaemia.  
Chapter 10 reported no association between preoperative neoadjuvant chemoradiotherapy 
(nCRT) and the magnitude of the postoperative systemic inflammatory response in patients 
undergoing surgery for rectal cancer.  Chapter 11 compared the postoperative systemic 
inflammatory response of patients undergoing surgery for colorectal cancer in the UK and 
Japan, using propensity scoring to match patients from each country by various 
demographic, pathological, and perioperative variables.  The results suggest a significant 
difference in the magnitude of the postoperative systemic inflammatory response, possibly 
dependent on ethnicity, which appears to be confirmed on further examination of the 
literature. 
Chapter 12 examined the possibility of a new paradigm of postoperative care following 
surgery for colorectal cancer.  At present the investigation of potential complications 
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following surgery is primarily reactive in nature and based on markers of patient 
physiology such as heart rate, core body temperature, blood pressure etc.  Chapter 12 
proposed the use of CRP on day 4 to prompt early investigation of such potential 
complications by computed tomography (CT) in the presence of an exaggerated 
postoperative systemic inflammatory response.  The results suggest that such a 
postoperative care protocol could result in the earlier and more accurate diagnosis of 
postoperative complications. 
Chapters 13 to 15 examined the use of single dose preoperative corticosteroids for the 
attenuation of the postoperative systemic inflammatory response and whether it might 
improve short term complications following surgery for colorectal cancer.  Meta-analysis 
of the existing randomised controlled trials in gastrointestinal cancer surgery in Chapter 13 
reported that corticosteroids result in lower postoperative CRP concentrations and fewer 
postoperative complications, but only in patients undergoing oesophageal and hepatic 
surgery and not in patients having a colorectal resection.  In Chapter 14, a propensity score 
matched analysis of the GRI cohort of patients given dexamethasone at the induction of 
anaesthesia, for the prevention of postoperative nausea and vomiting (PONV), reported a 
significant reduction in postoperative CRP concentrations and complications.  Finally, 
Chapter 15 set out a protocol for a randomised controlled trial of preoperative 
dexamethasone to assess dose response with relation to the magnitude of the postoperative 
systemic inflammatory response. 
In summary, the postoperative systemic inflammatory response may impact on the short 
and long term outcomes of patients undergoing surgery for colorectal cancer.  Attenuation 
of this postoperative systemic inflammatory response might reduce the rate of 
postoperative complications, although the impact of such strategies on long term outcomes 
is as yet unknown.  Future research in this area might examine various methods of 
attenuating the postoperative systemic inflammatory response; including anaesthetic 
techniques, the use of minimally invasive surgery, and pharmacological techniques such 
perioperative steroids and other anti-inflammatory drugs, and their impact on short and 
long term outcomes after surgery for colorectal cancer. 
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1.1 Epidemiology of colorectal cancer 
1.1.1 In the United Kingdom 
Colorectal cancer is the fourth most common cancer amongst men and women in the UK, 
and is the second leading cause of cancer death behind lung cancer. In 2013, there were 
around 41,000 new cases of colorectal cancer in the UK, which accounts for around 12% 
of all new cancer diagnoses (CRUK, 2013).  In the period of time 2011-2013 its incidence 
had increased 5% when compared to 2001-2003, with a slightly higher rate of new cases in 
men (56%) (CRUK 2013).  Over half of all new cases each year are diagnosed in those 
over 70 years old.   
As of 2011, in both sexes, only around 59% of those diagnosed with colorectal cancer 
survived 5 years or longer, however this figure increases to over 90% in stage I disease and 
drops to less than 10% in those with stage IV disease.  Furthermore, survival at 5 years 
following diagnosis with colorectal cancer continues to improve, having been only 49% in 
2001 (CRUK 2011).  Alongside ongoing improvements in treatment, a significant 
contributor to this is thought to be surgical subspecialisation, with the surgical treatment of 
colorectal cancers now only performed by specialist colorectal surgeons (Oliphant et al. 
2013).  Earlier presentation and diagnosis may also play a part in this survival 
improvement, and with the ongoing introduction of screening programmes throughout the 
UK this may come to be a more important factor.   
In Scotland around 4,000 new cases of colorectal cancer are diagnosed each year.  The 
statistics relating to increasing incidence, distribution by sex, and proportion of patients 
alive at 5 years are comparable to those for the UK as a whole (NHS ISD 2016).   
1.1.2 Worldwide 
In 2008 it was estimated that there were over 1.2 million new cases of colorectal cancer, 
with an estimated worldwide prevalence of over 3 million people in 2006 (Ferlay et al. 
2010).  The highest rates occur in the developed world: Europe, North America and 
Australasia, with a lower incidence in South East Asia and South America, and the lowest 
in Africa (Kamangar et al. 2006).  However, nations outside of those traditionally defined 
as “the West” are seeing an increase in the incidence of colorectal cancer, presumably due 
to changes in lifestyle and exposure to other risk factors (Ferlay et al. 2013a).   
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In Europe, colorectal cancer has a fairly similar distribution to that of the UK, comprising 
13% of all new cancer diagnoses, however the UK has been reported to have poorer rates 
of survival (Sant et al. 2009).  It has been suggested that this may relate to greater delayed 
presentation and poorer treatment outcomes in the UK, however care must be taken in 
interpretation of these findings due to significant differences in risk factor exposure, the 
use of screening programmes, diagnostic methods, and treatment protocols between 
countries.  Indeed, significant variation in both the incidence of, and survival with, 
colorectal cancer, is found between other European countries and not just with the UK 
(Ferlay et al. 2013b). 
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1.2 Aetiology of colorectal cancer 
Colorectal cancer, as it is presently understood, is a heterogeneous condition which is 
likely to represent an umbrella for a number of different diseases with varying genetic 
origins.  It is thought to occur over a relatively long period time with the accrual of genetic 
alterations gradually causing normal epithelium to become dysplastic then overtly 
malignant.   
The majority of colorectal cancers (98%) are adenocarcinomas, whilst the remainder are of 
either adenosquamous or adenocarcinoid carcinoma type histology.  In addition, a variety 
of benign tumours and hamartomas can affect the colon and rectum however are usually 
not considered colorectal cancer.  Rectal cancers are the most common single site with 
around 35-40% of all newly diagnosed tumours, followed by around 30% in the sigmoid 
and descending colon.  Colorectal cancers spread through multiple mechanisms including 
direct invasion of adjacent organs, via the portal venous system, lymphatics, and 
transcoelomic means. 
Between 10% and 20% of colorectal cancers will occur in patients who have a similarly 
affected first degree relative (Burt et al. 2005). Of this group, around one in four will be 
found to have a specific inherited genetic mutation which predisposes them to the disease 
(Ponz de Leon et al. 2004).  The remainder, and majority of new cases of colorectal cancer, 
are sporadic in nature and a mixture of genetic and environmental factors are thought to 
contribute to the development of the disease in these cases (Brenner et al. 2014).  A 
number of different carcinogenesis pathways have been described, mainly through work on 
the hereditary forms of colorectal cancer, each of which have different implications for 
clinical management and outcomes (Sadanandam et al. 2013). 
1.2.1 Adenoma carcinoma sequence 
Dysplastic adenomatous polyps of the colon and rectum are by far the most common 
premalignant precursor lesion in sporadic colorectal cancer (Jass 2007).  The original 
multi-step model which describes the development of these adenomas and the progression 
of dysplasia to invasive malignancy through the accrual of specific somatic genetic 
mutations, known as the “adenoma carcinoma sequence”, was first described by Fearon 
and Vogelstein over twenty-five years ago (Vogelstein et al. 1988).  The entire process is 
heavily associated with chromosomal instability, i.e. changes in both the number and 
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structure of chromosomes, and loss of heterozygosity through point mutation, rendering 
the individual susceptible to deletion of a remaining functional proto-oncogene or tumour 
suppressor gene (Lengauer et al. 1997).  
The first step in the traditional sequence is deletion of the adenomatous polyposis coli 
(APC) gene which gives rise to the colorectal adenoma itself, and is a defect found in 70% 
of these types of polyps (Kinzler et al. 1996).  Subsequent mutations in the K-ras oncogene 
promotes both growth and progressive dysplastic change of the polyp, followed by loss of 
the p53 tumour suppressor gene which allows progression to the final part of the sequence: 
adenocarcinoma (Fearon 2011). 
This model, although valuable, is now recognised to be over simplistic.  Even within those 
sporadic tumours which develop from adenomatous polyps, it is now recognised that the 
accrual of mutations in a variety of oncogenes and tumour suppressor genes such as src, 
myc, wnt, E-Cadherin, SMAD4, and many others, is likely to be an important factor and 
also explains the variation in genetic profiles found between colorectal cancers (Wood et 
al. 2007, Chittenden et al. 2008) 
 
Figure 1-1:The adenoma carcinoma sequence (adapted from Fearon et al. 1990) 
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1.2.2 Microsatellite instability 
High frequency microsatellite instability (MSI-H) is found in both around 15% of sporadic 
colorectal cancers and in the majority of patients with Hereditary Non-Polyposis Colon 
Cancer (HNPCC) (Aaltonen et al. 1993, Thibodeau et al. 1998).  These microsatellites are 
repetitive sequences of DNA found randomly throughout the human genome.  
Microsatellite instability is thought to be caused by deficient or defective DNA mismatch 
repair (MMR) and is associated with an accumulation of base pair mismatches and 
alteration in the length of the microsatellite sequences following DNA replication.  The 
same MMR deficiency is thought to allow the accumulation of mutations which are 
associated with carcinogenesis.   
Tumours are described as having high frequency microsatellite instability (MSI-H) if 2 or 
more of 5 validated microsatellites (D2S123, D5S346, D17S250, BAT-25 and BAT-26) 
are found to be unstable, having low frequency microsatellite instability (MSI-L) if one is 
found to be unstable, whilst the remainder are classified microsatellite stable (MSS) 
(Boland et al. 1998).   
In HNPCC (described in more detail below), mutations in one of six DNA MMR genes 
(MLH 1, MSH 2, MSH 3, MSH 6, PMS 1 and PMS2) can give rise to MSI (Papadopoulos 
et al. 1997).  In contrast, in sporadic colorectal cancers with the MSI-H phenotype, MMR 
deficiency is thought to arise as an epigenetic phenomenon, due to MLH-1 silencing by 
hypermethylation of its gene promoter region (Kane et al. 1997).  
Sporadic MSI-H colorectal cancers, in general, tend to be found in the right colon, in the 
elderly, are more likely to have associated synchronous lesions, and are less likely to have 
associated metastases at diagnosis (Jung et al. 2012).  MSI-H tumours are associated with a 
significant local lymphocytic inflammatory, or “Crohn’s like”, response (Dolcetti et al. 
1999).  It has been suggested that this relates to the creation of multiple tumour epitopes in 
the form of truncated proteins resulting from DNA MMR errors (Schwitalle et al. 2008).  It 
is postulated that this is why MSI-H tumours are associated with better prognosis (Popat et 
al. 2005, Galon et al. 2006) and that microsatellite status may predict treatment response, 
although the present evidence for this is somewhat conflicting (Bertagnolli et al. 2009).    
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1.2.3 Hypermethylation and the hyperplastic/serrated polyp pathway 
Hyperplastic colonic polyps have long been known about and, until fairly recently, were 
considered almost universally benign.  Some, in particular serrated adenomas, are now 
thought to represent premalignant precursor lesions for a type of colorectal cancer which 
does not follow the traditional adenoma carcinoma sequence, but is more closely 
associated with cancers which occur through microsatellite instability (Bettington et al. 
2013).  Indeed, it is thought that the silencing of tumour suppressor genes through 
hypermethylation of promoter and regulatory regions leads to eventual carcinogenesis 
rather than mutation of the genes themselves (Ferracin et al. 2008).  More specifically in 
colorectal cancer, specific epigenetic hypermethylation gives rise to the CpG Island 
Methylator Phenotype (CIMP) (Issa 2004).  In particular, hypermethylation of the MLH 1 
gene promoter region gives rise to sporadic MSI-H tumours as discussed above, with a 
similar pathological and clinical phenotype (Herman et al. 1998).  It must also be noted 
that CIMP positivity can be found in MSS colorectal cancers.  However, the considerable 
overlap between MSI and CIMP, along with their relationships with the oncogenes BRAF 
and K-ras (discussed in detail later), is in part what has lead researchers to attempt to 
classify colorectal cancers into discrete molecular subtypes as described below. 
1.2.4 Molecular subtypes of colorectal cancer 
As already stated, colorectal cancer is a heterogeneous disease in terms of its genetics, 
pathology, and response to therapy.  Recent consensus has been reached on the 
categorisation of colorectal cancer into four discrete subtypes based on patterns of genetic 
abnormality and gene expression: MSI Immune, Canonical, Metabolic, and Mesenchymal 
(Table 1.1) (Guinney et al. 2015).  The aim of this work is to make collaboration and 
comparison across future preclinical and clinical studies in colorectal cancer easier.  
However, concerns have been raised that the presence of variability in gene expression 
even within different areas of a single tumour, so called tumour heterogeneity, may 
undermine this proposed categorisation (Dunne et al. 2016). 
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Table 1-1: Consensus molecular subtypes of colorectal cancer (adapted from Guinney et al. 2015) 
CMS 1 
MSI Immune 
CMS 2 
Canonical 
CMS 3 
Metabolic 
CMS 4 
Mesenchymal 
14% 37% 13% 23% 
MSI, CIMP high, 
hypermutation 
SCNA high Mixed MSI status, 
SCNA low, CIMP low 
SCNA high 
BRAF mutations  K-ras mutations  
Immune infiltration WNT and MYC 
activation 
Metabolic deregulation Expanded tumour 
stroma, TGF-β 
activation, angiogenesis 
CMS colorectal molecular subtype, MSI microsatellite instability, SCNA somatic copy number alterations, 
CIMP CpG island methylator phenotype 
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1.3 Inherited forms of colorectal cancer 
Inherited forms of colorectal cancer account for around 5% of all new cases in the 
developed world, and their understanding has lead to much of what is known regarding 
carcinogenesis pathways in colorectal cancer (Jasperson et al. 2010). 
1.3.1 Familial adenomatous polyposis 
Familial adenomatous polyposis (FAP) is an autosomal dominant condition, the underlying 
genetic abnormality being germline mutation of the APC tumour suppressor gene 
(Segditsas et al. 2006).  Almost all affected patients will develop colorectal cancer by 
middle age if left untreated, due to the development of hundreds of colonic adenomas, 
some of which will inevitably undergo malignant transformation following the adenoma 
carcinoma sequence (Fearnhead et al. 2002).  Despite prophylactic colectomy, cancer is 
still a major cause of death in these patients due to the association between FAP and extra-
colonic lesions including desmoids tumours, pancreatic mucinous lesions, and 
hepatoblastoma (Belcehtz et al. 1996).  
1.3.2 Hereditary non-polyposis colon cancer 
Hereditary non-polyposis colon cancer (HNPCC, or Lynch syndrome), is an autosomal 
dominant inherited condition which confers those affected a 60-80% lifetime risk of 
colorectal cancer (Lynch et al. 1999).  As already discussed, HNPCC is caused by 
germline mutations in one or more of 6 genes associated with DNA mismatch repair 
(MMR): MLH 1, MSH 2, MSH 3, MSH 6, PMS 1 and PMS 2, causing HNPCC tumours to 
have high frequency microsatellite instability (MSH-H) and the associated “Crohn’s like” 
inflammatory infiltrate (Boland et al. 2010).  Patients with HNPCC are more likely to have 
a right sided lesion, synchronous disease, and are at increased risk of extracolonic 
malignancy, in particular endometrial, ovarian, gastric, ureteric, hepatobiliary, and small 
bowel tumours (Watson et al. 1994).  Diagnosis of HNPCC is based on assessment of the 
patient and their family history using one of two commonly used guidelines; the Revised 
Bethesda Guidelines (Umar et al. 2004) and the Amsterdam II Criteria (Vasen et al. 1999), 
followed by laboratory testing to identify specific genetic mutations.  There is some 
evidence to suggest that the broader Revised Bethesda Guidelines more accurately identify 
those patients with underlying deficient MMR (Jung et al. 2016). 
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1.3.3 Hamartomatous polyposis syndromes 
The hamartomatous polyposis syndromes represent a rarer group of mostly autosomal 
dominantly inherited diseases associated with the development of colorectal cancers and 
extracolonic tumours (Calva et al. 2008).  The group of disease includes Juvenile 
Polyposis, Peutz-Jeghers disease, and PTEN Hamartoma Tumour Syndrome (of which 
Cowden’s disease predominates in adults), which carry a colorectal cancer risk of 39-68%, 
39-57%, and 18% respectively (Campos et al. 2015).  The mechanism by which 
hamartomatous polyps progress to invasive malignancy is closely linked to the activity of 
each of the causal mutations but lies outside of those carcinogenesis pathways already 
discussed. 
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1.4 Acquired risk and preventative factors for colorectal cancer 
Unlike some cancers, e.g. lung, in which a single acquired risk factor accounts for the 
majority of sporadic new cases, multiple risk factors and preventative factors are thought to 
relate to the aetiology of colorectal cancer.  Indeed, many of these factors are interrelated 
and co-exist, some having an additive or multiplicative impact on risk (Brenner et al. 
2014).   
1.4.1 Age 
Increasing age is a significant risk factor for sporadic colorectal cancer, with over 50% of 
new cases in those over 70 years of age (CRUK).  Indeed, ageing is associated with a 
number of cancer types, and there are several theories as to why this might be the case 
(Smith et al. 2009).  Increasing age allows for an increasing total exposure to 
environmental factors associated with the development of cancer.  Methylation of DNA 
occurs to greater extent as time passes, which may relate to the length of time exposed to 
oxidative stressors, and can result in gene silencing (Adams et al. 2015).  At a 
chromosomal level telomeres degrade with time.  These chromosomal caps are thought to 
protect the structural integrity of chromosomes and so their shortening may allow for 
chromosomal instability (Hackett et al. 2003). 
1.4.2 Diet 
The hypothesis that the contact of carcinogens within digested food-stuff with the 
colorectal mucosa might increase the risk of colorectal cancer was first postulated in the 
1970’s following observational studies suggesting that diets higher in fibre, with faster 
colonic transit, were associated with reduced incidence of colorectal cancer (Burkitt 1971, 
Armstrong et al. 1975).  However, prospective studies published since have reported 
conflicting results and a more recent large meta-analysis of these prospective studies 
reported that, after adjustment for other known risk factors, dietary fibre was not 
independently associated with colorectal cancer incidence (Park et al. 2005).  However, 
other elements of diet are thought to represent a significant modifiable risk factor in 
colorectal cancer through the same mechanism.   
A recent meta-analysis of prospective studies investigating both fresh red meat and 
processed meat consumption reported that both types of food were associated with 
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increased risk of colonic and rectal cancer, with a non-linear dose-response relationship 
(Chan et al. 2011).  Indeed, the World Cancer Research Fund (WCRF) and American 
Institute for Cancer Research (AICR) consensus statement suggests that individuals should 
limit their intake of red meat, processed meats, and animal fat (AICR 2007). 
In contrast there is good evidence that the consumption of essential fatty acids, especially 
through fish oil and diets relatively high in fish, is associated with a modest reduction in 
the risk of colorectal cancer (Wu et al. 2012).  These fish oil omega fatty acids are thought 
to reduce colorectal carcinogenesis by anti-inflammatory action, through inhibition of 
cyclo-oxygenase (COX), and direct effects on colonic mucosal cell proliferation (Caygill et 
al. 1996, Larsson et al. 2004).  In addition, a meta-analysis of prospective studies has 
reported that diets high in fruit and vegetables are associated with reduced incidence of 
colorectal cancer (Aune et al. 2011), although the evidence for individual antioxidant 
vitamins A, C, and E, and the group of carotenoids, is less clear (Murtaugh et al. 2004, 
Mannisto et al. 2007).  Furthermore, a pooled analysis of 9 prospective observational 
studies has reported an association between dietary vitamin D and calcium 
supplementation and a reduced risk of colorectal cancer (Ma et al. 2011).  However, a 
recent randomised controlled trial of vitamin D in women who had just completed 
colonoscopy found no reduction in the risk of adenomatous polyp recurrence at follow up 
surveillance colonoscopy (Baron et al. 2015).  It may be that vitamin D reduces the risk of 
malignant progression of existing polyps rather than reducing polyp formation. 
1.4.3 Obesity 
Increasing body mass index (BMI), particularly into the obese category of >30kg/m2, is 
now well recognised to be associated with increased risk of colorectal cancer (Ma et al. 
2013).  Central obesity especially seems to have an important role, with the appearance of 
a dose-response relationship between waist circumference and colorectal cancer risk 
(Moghaddam et al. 2007).  Obesity is strongly related to other risk factors for colorectal 
cancer including diabetes, diet, exercise, and deprivation.  However, obesity may well 
contribute to colorectal carcinogenesis in its own right.  Adipocytes, particularly those of 
visceral fat found in central obesity, are neurohormonally and immunologically active 
cells.  It has been suggested that they chronically produce cytokines and pro-inflammatory 
mediators which may influence carcinogenesis (McMillan et al. 2006).  In addition, leptin, 
produced by adipocytes as part of the satiety response, may be involved in the 
development of colorectal cancer (Frezza et al. 2006). 
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1.4.4 Exercise 
Although levels of physical activity are often related to other colorectal cancer risk factors 
such as obesity, age, smoking, and cardiovascular disease, in the case of colorectal cancer 
there also appears to be a protective effect independent of these confounders (Colditz et al. 
1997).  Indeed, several meta-analyses have reported that exercise and physical activity 
reduce the risk of developing colorectal cancer (Wolin et al. 2007, Boyle et al. 2012).  The 
WCRF and AICR consensus statement suggests that any increase in levels of physical 
activity should confer some degree of risk reduction (AICR 2007).  Hypotheses as to why 
this should be the case include faster colonic transit in the physically active, exercise 
induced immunomodulation, and hormonal changes e.g. lower levels of circulating 
prostaglandins in those who are active (Samad et al. 2005). 
1.4.5 Alcohol 
Several recent meta-analyses have reported that alcohol intake is associated with colorectal 
cancer risk in a dose dependent manner (Fedirko et al. 2011, Bagnardi et al. 2015).  There 
are several possible mechanisms by which alcohol may have its carcinogenic effect 
including its metabolites, particularly acetaldehyde (Boffetta et al. 2006), impairment of 
folic acid absorption (Hamid et al. 2009), and alterations in production of oestrogens and 
androgens (Singletary et al. 2001).   
1.4.6 Smoking 
Tobacco smoking is associated with the production of numerous harmful and carcinogenic 
compounds, some of which are recognised to impact on the gastrointestinal tract 
epithelium (Jensen et al. 2012).  A meta-analysis of 106 observational studies reported a 
significant association between cigarette smoking and the development of colorectal 
cancer, related to the number of pack years, but only becoming statistically significant after 
3 decades of smoking history (Botteri et al. 2008). 
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1.4.7 Systemic inflammation 
It is now clear that cancer, including that of the colon and rectum, and inflammation are 
intimately linked.  Indeed, the presence of inflammation is now considered a hallmark of 
cancer, primarily as a factor promoting growth and metastases (Hanahan et al. 2011).  
Furthermore, the presence of systemic inflammation has been shown to predict poorer 
prognosis in a variety of cancers independent of stage (McMillan 2013).  In addition to its 
impact on established cancer, described in more detail below, there is good evidence to 
suggest that the presence of inflammation is associated with the subsequent development 
of colorectal cancer (Erlinger et al. 2004).  Clinical trials of anti-inflammatory medications 
have been shown to reduce the risk of development of colorectal cancer in high risk 
groups, discussed in more detail below (Burn et al. 2011).  However, systemic 
inflammation is also associated with numerous other risk factors for colorectal cancer 
including obesity, diabetes mellitus, and cardiovascular disease (Freeman et al. 2002, Choi 
et al. 2013, Stancel et al. 2016).  Therefore, it remains unclear whether systemic 
inflammation is an independent risk factor for the development of colorectal cancer or 
whether it is related in a greater degree to other associated factors. 
1.4.8 Medication 
A number of medications have been found to affect colorectal cancer risk, several of which 
have been key in elucidating potential mechanisms of carcinogenesis or disease 
progression. 
1.4.8.1 Aspirin and non-steroidal anti-inflammatory drugs 
Evidence that the non-steroidal anti-inflammatory group of drugs (NSAIDs) might reduce 
the risk of formation of colorectal adenomas, and colorectal cancer, was first reported in 
patients with the heritable forms of the disease (Giardiello et al. 1993), and in the CAPP 
trials of aspirin (Burn et al. 2011).  These findings have been extended to sporadic forms of 
the disease, with reduction in risk apparent after around 10 years of exposure (Vinogradova 
et al. 2007).  NSAIDs primarily act via inhibition of the cyclo-oxygenase (COX) pathway, 
and one potential mechanism of action is that the resultant reduction in prostaglandin 
synthesis has anti-proliferative effects alongside a reduction in platelet activation, reducing 
downstream cytokine release (Cha et al 2007).  The more selective COX-2 inhibitors have 
been found to be similarly efficacious, which is of interest as a proportion of colorectal 
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cancers over express COX-2 (Harris et al. 2008).  In addition, NSAIDs are believed to 
interact with the Wnt/β-catenin/NF-κB and PI3K/AKT pathways (Grosch et al. 2006).  
Furthermore, it is thought that NSAIDs may have direct effects on the local 
microenvironment and inflammatory response, described in more detail below (Park et al. 
2014a).  Despite such promising results, concerns regarding adverse drug events have 
prevented the adoption of these drugs as primary chemoprevention (US Preventive 
Services Task Force 2007).  
1.4.8.2 Statins 
The HMG-CoA reductase inhibitors, or “statins”, are a group of drugs primarily used for 
the treatment of hypercholesterolaemia and in cardiovascular secondary prevention.  They 
have, however, been found to be associated with a modest reduction in the risk of 
colorectal cancer (Bonovas et al. 2007, Bardou et al. 2010).  These anti-carcinogenic 
effects are thought to relate to statins’ pleiotropic effects on cell proliferation, cellular 
response to oxidative stress, angiogenesis, and inflammation (Park et al. 2014a).  Some of 
these pathways are mediated via downstream activity of HMG-CoA reductase, and some 
are independent of this pathway (Hindler et al. 2006, Coogan et al. 2007). 
1.4.8.3 H2 receptor antagonists 
Several studies have examined the potential survival benefit from the use of H2 receptor 
antagonists (H2RAs), such as cimetidine, in patients with colorectal cancer, with a recent 
Cochrane review suggesting a modest survival benefit as an adjuvant therapy in patients 
with resected disease (Deva et al. 2012).  The underlying mechanism for this action is yet 
to be fully accounted for.  H2RAs have been shown to increase the bioavailability of 5-
fluorouracil (5-FU), a common adjuvant chemotherapeutic agent (Harvey et al. 1984).  In 
addition, H2RAs have been shown to impact T-lymphocyte and natural killer cell (NK) 
activity at both the local and systemic levels (Nielsen et al.1995, Kelly et al. 1999). 
Furthermore, histamine is associated with cyclo-oxygenase dependent inflammatory 
pathways, and it may be that H2RAs reduce the risk of cancer recurrence through this 
pathway (Cianchi et al. 2005). 
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1.4.8.4 Metformin 
Metformin is a widely used drug which reduces peripheral insulin resistance in patients 
with type 2 diabetes mellitus (T2DM).  It has been shown to reduce the risk of developing 
colorectal cancer, and of disease recurrence, particularly in diabetic patients (He et al. 
2016).  Metformin is thought to have multiple modes of action which relate to the 
mechanisms by which diabetes increases the risk of colorectal cancer (discussed in more 
detail below).  These include the inhibition of growth factors such as insulin, insulin-like 
growth factor 1 (IGF-1), and leptin via the AMPK pathway (Sedhev et al. 2015). 
1.4.9 Acquired conditions associated with colorectal cancer 
1.4.9.1 Inflammatory bowel disease 
The group of inflammatory bowel diseases (IBD) of which Crohn’s disease and ulcerative 
colitis (UC) predominate form one of the single largest risk factors for colorectal cancer 
outside of the heritable forms and family history (Jess et al. 2012a).  Indeed, it is thought 
that around 1 in 6 deaths in patients with UC (Jess et al. 2012b), and 1 in 12 deaths in 
patients with Crohn’s disease are due to colorectal cancer (Jess et al. 2004).  Although 
patients with IBD tend to develop colorectal cancer at an earlier age than other sporadic 
cases of colorectal cancer, their prognosis once diagnosed is the same as those patients 
without IBD (Rhodes et al. 2002).  IBD is a chronic inflammatory disease of the 
gastrointestinal tract, therefore it is thought that the chronic exposure to pro-inflammatory 
cytokines leads to dysplasia and eventual carcinogenesis as described above.  Indeed, 
studies suggest that the degree of local inflammation, determined at endoscopy and by 
histology, relates to the risk of development of colorectal cancer (Rutter et al. 2004, 
Nieminen et al. 2014)   
1.4.9.2 Diabetes mellitus 
A recently updated meta-analysis of observational studies reports a significantly higher 
incidence of colorectal cancer amongst patients with diabetes mellitus (DM) (Wu L et al. 
2013).  Furthermore, patients with DM who develop colorectal cancer are more likely to 
die of the disease than those without, although no distinction was made between types 1 
and 2 DM (Jiang et al. 2011).  In particular, type 2 diabetes is associated with peripheral 
insulin resistance and compensatory hyperinsulinaemia.  This in turn leads to higher 
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circulating insulin-like growth factors (IGFs) which are thought to inhibit apoptosis and 
promote proliferation of colonocytes (Wu et al. 1995, Giovannuci 2001).  Furthermore, 
insulin resistance is associated with the production of proinflammatory cytokines including 
TNF-α, IL 6, and leptin, which are thought to have a role in colorectal carcinogenesis as 
described above (Fernandez-Veledo et al. 2009).  There is significant overlap between type 
2 DM and obesity, which is also associated with colorectal cancer, and similar mechanisms 
are likely to be involved. 
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1.5 Clinical presentation of colorectal cancer 
At present, colorectal cancer will be diagnosed in one of three clinical settings; elective 
presentations, emergency presentations, and through screening of asymptomatic 
individuals.  In the elective setting this usually occurs following either referral to a 
colorectal surgical clinic, or direct referral to investigation by the General Practitioner 
based on symptoms.  Emergency presentations include acute abdominal pain as a result of 
colonic perforation or obstruction, and significant rectal bleeding.  Resection for colorectal 
cancer performed in the acute or emergency setting is associated with higher postoperative 
mortality and poorer 5 year disease free survival (Anderson et al. 1992, McArdle et al. 
2004, Oliphant et al. 2014).  In the past, emergency presentation might have accounted for 
between 30% and 40% of new colorectal cancer diagnoses, a proportion which has been in 
slow but steady decline (Ananda et al. 2016).  This is most probably due to multiple factors 
including public education regarding symptoms of colorectal cancer, referral pathways for 
primary care, and the introduction of screening.    
1.5.1  Symptoms and signs 
Elective presentations of new colorectal cancer usually occur due to one, or a combination, 
of three symptoms: change in bowel habit, abdominal pain or rectal bleeding (Keddie et al. 
1968).  These symptoms are also common to a variety of other benign colorectal 
pathologies and therefore diagnosis based on symptoms alone is difficult.  For example, 
change in bowel habit alone has a positive predictive value (PPV) of only 9% for 
colorectal cancer, however, when combined with rectal bleeding, and increasing age the 
PPV increases considerably to 35% (Thompson et al. 2007).  This clearly still allows for 
considerable diagnostic error.  In some cases, patients present with either symptomatic or 
asymptomatic iron deficiency anaemia, discussed in more detail below.  Less commonly, 
patients present with clinical signs such as a palpable rectal or abdominal mass, or signs of 
metastatic disease.  
1.5.2 Diagnostic investigations 
Colonoscopy (flexible fibreoptic examination of the lumen of the colon following osmotic 
laxative bowel preparation) is considered the gold standard method for the diagnosis of 
colorectal cancer in both the symptomatic and in the asymptomatic screening populations.  
  
 
48 
 
In addition to lesion visualisation and location, colonoscopy allows for tissue biopsy of any 
lesions encountered, and even curative endoscopic resection of small polyp cancers.  It is 
however an invasive test and is associated with a colonic perforation rate of around 1 in 
2000 tests (Lorenzo-Zuniga et al. 2010). 
Computed tomography (CT) colonography (also known as CT pneumocolon and virtual 
colonoscopy) has superseded double contrast barium enema in the radiological diagnosis 
of colorectal cancer in the UK.  It requires osmotic laxative bowel preparation and the 
creation of a pneumocolon by rectal catheter insufflation.  It has been shown to be as 
sensitive as colonoscopy in diagnosing established colorectal cancers and polyps larger 
than 10mm (Halligan et al. 2005, Pickhardt et al. 2011).  It has a more favourable short 
term complication profile than colonoscopy and is able to detect extra-colonic 
abnormalities (Veerappan et al. 2010).  However, if a colonic lesion is detected then the 
patient will require to undergo colonoscopy to obtain tissue.  In addition, a CT colonogram 
will expose a patient to a not insignificant radiation dose (Liedenbaum et al. 2008).  Its use 
as a potential primary screening tool is currently being investigated, although its use is 
indicated within the Scottish Bowel Cancer Screening Programme in certain circumstances 
as described below (de Wijkerslooth et al. 2010). 
At present in Scotland, faecal blood based tests including guaiac faecal occult blood tests 
(gFOBT) and faecal immunochemical tests (FIT) are used only within screening (discussed 
below) and are not used as diagnostic tests in symptomatic patients.  
1.5.3 Scottish Bowel Cancer Screening Programme 
The Scottish Bowel Cancer Screening Programme was introduced in a staged manner 
across Scotland from 2007 onward and is coordinated centrally by the Scottish Bowel 
Screening Centre in Dundee.  All men and women aged between 50 and 74, registered with 
a General Practitioner in Scotland, are invited to participate. An opt-in system is in place 
for those patients over the age of 74 who wish to take part in screening.  Participants are 
sent a gFOBT kit and asked to provide 2 samples from 3 separate faecal specimens. These 
are placed on 6 oval windows, classified as positive if 5 out of 6 windows are positive, and 
weakly positive if 1- 4 windows are positive. In the case of a weakly positive or 
inconclusive result, a FIT is completed. The cut-off levels for a positive result for the 
gFOBT and FIT tests are 600µg Hb/g faeces and 10 µg Hb/g faeces respectively (Fraser et 
al. 2012). In the case of a negative test the patient is re-invited 2 years later at their next 
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screening round.  Following a positive test result, the local health board is contacted and 
are responsible for arranging further investigation. Individuals are pre-assessed and 
undergo colonoscopy if this is deemed suitable. If colonoscopy is unsuccessful then bowel 
imaging by CT colonography is performed. Early evidence from this screening programme 
suggests a shift toward earlier disease stage at diagnosis (Mansouri et al. 2015).  This 
should eventually lead to improved survival in colorectal cancer patients, although 
concerns remain regarding lead time bias and the lack of impact on overall life expectancy 
in the population as a whole (Hewitson et al. 2007).   
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1.6 Multidisciplinary management of colorectal cancer 
The Scottish Intercollegiate Guideline Network (SIGN) recommend that all patients 
diagnosed with colorectal cancer be discussed at a specialist colorectal oncology multi-
disciplinary team (MDT) meeting, before and after surgery and oncology treatments, 
composed of specialists likely to be involved in the patient’s staging, perioperative, and 
oncologic care (SIGN 2016).  This can include, but is not limited to, a colorectal surgeon, 
oncologist, radiologist, pathologist, and nurse specialist with subspecialty interest in 
colorectal cancer.  Indeed, there is evidence that the use of MDTs in treatment decision 
making and planning is associated with improved surgical and long term outcomes for 
patients with colorectal cancer (Burton et al. 2006, MacDermid et al. 2009).  
1.6.1 Neoadjuvant chemoradiotherapy 
In the UK, preoperative, or neoadjuvant chemoradiotherapy (nCRT), is primarily indicated 
in rectal cancers in which there is concern immediate surgical resection would leave 
involved circumferential margins (CRM) within the pelvis (SIGN 2016).  However, nCRT 
is also often given to patients with T3 or T4 rectal cancers, or where local nodal disease is 
evident on the staging CT or MRI (Engstrom et al. 2009).  In some cases, the use of nCRT 
can allow anal sphincter preservation in a tumour, which at diagnosis involves the 
sphincter complex, or would not allow for a clear margin without excision of the sphincters 
in primary surgery.  In the USA, the indications are wider and its use more common.  In 
addition, chemotherapy regimens and external beam radiation dosing strategies vary, and 
there is yet to be conclusive evidence as to which, if any, is superior in terms of involved 
CRM rates and longer term outcomes (NICE 2014).   
In general, a radio-sensitising chemotherapy agent such as capecitabine, or 5-flurouracil 
(5-FU) is given, followed by a pre-planned number of fractions of radiotherapy.  The high 
energy photons generated cause both direct damage to DNA and cause the production of 
reactive oxygen species leading to further DNA and cellular damage.  The greatest impact 
is felt by the metabolically and mitotically active tumour cells, however damage is also 
caused to surrounding healthy tissue leading to the more common side effects such as skin 
toxicity, radiation proctitis, enteritis, and cystitis.   
Complete clinical (i.e. no tumour on digital or endoscopic examination) and pathological 
(at the resected specimen) responses can be achieved in around 10-15% of patients in 
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reported series of nCRT for rectal cancer (Habr-Gama et al. 2010).  This represents a 
potentially significant move away from surgery for certain rectal cancer patients, although 
the long-term outcomes and appropriate management pathways are at present under 
investigation. 
1.6.2 Surgery 
Surgical resection remains the cornerstone of curative management for colorectal cancer.  
The tumour is resected along with a minimum 5cm margin (or 1cm distally in low rectal 
cancers) of healthy bowel along with the lymphatic and blood supply, taken as near their 
origin as possible, within its segment of mesocolon.  The last few decades have seen total 
mesorectal excision (TME) emerge as the gold standard oncologic resection for all rectal 
cancers due to the significant reduction in local recurrence achieved (Heald et al. 1986).  
Rectal cancers involving the sphincter complex, or within 8cm of the anal margin, usually 
require abdominoperineal resection (APR), with excision of the sphincters and formation 
of an end colostomy.  Those with circumferential, margin threatening disease, may require 
more radical extralevator (ELAPE) and exentrative procedures (Jones et al. 2016).  The use 
of minimally invasive surgical techniques, including laparoscopic surgery and robotic 
surgery, have been shown to be equivalent to traditional open surgery in terms of long term 
oncologic outcomes (Kim et al. 2014, Vennix et al. 2014, Jaap Bonjer et al. 2015).  
Minimally invasive transanal techniques such as TEM and TAMIS have been reported to 
have acceptable local recurrence rates in early invasive low rectal cancers when completely 
excised, however, the lack of lymph node tissue within the resected specimen means that 
distant recurrences can occur unexpectedly (Sajid et al. 2014). 
At the time of resection, the decision on whether to create a primary anastomosis, to create 
a permanent stoma, or indeed to create a temporary stoma to defunction a primary 
anastomosis will be dependent on numerous patient, anatomical, and tumour factors.  
Evidence suggests that the more distal an anastomosis the greater the risk of anastomotic 
dehiscence, and that temporary loop ileostomies may reduce both the likelihood and 
severity of any subsequent leak (Montedori et al. 2010).  Other factors which may 
encourage temporary stoma formation are those associated with anastomotic leak such as 
male sex, comorbidities, BMI, prolonged surgery, nCRT, and intraoperative blood loss 
(McDermott et al. 2015).   
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1.6.3 Adjuvant chemotherapy 
Adjuvant chemotherapy is currently recommended for patients found to have Union for 
International Cancer Control (UICC) stage III and above (i.e. that with at least lymph node 
involvement), or high risk stage II disease (SIGN 2016).  High-risk stage II disease is most 
commonly defined as that without any lymph node involvement but with one of the 
following pathological characteristics which form the Gloucester Prognostic Index (GPI): 
peritoneal involvement, venous invasion, involved margins, and tumour perforation 
(Petersen et al. 2002, Morris et al. 2007).  In addition, adjuvant therapy is commonly 
offered to those with T4 disease, and sometimes to patients with an inadequately resected, 
or sampled, number of lymph nodes, commonly defined as less than 12 (Benson et al. 
2004).   
Adjuvant chemotherapy has been shown to produce a 10% absolute risk reduction in terms 
of overall survival in patients with stage III disease (Moertel et al. 1995).  It is most 
commonly commenced at around 6 weeks following surgery to allow for wound healing 
and initial recovery.  There is limited evidence that delay beyond this period is associated 
with poorer long-term outcomes (Dahl et al. 2009).  Regimens commonly include 
capecitabine, an oral preparation of 5 FU which irreversibly inhibits the enzyme 
thymidylate synthetase, required for DNA replication.  Platinum based oxaliplatin, on the 
other hand, causes DNA crosslinking which leads to cellular apoptosis. 
1.6.4 Follow up of resected disease 
There is limited evidence that intensive follow up after surgery for colorectal cancer is 
associated with small improvements in overall survival (Jeffery et al. 2007).  In general, 
the nature and timing of follow up investigation varies by the risk of disease recurrence as 
estimated by pathological stage.  However, the quality of the evidence is relatively poor.  
This is partly reflected in the differences between the NICE and SIGN guidelines with 
regard to follow up (NICE 2014, SIGN 2016).  While both bodies agree that a combination 
of carcinoembryonic antigen (CEA), CT, and colonoscopy should be used, there is debate 
with regard to timing.  The table below shows an example of a follow up protocol which in 
fact borrows from both the NICE and SIGN guidelines. 
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Table 1-2: Example of follow up after surgery for colorectal cancer (adapted from the West of 
Scotland Cancer Network 2016) 
 
1.6.5 Metastatic disease 
Around 20% of patients with colorectal cancer will be found to have extracolonic, or 
metastatic, disease at presentation.  In a small number of these patients, curative treatment 
options, usually a combination of surgery and oncologic therapies, are pursued.  The most 
common site of colorectal cancer metastasis is the liver.  Patients with resectable liver 
metastases can undergo either synchronous colorectal and liver resection (de Santibanes et 
al. 2010) or staged resection, usually with the primary lesion being resected first and the 
liver lesion resected after recovery from the initial surgery (Choti et al. 2002).  In addition 
to cytotoxic adjuvant chemotherapy, cetuximab, a monoclonal antibody targeting the 
epidermal growth factor receptor (EGFR), has been shown to improve survival in patients 
with liver metastases and locally advanced disease who are found to have unmutated (or 
wild type) K-ras (Karapetis et al. 2008). 
1.6.6 Palliative treatment 
Approximately 80% of those patients with metastatic disease at presentation are found to 
be unsuitable for management with curative intent due to a number of factors including 
disease burden, comorbid state, and performance status (Mella et al. 1997).  Although there 
is some evidence that palliative resection of the primary lesion is associated with longer 
median survival (Park et al. 2013), modern palliative treatment is far more likely to be 
based on medical treatment options.  Palliative cytotoxic chemotherapy has been 
demonstrated to improve survival in both locally advanced and metastatic colorectal 
cancer, however not all patients desire this treatment option due to potential toxicities (de 
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Gramont et al. 2000). Radiotherapy, usually targeted toward pelvic lesions, has proven 
useful in the management of both pain and bleeding (Bae et al. 2011).  In addition, there 
are still non-resective palliative surgical options such as defunctioning via stoma, intestinal 
bypass, and colonic stenting, aimed usually at preventing symptoms of intestinal 
obstruction (Costi et al. 2014).  If patients are judged to be unsuitable even for these 
treatment options, they are referred for best supportive care through palliative care and 
hospice specialist services.   
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1.7 Staging colorectal cancer 
1.7.1 Preoperative Staging modalities 
Preoperative staging is conducted with the aim of determining the optimal management 
strategy for newly diagnosed patients and, at present, is primarily based on imaging 
techniques.  These techniques, along with the diagnostic colonoscopy, aim to inform the 
clinicians of the location and size of the tumour, its relation to surrounding structures, and 
whether there is evidence of nodal or distant metastases.  CT of the chest, abdomen, and 
pelvis is warranted in all cases of colorectal cancer.  Additional magnetic resonance 
imaging (MRI) of the liver may be performed to assess any indeterminate lesions (SIGN 
2011).  18 Fluorine Fluorodeoxyglucose Positron Emission Tomography Computed 
Tomography (18F FDG-PETCT) is a biological imaging technique which can be used in the 
preoperative staging of colorectal cancer patients (O’Connor et al. 2011). 18F FDG-PETCT 
measures the relative net glucose uptake in tumours, which are much more metabolically 
active than surrounding normal tissue, using a nuclear tracer.  This technique is primarily 
used to characterise lesions which are indeterminate on CT and MRI imaging but can also 
detect occult metastatic disease (Jadvar et al. 2009).  
Furthermore, in rectal cancers, i.e. tumours within 15cm of the dentate line, MRI of the 
pelvis is recommended to assess the degree of local, especially circumferential, invasion, 
the proximity to the anal sphincters and determine the presence of local nodal involvement.  
It has also been suggested that endoanal ultrasound scanning (USS) may be used in the 
assessment of rectal cancers, particularly to differentiating T1 and T2 lesions when local 
excision is being considered.  However due to its operator dependency, it is recommended 
to be used in addition, rather than as an alternative (SIGN 2011).   
1.7.2 Histopathology based staging 
Following surgical resection, the tumour specimen is processed, usually after formalin 
fixation, and reported by a pathologist following the Royal College of Pathologists 
guidelines (Williams et al. 2007).  This pathological stage is the most important prognostic 
indicator and also determines to a large extent whether the patient receives subsequent 
adjuvant treatments.  Staging based on local and distant spread from bowel to lymph nodes 
in the resected specimen, as a prognostic marker in colorectal cancer, was first described 
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by Dukes and subsequently modified to include distant organ spread (Dukes et al. 1958, 
Turnbull et al. 1967).  Currently in the UK, the 5th edition of tumour node metastases 
(TNM) staging system, produced by the American Joint Committee on Cancer (AJCC) and 
adopted by the UICC, is used.  The most recent, 7th edition, of the TNM system is 
estimated to upstage patients from lymph node negative to node positive disease in around 
3% of cases, however this has been estimated to have little additional prognostic value and 
does not have as established a body of evidence of reliability as the 5th edition (Nagtegaal 
et al. 2011, Ueno et al. 2012).  Several prefixes can be added to the components of the 
TNM stage, including “c” which denotes clinical staging without pathology from a 
resected specimen, “p” which denotes pathological staging from the resected specimen, 
and “y” which denotes the use of neoadjuvant therapy. 
Table 1-3: Pathological staging and colorectal cancer specific survival (adapted from CRUK) 
Dukes stage TNM stage T stage N stage M stage 5 year CSS 
(%) 
A I T1 – T2 N0 M0 95 
B II T3 – T4 N0 M0 80 
C1 III T1 – T4 N1 M0 
66 
C2 III T3 – T4 
N1 - N2 plus 
apical node 
M0 
D IV T1 – T4 N0 – N2 M1 7 
 CSS: cancer specific survival, T1: invades submucosa,  T2: invades muscularis, T3: invades through 
muscularis but not serosa, T4: invades through serosa and/or into adjacent organs, N1: 1-3 lymph nodes 
involved, N2: >3 lymph nodes involved, M1: distant metastatic disease present      
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1.8 Pathological and tumour characteristics associated with 
outcomes 
Although tumour stage is the single most important prognostic factor in colorectal cancer, 
a number of other pathological, metabolic, molecular, and genetic characteristics of the 
tumour are known to have additional prognostic value.  This information can be used to 
stratify patients in terms of treatment and in some cases has yielded targeted therapies. 
1.8.1 Pathological characteristics 
A number of pathological features of the resected specimen have been shown to be 
associated with higher stage disease and poorer survival in patients with colorectal cancer.  
Poorly differentiated tumours have a more invasive phenotype than well and moderately 
differentiated tumours, being significantly more likely to have associated nodal 
involvement (Derwinger et al. 2010) and poorer prognosis in both colonic (O’Connell et al. 
2004) and rectal cancers (McDermott et al. 1984).  
Tumour budding, the presence of small detached groups of viable tumour cells outside of 
the main lesion, is thought to represent the invasive front of the tumour, with some 
believing it to be an important part of the endothelial to mesenchymal transformation 
pathway, and a marker of local invasiveness.  Indeed, increased presence of tumour 
budding has been reported to be associated with poorer survival in patients with node 
negative disease (van Wyk et al. 2015).   
Venous invasion has been reported to be of particular prognostic significance in patients 
with node negative disease (Roxburgh et al. 2010).  The use of elastica staining by 
immunohistochemistry (IHC) to identify blood vessels within the resected specimen has 
been shown to both increase the incidence of reported venous invasion and increase its 
prognostic ability (Roxburgh et al. 2011).  The invasion of tumour cells into, and along, the 
local nerve sheaths, known as perineural invasion, has been reported to be associated with 
local recurrence and poorer prognosis, particularly in rectal cancer (Liebig et al. 2009).  
However, its presence is not routinely reported in current UK practice.    
Both tumour involvement of the serosa (the outermost layer of the colonic wall) and true 
tumour perforation through it, are recognised to be high risk pathological features 
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associated with local and distant recurrence and poor survival (Benson et al. 2004, Stewart 
et al. 2007).  In addition, tumour involvement of the longitudinal or circumferential 
surgical margin, defined as R1 (microscopic viable tumour cells within 1mm of the cut 
edge) or R2 (grossly visible tumour at the cut edge), are strongly associated with local 
disease recurrence (Birbeck et al. 2002).   
Due in part to the number and variety of adverse pathological features, Petersen and 
colleagues developed a scoring system for prognosis (Petersen et al. 2002).  Patients are 
graded from 0 to 5 based on pathological characteristics, with a score of 2 or more 
denoting high risk, with an estimated 50 % survival at 5 years (Morris et al. 2007).  In 
addition to prognostic value, many UK MDTs use this Petersen, or Gloucester Prognostic 
Index (PI, GPI), to identify high risk Stage II patients who are then offered adjuvant 
treatment in the absence of nodal disease. 
Table 1-4: Gloucester Prognostic Index (adapted from Petersen et al. 2002) 
Pathological characteristic Score 
Peritoneal involvement 1 
Extramural venous invasion 1 
Margin involvement 1 
Tumour perforation 2 
   
1.8.2 Tumour metabolism and necrosis 
The Warburg effect is the name given to the process by which tumour cells generate a 
significant proportion of their energy through the uptake and the breakdown of glucose by 
glycolysis even in the presence of normal tissue oxygenation. Although anaerobic 
glycolysis is a far less efficient method of producing adenosine triphosphate (ATP) from 
glucose when compared to aerobic cellular respiration, the reduced reliance on a reliable 
oxygen supply may allow for cell proliferation in the hostile environment created by host 
responses (Heiden et al. 2009). 
In patients with colorectal cancer, higher glucose metabolism, as determined by 18F FDG-
PETCT, has been associated with markers of tumour proliferation (Riedl et al. 2007, Deng 
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et al. 2015), lower likelihood of down staging following neoadjuvant chemoradiotherapy 
(Calvo et al. 2013) and poorer long-term survival (Shi et al. 1991, Lau et al. 2014, Marcus 
et al. 2016).  As tumours grow they release factors which promote the ingrowth of blood 
vessels, a process known as angiogenesis.  One of the key mediators released is vascular 
endothelial growth factor (VEGF), which has been shown to be associated with reduced 
recurrence free survival in colorectal cancer at meta-analysis (Des Guetz et al. 2006).  
The presence of tumour necrosis has been reported to be associated with poorer disease 
specific survival in colorectal cancer (Pollheimer et al. 2010, Richards et al. 2012a).  
Tumour necrosis is a common finding in solid tumours, and is thought to be generated by 
tumour growth rate outstripping blood supply, leading to ischaemia.  In colorectal cancer, 
tumour necrosis has been reported to be associated with other adverse prognostic factors 
such as increasing tumour size and poor differentiation (Gao et al 2005, Pollheimer et al. 
2010).  In addition, some studies have reported an inverse association between tumour 
necrosis and the local inflammatory response (Gao et al. 2005, Knutsen et al. 2006).  
Furthermore, tumour necrosis has been associated with the preoperative host systemic 
inflammatory response in patients undergoing surgery for colorectal cancer (Richards et al. 
2012a).   
Tumour metabolism, angiogenesis, and tumour necrosis are clearly important processes in 
the growth of the primary tumour and in the development of distant metastases.  However, 
their inter-relationship, the exact mechanisms by which they influence prognosis, and their 
associations with the local and systemic host immune responses remain unclear.      
1.8.3 Molecular and genetic markers 
A variety of molecular and genetic markers have been proposed as prognostic markers in 
colorectal cancer, although only a relative few, namely carcinoembryonic antigen (CEA) 
and K-ras, have been adopted into widespread clinical practice.  
CEA is widely used as a tumour marker in colorectal cancer, particularly in the detection 
of recurrent disease during follow up after surgery (Graham et al. 1998).  This is despite 
there being very little evidence as to the impact of this kind of use on survival (Duffy 
2001).  CEA has also been considered for use in both a screening and diagnostic role in 
colorectal cancer, however its poor discriminatory ability has prevented its adoption in 
either clinical scenario (Begent 1984, Fletcher 1986)  
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K-ras, a member of the RAS family, is one of the most commonly mutated oncogenes in 
colorectal cancer (and in several other adenocarcinomas) associated with uncontrolled cell 
proliferation (Forrester et al. 1987).  Studies have reported a variable impact on prognosis 
based on K-ras mutation status (Andreyev et al. 1998, Andreyev et al. 2001, Westra et al. 
2004).  However, K-ras has found clinical use in determining the utility of the anti-EGFR 
monoclonal antibody cetuximab in patients with locally advanced and metastatic disease.  
Indeed, EGFR is itself an oncogene, associated with cellular adhesion and metastatic 
disease.  Cetuximab has been shown to increase median survival in this group of patients, 
but only in those without K-ras mutation (Karapetis et al. 2008).   
Several other genetic and molecular markers have been considered for their prognostic 
value including: p53 mutation, deleted in colorectal cancer (DDC), indices of cellular 
proliferation (most notably Ki67), carbohydrate antigen 19-9 (Ca 19-9), thymidylate 
synthase (TS), and matrix metalloproteinases (MMP).  However, heterogeneity in results 
with regard to prognostic impact has limited their use to trials in colorectal cancer 
(Graziano et al. 2003). 
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1.9 The immune response to colorectal cancer and host factors 
associated with outcomes 
It is increasingly recognised that colorectal cancer outcomes are not only determined by 
the intrinsic characteristics of the tumour itself, but also by the patient.  Some of these 
factors, such as age and the presence and severity of comorbidity, may have their impact 
through the ability or otherwise of the patient to tolerate those treatments which are 
available.  Other host factors, such as the host immune response to cancer, may have a 
more direct impact on the tumour biology and response to treatment.  The host immune 
response, at the local and systemic levels, represents the body’s intrinsic natural ability to 
detect, prevent and eradicate cancer.  As already discussed, inflammation and cancer are 
closely associated in terms of both carcinogenesis and in established cancer as one of the 
acquired key components of tumour biology which allow it to survive, proliferate and 
disseminate (Hanahan et al. 2011).  Indeed, host systemic inflammation is so closely linked 
to disease progression and metastases in cancer that it has been referred to as the “tip of the 
iceberg” (McAllister et al. 2014).  In addition, such is the evidence regarding the impact of 
the host immune response on colorectal cancer outcomes that there have been calls to both 
stage and treat this host response to determine if there is, and treat, any dysregulation 
(Diakos et al. 2014, Roxburgh et al. 2014).   
1.9.1 The host immune response 
The immune system is the body’s method of detecting and removing organisms identified 
as non-self, primarily pathogens such as bacteria, yeasts, fungi, and helminths.  It also 
targets host cells which display non-self antigens, including cells infected by viruses, and 
cancer cells.  This process of cancer immunosurveillance, or immunoediting as it has been 
more recently described, is thought to be a continuous one, with the appearance of 
individual malignant cells presenting cancer-specific antigens which are for the most part 
identified and destroyed by the immune system (Dunn et al. 2004).  In some cases, 
however, the cancer cells are not completely destroyed by the immune system and reach a 
stable existence, or equilibrium, within the host.  Subsequent evasion of the immune 
system allows growth at the primary site and eventual distant dissemination, and is thought 
to be a key step in the development of established cancer (Dunn et al. 2002).    
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The immune system is vastly complex and relatively poorly understood, with numerous 
components, each of which have multiple and complex interactions.  Numerous tissues 
form part of the immune system as a whole, including lymph nodes, the spleen, bone 
marrow and liver, alongside the considerable portion resident in circulation.  However, 
these can be thought of as falling into one of two broad parts: the innate (or non-specific) 
immune system and the adaptive (or acquired) immune system.    
The innate immune system generates a non-specific response to pathogens and tissue 
injury.  The epithelium lined body surfaces (i.e. the skin, gastrointestinal tract, respiratory 
tract and genitourinary tract) form a first-line barrier defence.  If they are breached or 
injured the innate immune system is activated.  It is comprised of both circulating humoral 
factors (namely the complement cascade), and cellular components including phagocytes 
(neutrophils and macrophages), granulocytes (basophils, eosinophils, and mast cells), and 
directly cytotoxic natural killer cells (NK).  The response is generated and directed through 
the production of small molecules known as cytokines and chemokines, as a direct result of 
tissue injury or following contact with a pathogen (Janeway et al. 2002).  Initially pro-
inflammatory mediators recruit a rapid and effective innate response, following which anti-
inflammatory mediators cause it to wane and allow the restoration of normal tissue 
structure and function (Janeway 2001).  In most circumstances, activation of the innate 
immune system also leads to activation of the adaptive immune system, e.g. through 
antigen presentation by phagocytes.      
The adaptive immune system provides a more specific response to pathogens and other 
non-self antigens, including cancer cells, and in addition provides the immune system’s 
stored “memory” of previous encounters with specific antigens.  The adaptive immune 
system is composed primarily of the lymphocytes, which mature in either the bone marrow 
(B cells) or thymus (T cells).  These lymphocytes tend to become activated through the 
presentation of non-self antigens by a group of cells known as antigen presenting cells 
(APCS) of which the neutrophils and macrophages of the innate immune system form a 
part.  B cells form part of the humoral immune system and, following activation, produce 
antibodies against the specific antigen encountered.  These antibodies can have direct toxic 
effects on pathogens but also recruit the innate immune system following antibody-antigen 
binding, both as opsonins which encourage phagocytosis and by activating the complement 
cascade.  T cells have their action through the binding of the T cell receptor (TCR) with 
non-self antigens.  T cell subsets are classified by the presentation of specific membrane 
proteins linked to TCR binding, called cluster determinants (CD).  The subset of T cells 
  
 
63 
 
which are the primary effectors of this specific cell mediated immune response are the 
cytotoxic T cells (CD8+), which upon TCR binding produce cytotoxins.  A number of 
other subsets of T cells exist, each with specific roles including antigen presentation 
(CD4+ helper T cells), antigen memory (CD45R0+ memory T cells), and regulation of the 
adaptive immune response (FOXP3+ T regs). 
In general, the adaptive immune system is regarded as that which has the most important 
role to play in cancer immunoediting.  Indeed, it is thought that innate immune driven 
inflammation can promote tumour progression, in part through suppression of the adaptive 
response (Qian et al. 2010). 
1.9.2 The local inflammatory response 
For a considerable time, the local inflammatory response, i.e. the extent and type of intra- 
and peri-tumoural immune infiltration, has been thought to relate to the effectiveness of the 
host’s antitumour immunity and thus disease prognosis (House et al. 1979).  As time goes 
on it is increasingly appreciated that the interaction between tumour cells, the local 
inflammatory infiltrate, and the tumour microenvironment (the medium in which the 
tumour cells develop or otherwise) is important in terms of prognosis and as a potential 
therapeutic target.  In general, the presence of a strong, adaptive or lymphocytic 
inflammatory infiltrate at the local level is associated with a good prognosis (Jass 1986).  
This has been defined in multiple ways as described in more detail below.  In contrast, 
local infiltration by cells of the innate response, including tumour associated macrophages 
(TAMs) and neutrophils, is thought to result in a pro-tumour environment and poorer 
prognosis (Kim et al. 2016).  
1.9.2.1 Crohn’s like reaction 
Following on from the work of Jass, the term “Crohn’s like reaction” (CLR) was coined to 
describe aggregates of lymphocytes around the tumour which were associated with 
improved prognosis in colorectal cancer (Graham et al. 1990).  It is of interest that this 
CLR is now often described in the context of MSI-H tumours, and that this has in part led 
to MSI-H and CIMP tumours falling into the “Immune” colorectal cancer subtype.  
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1.9.2.2 Klintrup-Makinen grade 
The Klintrup-Makinen grade is a semi-quantitative method of grading the generalised 
inflammatory infiltrate, primarily at the invasive margin, using haematoxylin and eosin 
(H&E) stained slides (Klintrup et al. 2005).  The initial study reported a significant 
association between a high grade inflammatory infiltrate and improved prognosis in 
colorectal cancer patients, a finding which has since been externally validated (Roxburgh 
et al. 2009).   
1.9.2.3 Galon Immunoscore 
The Galon Immunoscore utilises immunohistochemistry and assigns scores based on the 
density of CD8+ and CD3+ T cells in the tumour and at the invasive margin.  Those 
patients with a strong infiltrate at both locations have been shown to have a better 
prognosis, and a reduced risk of colorectal cancer recurrence after surgery than those with 
weaker infiltrates (Galon et al. 2006, Mlecnik et al. 2011).   There is some evidence to 
suggest that this method of assessing the local adaptive immune response provides greater 
prognostic accuracy than that of the Klintrup-Makinen grade alone (Park et al. 2016a).  
1.9.2.4 The tumour microenvironment 
The tumour microenvironment forms the true interface between cancer and host. It is 
composed of the infiltrating immune cells, blood vessels, and the extracellular matrix and 
supporting cells of the tumour stroma.  An expanded tumour stroma has been reported to 
be associated with poorer prognosis, however the mechanism by which it may facilitate 
tumour progression has not been fully elucidated.  Several theories include factors from the 
stroma influencing local and systemic inflammation, tumour pH, and tumour metabolism 
(Park et al. 2016a).  Tumour cells favour glycolysis as a method of glucose metabolism, 
even in the presence of normoxia (Vander Heiden et al. 2009). Indeed, this phenomenon 
termed the Warburg effect may be facilitated by the tumour-supporting stroma. It has 
previously been reported that in patients with colorectal cancer, increased tumour cell 
expression of enzyme pathways associated with anaerobic metabolism and lactate 
extrusion - including lactate dehydrogenase isoenzyme 5 (LDH 5), hypoxia inducible 
factor (HIF) and monocarboxylate transporter 1 (MCT1) - was associated with an increase 
in the ability of cancer associated fibroblasts to uptake and oxidise lactate, suggesting a 
reciprocal role in supporting tumour cell metabolism (Giatromanolaki et al. 2007).   
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1.9.2.5 The Glasgow Microenvironment Score 
As already discussed, the presence of a strong inflammatory cell infiltrate, as assessed by 
the Klintrup-Makinen grade and by the Galon Immunoscore, is associated with improved 
survival in colorectal cancer (Richards et al. 2014).  Recently, the degree of tumour stroma 
expansion, as defined by tumour stroma percentage (TSP), has been reported to further 
stratify survival in those patients with a weak inflammatory cell infiltrate as defined by the 
Klintrup-Makinen grade (Table 1.2), leading to the creation of the Glasgow 
Microenvironment Score (GMS) (Park et al. 2015, Park et al. 2016a).   
Table 1-5: The Glasgow Microenvironment Score (GMS) and its association with 5 year survival 
following surgery for stage I-III colorectal cancer (adapted from Park et al. 2015) 
GMS K-M TSP 5 year CSS 
0 strong - 89% 
1 weak low 75% 
2 weak high 51% 
GMS Glasgow Microenvironment Score, K-M Klintrup-Makinen grade, TSP tumour stroma percentage, CSS 
cancer specific survival 
1.9.2.6 Faecal calprotectin 
Calprotectin is a calcium and zinc binding protein of the S-100 family which is found in 
both serum and stool.  It has both antimicrobial and apoptotic properties and is associated 
with gastrointestinal inflammation (Sherwood 2012).  Indeed, faecal calprotectin is now a 
widely clinically used biomarker primarily in the monitoring of inflammatory bowel 
disease (Mowat et al. 2016).  The use of faecal calprotectin in the diagnosis and disease 
monitoring of colorectal cancer has also been studied, however no consensus exists as to 
its use and its place amongst other established methods of screening, detection, and 
monitoring (Kristinsson et al. 1998, Limburg et al. 2003, Hoff et al. 2004). 
1.9.3 The systemic inflammatory response 
The systemic inflammatory or “acute phase” response is a significant mobilisation, 
predominantly of the non-specific innate immune system, as a result of tissue injury or the 
presence of pathogens (Gabay et al. 1999).  It temporarily replaces normal homeostasis and 
is, at first, a useful process which aims to neutralize pathogens and promote tissue healing 
before anti-inflammatory processes become dominant and the acute phase wanes.  
Systemic inflammation involves numerous cell types, cytokines, and acute phase proteins.  
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The process is regulated by a balance of cytokine production at different times, with pro-
inflammatory cells such as neutrophils and macrophages, and cytokines such as interleukin 
(IL) 1, IL 6, tumour necrosis factor (TNF) α and IGF-1 balanced by the anti-inflammatory 
regulatory cells and cytokines, such as IL 4 and IL 10.  In some cases, however, the 
balance between pro- and anti-inflammatory processes is lost, leading to prolonged and 
excessive inflammation which can be deleterious in its effects and is discussed in more 
detail below (Bone 1999).  The presence of a prolonged and inappropriate systemic 
inflammatory response has been described in a variety of solid tumours and is almost 
universally associated with poor prognosis (McMillan 2013).  This response may be 
produced and maintained through the production of proinflammatory cytokines and 
mediators by the tumour cells themselves as they bid to proliferate and invade, or by the 
peritumoural and intratumoural infiltrating cells of the immune system (Burke et al. 1996, 
Koong et al. 2000).  It is hypothesised that the presence of an innate inflammatory 
response inhibits the more useful, in terms of anti-tumour activity, adaptive immune 
response (Roxburgh et al. 2013).  The presence and magnitude of the systemic 
inflammatory response has been measured and defined in numerous ways and using many 
individual or combined components of the immune response, as discussed below. 
1.9.3.1 C-reactive protein 
C-reactive protein (CRP) is one of the family of pentraxins, discovered in 1930 and so 
named due to its reactivity with the pneumococcal C-polysaccharide (Gabay et al. 1999).  
It is a positive acute phase protein (Figure 1.2), and is perhaps currently the most widely 
clinically used marker of the systemic inflammatory response, although others such as 
erythrocyte sedimentation rate (ESR), white cell count (WCC) and procalcitonin are also in 
use.  CRP is produced by hepatocytes following IL 6 secretion by macrophages and T 
cells.  Its physiological role is to bind to lysophosphatidylcholine expressed on the surface 
of dying or damaged cells and some bacterial cell membranes.  It acts as an opsonin and 
also activates the complement cascade, aiding further recruitment of the innate immune 
system.  The presence of a raised preoperative CRP, at a variety of concentrations, in 
resectable colorectal cancer has widely been reported to be associated with poorer 
prognosis independent of disease stage (Nozoe et al. 1998, Nielsen et al. 2000, McMillan 
et al. 2003).  Furthermore, CRP concentrations in the postoperative period have been 
reported to be associated with anastomotic leak and other infective complications 
following colorectal resection as discussed later.  
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1.9.3.2 Albumin 
Albumin is the most prevalent plasma transport protein and a negative acute phase reactant 
(Figure 1.2).  Low preoperative concentrations of serum albumin have been reported to be 
associated with poor prognosis in resected rectal and colon cancer (Longo et al. 1998, 
Cengiz et al. 2006). 
1.9.3.3 The Glasgow Prognostic Scores 
The Glasgow Prognostic Scores combine preoperative threshold values of serum CRP 
(>10mg/L) and albumin (<35g/L) to stratify the prognostic significance of each 
component.  Both the original score (GPS) and modified GPS (Table 1.3) are 
independently prognostic in colorectal cancer and a variety of solid tumours (McMillan 
2013).  Indeed, the mGPS has recently been reported to stratify prognosis within patients 
of the same TNM stage (Park et al. 2016b).  Furthermore, with the development of high-
sensitivity serum CRP determination, the high sensitivity mGPS (hs-mGPS) has also been 
described using a CRP threshold of 3mg/L (Proctor et al. 2013).  In particular, it has gained 
favour in studies conducted in Asian populations, as prior reports suggest a much lower 
incidence of cancer related inflammation in this particular ethnic group when the 
traditional CRP thresholds were applied (Kobayashi et al. 2010, Jiang et al. 2012). 
Table 1-6: The original and modified Glasgow Prognostic Scores and their association with survival 
in patients following surgery for colorectal cancer (modified from McMillan et al. 2007) 
Biochemical results Points 
allocated 
3 year 
CSS (%) 
GPS   
CRP <10mg/L and albumin >35g/L 0 90 
CRP <10mg/L and albumin <35g/L 1 94 
CRP >10mg/L and albumin >35g/L 1 62 
CRP >10mg/L and albumin <35g/L 2 50 
   
mGPS   
CRP <10mg/L 0 91 
CRP >10mg/L and albumin >35g/L 1 75 
CRP >10mg/L and albumin <35g/L 2 52 
GPS Glasgow Prognostic Score, mGPS modified Glasgow Prognostic Score, CRP C-reactive protein 
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1.9.3.4 White cell count 
Total circulating white cell count (WCC) is a common laboratory measure of the systemic 
inflammatory response and itself has been reported to be associated with mortality in 
patients with cancer (Shankar et al. 2006).  In addition, the components of the circulating 
white cell population, along with a number of ratios and scoring systems based on their 
concentrations, have been reported to be prognostic. 
1.9.3.5 Neutrophils and the neutrophil lymphocyte ratio 
Neutrophils make up the majority of the circulating white cell population and are the key 
effector cells of the innate immune system.  The ratio of neutrophils to lymphocytes (NLR) 
is an indicator of the magnitude of an immune response and an indicator as to whether it is 
predominantly innate or adaptive.  NLR, in particular at ratios of greater than 3, or in other 
reports greater than 5, has been reported to be prognostic in colorectal cancer independent 
of stage (Guthrie et al. 2013).  However, more recent evidence suggests that neutrophils 
are the most important component of the two, and that lymphocytes add little extra 
prognostic value (Watt et al. 2015a).  
1.9.3.6 Platelets and the platelet lymphocyte ratio 
Thrombocytosis is, in itself, a sensitive marker of systemic inflammation, and its ratio with 
lymphocytes (PLR) is associated with prognosis in several gastrointestinal cancers (Smith 
et al. 2008).  
1.9.3.7 Monocytes and the lymphocyte monocyte ratio 
The lymphocyte monocyte ratio (LMR) represents another method of assessing the 
magnitude and balance of a cancer immune response which has been reported to be of 
greater prognostic value in resected colorectal cancer when compared to the mGPS, NLR, 
and PLR (Chan et al. 2016).  However, the primary endpoint in that particular study was 
overall survival and a more useful comparison in terms of disease specific survival has yet 
to be published. 
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1.9.3.8 Neutrophil platelet score 
The neutrophil platelet score (NPS) combines two components of the innate immune 
response, each with prognostic significance, and has been reported to further stratify 
survival independent of stage (Watt et al. 2015b). 
Table 1-7: The Neutrophil Platelet Score (NPS) and its association with survival in patients with 
resected colorectal cancer (adapted from Watt et al. 2015) 
Haematological results Points 
allocated 
5 year 
CSS (%) 
Neutrophils < 7.5x109/L and platelets < 400x109/L 0 79 
Neutrophils > 7.5x109/L or platelets > 400x109/L 1 69 
Neutrophils > 7.5x109/L and platelets > 400x109/L 2 65 
CSS cancer specific survival 
1.9.4 Cancer cachexia 
Disease progression in cancer is often associated with a gradual process of involuntary loss 
of weight, muscle mass, and function, an entity known as cachexia (Aapro et al. 2014).  
Indeed, cancer cachexia is recognised to be a poor prognostic factor in a variety of tumours 
(Trajkovic-Vidakovic et al. 2012).  Definitions of cancer cachexia have traditionally 
focused on loss of weight or changes in body mass index (BMI), however as the overall 
weight of the world’s population increases, measures of body composition have been 
recognised to be more useful (Martin et al. 2013).  In particular, it has been recognised that 
the loss of both the quantity and quality of lean tissue is especially prognostic in colorectal 
cancer (Malietzis et al. 2016a).  Furthermore, recent evidence suggests that systemic 
inflammation may be a key underlying mechanism driving this catabolic process, however 
its exact nature is uncertain (Douglas et al. 2014, Malietzis et al. 2016b). 
1.9.5 Anaemia 
Anaemia is commonly defined as haemoglobin (Hb) concentrations of <11g/dL in women 
and <13g/dL in men (WHO 2004).  Anaemia has been reported to be present 
preoperatively in as many as 80% of patients with advanced disease (Knight et al. 2004), 
and is associated with both poorer outcomes (Leitchle et al. 2011) and poorer response to 
chemotherapy (Tampellini et al. 2006).  Classically, colorectal cancer has been associated 
with iron deficiency anaemia secondary to frank or occult gastrointestinal blood loss.  Iron 
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deficiency is defined as: serum ferritin <15μg/L, transferrin saturation <16%, or an Hb 
increase of 1g/dL after 1-2 months of iron supplementation (although values vary with 
pregnancy and ethnicity) (WHO 2001).  However, systemic inflammation is associated 
with functional iron deficiency (FID).  FID is a state in which iron is inadequately 
incorporated into erythroid precursors despite sufficient iron stores. This may occur in 
patients with infectious, inflammatory or malignant conditions and is a major component 
of the anaemia of chronic disease (Thomas et al. 2013). This process is believed to be 
mediated by the inhibition of the iron transport protein ferroportin due to the influence of 
IL 6 on hepcidin, a key regulator of iron homeostasis (vonDrygalski et al. 2013).  
Diagnosis of iron deficiency becomes problematic as ferritin and iron study results are 
affected by systemic inflammation.  Therefore, many patients with colorectal cancer who 
are inflamed may in fact have FID rather than true iron deficient anaemia, although there is 
little data to this effect in terms of either the degree of derangement of measures of iron 
status, or the prevalence within patients with colorectal cancer.   
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1.10 The postoperative systemic inflammatory response in 
colorectal cancer 
The body’s natural response to any physical trauma, including that of surgery, is to initiate 
a stereotypical neurohormonal and inflammatory response.  If this response is appropriate 
in terms of both its duration and magnitude, it seeks initially to stabilise the patient’s 
physiology and then promote healing: the return to normal tissue structure and function 
(Cuthbertson 1979).  However, if the duration of the response is too long, or the magnitude 
of the response too great, this can have a negative impact on short- and long-term 
outcomes following surgery for colorectal cancer.    
1.10.1 Local response to surgery  
The complex local response to tissue injury is usually divided into four phases: 
coagulative, inflammatory, proliferative, and remodelling (Stadelmann et al. 1998a).  The 
initial phase is that of haemostasis through activation of the clotting cascade, followed by 
the creation of a locally pro-inflammatory environment.  The processes of vasodilatation, 
cellular adhesion, and diapedesis, enhanced by factors released by damaged cells and 
activation of the complement cascade, encourage the influx of neutrophils and 
macrophages to the injured area.  These myeloid cells neutralize any pathogens which have 
entered the area and remove damaged cells and tissue.  This is almost immediately 
followed by an anti-inflammatory response which causes the inflammatory phase of the 
wound healing process to wane.  During the proliferative and remodelling phases, 
fibroblasts and myofibroblasts are recruited to produce collagen and elastin, in the case of 
granulation tissue, and where possible stem cell division replaces tissue like for like.  A 
number of factors can contribute to delayed healing of such wounds including 
insufficiency of the local vascular supply, diabetes mellitus, infection, and 
immunosuppressive and anti-inflammatory drugs (Stadelmann et al. 1998b).  
1.10.2 Systemic inflammatory or “stress” response to surgery 
Alongside the local response to trauma, a combined systemic neuroendocrine and 
inflammatory response occurs to varying degrees (Baigrie et al. 1992).  As with the local 
inflammatory response, the evolutionary goal of this process is to return the patient to 
normal homeostasis and promote healing.  Initially, activation of the clotting cascade leads 
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to thrombocytosis.  Activation of the sympathetic nervous system, through direct effects 
and the release of catecholamines by the adrenal medulla, initially causes cardiovascular 
responses, such as tachycardia and vasoconstriction, and respiratory responses, such as 
tachypnoea and increased tidal volumes.  Changes in renal perfusion lead to the activation 
of the renin-angiotensin-aldosterone system (RAAS) which leads to increased reabsorption 
of filtered sodium and water with the net result of oliguria.  The hypothalamic-pituitary-
adrenal (HPA) axis is activated, leading to the production of the stress hormone cortisol by 
the adrenal cortex.  Pro-inflammatory cytokines are released by damaged tissue and by 
activated cells of the innate immune system, which in turn lead to an increase in the 
number of circulating neutrophils and macrophages.  Pro-inflammatory cytokines such as 
TNF α, IL 1 and IL 6, drive rapid changes in the synthesis of the positive and negative 
acute phase proteins by the liver, including CRP, albumin, transferrin, and ferritin.  
Catabolism of lean tissue provides the required energy and substrates. 
Figure 1-2: Change in plasma concentrations of some acute phase proteins after a moderate 
inflammatory stimulus (adapted from Gabay and Kushner 1999) 
Plasma concentrations of IL 6 and CRP have been shown to be reliable and reproducible 
markers of the magnitude of the postoperative systemic inflammatory/stress response 
following surgery across a wide variety of operation types and surgical specialities (Watt et 
al. 2015c).  They have been shown to be superior to various other cytokines, acute phase 
proteins, white blood cell and haematological parameters, and circulating stress hormones 
in stratifying the magnitude of surgical trauma across various operations and surgical 
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specialities.  IL 6 peaks at around 24 hours postoperatively, but due to costs and techniques 
has not been adopted into wide-spread clinical practice as of yet, remaining a research tool 
(Sakamoto et al. 1994).  CRP, in contrast, is routinely measured and available in the 
clinical setting, usually peaking between 48 and 72 hours after surgery. 
As with the local response, a systemic anti-inflammatory response then replaces the pro-
inflammatory, allowing a gradual return to normal homeostasis and physiology.   
1.10.3 Immunologic dissonance 
In some cases, the balance between the pro- and anti-inflammatory responses is lost 
(immunologic dissonance) and the systemic inflammatory response becomes either 
overwhelming or persistent.  The exaggerated pro-inflammatory response drives 
cardiovascular, respiratory and metabolic effects which can lead to the development of the 
Systemic Inflammatory Response Syndrome (SIRS), shock, and end organ dysfunction 
(Bone et al. 1992). 
The Compensatory Anti-Inflammatory Response Syndrome (CARS), in contrast, can lead 
to a relative state of immunosuppression (Bone 1996).  In the immediate postoperative 
period, this can lead to a greater susceptibility to infective complications.  Furthermore, in 
the case of colorectal cancer, this state is thought to promote tumour recurrence and 
metastasis (Colotta et al. 2009).  One of the mechanisms by which this is hypothesised to 
happen is through neutrophil dysfunction (Leliefeld et al. 2016).  The impact of 
immunological dissonance is thought to render neutrophils less effective in terms of their 
innate anti-pathogen activity, and also causes them to suppress adaptive anti-tumour 
effector cells. 
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Table 1-8: Criteria for the Systemic Inflammatory Response Syndrome (SIRS): score >1 (adapted 
from Bone et al. 1992) 
Physiological parameter Threshold Score 
Temperature >38C or <36C 1 
Heart rate >90 beats per minute 1 
Respiratory rate >20 breaths per minute or 
-PaCO2 <32mmHg 
1 
White cell count >12 or <4 x109/L 1 
C Celsius, PaCO2 partial pressure of carbon dioxide 
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Figure 1-3: Outline of the processes leading to the Systemic Inflammatory Response Syndrome (SIRS), 
Compensatory Anti-Inflammatory Response Syndrome (CARS) and immunologic dissonance after 
surgery (adapted from Bone 1996) 
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1.10.4 Factors known to modulate the postoperative systemic 
inflammatory response 
If the magnitude of the postoperative systemic inflammatory response is thought to have an 
impact on both complications and disease recurrence after surgery for colorectal cancer 
then an understanding of those factors, modifiable and non-modifiable, which determine or 
modify it is clearly desirable.   
There is good evidence that laparoscopic and other minimally invasive surgical techniques 
results in a lower postoperative systemic inflammatory response than traditional open 
abdominal surgery across a variety of specialities including colorectal surgery (Watt et al. 
2015c).  Whether this simply relates to the smaller abdominal wounds required, or whether 
other factors such as the use of carbon dioxide for insufflation, or the no-touch isolation 
technique generally used, remains unclear. 
There is some interest in factors surrounding perioperative care that might be targeted in a 
bid to modify the postoperative systemic inflammatory response.  A number of general 
anaesthetic agents including propofol, and volatile anaesthetics, are thought to have an 
impact on both the immune system in the perioperative period and long-term oncologic 
outcomes (Piegeler et al. 2016).  The use of regional anaesthetic technique may be 
important, with both the use of epidural anaesthesia in addition to general anaesthesia 
(Chen et al. 2015), and the use of intravenous lignocaine (Sridhar et al. 2014), reported to 
be associated with lower postoperative CRP concentrations after abdominal surgery.   
Enhanced Recovery After Surgery (ERAS) and other “fast-track” perioperative protocols 
were introduced with the aim of reducing postoperative length of stay and morbidity, 
through a reduction in the postoperative stress response, and earlier return to normal 
function (Lassen et al. 2009).  Despite this, there is very little evidence that commonly 
used components of these protocols actually have any impact on the postoperative systemic 
inflammatory response (Watt et al. 2015d).  Two studies examining the impact of goal 
directed fluid therapy on postoperative IL 6 after major gastrointestinal surgery reported 
conflicting results (Wakeling et al. 2005, Noblett et al. 2006).  A single randomised 
controlled trial investigating preoperative carbohydrate loading reported no significant 
association with postoperative IL 6 or CRP in patients undergoing major abdominal 
surgery (Mathur et al. 2010).  No studies have reported the impact of other ERAS 
components, including mechanical bowel preparation, antibiotics prophylaxis, early enteral 
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nutrition, early mobilisation, the avoidance of routine nasogastric and peritoneal drainage, 
and the postoperative systemic inflammatory response (Watt et al. 2015d).      
With regard to patient factors which might influence the magnitude of the postoperative 
systemic inflammatory response, there is some preliminary evidence that emergency 
presentation, preoperative systemic inflammation, BMI, and co-morbid state may play a 
role (Ramanathan 2015).  Modifiable patient risk factors present multiple potential targets 
for intervention, however, the exact nature of these underlying relationships need to be 
clarified prior to such future studies.    
1.10.5 Association with postoperative complications 
In line with hypotheses regarding immunologic dissonance, there is increasing evidence 
that the magnitude of the postoperative systemic inflammatory response is associated with 
complications following colorectal surgery.  In particular, there have been significant 
attempts to predict the presence of developing complications prior to the onset of obvious 
clinical symptoms and signs using CRP concentrations in the early postoperative period 
(Adamina et al. 2015).  Much of the focus has been on the early detection of anastomotic 
leak and infective complications, discussed in more detail below (Platt et al. 2012).  
Clinically relevant thresholds have been sought, with varying values on varying 
postoperative days promoted by different interested groups (Ramanathan et al. 2013, Singh 
et al. 2014a).  Such threshold values of CRP have been found to have a high negative 
predictive value but a poor positive predictive value in terms of both complications and 
readmission after colorectal surgery (Table 1-9).  Furthermore, although laparoscopic 
surgery has been shown to be associated with a lower postoperative systemic inflammatory 
response, the postoperative CRP thresholds used for the prediction of postoperative 
infective complications remain the same as those used in open surgery (Ramanathan et al. 
2015b).   More recently, a consensus review has suggested that exceeding a CRP 
concentration of 150mg/L on postoperative days 3 to 5 after colorectal surgery should both 
prompt further investigation for potential complications, and prevent early discharge from 
hospital (McDermott et al. 2015).  In addition, other studies have investigated the use of 
other markers associated with the development of postoperative complications, for 
example procalcitonin, however the IMACORS study reported that CRP was more 
accurate in the detection of postoperative infective complications following colorectal 
surgery (Facy et al. 2016). Furthermore, it has long been recognised that albumin is also a 
marker of the postoperative stress response (Gabay and Kushner 1999) and is associated 
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with postoperative complications and mortality (Gibbs et al. 1999). It remains to be 
determined whether albumin, in terms of predicting postoperative complication, offers 
additional predictive or prognostic value in addition to that of CRP.  Indeed, several issues 
remain to be determined.  Is type or severity of complication more important in terms of 
the postoperative systemic inflammatory response, and longer term outcomes?  Also, is 
there a causal relationship between the magnitude of the postoperative systemic 
inflammatory response and complications, or is one simply an epiphenomenon of the 
other?  
Table 1-9: Meta-analytic data reporting accuracy of C-reactive protein to detect complications 
following colorectal (adapted from Singh et al. 2014) and abdominal (adapted from Adamina et al. 
2015) surgery 
Complication 
Type 
POD n Prevalance 
(%) 
CRP cut off 
(mg/L) 
AUC Sens 
 (%) 
Spec 
 (%) 
NPV 
(%) 
PPV 
(%) 
Anastomotic 
leak 
                  
  3 2,126 7.9 172 0.81 76 76 97 21 
  4 1,987 9.1 124 0.80 79 70 97 21 
                    
Infective 
complication 
                  
  3 507 38 169 0.70 61 70 82 46 
  4 624 34 96 0.76 76 61 86 45 
POD postoperative day, CRP C-reactive protein, AUC area under the curve, NPV negative 
predictive value, PPV positive predictive value, Sens sensitivity, Spec specificity   
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1.11 Complications following surgery for colorectal cancer 
Surgical resection continues to be the mainstay of treatment for colorectal cancer. 
However, it is associated with a significant level of postoperative complication and 
morbidity. These postoperative complications are associated with increased postoperative 
mortality, poorer quality of life after surgery, and a significant health care and societal cost 
(Ghaferi et al. 2011).  It has also been increasingly recognised that these postoperative 
complications may not only have negative implications for short-term outcomes, but also 
for oncologic outcomes (Law et al. 2007a, Law et al. 2007b, Mirnezami et al. 2011) and 
long-term survival (McArdle et al. 2005, Khuri et al. 2005, Pucher et al. 2014).  
Postoperative complications can be described as “deviation from the normal postoperative 
course” (Dindo et al. 2004). They have been classified in a number of ways.  Variation in 
classification of complications has important implications in both clinical and research 
practice due to the ability to directly compare outcomes, and with regard to the underlying 
mechanisms linking complications to short and long-term outcomes.  
1.11.1 Classification by type 
Complications have been traditionally classified by type, in a descriptive manner.  
Following this, particular interest arose in infective type complications, with studies 
reporting that this sub group of complications had a negative impact on long-term 
oncologic outcomes (Law et al. 2007a, Nespoli et al. 2004).  Some further considered the 
site of infection (Law et al. 2007a, Khuri et al. 2005, Miki et al. 2006, Tsujimoto et al. 
2010), reporting that intra-abdominal and pulmonary infective complications had a greater 
impact on long-term outcomes than wound infections. 
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Table 1-10: Type of complications: accepted definitions of infective complications 
Type Location Complication Definition 
Infective    
 SSI wound infection The presence of pus in the wound either 
discharging spontaneously or requiring drainage 
  anastomotic 
leak 
Anastomotic defect diagnosed radiologically, at 
endoscopy or laparotomy 
  intra-abdominal 
collection 
Surgical or radiologically guided aspiration of 
pus from abdominal cavity 
 RSI pneumonia Fever above 38.5C, or SIRS, associated with 
positive chest x-ray findings 
  septicaemia SIRS with positive blood culture 
  UTI Lower urinary tract symptoms, or fever, with 
positive urinalysis and/or urine culture 
Non-
infective 
   
 wound seroma Sterile superficial wound collection without 
fever or surrounding cellulitis 
  dehiscence Deep or superficial separation of the wound 
without fever, pus or surrounding cellulitis 
 surgical 
site 
haemorrhage Bleeding requiring radiological or operative 
intervention 
 cardiac MI Myocardial ischaemia causing ECG changes 
and raised cardiac enzymes/markers 
  arrhythmia New, resting ECG arrhythmia, requiring 
medical intervention 
 vascular VTE Deep or pulmonary venous thrombosis with 
clinical symptoms, confirmed radiologically 
  CVA Persistent focal neurological deficit with 
radiological evidence of cerebral vascular 
territory infarction 
 urinary renal failure Oliguria/anuria with decreasing GFR, with or 
without need for renal replacement therapy 
  acute urinary 
retention 
Painful/painless anuria with inability to void 
requiring urinary catheterisation 
 GI ileus Paralytic/non-mechanical small bowel 
obstruction 
SSI: surgical site infection, RSI: remote site infection, SIRS: systemic inflammatory response syndrome, 
UTI: urinary tract infection, MI: myocardial infarction, ECG: electrocardiogram, VTE: venous 
thromboembolism, CVA: cerebrovascular accident, GFR: glomerular filtration rate, GI: gastrointestinal 
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1.11.2 Classification by severity  
Postoperative complications are increasingly described by their severity, for example as 
“minor” and “major” based on pre-defined diagnoses or their perceived significance 
(Rutegard et al. 2012). In particular, a recently developed method is to describe the 
severity of a complication objectively based on the action taken by the surgical team to 
remedy it (Dindo et al. 2004). This Clavien Dindo scale has become increasingly popular 
and has been validated across various surgical specialities, professionals, and countries 
(Clavien et al. 2009). Initial applications in other cancer types have shown that 
increasingly severe complications have a negative impact on long-term outcomes 
(Petermann et al. 2013). 
Table 1-11: Severity of postoperative complications: the Clavien Dindo scale (adapted from Dindo et 
al. 2004) 
Clavien Dindo 
grade 
Description 
0  No complication 
1 
 
Any deviation from the normal postoperative course without the 
need for pharmacological treatment or surgical, endoscopic and 
radiological interventions.  Acceptable therapeutic regimens are: 
drugs such as antiemetics, antipyretics, analgesics, diuretics, 
electrolytes and physiotherapy.  This grade also includes wound 
infections opened at the bedside. 
2 
 
Requiring pharmacological treatment with drugs other than such 
allowed for grade 1 complications 
3  Requiring surgical, endoscopic, or radiological intervention 
 3A Intervention not under general anaesthesia 
 3B Intervention under general anaesthesia 
4 
 
Life threatening complication requiring ICU management including 
CNS complications 
 4A Single organ dysfunction (including dialysis) 
 4B Multi organ dysfunction 
5  Death 
ICU: intensive care unit, CNS: central nervous system 
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1.11.3 Meta-analysis of impact of complication type and severity on long 
term outcomes after surgery for colorectal cancer and colorectal 
liver metastases 
This systematic review of published literature was conducted with two primary areas of 
interest; the impact of type of complications (infective compared to non-infective 
complications) and the impact of severity of complications (as defined by the Clavien 
Dindo scale) on long-term outcome following surgery for colorectal cancer.  There was 
also a secondary interest in whether both definitions were capturing the same underlying 
mechanistic process that was impacting long-term outcomes. 
A literature search was made of the US National Library of Medicine (MEDLINE), 
PubMed, the Cochrane Database of Systematic Reviews (CDSR) and Web of Science 
(WoS) databases from inception to 22nd October 2014.  The following search term  was 
used in free text and medical subject heading (MeSH) “colorectal AND (cancer OR 
metastases) AND (surgery OR resection) AND (complications OR morbidity) AND 
((infective OR infectious) OR (severity OR Clavien OR Dindo)) AND ((long-term AND 
outcome) OR survival)”.  This search term was chosen following a number of pilot 
searches using more inclusive terms that returned large numbers of abstracts which on 
initial assessment were irrelevant to the present review topic. 
The title and abstracts of all studies returned by the search were examined for relevance.  
Animal and pre-clinical studies were not considered.  Review articles, non-English papers, 
duplicate data sets and abstract only results were excluded.  The full text of each study 
deemed potentially relevant was obtained and analysed.  To be included a study had to 
examine the impact of complications following surgery for colorectal cancer on disease 
free survival or long-term overall survival in terms of either infective and non-infective 
type complications, or of severity defined by Clavien Dindo complication scale.  Reference 
lists of included papers were hand searched for additional relevant studies.  Selection and 
extraction was completed by one author (SM) with any uncertainties resolved by 
discussion with the senior author (DM).   
Data analysis was performed using Review Manager version 5.3 (The Nordic Cochrane 
Centre, The Cochrane Collaboration, Copenhagen, Denmark,).  Meta-analysis of overall 
and disease free survival was undertaken in terms of complication type and severity 
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individually.  Hazard Ratios (HRs) for each survival outcome, from each study, were 
combined using a random effects model to account for variability in methodology and 
complication reporting.  The Z test was used to assess the overall impact of complication 
type and severity on long-term outcomes.  Heterogeneity was assessed by the I2 test and 
two-tailed p-values <0.05 were considered to be statistically significant.  Publication bias 
was assessed using funnel plots.  The review methodology and reporting was designed and 
completed in keeping with the PRISMA statement (Moher et al. 2010) 
1.11.4 Impact on long term outcomes 
Fourteen studies have reported the impact of postoperative complications by either their 
type, or severity, on survival after surgery for colorectal cancer, or colorectal liver 
metastases. 
1.11.4.1 Complication type 
Two studies (Artinyan et al. 2014, Richards et al. 2011), with 12,498 patients, directly 
compared infective and non-infective complications and their impact on long-term 
outcomes after colorectal resection for cancer. The largest study (n=12,075), by Artinyan 
et al. (2014), examined only the effect on 5 year overall survival, finding a poorer median 
survival when those with infective complications (32.9 months, HR 1.31, p<0.001) were 
compared with those with non-infective complications (39.9 months, HR 1.05, p=0.510) 
and with those with no complications (41.9 months). Richards et al. (2011) (n=423) found 
no significant impact on either disease free survival (HR 1.06, p=0.762) or overall survival 
(HR 1.26, p=0.163) when comparing those with infective complications after colorectal 
resection to those without.  Two studies (Farid et al. 2010, Neal et al. 2011), with a total 
907 patients examined the effect of infective and non-infective complications on long term 
outcome after hepatic resection of colorectal liver metastases. Farid et al. (2010) (n=705) 
reported that both those with infective complications (HR 1.60, p<0.001) and non-infective 
complications (HR 1.98, p<0.001) had a lower 5 year overall survival compared with those 
with no complications.  They reported a similar decrease in disease free survival amongst 
those with infective complications (HR 1.53, p=0.004) but not those with non-infective 
complications (HR 1.25, p=0.099). Neal et al. (2011) (n=202) also found that, when 
compared to those with no complications, those with infective complications had poorer 
disease free survival (HR 1.72, p = 0.010) and poorer 5 year over-all survival (HR 1.86, 
p=0.01). However, no significant difference was found in disease free survival (HR 0.98, 
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p=0.94) or overall survival (HR 1.37, p=0.4) in those with non-infective complications. 
Both Farid et al. (2010) and Neal et al. (2011) found that wound infection had no 
significant effect on disease free survival (p=0.178 and p=0.650 respectively) or overall 
survival (p=0.658 and p=0.260, respectively). Neal et al. (2011) demonstrated that all other 
infective complications (i.e. non-wound) decreased disease free survival (p=0.005) and 
overall survival (p=0.020) significantly. Farid et al. (2010) further divided non-wound 
complications into respiratory infections and intra-abdominal infections, finding both to 
have a negative impact on disease free survival (p=0.005 and p=0.039, respectively) and 
overall survival (p=0.001 and p<0.001). 
Table 1-12: Studies comparing the impact of complication type on long term outcome 
Type Author Country Year N Effect of infective and non-infective 
complications compared to no complication on 
outcomes 
DFS OS 
Colorectal       
 Richards et al. UK 2011 423 infective: HR 1.06 
(p=0.762) 
 non-infective: HR 1.28 
(p=0.371) 
infective: HR 1.26 
(p=0.163)  
non-infective: HR 1.18 
(p=0.499) 
 Artinyan et al. USA 2014 12075 NR infective: HR 1.31 
(p<0.001)  
non-infective: HR 1.05 
(p=0.510)  
CRLM       
 Farid et al. UK 2010 705 infective: HR 1.53 
(p=0.004) 
non-infective: HR 1.25 
(p=0.099) 
infective: HR 1.60 
(p<0.001)  
non-infective: HR 1.98 
(p<0.001) 
 Neal et al. UK 2011 202 infective: HR 1.72 
(p=0.010) 
non-infective: HR 0.98 
(p=0.940) 
infective: HR 1.86 
(p=0.010) 
non-infective; HR 1.37 
(p=0.400) 
OS: overall survival, DFS: disease free survival, HR: hazard ratio, NR: not recorded, CRLM: colorectal liver 
metastases 
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Meta-analysis of the 3 studies (Richards et al. 2011, Farid et al. 2010, Neal et al. 2011), 
including 1,330 patients, reporting the impact of complication type on disease free 
survival, found a statistically significant impact related to infective complications (HR 
1.41, 95% CI 1.08–1.83, p=0.01) but not non-infective complications (HR 1.21, 95% CI 
0.97–1.52, p=0.09). There was a moderate degree of heterogeneity in data relating to 
infective complications (I2=37%) and no heterogeneity in data relating to non-infective 
complications (I2= 0%).  
 
Figure 1-4: Forest plot - impact of complication type on disease free survival 
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Meta-analysis of the 4 studies (Artinyan et al. 2014, Richards et al. 2011, Farid et al. 2010, 
Neal et al. 2011), including13,405 patients, reporting the impact of complication type on 
overall survival, found a statistically significant impact related to infective complications 
(HR 1.37, 95% CI 1.22–1.55, p<0.001) but not non-infective complications (HR 1.35, 95% 
CI 0.92–1.97, p=0.12). There was a minimal degree of heterogeneity in data relating to 
infective complications (I2=21%) and considerable heterogeneity in data relating to non-
infective complications (I2= 80%). 
 
Figure 1-5: Impact of complication type on overall survival 
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1.11.4.2 Complication severity 
Three papers (Mrak et al. 2013, Odermatt et al. 2015, Xia et al. 2014), including 1,879 
patients, reported the effect of complication severity on long term outcomes following 
resection of primary colonic and rectal cancer using the Clavien Dindo scale. Mrak et al.’s 
(2013) study (n=811) examined curative surgery for rectal cancer only.  They excluded 
those who died within 30 days of surgery (Clavien Dindo grade 5, 1.5%), then divided 
patients into 3 groups; those with no complication (Clavien Dindo grade 0, 65.5%), minor 
complications (Clavien Dindo grades 1 and 2, 20.3%) and major complications (Clavien 
Dindo grades 3 and 4, 12.7%). When the 3 groups were compared they found no 
significant difference in 5 year disease free survival (65.7% vs. 61.6% vs. 66.8%) or 10 
year disease free survival (52.5% vs. 45.1% vs. 59.3%). Furthermore, there was no 
significant difference in 5 year overall survival (72.4% vs. 68.4% vs. 71.8%), or 10 year 
overall survival (56.1% vs. 50.1% vs. 61.2%). In contrast, Odermatt et al. (2015), in a 
similar number of patients (n=844), examined this in patients undergoing curative elective 
surgery for both colonic and rectal tumours. Patients were grouped into those who had 
major postoperative complications (Clavien Dindo grades 3B and 4, 4.6%) or did not 
(Clavien Dindo grades 0 to 3A, 95.4%). They reported a significantly lower 5 year overall 
survival in those in the major complication group than the remainder (65% vs. 78%, HR 
2.42, p=0.009) but not with 5 year recurrence free survival (65% vs. 73%, HR 1.77, 
p=0.096). Xia et al. (2014) studied patients undergoing laparoscopic resection of colon 
cancer, excluding rectal lesions and open surgery (n=224). When patients were grouped 
into Clavien Dindo grades 0–1 and 2–4, a significant effect was found on both 5 year 
recurrence free survival (82.1% vs. 40.9%, HR 4.25, p<0.001) and 5 year overall survival 
(78.5% vs. 41%, HR 2.74, p<0.001).   
Eight papers (Farid et al., 2010; de Haas et al., 2011; Pang et al.,2015; Lodewick et al., 
2014; Tanaka et al., 2010; Mavros et al.,2013; Schiesser et al., 2008; Ito et al., 2008), 
comprising 4,032 patients, examined the impact of postoperative complications on long-
term outcomes using the Clavien Dindo scale in the context of surgery for colorectal liver 
metastases. Two papers, with 1,010 (de Haas et al. 2011) and 224 patients (Pang et al. 
2015) respectively, found no significant impact of the severity of complications on 5 year 
disease free or overall survival. Lodewick et al.’s (2014) study (n =266) reported a 
significant reduction in disease free survival when those with grade 3–4 complications 
were compared to those without complications (19.4% vs. 29.4%,p=0.045) but not for 
overall survival (36.2% vs. 46.7%, p=0.160).Tanaka et al.’s (2010) study (n =312) reported 
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a significant reduction in disease free (31.3% vs. 27.8% vs. 11.3%, p<0.010) and overall 
survival (55.4% vs. 54.5% vs. 33.7%, p<0.010) when those with no complication (Clavien 
Dindo grade 0), were compared to those with minor (grade 1–2) and major complication 
(grade 3–4). The remaining four studies (n = 2,220) all reported a significant reduction in 
both disease free and overall survival when patients with postoperative complications 
(Clavien Dindo grade 1–4) were compared to those without (Farid et al., 2010; Schiesser et 
al., 2008; Ito et al., 2008). Furthermore, Tanaka et al. (2010), Mavros et al. (2013), and 
Farid et al. (2010), reported poorer disease free survival (p=0.016 and p=0.008, 
respectively) and overall survival (p=0.004 and p=0.022, respectively) with increasing 
severity of complications when patients were stratified to no complication (Clavien Dindo 
grade 0), minor complication (grade 1–2), and major complication (grade 3–4). One study 
did not present hazard ratios for the impact of complication severity on long term outcomes 
and so was not included in subsequent meta-analysis (Pang et al. 2014). 
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Table 1-13: Studies investigating the impact of complication severity on long term outcome 
Type Author Country Year N Effect of C-D complication severity on 
long-term outcomes 
DFS OS 
Rectal Mrak et 
al. 
Austria 2013 811 C-D 0: 65.7% 
C-D 1-2: 61.6%  
C-D 3-4: 66.8% 
C-D 0: 72.4%  
C-D 1-2: 68.4%  
C-D 3-4: 71.8% 
Colorectal Odermatt 
et al. 
UK 2015 844 C-D 0-2: 73% 
C-D 3-4: 65% 
p=0.096 
C-D 0-2: 78% 
C-D 3-4: 65% 
p=0.009 
Colon Xia et al. China 2014 224 C-D 0-1: 82.1% 
C-D 2-4: 40.9% 
p<0.001 
C-D 0-1: 78.5% 
C-D 2-4: 41% 
 p<0.001 
CRLM       
 Ito et al. USA 2008 1067 C-D 0: 48% 
C-D 1-4:41% 
p=0.0059 
C-D 0: 48% 
C-D 1-4: 41% 
p<0.001  
 Schiesser 
et al. 
Switzerland/
Australia 
2008 197 C-D 0: 1.8 yr 
C-D 1-4: 1.4yr 
 p=0.040 
C-D 0: 4.1yr 
C-D 1-4: 2.1yr 
p<0.012  
 Farid et al. UK 2010 705 C-D 0: 26% 
C-D 1-4: 13% 
p=0.001   
C-D 0: 37% 
C-D 1-4: 24% 
p=0.026 
 Tanaka et 
al. 
Japan 2010 312 C-D 0: 31.3% 
C-D 1-2: 27.8% 
C-D 3-4: 11.3% 
p<0.010 
C-D 0: 55.4% 
C-D 1-2: 54.5% 
C-D 3-4: 33.7% 
p<0.010 
 de Haas et 
al. 
Netherlands 2011 1010 C-D 0-2: 17% 
C-D 3-4: 16% 
p=0.250 
C-D 0-2: 52% 
C-D 3-4: 42% 
p=0.110 
 Mavros et 
al. 
USA 2013 251 C-D 0: 19.7 months 
C-D 1-4: 11.8 
months 
p=0.005 
C-D 0: 53 months 
C-D 1-4: 36.6 
months 
p=0.009 
 Pang et al. Australia 2014 224 C-D 0-1: 17 months  
C-D 2-4: 18 months 
p=0.658 
C-D 0-1: 51 
months 
C-D 2-4: 49 
months 
p=0.877 
 Lodewick 
et al. 
Netherlands 2014 266 C-D 0: 29.4% 
C-D 3-4: 19.4% 
p=0.045 
C-D 0: 46.7% 
C-D 3-4 36.2% 
p=0.160 
C-D Clavien Dindo, OS overall survival, DFS disease free survival, CRLM colorectal liver metastases 
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Meta-analysis of the 10 studies (Farid et al. 2010, Mrak et al.2013, Odermatt et al. 2015, 
Xia et al. 2014, de Haas et al. 2011, Lodewick et al. 2014, Tanaka et al. 2010, Mavros et al. 
2013, Schiesser et al. 2008, Ito et al. 2008), including 5687 patients, reporting the impact 
of complication severity on disease free survival, found a statistically significant impact 
(HR 1.41, 95% CI1.18–1.68, p<0.001) with considerable heterogeneity (I2= 80%). At 
subgroup analysis, the three studies of colorectal resection (Mrak et al. 2013, Odermatt et 
al. 2015, Xia et al. 2014), including 1,879 patients, found that complication severity had no 
significant impact on disease free survival (HR 1.89, 95% CI 0.83–4.34, p=0.13). 
However, the 7 studies of liver resection for colorectal metastases (Farid et al. 2010, de 
Haas et al. 2011, Lodewick et al. 2014, Tanaka et al. 2010, Mavros et al. 2013, Schiesser et 
al. 2008, Ito et al. 2008), including 3,808 patients, did find a statistically significant impact 
(HR 1.30, 95% CI 1.11–1.53, p=0.001). There was considerable heterogeneity amongst 
both the colorectal and liver resection subgroups (I2=87% and 75%, respectively).  
 
Figure 1-6: Forest plot - impact of complication severity on disease free survival 
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Meta-analysis of the 10 studies (Farid et al. 2010, Mrak et al. 2013, Odermatt et al. 2015, 
Xia et al. 2014, de Haas et al. 2011, Lodewick et al. 2014, Tanaka et al. 2010, Mavros et al. 
2013, Schiesser et al. 2008, Ito et al. 2008), including 5,687 patients, reporting the impact 
of complication severity on overall survival, found a statistically significant impact 
(HR1.45, 95% CI 1.25–1.69, p<0.001) with substantial heterogeneity (I2= 67%). At 
subgroup analysis, the three studies of colorectal resection (Mrak et al. 2013, Odermatt et 
al. 2015, Xia et al. 2014), including 1,879 patients, found that complication severity had no 
significant impact on overall survival (HR 1.66, 95% CI 0.77–3.56, p=0.19). However, the 
seven studies of liver resection for colorectal metastases (Farid et al. 2010, de Haas et al. 
2011, Lodewick et al. 2014, Tanaka et al. 2010, Mavros et al. 2013, Schiesser et al. 2008, 
Ito et al. 2008), including 3,808 patients, did find a statistically significant impact (HR 
1.43, 95% CI 1.25–1.65, p<0.001). There was considerable heterogeneity amongst both the 
colorectal and liver resection subgroups (I2= 84% and 60%, respectively). 
 
Figure 1-7: Forest plot - impact of complication severity on overall survival 
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The main limitation of this meta-analysis was the heterogeneity of the included studies in 
terms of population, complication severity grouping, and long-term outcome measures.  In 
particular, in the analysis of infective and non-infective complications studies reporting 
resection of colorectal primaries and CRLMs were grouped together.  Given the 
significantly poorer prognosis of patients with CRLM this may have resulted in bias in 
favour of association with poorer survival.  In addition, the majority of studies reporting 
the impact of complications on survival following resection of CRLMs reported 
associations between complications and prognostic variables including number of 
metastases, size of metastases and increasing extent of resection.  However, most studies 
went on to report their findings in terms of survival using a multivariate model accounting 
for these associations.  Furthermore, Xia et al reported that complications of greater 
severity were associated with a an almost halving of DFS in that patient group, suggesting 
the possibility of observation or selection bias in that study. Finally, although there is a 
significant body of literature regarding the type and severity of postoperative complication, 
to our knowledge only one study (Artinyan et al. 2014) directly compared the two in their 
effect on long-term outcome, but did not use the Clavien Dindo scale, instead using 
complication site as a surrogate. 
The results of the present review indicate that infective complications have a negative 
impact on overall and disease free survival following surgery for colorectal cancer and 
CRLM when grouped together.  Complications of greater severity were associated with 
poorer overall and disease free survival in patients undergoing surgery for CRLM but not 
primary colorectal surgery.  It is likely in these patients that complications of greater 
severity are infective in nature (e.g. anastomotic leak, collection) however few studies have 
directly compared the impact of the two methods of categorisation. 
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2 Summary and Aims 
Colorectal cancer is the fourth most common cancer and the second most common cause of 
cancer death in the UK.  Despite advances in treatment, only around half of patients with 
colorectal cancer are still alive 5 years after diagnosis. Surgery remains the cornerstone of 
its management, however it is associated with significant rates of postoperative 
complication and mortality.  Although disease stage at diagnosis remains the most 
important prognostic factor, these postoperative complications are now also recognised to 
be associated with poorer oncologic outcomes.  
The magnitude of the postoperative systemic inflammatory response, in particular 
exceeding C-reactive protein (CRP) concentrations of 150mg/L on postoperative days 3 or 
4, has been reported to be associated with the development of infective type postoperative 
complications following surgery for colorectal cancer.  However, it remains unclear 
whether the postoperative systemic inflammatory response has a causal relationship with 
these postoperative complications, or whether it is simply an epiphenomenon of 
developing infection.  One hypothesis is that an exaggerated innate immune response to 
surgery leads to immunologic dissonance and relative suppression of the adaptive immune 
system.   
If the postoperative systemic inflammatory response is found to have a direct and causal 
relationship with postoperative complications, and also with long term prognosis, then 
strategies to manage it will become important in optimising postoperative outcomes in 
surgery for colorectal cancer.  High BMI, comorbid disease, and the presence of 
preoperative systemic inflammation increase the postoperative systemic inflammatory 
response.  Conversely, only the use of laparoscopic surgery is at present known to 
objectively reduce the magnitude of the postoperative systemic inflammatory response.  If 
the postoperative systemic inflammatory response is to become a therapeutic target, with 
the aim of improving short and long term outcomes following surgery for colorectal 
cancer, then additional methods of attenuation will be required.  This might include 
strategies to preoperatively optimise patients in terms of fitness and pre-existing 
inflammation, adjustments to surgical and anaesthetic techniques, and the use of drugs 
including corticosteroids and anti-inflammatories. 
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The present thesis aims to further examine the relationship between the postoperative 
systemic inflammatory response, postoperative complications, and long term oncologic 
outcomes following surgery for colorectal cancer, and specifically to:   
1. Determine whether the magnitude of the postoperative systemic inflammatory 
response is associated with postoperative complications when defined by their 
severity. 
2. Determine whether the postoperative systemic inflammatory response is itself a 
prognostic factor in patients who have undergone surgery for colorectal cancer. 
3. Determine what additional patient and operative variables influence the magnitude 
of the postoperative systemic inflammatory response, including cardiorespiratory 
fitness, the use of neoadjuvant chemoradiotherapy prior to surgery for rectal cancer, 
the formation of a temporary defunctioning stoma, the duration of surgery, and 
patient ethnicity. 
4. Determine whether established thresholds of CRP in the postoperative period might 
be used along with existing perioperative care strategies to improve the early 
detection of postoperative complications. 
5. Determine whether the use of perioperative corticosteroids is associated with the 
attenuation of the postoperative systemic inflammatory response, and whether this 
is associated with improved short-term postoperative outcomes.  
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3 Postoperative C-reactive protein measurement 
predicts the severity of complications following 
surgery for colorectal cancer 
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 Introduction 
Although long-term outcome is mostly related to stage at initial presentation, studies have 
shown that infective postoperative complications (Artinyan et al. 2014), and in particular 
anastomotic leak (Mirnezami et al. 2011), have a negative impact on both short and long-
term survival following surgery for colorectal cancer. 
Postoperative complications have previously been defined as “deviation from the normal 
postoperative course” (Dindo et al. 2004).  They have been classified by type, primarily as 
infective or non-infective (McArdle et al. 2005, Richards et al. 2011), or by severity using 
the Clavien Dindo scale (Dindo et al. 2004, Mrak et al. 2013, Clavien et al. 2009).   
Two recent meta-analyses (Warschkow et al. 2012a, Singh et al. 2014a), including more 
than 2,000 patients, have reported the utility of postoperative serum CRP measurement in 
the early diagnosis of postoperative infective type complications and anastomotic leak after 
colorectal surgery.  A recent comprehensive review suggests that values of CRP above 
150mg/L on postoperative days 3-5 are associated with postoperative complications 
following colorectal surgery and should prompt clinical review (McDermott et al. 2015).  
Serum albumin has also been investigated, and a concentration below 25g/L on 
postoperative day 3 has been reported to be associated with the development of infective 
complications after surgery for colorectal cancer (Platt et al. 2012). 
An alternative approach is to classify the severity of the complication based upon the 
intervention required to treat it (Dindo et al. 2004).  A recent retrospective study (Selby et 
al. 2014), with a small cohort of 127 patients who had undergone elective colorectal cancer 
surgery, used the Clavien Dindo classification of postoperative complications and reported 
that the severity of a complication increased with the magnitude of the postoperative day 3 
CRP.   
The aim of the present study was to examine the relationship between the established 
postoperative serum CRP and albumin thresholds for the development of infective 
complications and the severity of complications as defined by the Clavien Dindo 
classification following elective surgery for colorectal cancer.   
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 Patients and Methods 
3.2.1 Patients 
This observational study included patients who underwent elective, potentially curative 
resection for histologically confirmed colorectal cancer in two hospitals between January 
2011 and January 2013.  Patients who underwent emergency surgery, who received 
neoadjuvant chemotherapy or radiotherapy, or who had existing inflammatory conditions, 
e.g. inflammatory bowel disease and the systemic vasculitides, were excluded.   
The decision to perform laparoscopic or open resection was at the discretion of the 
operating surgeon.  All patients received prophylactic antibiotics and venous 
thromboprophylaxis prior to the induction of anaesthesia as per hospital policy.  On each 
postoperative day, patients were clinically assessed and had blood samples, including 
serum CRP and albumin, obtained as standard until discharged.  Further postoperative 
investigation and intervention was at the discretion of the patient’s surgical team, who 
were not blind to serum CRP or albumin results. 
3.2.2 Methods 
All data was collected prospectively in a database, anonymised, and was subsequently 
analysed.  Recorded information included patient demographics, tumour site, TNM stage 
(TNM, AJCC), surgical approach, complications, preoperative and postoperative serum 
CRP measurements.  Data regarding the nature, severity and management of complications 
was retrospectively categorised using the Clavien Dindo scale.  Any uncertainties were 
addressed by review of electronic and/or physical case notes. This study was approved as 
part of surgical audit.    
Serum concentrations of CRP (mg/L) were measured using an autoanalyzer (Architect; 
Abbot Diagnostics, Maidenhead, UK) with a lower detectable limit of 0.2 mg/L, as was 
serum albumin (normal range 35-50g/L).   
The validated Clavien Dindo classification (Clavien et al. 2009), rather than defining the 
complication itself, assigns a value from 0 (no complication) to 5 (death) based on the 
intervention required to treat the complication.  
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The preoperative modified Glasgow Prognostic Score (mGPS), which is associated with 
cancer specific survival independent of disease stage (McMillan 2013), was calculated in 
patients for whom preoperative serum CRP and albumin were available.  
The neutrophil lymphocyte ratio (NLR), which is associated with cancer specific survival 
independent of disease stage (Guthrie et al. 2013), was also calculated for each patient for 
whom preoperative neutrophil and lymphocyte counts were available. 
3.2.3 Statistical Analysis 
Categorical data regarding patient characteristics were compared using the Chi square test.  
Data regarding postoperative CRP were non-normally distributed and are presented as 
medians and ranges.  Medians of multiple groups were compared using the Kruskal-Wallis 
test.  The magnitude of CRP by each postoperative day was displayed as 95% confidence 
intervals of the median.  In all tests, a two sided p value <0.05 was considered statistically 
significant.  Statistical analyses were performed using IBM SPSS version 21 for Windows 
(Chicago, IL, USA).           
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 Results 
In total, 241 patients were included in the study.  142 (59%) were male and 166 (69%) 
were over 65 years old.  Most had colonic (86%) and node negative (65%) disease.  11 
patients (5%) had metastatic disease at the time of surgery, of whom 7 had synchronous 
hepatectomy to treat liver metastases. The remaining 4 were referred to other specialities 
for curative surgical management of their metastatic disease following their colorectal 
surgery.  112 (46%) patients had laparoscopic surgery with a further 11 (5%) having an 
initial laparoscopic approach but requiring conversion to open surgery. 
Of the 241 patients, a complication occurred in 119 (49%) as shown in Table 3-1.  The 
majority of complications required minimal postoperative intervention and fell into 
Clavien Dindo grades 1 (22, 9%) and 2 (69, 28%).  Complications in fewer patients 
required more significant action, with Clavien Dindo grade 3 representing surgical or 
radiological intervention (15, 6%) and 4 of critical care requirement or organ failure (6, 
3%).  Death (Clavien Dindo grade 5) occurred in 7 patients (3%).  Of the 119 
complications, 94 (79%) were due to either surgical site (65) or remote site (29) infection, 
and the remaining 25 (21%) were non-infective complications.   
The relationship between the severity of complication and the perioperative serial CRP is 
shown in Figure 3-1.  In both cases there was little difference in the median preoperative 
and first postoperative day CRP.  Those who developed a complication then sustained a 
higher median CRP from postoperative day 2 onward.   
Table 3-2 shows patients’ perioperative characteristics when grouped by Clavien Dindo 
grade 0 (no complication), grade 1-2, and grade 3-5 complications.  No significant 
difference was found in age group, gender, TNM stage, or tumour site.  A significantly 
higher proportion of patients who suffered a Clavien Dindo grade 3-5 complication 
underwent open surgery (16%) compared to those who underwent laparoscopic surgery 
(7%, p=0.001).  In addition, a significantly higher proportion of patients who underwent 
open surgery exceeded the established postoperative CRP threshold of 150mg/L on 
postoperative days 3 (67% vs. 35%, p<0.001) and 4 (53% vs. 39%, p=0.044).  A 
significantly greater proportion of patients who suffered a Clavien Dindo grade 3-5 
complication had an mGPS score of 2 (44%) than those who experienced a grade 1-2 
(19%) or no complication (17%, p=0.02).  Preoperative neutrophil lymphocyte ratio (NLR) 
was not significantly associated with the different Clavien Dindo classification groups.  
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When compared between Clavien Dindo grade groups 0, 1-2, and 3-5 (Table 3-2) there 
was a significant difference in median CRP on postoperative day 3 (118mg/L vs. 208mg/L 
vs. 251mg/L, p<0.001) and day 4 (98mg/L vs. 161mg/L vs. 243mg/L, p<0.001).  When 
compared between Clavien Dindo grade groups 0, 1-2 and 3-5, the established 
postoperative day 3 CRP threshold of 150mg/L was exceeded by 31%, 54%, and 79% of 
patients respectively (p<0.001).  When compared between Clavien Dindo grade groups 0, 
1-2 and 3-5, the established postoperative day 4 CRP threshold of 150mg/L was exceeded 
by 42%, 64%, and 86% respectively (p<0.001). 
When compared between Clavien Dindo Grade groups 0, 1-2, and 3-5 (Table 3-2) there 
was a significant difference in median albumin on postoperative day 3 (28g/L vs. 26g/L vs. 
23g/L, p<0.001) and day 4 (27g/L vs. 25g/L vs. 23g/L, p<0.001).  When compared 
between Clavien Dindo grade groups 0, 1-2, and 3-5, the established postoperative day 3 
albumin threshold of 25g/L was breached by 23%, 48%, and 64% respectively (p<0.001). 
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 Discussion 
The results of the present study demonstrate that established postoperative serum CRP and 
albumin thresholds, as measured on days 3 and 4 following elective surgery for colorectal 
cancer, are not only associated wth the type, but also the severity of postoperative 
complications, as defined by the Clavien Dindo scale.  In particular, those patients who 
required significant surgical or radiological intervention, ITU admission, or who died 
(grades 3-5) exceeded those thresholds previously defined for the development of infective 
complications. 
In the present study, the proportion of patients in Clavien Dindo grades 1-5 were similar 
(49%) to that in Selby and colleague’s paper (43%) as were the proportions in grades 3-5 at 
12% and 11% respectively, although the present study had almost double the number of 
patients.  Similarly, Selby and co-workers included only elective operations for colorectal 
cancer however it was not clear whether they included patients who had undergone 
neoadjuvant treatment nor was there data regarding the site of tumours or whether patients 
underwent laparoscopic surgery.  
The use of the postoperative systemic inflammatory response as evidenced by CRP 
measurement in colorectal cancer surgery to detect infective complications has been 
applied successfully to other cancer surgery (Dutta et al. 2011, Warschkow et al. 2012b, 
Warschkow et al. 2012c) and in surgery for benign conditions (Warschkow et al. 2012d).  
It may be that the findings of the present study with regard to complication severity can 
also be applied to surgery for other cancers and benign disease.   
In the present study, approximately half of the patients underwent laparoscopic surgery.  It 
was of interest that fewer patients who underwent laparoscopic surgery developed Clavien 
Dindo grade 3 to 5 complications when compared to open surgery.  In addition, and in 
keeping with prior studies, a lower proportion of patients who underwent laparoscopic 
surgery exceeded the established CRP threshold of 150mg/L on postoperative days 3 and 4 
(Wichmann et al. 2005, Ortega-Deballon et al. 2010, Ramanathan et al. 2015b).  Given that 
laparoscopic surgery is recognised to generate a smaller systemic inflammatory response 
than open surgery (Watt et al. 2015c), it might be hypothesised that there is a causal 
relationship between the magnitude of the surgical trauma and the severity of 
complications following surgery for colorectal cancer.  Further work investigating the 
relationship between the magnitude of the postoperative systemic inflammatory response 
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and the severity of complications in patients undergoing surgery for colorectal cancer is 
warranted. 
Moreover, complications of increasing severity may also lead to poorer long-term 
outcomes, although only a small number of studies have examined this in the context of the 
Clavien Dindo classification (Pucher et al.  2014).  This raises the possibility that the 
mechanism by which postoperative complications lead to poorer oncologic outcomes is 
mediated by the postoperative systemic inflammatory response. However, it remains to be 
determined whether strategies to reduce the magnitude of the postoperative systemic 
inflammatory response might also reduce the severity of postoperative complications 
and/or influence longer term outcomes. 
The main limitation of the present study was the relatively small number of patients 
examined, particularly with regard to those with Clavien Dindo grade 3-5 complications, 
although the proportion of patients in each grade were similar to that in Selby and 
colleagues’ report with 127 patients.  Due to the retrospective nature of the study not all 
patients had CRP measured on each postoperative day, with almost 20% of included 
patients not having a recorded postoperative day 4 CRP.  Despite BMI being a factor 
thought to be associated with the postoperative systemic inflammatory response it was not 
available from both centres and therefore could not be included as a confounder.  Using the 
Clavien Dindo system may lead to some bias as surgeons, anaesthetists, and ward staff 
may manage a given case or complication differently from one another.  The surgical 
teams caring for each patient were not blind to the postoperative CRP or albumin 
concentration as it was used as a part of routine clinical care and may have guided, in part, 
the patient management on which the Clavien Dindo definitions depend.   
In summary, there was a direct association between the postoperative systemic 
inflammatory response, as evidenced by serum CRP and albumin, and the severity of 
complications following surgery in patients with colorectal cancer.  
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 Tables and Footnotes 
Table 3-1: Frequency of complication by Clavien Dindo grade 
Clavien Dindo Grade N % 
0 
1 
2 
3 
4 
5 
Total 
122 51 
22 9 
69 28 
15 6 
6 3 
7 3 
241 100 
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Table 3-2: Patient characteristics and postoperative systemic inflammation by Clavien Dindo grade 
Characteristic All Clavien Dindo complication grade 
  0a 1-2b 3-5c P 
Age (<65/65-74/>74) 75/74/92 40/37/45 29/29/33 6/8/14 0.695 
Gender (male/female) 142/99 65/57 58/33 19/9 0.183 
TNM stage (I/II/III/IV) 58/99/73/11 27/57/34/4 24/32/32/3 7/10/7/4 0.135 
Site (colon/rectum) 209/32 110/12 75/16 24/4 0.254 
Preop mGPS (0/1/2) 152/20/46 84/7/19 56/11/16 12/2/11 0.02 
Preop NLR (≤5/>5) 202/33 102/17 77/12 23/4 0.98 
Approach (open/lap) 129/112 50/72 59/32 20/8 <0.001 
      
POD3 CRP (median,range,mg/L) 158(11-601) 118(11-316) 208(35-601) 251(109-346) <0.001 
POD4 CRP(median,range,mg/L) 143(21-528) 98(21-346) 161(25-528) 243(67-403) <0.001 
POD3 CRP>150mg/L (no/yes) 106/119 75/39 27/58 4/22 <0.001 
POD4 CRP>150mg/L (no/yes) 102/93 58/26 38/45 6/22 <0.001 
      
POD3 albumin (median,range,g/L) 26(9-40) 28(15-40) 26(12-34) 23(9-33) <0.001 
POD4 albumin (median,range,g/L) 25(10-38) 27(16-38) 25(10-32) 23(11-30) <0.001 
POD3 albumin <25g/L (no/yes) 134/80 82/25 43/39 9/16 <0.001 
mGPS preoperative modified Glasgow Prognostic score (0 = CRP<10mg/L, 1 = CRP≥10mg/L and albumin ≥35g/L, 2 = 
CRP≥10mg/L and albumin <35g/L).  NLR preoperative neutrophil lymphocyte ratio.  POD postoperative day. a) 0 = no 
complication, b) 1-2 = complication requiring minor intervention, c) 3-5 = complication requiring significant intervention 
    
 
 
 
1
0
5
 
 Figures and Legends 
 
 
Figure 3-1: (A) perioperative CRP (mg/L) and (B) albumin concentrations on postoperative days 1-7 by Clavien Dindo grade 
A B 
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4 A comparison of the magnitude of the postoperative 
systemic inflammatory response and complication 
severity and their impact on survival following 
surgery for colorectal cancer. 
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 Introduction 
There is good evidence that infective type complications have a significant negative impact 
on survival following surgery for colorectal cancer (Artinyan et al. 2015), whilst 
anastomotic leak is associated with disease recurrence (Mirnezami et al. 2011).  Fewer 
studies have examined the impact of complication severity on long-term outcomes, 
although those which have, reported poorer disease free and overall survival (Xia et al. 
2014, Odermatt et al. 2014).  Indeed, a recent meta-analysis reported that severe 
complications had a greater impact on long-term outcomes following surgery for colorectal 
liver metastases, although the association between Clavien Dindo grade and survival 
following resection of primary colorectal tumours did not reach statistical significance 
(McSorley Introduction).   
The magnitude of the systemic inflammatory response, as evidenced by postoperative 
CRP, has been reported to be associated with the development of postoperative infective 
type complications (Ramanathan et al. 2013, Singh et al. 2014a, Platt et al. 2012).  As 
discussed in the previous chapter, two recent studies have examined the relationship 
between the magnitude of the postoperative systemic inflammatory response, as measured 
by CRP, and the severity of complications following surgery for colorectal cancer (Selby et 
al. 2014, McSorley Chapter 3). More recently, a comprehensive review suggested that CRP 
concentrations above a threshold of 150mg/L on postoperative days 3 to 5 should prompt 
investigation and or treatment of potential postoperative complications in colorectal 
surgery (McDermott et al. 2015). 
Therefore, it could be assumed that the postoperative systemic inflammatory response does 
have a negative impact on long term outcomes, through its relationship with postoperative 
complications.  However, two recent studies in oesophagogastric cancer have suggested 
that CRP concentrations in the postoperative period are significantly associated with long-
term outcomes independent of such postoperative complications (Matsuda et al 2015, Saito 
et al. 2015).  To the author’s knowledge no study investigating the interaction between the 
magnitude of the postoperative systemic inflammatory response, complications, and their 
impact on long-term outcomes has been carried out in colorectal cancer surgery. 
 Therefore, the aims of the present study were to examine the relationship between the 
magnitude of the postoperative systemic inflammatory response and complication severity, 
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and to determine which, if any, had the greatest impact on long-term outcomes following 
surgery for colorectal cancer.  
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 Patients and Methods 
4.2.1 Patients 
This observational study included patients who underwent elective, potentially curative 
surgery for histologically confirmed colorectal cancer in a single centre between March 
2008 and May 2013.  Patients with metastatic disease, who underwent palliative 
procedures, or had existing inflammatory conditions, were excluded.   
All patients received prophylactic antibiotics and venous thromboprophylaxis prior to the 
induction of anaesthesia as per hospital policy.  On each postoperative day, patients were 
clinically assessed and had blood samples, including serum CRP, obtained as standard until 
discharged.  Further postoperative investigation and intervention was at the discretion of 
the patient’s surgical team who were not blind to postoperative blood results. 
4.2.2  Methods 
All data was collected prospectively in a database, anonymised, and was subsequently 
analysed.  Recorded information included patient demographics, tumour site, TNM stage 
(TNM, AJCC), surgical approach, whether adjuvant or neoadjuvant treatment was given, 
whether the presentation was elective or emergency, the presence of complications, 
preoperative serum CRP, and albumin measurements.  Data regarding the nature, severity, 
and management of complications was retrospectively categorised using the Clavien Dindo 
scale (Dindo et al. 2004).  For patients with multiple complications, the most serious was 
recorded using both the type and Clavien Dindo grade.  Any uncertainties were addressed 
by review of electronic and/or physical case notes.  Date and cause of death were cross-
checked with the Registrar General (Scotland).  Death records were complete until 30th 
June 2015 which served as the censor date.  The study was approved by the West of 
Scotland Research Ethics Committee, Glasgow. 
Serum concentrations of CRP (mg/L) were measured using an autoanalyzer (Architect; 
Abbot Diagnostics, Maidenhead, UK) with a lower detectable limit of 0.2 mg/L, as was 
serum albumin (normal range 35-50g/L).  The preoperative modified Glasgow Prognostic 
Score (mGPS) was calculated from preoperative serum CRP and albumin (McMillan 
2013).   
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4.2.3 Statistical Analysis 
Categorical data regarding patient characteristics were compared using the Chi square test 
and Chi square test for linear association where appropriate.  Patients who underwent 
colonic resection were analysed as a subgroup due to significant differences in 
postoperative complication rates between those with colonic and rectal cancers.  Those 
patients who died within 30 days of surgery or during the same admission (Clavien Dindo 
grade 5 complications) were excluded from survival analysis.  Univariate and multivariate 
survival data were analysed using Cox’s proportional hazards model.  Variables associated 
with disease specific or overall survival at a significance level of p <0.1 on univariate 
analysis were included in multivariate modelling using backward conditional regression 
where a two sided p value <0.05 was considered statistically significant.  Disease specific 
survival was defined as time from date of surgery to date of cancer specific death.  Overall 
survival was defined as time from date of surgery to date of death from any cause.    
Statistical analyses were performed using IBM SPSS version 22 for Windows (Chicago, 
IL, USA). 
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 Results 
4.3.1 Patients 
377 patients were included having undergone potentially curative surgery for colorectal 
cancer in the absence of metastatic disease.  The majority were male (55%), over 65 years 
old (68%), with colonic (63%) and node negative disease (66%).  110 patients (29%) had a 
laparoscopic resection with the remainder having open surgery.  Amongst the 138 patients 
with rectal cancer, 65 (47%) with locally advanced or margin threatening disease had 
neoadjuvant treatment, of which 10 (15%) were subsequently found to have had a 
pathological complete response.  Of all included patients, 29% went on to have adjuvant 
treatment following surgery.   
4.3.2 Complications 
Of 377 patients, 138 (37%) experienced complications (Table 4-1).  4 patients (1%) died 
within 30 days of surgery or during the same admission.  When classified using the 
Clavien Dindo scale, 108 (30% of all patients) were grade 1-2 (i.e. required minor 
intervention) and 26 (6%) were grade 3-4 (i.e. necessitated major intervention).  When 
patient’s demographic, pathological, and clinical characteristics were compared across 
complication severity (Table 4-2), male gender (p<0.01), ASA score (p<0.05), smoking 
status (p<0.05), and rectal cancer (p<0.05) were significantly associated with Clavien 
Dindo grade.  There was a significant association between complication severity and the 
proportion of patients breaching the established CRP threshold of 150mg/L on 
postoperative days 2 (p=0.004), 3, and 4 (both p<0.001).  
4.3.3 Follow up 
After exclusion of postoperative mortality (4, 1%), death due to any cause occurred in 81 
patients (22%) with 53 (14%) being cancer specific.  The median follow up for patients 
alive at the time of their censoring was 46 months (range 24-86 months).   
4.3.4 Disease Specific Survival 
On univariate analysis (Table 4-3), age (HR 1.54, 95% CI 1.08-2.21, p=0.018), ASA score 
(HR 1.69, 95% CI 1.16-2.46, p=0.007), TNM stage (HR 2.50, 95% CI 1.63-3.85, p<0.001), 
mGPS (HR 1.67, 95% CI 1.23-2.26, p=0.001), breaching the established CRP threshold of  
150mg/L on  postoperative day 3 (HR 1.84,  95% CI 1.01-3.35, p=0.047), and 
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postoperative day 4 (HR 2.53, 95% CI 1.43-4.48, p=0.001), infective complications (HR 
2.02 (95% CI 1.16-3.52) and complication severity (HR 1.66, 95% CI 1.13-2.43, p=0.009), 
were associated with disease specific survival and included in multivariate analysis.  On 
multivariate analysis (Table 4-3), ASA score (HR 1.52, 95% CI 1.01-2.28, p=0.044), 
mGPS (HR 1.49, 95% CI 1.08-2.07, p=0.016), TNM stage (HR 2.46, 95% CI 1.52-3.96, 
p<0.001), and breaching the established CRP threshold of 150mg/L on postoperative day 4 
(HR 2.00, 95% CI 1.12-3.59, p=0.020) remained independently associated with poorer 
disease specific survival.  Breaching the established CRP threshold of 150mg/L on 
postoperative day 3 was not included in multivariate analysis as it was directly associated 
with breaching the established CRP thresholds of 150mg/L on postoperative day 4, which 
had a greater statistical significance on univariate analysis.     
4.3.5 Overall survival 
On univariate analysis (Table 4-3), age (HR 1.83, 95% CI 1.36-2.48, p<0.001), ASA score 
(HR 1.92, 95% CI 1.41-2.61, p<0.001), mGPS (HR 1.52, 95% CI 1.18-1.96, p=0.001), 
TNM stage (HR 1.70, 95% CI 1.25-2.31, p=0.001), breaching the established CRP 
threshold of 150mg/L on postoperative day 2 (HR 1.99, 95% CI 1.22-3.26, p=0.006, 
postoperative day 3 (HR 1.76, 95% CI 1.08-2.85, p=0.022), and postoperative day 4 (HR 
2.02, 95% CI 1.27-3.20, p=0.003), and adjuvant treatment (HR 0.64, 95% CI 0.37-1.09, 
p=0.098) were associated with overall survival and included in multivariate analysis.  On 
multivariate analysis (Table 4-3), ASA score (HR 1.49, 95% CI 1.05-2.10, p=0.024), TNM 
stage (HR 2.12, 95% CI 1.45-3.09, p<0.001), breaching the established CRP threshold of 
150mg/L on postoperative day 4 (HR 2.14, 95% CI 1.34-3.41, p=0.001), and adjuvant 
treatment (HR 0.33, 95% CI 0.17-0.64, p=0.001) all remained independently associated 
with overall survival.  Breaching the established CRP threshold of 150mg/L on 
postoperative day 3 was not included in multivariate analysis as it was directly associated 
with breaching the established CRP thresholds of 150mg/L on postoperative day 4, which 
had a greater statistical significance on univariate analysis.     
4.3.6 Colonic resection 
When the subgroup of 239 patients who underwent surgery for colonic cancer were 
considered, 79 (33%) experienced complications (Table 4-4).   No patients died within 30 
days of surgery or during the same admission.  When classified using the Clavien Dindo 
scale, 63 were grade 1-2 and 16 were grade 3-4.  When patients’ demographic, 
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pathological, and clinical characteristics were compared across complication severity 
(Table 4-4) only smoking status (p=0.047) was significantly associated.  There was a 
significant association between complication severity and the proportion of patients 
breaching the established CRP threshold of 150mg/L on postoperative days 2 (p=0.032), 3 
(p=0.002), and 4 (p=0.005).   
On multivariate analysis (Table 4-5) mGPS (HR 1.81, 95% CI 1.20-2.72, p=0.005), TNM 
stage (HR 2.28, 95% CI 1.23-4.21, p=0.009), and breaching the established CRP threshold 
of 150mg/L on postoperative day 4 (HR 2.42, 95% CI 1.13-5.18, p=0.023) were 
independently associated with disease specific survival after surgery for colonic cancer.  
ASA score (HR 1.99, 95% CI 1.28-3.10, p=0.002), mGPS (HR 1.53, 95% CI 1.11-2.10, 
p=0.010) and breaching the established CRP threshold of 150mg/L on postoperative day 4 
(HR 2.32, 95% CI 1.29-4.20, p=0.005) were independently associated with overall survival 
after surgery for colonic cancer. 
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 Discussion 
The results of the present study report a significant association between the magnitude of 
the postoperative systemic inflammatory response and complication severity following 
surgery for colorectal cancer.  Furthermore, the magnitude of the postoperative systemic 
inflammatory response, in particular CRP on postoperative day 4, was significantly 
associated with disease specific and overall survival independent of postoperative 
complications.  These relationships remained in a subgroup of patients who underwent 
colonic surgery.  Therefore, the present results suggest that the magnitude of the 
postoperative systemic inflammatory response may also be an important factor in relation 
to long term oncologic outcomes in this group of patients. 
The results of the present study are consistent with previous studies showing an association 
between male gender, preoperative ASA score, smoking status and complication severity 
following colorectal surgery (McDermott et al. 2015, Kirchoff et al. 2008, Lipska et al. 
2006).  Moreover, two recent studies reported the association between complication 
severity and the magnitude of the postoperative systemic inflammatory response in patients 
with colorectal cancer (Selby et al. 2014, McSorley Chapter 3), and also in patients 
undergoing surgery for gastric and oesophageal cancer (Matsuda et al 2015, Saito et al. 
2015).   
A recent meta-analysis reported that complication type and severity were independently 
associated with poorer oncologic outcomes following colorectal surgery, and liver 
resection for colorectal cancer (McSorley Introduction).  However, the present study is the 
first to include a measure of the magnitude of the systemic inflammatory response together 
with the severity of complication in survival analysis following surgery for colorectal 
cancer.  Although the relationship between postoperative infective complications and 
poorer survival in patients with colorectal cancer has been extensively documented, 
complication severity using the Clavien Dindo scale provides a validated, objective 
framework for the definition of such postoperative complications (Clavien et al. 2009).   
Taken together, the implications of these results are important.  They would suggest that 
the mechanisms that link the magnitude of the postoperative systemic inflammatory 
response, postoperative complications, and poorer oncological outcomes are inflammatory 
in aetiology (Powell et al. 2015).  In previous work, it has been reported that the presence 
of preoperative systemic inflammation, as measured by the mGPS, but not postoperative 
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complication, was associated with poorer long-term outcomes following surgery for 
colorectal cancer (Richards et al. 2011).  However, the magnitude of the postoperative 
systemic inflammatory response was not considered.  More recently, it is now recognised 
that the magnitude of the systemic inflammatory response following surgery for colorectal 
cancer is associated with the extent of postoperative complications (Singh et al. 2014a, 
Platt et al. 2012, Selby et al. 2014, McSorley Chapter 3).  The present study shows that 
both the pre and postoperative systemic inflammatory responses are associated with 
oncologic outcomes independent of tumour stage and postoperative complications.   
The exact mechanisms underlying these relationships are unclear.   However, the presence 
of an innate immune driven systemic inflammatory response can suppress cytotoxic 
immunity and promote the development of postoperative complications and tumour 
progression (Roxburgh et al. 2013, Roxburgh et al. 2016, McAllister and Weinberg 2014).  
If this were proven to be the case it would therefore be rational to consider the 
postoperative systemic inflammatory response a target for therapeutic intervention.  
Clearly, such therapeutic intervention would also test the above hypothesis since it would 
be anticipated that a reduction in the postoperative systemic inflammatory response would 
not only result in a reduction in the severity of postoperative complications but also 
improve long-term outcomes, not only in colorectal cancer surgery, but in surgery for all 
solid tumours.  It remains to be determined whether the modulation of the postoperative 
systemic inflammatory response may reduce the frequency and/or severity of postoperative 
complications or improve long-term outcomes following surgery for colorectal cancer.  
A main limitation of the present study was the relatively short follow up period.  This may 
be in part responsible for the seemingly large treatment effect size of adjuvant therapy, 
disproportionate to that recognised within the established literature.  The retrospective 
nature of the study leads to missing data and the possibility of missing patients.  Not all 
patients had CRP measured on each postoperative day, with almost 20% of included 
patients not having a recorded postoperative day 4 CRP.  In addition, a relatively small 
number of Clavien Dindo grade 3-4 complications occurred.  The significant difference in 
frequency of severe complication between colonic and rectal resection led to the separate 
analysis of patients undergoing colonic resection.  Nevertheless, comparative analysis 
showed similar significant relationships with survival when compared to the whole cohort.   
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In summary, the results of the present study report that the magnitude of the postoperative 
systemic inflammatory response was associated with oncologic outcome following surgery 
for colorectal cancer, independent of postoperative complications or disease stage. 
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 Tables and Footnotes: 
Table 4-1: Postoperative complications by type and severity 
Complication   n % 
No complication   239 63 
Any complication   138 37 
Complication type     
Infective All infective complications  94 25 
 SSI wound infection 43 11.5 
  anastomotic leak 16 4 
  intra-abdominal abscess 6 2 
 RSI pneumonia 23 6 
  septicaemia 2 0.5 
  UTI 4 1 
Non-infective All non-infective complications  44 12 
 wound seroma 2 0.5 
  dehiscence 4 1 
 surgical site haemorrhage 1 0.25 
 cardiac MI 4 1 
  arrhythmia 9 2.5 
 vascular VTE 3 0.75 
  CVA 2 0.5 
 urinary renal failure 4 1 
  acute urinary retention 3 0.75 
 gastrointestinal diarrhoea (non-infective) 4 1 
  ileus 8 2.25 
Complication 
severity 
    
 Clavien Dindo Grade 0 239 63 
  1 36 10 
  2 72 20 
  3 18 4 
  4 8 2 
  5  4 1 
SSI surgical site infection, RSI remote site infection, UTI urinary tract infection, MI myocardial infarction, 
VTE venous thromboembolism, CVA cerebrovascular accident 
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Table 4-2: Patient characteristics by severity of complication following surgery for colorectal cancer 
Characteristic All  Clavien Dindo complication grade 
  0a 1-2b 3-4c 5d P 
N (%) 377 (100) 239 (63) 108 (30) 26 (7) 4 (1) - 
Age (<65/65-74/>74) 122/149/106 82/96/61 31/44/33 9/7/10 0/2/2 0.451 
Sex (male/female) 208/169 116/123 74/34 15/11 3/1 0.005 
BMI (<20/20-25/26-
30/>30) 
16/112/114/90 12/69/75/55 3/32/31/28 1/8/8/6 0/3/0/1 0.833 
ASA score (1/2/3/4) 48/169/145/14 36/112/83/7 9/45/48/6 3/11/12/0 0/1/2/1 0.014 
Smoking 
(never/ex/current) 
159/150/61 114/89/31 37/46/23 8/11/7 0/4/0 0.015 
Preop mGPS (0/1/2) 284/37/56 180/23/36 82/9/17 18/5/3 4/0/0 0.636 
Site (colon/rectum) 239/138 160/79 63/45 16/10 0/4 0.024 
TNM stage (0/I/II/III) 10/80/159/128 8/54/101/76 1/20/43/44 0/5/14/7 1/1/1/1 0.120 
Neoadjuvant treatment 
(no/yes) 
299/65 191/40 84/19 21/5 3/1 0.970 
       
Approach 
(open/laparoscopic) 
266/110 162/77 83/24 18/8 3/1 0.323 
Surgery >4h (yes/no) 83/247 51/154 22/76 9/16 1/1 0.456 
Stoma (yes/no) 115/262 65/174 39/69 8/18 1/1 0.087 
       
POD 2 CRP >150mg/L 
(yes/no) 
205/162 114/117 72/35 16/9 3/1 0.004 
POD 3 CRP >150mg/L 
(yes/no) 
187/169 100/124 67/38 19/5 1/2 <0.001 
POD 4 CRP >150mg/L 
(yes/no) 
126/200 58/137 51/51 16/10 1/2 <0.001 
       
Adjuvant treatment 
(no/yes) 
269/108 171/68 73/35 21/5 4/0 0.323 
mGPS preoperative modified Glasgow Prognostic score (0 = CRP<10mg/L, 1 = CRP≥10mg/L and albumin 
≥35g/L, 2 = CRP≥10mg/L and albumin <35g/L).  POD postoperative day.   a) 0 = no complication, b) 1-2 = 
complication requiring minor intervention, c) 3-4 = complication requiring significant intervention, d) 5 = 
death 
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Table 4-3: Impact of complication severity on survival following surgery for colorectal cancer 
Survival Variable Univariate HR 
(95% CI) 
P Multivariate HR 
(95% CI) 
P 
DSS Age 1.54 (1.08-2.21) 0.018 - 0.225 
 Sex 0.77 (0.45-1.32) 0.344 - - 
 BMI 0.88 (0.62-1.23) 0.446 - - 
 ASA score 1.69 (1.16-2.46) 0.007 1.52 (1.01-2.28) 0.044 
 Smoking 1.00 (0.69-1.46) 0.984 - - 
 mGPS 1.67 (1.23-2.26) 0.001 1.49 (1.08-2.07) 0.016 
 Rectal 1.00 (0.57-1.74) 0.998 - - 
 TNM stage 2.50 (1.63-3.85) <0.001 2.46 (1.52-3.96) <0.001 
 Neoadjuvant treatment 1.23 (0.63-2.39) 0.548 - - 
 POD 2 CRP >150mg/L 1.62 (0.91-2.89) 0.101 - - 
 POD 3 CRP >150mg/L 1.84 (1.01-3.35) 0.047 - - 
 POD 4 CRP >150mg/L 2.53 (1.43-4.48) 0.001 2.00 (1.17-3.59) 0.020 
 Infective complications 2.02 (1.16-3.52) 0.013 - 0.211 
 Clavien Dindo grade 1.66 (1.13-2.43) 0.009 1.51 (0.98-2.33) 0.061 
 Adjuvant treatment 0.78 (0.42-1.46) 0.432 - - 
      
OS Age 1.83 (1.36-2.48) <0.001 1.35 (0.97-1.87) 0.074 
 Sex 1.06 (0.68-1.64) 0.799 - - 
 BMI 0.85 (0.65-1.12) 0.242 - - 
 ASA score 1.92 (1.41-2.61) <0.001     1.49 (1.05-2.10) 0.024 
 Smoking 1.20 (0.89-1.61) 0.238 - - 
 mGPS 1.52 (1.18-1.96) 0.001 - 0.170 
 Rectal 0.78 (0.49-1.25) 0.308 - - 
 TNM stage 1.70 (1.25-2.31) 0.001 2.12 (1.45-3.41) <0.001 
 Neoadjuvant treatment 0.97 (0.54-1.73) 0.914 - - 
 POD 2 CRP >150mg/L 1.99 (1.22-3.26) 0.006 - - 
 POD 3 CRP >150mg/L 1.76 (1.08-2.85) 0.022 - - 
 POD 4 CRP >150mg/L 2.02 (1.27-3.20) 0.003 2.14 (1.34-3.41) 0.001 
 Infective complications 1.40 (0.87-2.25) 0.170 - - 
 Clavien Dindo grade 1.30 (0.93-1.81) 0.127 - - 
 Adjuvant treatment 0.64 (0.37-1.09) 0.098 0.33 (0.17-0.64) 0.001 
HR Hazard Ratio, CI Confidence Interval, DSS disease specific survival, OS overall survival, mGPS 
modified Glasgow Prognostic Score, POD postoperative day  
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Table 4-4: Patient characteristics by severity of complication following surgery for colonic cancer 
Characteristic All  Clavien Dindo complication grade 
  0a 1-2b 3-4c 5d P 
N (%) 239 160 63 16 0 - 
Age (<65/65-74/>74) 66/88/85 48/59/53 14/24/25 4/5/7 0/0/0 0.724 
Sex (male/female) 127/112 77/83 42/21 8/8 0/0/0 0.111 
BMI (<20/20-25/26-
30/>30) 
11/64/68/60 9/41/50/38 1/19/12/19 1/4/6/3 0/0/0/0 0.430 
ASA score (1/2/3/4) 24/99/105/11 20/70/63/7 2/23/34/4 2/6/8/0 0/0/0/0 0.227 
Smoking 
(never/ex/current) 
103/91/40 79/54/23 20/30/12 4/7/5 0/0/0 0.047 
Preop mGPS (0/1/2) 170/28/41 115/18/27 46/6/11 9/4/3 0/0/0 0.513 
TNM stage 
(0/I/II/III) 
0/50/112/77 0/33/73/54 0/14/29/20 0/3/10/3 0/0/0/0 0.734 
       
Approach 
(open/laparoscopic) 
83/156 57/103 20/43 6/10 0/0 0.836 
Surgery >4h (yes/no) 28/179 17/118 7/50 4/11 0/0 0.303 
Stoma (yes/no) 14/158 7/113 6/37 1/8 0/0 0.277 
       
POD 2 CRP 
>150mg/L (yes/no) 
129/105 78/78 43/19 8/8 0/0 0.032 
POD 3 CRP 
>150mg/L (yes/no) 
121/105 69/81 41/20 11/4 0/0 0.002 
POD 4 CRP 
>150mg/L (yes/no) 
81/117 41/84 31/26 9/7 0/0 0.005 
       
Adjuvant treatment 
(no/yes) 
69/170 48/112 18/45 3/13 0/0 0.638 
mGPS preoperative modified Glasgow Prognostic score (0 = CRP<10mg/L, 1 = CRP≥10mg/L and albumin 
≥35g/L, 2 = CRP≥10mg/L and albumin <35g/L).  POD postoperative day.   a) 0 = no complication, b) 1-2 = 
complication requiring minor intervention, c) 3-4 = complication requiring significant intervention, d) 5 = 
death 
  
    
 
121 
 
Table 4-5: Impact of complication severity on survival following surgery for colonic cancer 
Survival Variable Univariate HR 
(95% CI) 
P Multivariate HR 
(95% CI) 
P 
DSS      
 Age 1.52 (0.96-2.41) 0.073 - 0.316 
 Sex 0.72 (0.37-1.44) 0.356 - - 
 BMI 0.69 (0.44-1.09) 0.109 - - 
 ASA score 1.63 (1.00-2.67) 0.051 1.70 (0.99-2.93) 0.057 
 Smoking 0.94 (0.58-1.52) 0.792 - - 
 mGPS 1.95 (1.34-2.82) <0.001 1.81 (1.20-2.72) 0.005 
 TNM stage 2.27 (1.32-3.90) 0.003 2.28 (1.23-4.21) 0.009 
 POD 2 CRP >150mg/L 1.69 (0.82-3.48) 0.157 - - 
 POD 3 CRP >150mg/L 1.97 (0.89-4.36) 0.094 - - 
 POD 4 CRP >150mg/L 2.78 (1.31-5.91) 0.008 2.42 (1.13-5.18) 0.023 
 Infective complications 1.81 (0.86-3.82) 0.117 - - 
 Clavien Dindo grade 1.34 (1.01-1.78) 0.043 - 0.164 
 Adjuvant treatment 0.77 (0.35-1.70) 0.516 - - 
      
OS      
 Age 1.78 (1.23-2.57) 0.002 1.43 (0.94-2.15) 0.092 
 Sex 1.04 (0.61-1.78) 0.873 - - 
 BMI 0.75 (0.53-1.06) 0.100 - - 
 ASA score 1.98 (1.34-2.93) 0.001 1.99 (1.28-3.10) 0.002 
 Smoking 1.19 (0.83-1.70) 0.354 - - 
 TNM stage 1.53 (1.04-2.25) 0.030 - 0.114 
 mGPS 1.66 (1.23-2.23) 0.001 1.53 (1.11-2.10) 0.010 
 POD 2 CRP >150mg/L 2.18 (1.20-3.96) 0.010 - - 
 POD 3 CRP >150mg/L 1.88 (1.03-3.42) 0.040 - - 
 POD 4 CRP >150mg/L 2.33 (1.31-4.17) 0.004 2.32 (1.29-4.20) 0.005 
 Infective complications 1.03 (0.53-2.00) 0.920 - - 
 Clavien Dindo grade 1.08 (0.84-1.39) 0.548 - - 
 Adjuvant treatment 0.67 (0.35-1.27) 0.205 - - 
HR Hazard Ratio, CI Confidence Interval, DSS disease specific survival, OS overall survival, mGPS 
modified Glasgow Prognostic Score, POD postoperative day  
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5 The relationship between CT derived measures of 
body composition, tumour and host characteristics in 
male and female patients with primary operable 
colorectal cancer: implications for a systemic 
inflammation based framework for cancer cachexia. 
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 Introduction 
With disease progression in colorectal cancer there is an increased incidence of progressive 
involuntary weight loss, poor food intake, loss of lean tissue, poor functional status, poorer 
quality of life, and ultimately, survival (Fearon et al. 2011, Aapro et al. 2014, Malietzis et 
al. 2016c).  Measuring simple weight loss is problematic since many patients in the 
developed world will be overweight but with significant loss of lean tissue (Richards et al. 
2012b, Douglas et al. 2014). Indeed, methods such as CT scanning have shown that there 
are body compositional changes in the absence of overt weight loss (Martin et al. 2013).  
In particular, the disproportionate loss of lean tissue has been associated with 
chemotherapy toxicity (Antoun et al. 2010, Prado et al. 2007, Prado et al. 2009, Prado et al. 
2011), increased risk of post-operative complications (Peng et al. 2011), poorer outcome, 
and poorer survival (Prado et al. 2008).  Recently, based on such CT analyses, the terms 
visceral obesity, myopenia, myopenic obesity, and myosteatosis have been defined in the 
literature (Malietzis et al. 2016c, Martin et al. 2013, Prado et al. 2008, Doyle et al. 2013).   
It has been recently proposed that a systemic inflammatory response, as evidenced by the 
Glasgow Prognostic Score (GPS), given its association with loss of lean tissue (McMillan 
2009) and its established prognostic value (McMillan 2013), would form a method of 
simply and objectively identifying patients with different cachexia states (Bye et al. 2016). 
Indeed, systemic inflammation, as evidence by C-reactive protein (CRP), neutrophil 
lymphocyte ratio (NLR) and the GPS, is associated with the depletion of skeletal muscle in 
cancer patients (Reisinger et al. 2015), with a consequent effect on quality of life (Laird et 
al. 2016). However, it was not clear whether this association was independent of other 
potential confounders, in particular, sex.  
In addition, it is increasingly recognised that postoperative complications have a significant 
impact on long-term oncologic outcomes following surgery for colorectal cancer (Artinyan 
et al. 2015).  The magnitude of the postoperative systemic inflammatory response is 
associated with the development of, and severity of, complications following surgery for 
colorectal cancer (McSorley Chapter 3).  Indeed, threshold values of CRP have been 
established in the postoperative period which are associated with the development of 
complications (McDermott et al. 2015).  There is some evidence that BMI might influence 
the magnitude of the postoperative systemic inflammatory response after surgery for 
colorectal cancer (Ramanathan 2016).  In addition, body composition has been reported to 
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be associated with postoperative complications following colorectal surgery (Lieffers et al. 
2012).  However, there is no evidence directly linking CT derived measures of body 
composition, the postoperative systemic inflammatory response, and complications.   
Therefore, the aim of the present observational study was to examine the relationship 
between BMI, CT derived measures of body composition, the systemic inflammatory 
response both before and after surgery, and postoperative complications in male and 
female patients with primary operable colorectal cancer. 
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 Patients and Methods 
5.2.1 Patients 
Consecutive patients who underwent elective, potentially curative resection for colorectal 
cancer between March 2008 and May 2013 at a single centre were identified from a 
prospectively maintained database.  Those patients with a preoperative CT scan and a 
recorded height were included.  Patients who had undergone emergency surgery, palliative 
surgery, or with metastatic disease were not considered for inclusion.   
Patients were classified according to Body Mass Index (BMI) as underweight (BMI 
<18.5), normal weight (BMI 18.5–24.9), overweight (BMI 25.0–29.9) or obese (BMI >30).  
ASA score was recorded. All tumours were staged according to TNM 5th edition.  
On each postoperative day patients were clinically assessed and had blood samples, 
including serum CRP, obtained as standard until discharged.   
The study was approved by the West of Scotland Research Ethics Committee, Glasgow. 
5.2.2 Methods 
CT images were obtained at the level of the third lumbar vertebra as previously described 
(Richards et al. 2012b). Each image was analysed using a free-ware program (NIH Image J 
version 1.47, http://rsbweb.nih.gov/ij/) shown to provide reliable measurements.  
Region of interest (ROI) measurements (cm2)  were made of visceral fat (VFA), 
subcutaneous fat (SFA) (Figure 5-1), and skeletal muscle areas (SMA) (Figure 5-2) using 
standard Hounsfield Unit (HU) ranges (adipose tissue -190 to -30, and skeletal muscle -29 
to +150). These were then normalised for height2 to create indices; total fat index (TFI, 
cm2/m2), subcutaneous fat index (SFI, cm2/m2), visceral fat index (VFI, cm2/m2), and 
skeletal muscle index (SMI, cm2/m2).  Skeletal muscle radiodensity (SMD, HU) was 
measured from the same ROI used to calculate SMA, as its mean HU.  Visceral obesity 
was defined as VFA >160cm2 for male patients and >80cm2 for female patients (Doyle et 
al. 2013).  Myopenia was defined as SMI for male patients of <52.4cm2/m2 and 
<38.5cm2/m2 for female patients (Prado et al. 2008).  Myopenic obesity was defined as the 
presence of myopenia and BMI>30kg/m2 (Malietzis et al. 2016c).  Myosteatosis was 
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defined by SMD <41HU in patients with BMI <25kg/m2 and <33HU in patients with BMI 
>25kg/m2 (Martin et al. 2013). 
Measurements were made by one individual (DB) blind to clinicopathological and 
demographic data.  Another individual (SM) performed an independent measurement of 40 
patient images to assess inter-rater reliability using intra-class correlation coefficients 
(ICCC) (TFA ICCC= 0.999, SFA ICCC=0.997, VFA ICCC=0.996, SMA ICCC=0.995, 
SMD ICCC=0.996). 
Serum concentrations of CRP (mg/L) and albumin (g/L) were measured using an 
autoanalyzer (Architect; Abbot Diagnostics, Maidenhead, UK).  The preoperative GPS was 
calculated from CRP and albumin as previously described (McMillan 2013). The more 
recent mGPS was not used as greater evidence exists validating GPS with regards to 
measures of body composition and cachexia.  The neutrophil lymphocyte ratio (NLR) was 
calculated for each patient for whom preoperative neutrophil and lymphocyte counts were 
available, values >3 were considered raised (Malietzis et al. 2016b).   
Exceeding the established CRP threshold of 150 mg/L on postoperative days 3 or 4 was 
recorded (McDermott et al. 2015).  Postoperative complications were recorded and 
categorised by severity using the Clavien Dindo scale (Dindo et al. 2004). Infective 
complications were categorised as described previously (Platt et al. 2012).    
5.2.3 Statistical analysis 
Body composition indices were presented as median and range, and compared using 
Mann-Whitney or Kruskal-Wallis tests.  Categorical variables were analysed using χ2 test 
for linear-by-linear association, or χ2 test for 2 by 2 tables.   
Missing data were excluded from analysis on a variable by variable basis.  Two sided p 
values <0.05 were considered statistically significant.  Statistical analysis was performed 
using SPSS software (Version 21.0. SPSS Inc., Chicago, IL, USA).  
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 Results 
5.3.1 Patients 
377 patients were eligible for inclusion over the study period, however 55 were excluded 
due to either missing anthropometric data or unavailable preoperative CT images, giving 
n=322 (Table 5-1).  In both females and males, the majority of patients were over 65 years 
old (68% and 66% respectively), were overweight or obese (63% and 61% respectively), 
had some comorbid disease (87% and 89% respectively), and had node negative disease 
(64% in each).  There were no significant differences in clinicopathological characteristics 
between the sexes.   
There was no significant difference in BMI between the sexes (Table 5-1).  Female 
patients had a significantly higher median SFI (92 vs. 60 cm2/m2, p<0.001), lower median 
VFI (58 vs. 74 cm2/m2, p<0.001), and lower SMI (41 vs. 49 cm2/m2, p<0.001) when 
compared to male patients.  In addition, a significantly lower proportion of female patients 
were considered myopenic (34% vs. 61%, p<0.001).   
There were a total of 112 (35%) postoperative complications of which 77 were infective, 
86 were Clavien Dindo grade 1-2, and 26 were Clavien Dindo grade 3-5.  There was a 
significant association between male sex and higher incidence of any postoperative 
complication (42 % vs. 26%, p=0.003), infective complication (29% vs. 18%, p=0.018), 
and Clavien Dindo grade (p=0.005).  Due to these profound differences in body 
composition and postoperative outcomes, subsequent analysis was carried out separately in 
male and female patients. 
5.3.2 Females 
There was a significant association (Table 5-2) between BMI defined obesity and 
exceeding the established CRP threshold of 150mg/L on postoperative days 3 (p=0.030), 
and 4 (p=0.024).  There was a significant association between visceral obesity and ASA 
score (p=0.015), exceeding the established CRP threshold of 150mg/L on postoperative 
days 3 (p=0.003), and 4 (p=0.020), any postoperative complication (p=0.017), infective 
complications (p=0.005), and Clavien Dindo grade (p=0.032).  There was a significant 
association between myopenia and age (p<0.001), and a non-signficant trend (p=0.054) 
toward an increasing proportion of myopenic female patients with increasing GPS.  
Myopenic obesity was not significantly associated with any clinicopathological or systemic 
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inflammatory response variable.  Myosteatosis was significantly associated with increasing 
age (p<0.001), increasing ASA score (p<0.001), increasing GPS (p=0.019), NLR 
(p=0.007), and exceeding the established CRP threshold of 150mg/L on postoperative day 
4 (p=0.046). 
5.3.3 Males 
 There was a significant inverse association (Table 5-3) between BMI defined obesity and 
increasing age (p=0.003), and GPS (p=0.001).  There was a significant association between 
visceral obesity and GPS (p=0.007) with a trend toward a higher proportion of visceral 
obesity in higher TNM stage disease (p=0.050).  There was a significant association 
between myopenia and increasing age (p<0.001), GPS (p<0.001), and NLR (p=0.043).  
Myopenic obesity was not significantly associated with any clinicopathological or systemic 
inflammatory response variable.  There was a significant association between myosteatosis 
and increasing age (p<0.001), and GPS (p=0.004).   
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 Discussion 
In the present study, there were clear differences in CT body composition indices and their 
relationship with clinicopathological characteristics, the magnitude of the postoperative 
systemic inflammatory response, and postoperative complications between females and 
males. 
Myosteatosis was consistently associated with patient characteristics and measures of the 
preoperative systemic inflammatory response in both sexes.  Recently Malietzis and 
colleagues reported a significant inverse relationship between NLR, myopenia, and 
myosteatosis in patients with operable colorectal cancer (Malietzis et al. 2016b, Malietzis 
et al. 2016c).  As in the present study, there were significant differences in CT derived 
measures of body composition between the sexes.  However, this observation was not 
commented on and sex specific analysis was not carried out.  These results would suggest 
that not only the quantity but also the quality of skeletal muscle is influenced by the 
preoperative systemic inflammatory response.  The mechanism by which a systemic 
inflammatory response appears to promote a greater catabolic state in males is not clear.  
The present results are also consistent with longitudinal studies (Malietzis et al. 2016a), 
including historical work (McMillan et al. 1998), and the recent work of Wallengren and 
colleagues who reported that, patients with advanced cancer and a CRP>10mg/L had less 
muscle mass and lost muscle mass at an accelerated rate during cancer progression 
(Wallengren et al. 2015).  However, it remains to be determined whether there is a sex 
specific effect on these longitudinal relationships.   
Taken together, it is clear that measures of systemic inflammation are associated with a 
lower quantity and quality of skeletal muscle, and is consistent with the concept that the 
systemic inflammatory response is a major driver of the loss of lean tissue.  These results 
have a number of important implications for the classification, monitoring and treatment of 
cachexia.  For example, these results point to a revised systemic inflammation based 
framework for the assessment of cancer cachexia.  Further longitudinal and interventional 
studies will be required to confirm the importance of the present observations. 
A comparison of the predictive value of such body composition analysis in the 
development of postoperative infective complications in both males and females in a large 
cohort of patients with colorectal cancer has been called for (Reisinger et al. 2015).  With 
regard to the postoperative systemic inflammatory response, and complications following 
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elective surgery for colorectal cancer, the present study again reports clear differences 
between the sexes.  In female patients, increasing BMI was associated with an exaggerated 
postoperative systemic inflammatory response.  This was also the case with CT derived 
visceral obesity which, in addition, was associated with a greater number and severity of 
postoperative complications.  Neither BMI, or any CT derived measure of body 
composition, was associated with the postoperative systemic inflammatory response or 
complications in male patients.    
There is some existing evidence that BMI, a crude measure of body composition, is 
associated with the magnitude of the postoperative systemic inflammatory response 
following surgery for colorectal cancer (Ramanathan 2016).  The present study adds to this 
evidence but suggests a sex specific difference.  It may be that obesity leads to increased 
postoperative complications through direct mechanical problems such as the requirement 
for longer and deeper wounds at laparotomy, difficulty mobilising in the postoperative 
period, and problems surrounding glycaemic control.  However, fat, in particular visceral 
fat, is well understood to be a potent pro-inflammatory tissue, and it may be that the sex 
specific difference in fat distribution reported in the present study has a role to play 
(Schrager et al. 2007).     
Limitations of the present study include its retrospective nature and that only patients with 
an available CT scan were included.  Also, that other methods of body composition and 
assessments of physical function were not included.  However, it does highlight the 
importance of sex in the relationship between body composition, the systemic 
inflammatory response, and outcome in patients with primary operable colorectal cancer.     
The results of the present study suggest that BMI and visceral obesity are associated with 
the magnitude of the postoperative systemic inflammatory response and complications in 
female patients following surgery for colorectal cancer.  This factor will need to be 
accounted for in future work examining the magnitude of the postoperative systemic 
inflammatory response and outcomes following surgery for colorectal cancer.  
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 Tables and Footnotes 
Table 5-1: Association between sex, clinicopathological characteristics, systemic inflammation, CT 
derived measures of body composition and postoperative outcomes following elective surgery for 
colorectal cancer 
Characteristic  Female n= 148(%) Male n=174 (%) P 
Clinicopathological     
Age <65 47 (32) 59 (34) 0.327 
65-74 55 (37) 72 (41)  
>74 46 (31) 43 (25)  
ASA score 1 19 (13) 19 (11) 0.334 
 2 71 (48) 80 (46)  
 3 54 (37) 69 (40)  
 4 3 (2) 6 (3)  
TNM stage 0 3 (2) 4 (2) 0.695 
1 30 (20) 39 (22)  
2 61 (41) 69 (40)  
3 54 (37) 62 (36)  
Tumour site Colon    
 Rectum    
Neoadjuvant No    
 Yes    
Systemic inflammation     
GPS  0 87 (59) 103 (59) 0.824 
 1 (CRP) 15 (10) 15 (9)  
 1 (albumin) 25 (17) 32 (18)  
 2 21 (14) 24 (14)  
NLR ≤3 88 (59) 93 (54) 0.312 
 >3 60 (41) 80 (46)  
     
Body composition     
BMI (kg/m2) Underweight (<20) 9 (7) 4 (2) 0.506 
 Normal (20-25) 41 (30) 60 (37)  
 Overweight (26-30) 43 (31) 61 (37)  
 Obese (>30) 44 (32) 39 (24)  
TFI (median, range, cm2/m2)  149 (18-443) 134 (30-437) 0.126 
SFI (median, range, cm2/m2)  92 (12-270) 60 (22-275) <0.001 
VFI (median, range, cm2/m2)  58 (4-189) 74 (8-195) <0.001 
SMI (median, range, cm2/m2)  41 (16-74) 49 (26-77) <0.001 
SMD (median, range, HU)  35 (5-56) 34 (9-68) 0.712 
     
Outcomes     
POD 3 CRP (mg/L) ≤150 76 (54) 79 (49) 0.359 
 >150 65 (46) 84 (51)  
POD 4 CRP (mg/L) ≤150 77 (64) 95 (61) 0.706 
 >150 43 (36) 60 (39)  
Any complication No 109 (74) 101 (58) 0.003 
 Yes 39 (26) 73 (42)  
Infective complication No 122 (82) 123 (71) 0.018 
 Yes 26 (18) 51 (29)  
Clavien Dindo grade 0 108 (73) 98 (57) 0.005 
 1-2 30 (20) 56 (33)  
 3-5 9 (7) 17 (10)  
BMI body mass index, ASA American Society of Anaesthesiology, CRP C-reactive protein, GPS Glasgow Prognostic Score, mGPS 
modified Glasgow Prognostic Score, NLR neutrophil lymphocyte ratio, HU Hounsfield units, TFI total fat index, SFI subcutaneous fat 
index, VFI visceral fat index, SMI skeletal muscle index, SMD skeletal muscle density, POD postoperative day
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Table 5-2: Relationship between CT derived measures of body composition, clinicopathological characteristics, markers of systemic inflammation, and 
postoperative outcomes in female patients 
Characteristic  BMI obesity 
no/yes (n) 
P Visceral 
obesity 
no/yes (n) 
P Myopenia 
no/yes (n) 
P Myopenic 
obesity 
no/yes (n) 
P Myosteatosis 
no/yes (n) 
P 
Clinicopathological            
Age <65 27/20 0.295 12/35 0.953 41/6 <0.001 46/1 0.138 33/14 <0.001 
65-74 44/11  12/43  32/23  53/2  26/29  
>74 31/15  12/43  24/22  42/4  11/35  
ASA Score 1 17/2 0.060 10/9 0.015 11/8 0.202 19/0 0.568 17/2 <0.001 
 2 49/22  16/55  45/26  67/4  36/35  
 3 34/20  9/45  37/17  51/3  17/37  
 4 2/1  1/2  3/0  3/0  0/3  
TNM stage 0 3/0 0.755 0/3 0.294 1/2 0.697 3/0 0.298 2/1 0.759 
1 22/8  9/21  22/8  30/0  16/14  
2 38/23  18/43  40/21  57/4  22/39  
3 39/15  9/45  34/20  51/3  30/24  
Systemic 
inflammation 
           
GPS 0 61/26 0.668 19/68 0.959 63/24 0.054 83/4 0.839 49/38 0.019 
 1 (CRP) 15/10  4/11  9/6  13/2  8/17  
 1 (albumin) 9/6  9/16  14/11  24/1  7/8  
 2 17/4  4/17  11/10  21/0  6/15  
NLR ≤3 64/24 0.278 24/64 0.336 62/26 0.159 86/2 0.120 50/38 0.007 
 >3 38/22  12/48  35/25  55/5  20/40  
Outcomes            
POD 3 CRP (mg/L) <150 58/18 0.030 27/49 0.003 48/28 0.374 74/2 0.248 40/40 0.414 
 >150 38/27  9/56  46/19  60/5  30/41  
POD 4 CRP (mg/L) >150 59/18 0.024 22/55 0.020 47/30 0.239 75/2 0.348 44/40 0.046 
 <150 24/19  4/39  31/12  40/3  16/32  
Any complication No 79/30 0.158 32/77 0.017 73/36 0.560 104/5 1.000 55/54 0.262 
 Yes 23/16  4/35  24/15  37/2  15/24  
Infective complication No 88/34 0.100 35/87 0.005 81/41 0.654 116/6 1.000 61/61 0.196 
 Yes 14/12  1/25  16/10  25/1  9/17  
Clavien Dindo grade 0 77/30 0.241 31/76 0.032 72/35 0.448 102/5 0.646 53/54 0.344 
 1-2 17/13  3/27  19/11  29/1  11/9  
 3-5 6/3  1/8  5/4  8/1  4/5  
BMI body mass index, ASA American Society of Anaesthesiology, CRP C-reactive protein, GPS Glasgow Prognostic Score, mGPS modified Glasgow Prognostic Score, NLR neutrophil lymphocyte ratio,  HU 
Hounsfield units, TFI total fat index, SFI subcutaneous fat index, VFI visceral fat index, SMI skeletal muscle index, SMD skeletal muscle density, POD postoperative day, * Visceral obesity; VFA = males >160cm2, 
females >80cm2 , £ Myopenia; SMI = Males <52.4cm2/m2, Females <38.5cm2/m2, $ Myopenic obesity; myopenia and BMI >30kg/m2,  ¥  Myosteatosis; BMI <25kg/m2 and SMD <41HU, or BMI >25kg/m2 and SMD 
<33HU  
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Table 5-3: Relationship between CT derived measures of body composition, clinicopathological characteristics, markers of systemic inflammation, and 
postoperative outcomes in male patients 
Characteristic  BMI obesity 
no/yes (n) 
P Visceral 
obesity 
no/yes (n) 
P Myopenia 
no/yes (n) 
P Myopenic 
obesity 
no/yes (n) 
P Myosteatosis 
no/yes (n) 
P 
Clinicopathological            
Age <65 39/19 0.003 21/38 0.492 36/23 <0.001 56/3 0.968 37/21 <0.001 
65-74 47/25  17/55  28/44  65/7  24/48  
>74 41/2  19/24  3/40  41/2  4/39  
ASA Score 1 17/2 0.771 6/13 0.547 9/10 0.403 19/0 0.909 10/9 0.132 
 2 53/27  24/56  31/49  72/8  31/49  
 3 51/17  25/44  25/44  65/4  22/46  
 4 6/0  2/4  2/4  6/0  2/4  
TNM stage 0 3/1 0.879 4/0 0.050 2/2 0.816 4/0 0.705 2/2 0.413 
1 27/12  12/27  17/22  35/4  18/21  
2 53/16  26/43  20/49  65/4  22/47  
3 44/17  15/47  28/34  58/4  23/38  
Systemic 
inflammation 
           
GPS 0 65/38 0.001 26/77 0.007 55/48 <0.001 95/8 0.947 48/55 0.004 
 1 (CRP) 28/3  14/18  4/11  31/1  5/10  
 1 (albumin) 12/3  3/12  8/24  14/1  8/23  
 2 22/2  14/10  0/24  22/2  4/20  
NLR ≤3 62/30 0.055 22/71 0.006 42/51 0.043 84/9 0.146 40/52 0.116 
 >3 65/15  35/45  24/56  77/3  25/55  
Outcomes            
POD 3 CRP (mg/L) <150 59/20 0.859 29/50 0.508 30/49 1.000 75/4 0.537 32/47 0.518 
 >150 60/23  26/58  32/52  77/7  29/54  
POD 4 CRP (mg/L) >150 70/25 1.000 30/65 0.860 38/57 1.000 89/6 1.000 36/59 0.864 
 <150 44/15  18/42  24/36  56/4  21/38  
Any complication No 75/26 0.862 32/69 0.746 38/63 0.875 94/7 1.000 40/61 0.529 
 Yes 52/20  25/48  29/44  68/5  25/47  
Infective complication No 92/31 0.570 40/83 1.000 44/79 0.305 115/8 0.749 43/80 0.301 
 Yes 35/15  17/34  23/28  47/4  22/28  
Clavien Dindo grade 0 73/25 0.523 32/66 0.903 37/61 0.789 91/7 0.798 39/59 0.240 
 1-2 40/15  19/37  23/33  53/3  21/34  
 3-5 12/6  6/12  7/11  16/2  4/14  
BMI body mass index, ASA American Society of Anaesthesiology, CRP C-reactive protein, GPS Glasgow Prognostic Score, mGPS modified Glasgow Prognostic Score, NLR neutrophil lymphocyte ratio, HU 
Hounsfield units, TFI total fat index, SFI subcutaneous fat index, VFI visceral fat index, SMI skeletal muscle index, SMD skeletal muscle density, POD postoperative day, * Visceral obesity; VFA = males >160cm2, 
females >80cm2,  £ Myopenia; SMI = Males <52.4cm2/m2, Females <38.5cm2/m2, $ Myopenic obesity; myopenia and BMI >30kg/m2 , ¥  Myosteatosis; BMI <25kg/m2 and SMD <41HU, or BMI >25kg/m2 and SMD 
<33HU
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 Figures and Legends 
 
Figure 5-1: Example of selection of CT body composition fat areas using ImageJ software: (A) mid-L3 
vertebra axial slice from preoperative portal venous CT, (B) threshold selection of adipose tissue using 
automatic selection of pixels of radiodensity ranging -190 to -30 Hounsfield Units (HU), (C) region of 
interest selection for total fat area (TFA, cm2), (D) ROI selection for visceral fat area (VFA, cm2) 
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Figure 5-2: Example of selection of CT body composition skeletal muscle area using ImageJ software: (A) mid-L3 vertebra axial slice from preoperative portal venous phase 
CT, (B) threshold selection of skeletal muscle tissue using automatic selection of pixels of radiodensity ranging -29 to 150 Hounsfield Units (HU), (C) region of interest (ROI) 
selection for skeletal muscle area (SMA, cm2) 
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6 The relationship between cardiopulmonary exercise 
test variables, the postoperative systemic 
inflammatory response, and complications following 
surgery for colorectal cancer 
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 Introduction 
Colorectal cancer is a leading cause of death in the developed world (Cancer Research 
UK).  Surgery continues to form the mainstay of treatment in the majority of cases, 
however there is a significant associated degree of morbidity and mortality (Ghaferi et al. 
2011).  Long-term survival is primarily dictated by tumour differentiation and stage at 
presentation, however it is increasingly recognised that postoperative complications have a 
significant impact on long-term oncologic outcomes (Khuri et al. 2005, Law et al. 2007, 
Mirnezami et al. 2011).   
Cardiopulmonary exercise testing (CPET/CPX) has been developed as a method of 
assessing patients’ ability to meet the increased oxygen demand of major surgery (Older et 
al. 1993).  It represents a dynamic, non-invasive assessment of a patient’s cardiovascular 
and pulmonary reserve (Smith et al. 2009).  Two key measurements relating to oxygen 
delivery can be derived via CPET: oxygen consumption at the anaerobic threshold (VO2 at 
AT) which represents the point at which anaerobic metabolism is required in addition to 
aerobic metabolism to meet tissue energy demand, and oxygen consumption at peak 
exercise (VO2 at peak).  Patients with VO2 at AT <11ml/min/kg or VO2 at peak 
<19ml/min/kg are at significant risk of postoperative cardiovascular death and also of 
surgical complications following major abdominal surgery (Older et al. 1999).  Very 
similar thresholds have also been found to predict the development of postoperative 
complications in surgery for oesophagogastric cancer (Moyes et al. 2013), rectal cancer 
(West et al. 2014a) and colon cancer (West et al. 2014b). 
The magnitude of the postoperative systemic inflammatory response is associated with 
infective complications, and complications of greater severity, following surgery for 
colorectal cancer (Platt et al. 2012, McSorley Chapter 3).  Indeed, threshold values of the 
acute phase reactant, C-reactive protein (CRP) have been established in the postoperative 
period which are associated with the development of postoperative complications and the 
need for investigation (Adamina et al. 2015, McDermott et al. 2015).  The exact 
mechanism by which poor VO2 at AT and VO2 at peak exercise are linked to the 
development of postoperative complications is incompletely understood.  It may be that 
poor cardiopulmonary exercise tolerance leads to the development of postoperative 
complications due to an exaggerated postoperative systemic inflammatory response. 
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Therefore, the aim of the present pilot study was to investigate the relationship between 
CPET measurements, the preoperative systemic inflammatory response as measured by 
mGPS, the postoperative systemic inflammatory response as evidenced by CRP, and 
complications following surgery for colorectal cancer.  
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 Patients and Methods 
6.2.1 Patients 
This observational pilot study included patients who had undergone CPET prior to elective 
surgery for histologically confirmed colorectal cancer in a single centre between 
September 2008 and April 2017. 
All patients received prophylactic antibiotics and venous thromboprophylaxis prior to the 
induction of anaesthesia as per hospital policy.  Further postoperative investigation and 
intervention was at the discretion of the patient’s surgical team. 
6.2.2 Methods 
Clinicopathological data were collected prospectively in a database and anonymised.  
Recorded information included patient demographics, American Society of Anesthesiology 
score (ASA), body mass index (BMI), smoking status, tumour site, TNM stage (TNM, 
AJCC), surgical approach, preoperative and postoperative serum CRP and albumin 
measurements.  Data regarding the nature, severity, and management of complications was 
retrospectively categorised using the Clavien Dindo scale (Dindo et al. 2004).  Any 
uncertainties were addressed by review of electronic and/or physical case notes.  The study 
was approved by the West of Scotland Research Ethics Committee, Glasgow. 
Serum concentrations of CRP (mg/L) were measured using an autoanalyzer (Architect; 
Abbot Diagnostics, Maidenhead, UK) with a lower detectable limit of 0.2 mg/L as was 
serum albumin (normal range 35-50g/L).  The preoperative modified Glasgow Prognostic 
Score (mGPS) was calculated from preoperative serum CRP and albumin (McMillan 
2013).   
Cardiopulmonary exercise testing was performed in a single respiratory function laboratory 
using a ZAN 600 (nSpire Health, Hertford, UK) and Ergoselect bicycle ergometer 
(Ergoline, Bitz, Germany).  A doctor and resuscitation equipment were present during all 
tests.  Several variables were recorded including electrocardiography, blood pressure, 
oxygen uptake, and carbon dioxide output from analysis of inspiratory and expiratory 
gases.  Patients were exposed to an incremental physical exercise protocol to their 
maximally tolerated level which was determined by exhaustion, symptomatic 
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breathlessness, or pain.  The measured variables along with the exercise protocol allowed 
VO2 at AT and at peak exercise to be quantified. 
6.2.3 Statistical Analysis 
In addition to being analysed as continuous variables, patients were grouped according to 
the previously described thresholds of VO2 at AT (<11 or >11 ml/min/kg) and at peak 
exercise (<19 or >19 ml/min/kg).  Categorical data were compared using the Chi-square 
test or Fisher’s exact test where appropriate.  Continuous data were presented as median 
and range and were compared using the Mann-Whitney U test or Kruskal-Wallis test in 
multiple groups.  Postoperative CRP concentrations were displayed graphically by 
postoperative day as median and 95% confidence interval.  Correlation between VO2 at AT 
and VO2 at peak exercise and the peak postoperative CRP concentration was assessed 
using Spearman’s correlation coefficients.  Two sided p values <0.05 were considered 
statistically significant.  Statistical analyses were performed using IBM SPSS version 22 
for Windows (Chicago, IL, USA). 
  
     
 
141 
  
 Results 
6.3.1 Patients 
38 patients completed CPET prior to elective surgery for colorectal cancer at Glasgow 
Royal Infirmary between 2008 and 2017 (Table 6-1).  The majority were male (30, 79%), 
over 65 years old (30, 79%), with colonic cancer (23, 61%) and node negative disease (24, 
63%).  14 patients (37%) had open surgery and 24 (63%) had a laparoscopic resection.  
Prior to surgery, 3 patients with locally advanced or margin threatening rectal cancer 
underwent neoadjuvant chemoradiotherapy (nCRT).  There were no cases of pathological 
complete response. 
6.3.2 Complications 
Of the 38 patients, 15 (39%) experienced complications (Table 6-1).  No patients died 
within 30 days of surgery or during the same admission.  Of the patients with 
complications, 10 were infective and 5 were non-infective.  When classified using the 
Clavien Dindo scale, 12 were grade 1-2 (i.e. required minor intervention) and 3 were grade 
3-4 (i.e. necessitated major intervention).   
6.3.3 Associations between CPET variables, co-morbidity and mGPS 
There was a significant positive correlation (rs=0.628, p<0.001) between VO2 at anaerobic 
threshold (AT) and VO2 at peak exercise (Figure 6-1).  An increasing burden of co-
morbidity, as measured by ASA score (Figure 6-2), was significantly associated with 
progressively lower VO2 at peak exercise (median 22 vs. 19 vs. 15 vs. 12 ml/kg/min, 
p=0.014) but not VO2 at AT (p=0.058).   
When VO2 at AT was compared as a continuous variable amongst patients grouped by 
preoperative mGPS 0, 1, and 2 (Figure 6-3), there was no significant association 
(p=0.147).  However, when VO2 at peak exercise was compared as a continuous variable 
amongst patients grouped by mGPS 0, 1, and 2 (Figure 6-3), higher mGPS was 
significantly associated with progressively lower VO2 at peak exercise (median 18 vs. 16 
vs. 14 ml/kg/min respectively, p=0.039).   
There was a non-significant linear trend toward greater preoperative systemic 
inflammation in patients with a higher ASA score (p=0.058).     
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6.3.4 VO2 at anaerobic threshold and the postoperative SIR 
14 patients (37%) had VO2 at AT >11ml/min/kg and 24 patients (63%) had VO2 at AT 
<11ml/min/kg (Table 6-1).  When the two groups were compared there was a significant 
association between VO2 at AT and ASA score (p=0.041).  There was no significant 
association between VO2 at AT and other preoperative characteristics including patient 
age, sex, BMI, smoking status, tumour site, TNM stage, preoperative mGPS, or 
neoadjuvant treatment (Table 6-1).   
There were no significant associations between VO2 at AT and postoperative 
complications, the established CRP thresholds on postoperative days 3 or 4 (Table 1), or 
the postoperative CRP trend (Figure 6-2).  When both VO2 at AT and peak postoperative 
CRP (day 4) concentrations were compared as continuous variables (Figure 6-5), there was 
no significant correlation (p=0.885). 
6.3.5 VO2 at peak exercise and the postoperative SIR 
13 patients (34%) had VO2 at peak exercise >19ml/min/kg and 25 patients (66%) had VO2 
at peak exercise <19ml/min/kg (Table 6-1).  When the two groups were compared (Table 
1) there was a significant association between VO2 at peak exercise and ASA score 
(p=0.004).  A significantly higher proportion of patients with VO2 at peak exercise 
<19ml/min/kg had an mGPS of 1-2 (41% vs. 8%, p=0.036).  A significantly lower 
proportion of patients with VO2 at peak exercise <19ml/min/kg underwent nCRT (0% vs. 
23%, p=0.034).  With regard to intraoperative variables (Table 6-1), a significantly higher 
proportion of patients with VO2 at peak exercise <19ml/min/kg underwent laparoscopic 
surgery (84% vs. 23%, p<0.001).   
There was no significant association between VO2 at peak exercise and postoperative 
complications, established CRP thresholds on postoperative days 3 or 4 (Table 6-1), or the 
postoperative CRP trend (Figure 6-4).  When VO2 at peak exercise and peak postoperative 
CRP (day 3) concentrations were compared as continuous variables (Figure 6-5), there was 
no significant correlation (p=0.898).  
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 Discussion 
The present pilot study confirms the relationship between CPET derived measures of 
exercise tolerance and co-morbidity as measured by ASA score in patients prior to surgery 
for colorectal cancer.  Moreover, the present results show for the first time an inverse 
relationship between the VO2 at peak exercise and the preoperative systemic inflammatory 
response.  There was no significant association with the magnitude of the postoperative 
systemic inflammatory respons, however, given the small numbers of patients examined, 
these relationships warrant further investigation.   
The neuroendocrine, metabolic, and immune responses to surgical trauma lead to an 
increase in oxygen requirement from baseline usually supplied by increasing tissue oxygen 
extraction and cardiac output in the postoperative period, with the aim of increasing 
oxygen delivery (Shoemaker et al. 1979).  However, not all patients are able to utilise these 
mechanisms sufficiently to prevent the accrual of an “oxygen debt”, when oxygen delivery 
is outstripped by tissue oxygen requirement (Waxman et al. 1981).  CPET thus uses graded 
exercise to quantify a given patient’s anaerobic threshold and other measures including 
VO2 at peak exercise and MET.  These CPET variables are associated with postoperative 
outcomes following abdominal and colorectal surgery (Older et al. 1999, West et al. 2014a, 
West et al. 2014b).   
In the present study, there was a significant association between poorer VO2 at peak 
exercise and an increasing burden of co-morbidity as defined by ASA score.  Although the 
relationship between VO2 at the anaerobic threshold and ASA score did not reach 
significance, there was a strong inverse trend.  This may simply relate to the small numbers 
of included patients.  However, it may also reflect the differences in the two CPET derived 
variables and be explained by how ASA score is assigned.  ASA score is assigned both by 
the presence of co-morbidity and by overall physical limitation caused by these co-
morbidities.  Although such co-morbidities will likely reduce a patient’s anaerobic 
threshold, it may be that the physical limitation denoted by their ASA score is better 
encapsulated by their maximal exercise ability and thus VO2 at peak exercise. 
It was of interest that a significant association was found between VO2 at peak exercise 
and the preoperative mGPS at the univariate level.  It remains unclear whether this 
relationship is explained by the association between preoperative systemic inflammation 
and co-morbid state, or other effects.  Indeed, the preoperative systemic inflammatory 
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response has previously been shown to be directly associated with preoperative co-
morbidity in patients undergoing surgery for colorectal cancer (Richards et al. 2010), and it 
may be this which links mGPS to reduced peak exercise tolerance. This finding was not 
confirmed by the results of the present study.  However, the trend to association between 
mGPS and ASA score was likely non-significant due to patient numbers.  Alternatively, 
systemic inflammation has a key causal role in the development of the cancer cachexia 
syndrome, with loss of skeletal muscle quantity and quality, and resultant loss of physical 
function in patients with cancer (McSorley et al. 2017).  It may be that systemic 
inflammation exerts its influence on exercise tolerance through this mechanism.   
The degree of oxidative stress placed on the patient during surgery has been found to be 
associated with the production of pro-inflammatory cytokines (Rixen et al. 2000).  It has 
been postulated that oxidative stress and resultant tissue hypoxia, especially in the gut, 
drives a significant proportion of the postoperative systemic inflammatory response 
(Mainous et al. 1995).  Indeed, it is well recognised that tissue hypoxia can lead to 
activation and augmentation of the innate immune system via hypoxia-inducible factor 1α 
(HIF-1α) (Peyssonnaux et al. 2005, Nizet et al .2009).   
Although previous studies in colorectal surgery have reported an association between 
patients with VO2 at AT <11ml/min/kg and VO2 at peak exercise <19ml/min/kg and the 
development of postoperative complications (West et al. 2014a, West et al. 2014b), this was 
not confirmed in the present study.  This is most likely due to the small number of patients 
in the present study.  Postoperative complications, whether categorised by their type or 
severity, are associated with poorer long-term oncologic outcomes following surgery for 
colorectal cancer (McSorley, Introduction). The magnitude of the postoperative systemic 
inflammatory response, as evidenced by CRP, is increasingly understood to be associated 
with the development of postoperative complications following surgery for colorectal 
cancer (Singh et al. 2014).  Indeed, a recent comprehensive review suggests that CRP 
concentrations >150mg/L on postoperative days 3-5 are associated with the development 
of postoperative complications and should prompt investigation by the surgical team 
(McDermott et al. 2015).  Furthermore, studies in surgery for oesophageal and gastric 
cancer suggest that the magnitude of the postoperative systemic inflammatory response is 
itself a prognostic factor (Matsuda et al. 2015, Saito et al. 2015).   
The main limitation of the present study is the small number of included patients.  
Preoperative CPET is not routinely used as an evaluation of fitness for colorectal surgery 
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in our unit at present.  These small numbers lead to limited ability to make confident 
statements about the association between CPET, postoperative CRP, and complications.  
Indeed, there were significant differences in the proportion of patients undergoing open or 
laparoscopic surgery when divided into groups by CPET variables.  Although laparoscopic 
surgery has been shown to reduce the magnitude of the postoperative systemic 
inflammatory response, small numbers prevented any further, meaningful subgroup 
analysis (Watt et al. 2015). 
In conclusion, the present pilot study reports a possible association between preoperative 
CPET derived measures of exercise tolerance and the preoperative systemic inflammatory 
response in patients undergoing surgery for colorectal cancer.  The mGPS may be a 
surrogate for overall “fitness” in these patients, or may be more directly related to poorer 
exercise testing results through effects on skeletal muscle quality and quantity.  No 
association was found between CPET derived measures and the magnitude of the 
postoperative systemic inflammatory response, however small numbers and the presence 
of important confounders mean that further work in a larger cohort of patients is warranted. 
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 Tables and Footnotes 
Table 6-1: Patient characteristics and postoperative C-reactive protein concentrations grouped by VO2 
at the anaerobic threshold and peak exercise 
Characteristic 
Cardiopulmonary exercise test variable 
VO2 at AT 
<11ml/kg/mi
n (n) 
VO2 at AT 
>11ml/kg/mi
n (n) 
P 
VO2 at peak 
<19ml/kg/mi
n (n) 
VO2 at peak 
>19ml/kg/m
in (n) 
P 
Preoperative       
Age (<65/65-74/>74) 5/8/11 3/7/4 0.488 4/9/12 4/6/3 0.130 
Sex (male/female) 19/5 11/3 1.000 19/6 11/2 0.689 
ASA score (1/2/3/4) 0/11/12/1 2/8/4/0 0.041 0/10/14/1 2/9/2/0 0.004 
BMI (<20/20-25/26-30/>30, kg/m2) 1/4/7/12 1/4/5/4 0.206 1/4/7/13 1/4/5/3 0.106 
Smoker (never/ex/current) 11/9/4 6/6/2 0.981 10/12/3 10/12/3 0.912 
Site (colon/rectum) 16/8 7/7 0.492 17/8 6/7 0.295 
TNM stage (I/II/III/IV) 2/12/9/0 3/7/3/1 0.510 3/13/9/0 2/6/3/1 0.969 
Preop mGPS (0/1-2) 14/8 11/2 0.259 13/9 12/1 0.036 
Neoadjuvant (yes/no) 1/23 2/12 0.542 0/25 3/10 0.034 
Intraoperative       
Approach (open/laparoscopic) 6/18 8/6 0.081 4/21 10/3 <0.001 
Stoma (yes/no) 10/13 6/8 1.000 11/13 5/8 0.666 
Transfusion (yes/no) 1/20 0.10 1.000 1/20 0/10 1.000 
Surgery > 4h (yes/no) 14/10 6/8 0.503 16/9 4/9 0.087 
Postoperative       
Any complication (yes/no) 9/15 6/8 1.000 10/15 5/8 1.000 
Clavien Dindo grade 3-5(yes/no) 8/16 2/12 0.268 2/23 1/12 1.000 
Length of stay (median,range,days) 8 (3-19) 8 (5-15) 0.790 8 (3-15) 9 (5-19) 0.169 
POD 3 CRP >150mg/L (yes/no) 11/12 8/4 0.476 12/12 7/4 0.493 
POD 4 CRP >150mg/L (yes/no) 5/12 5/9 0.709 6/13 4/8 0.919 
ASA American Society of Anesthesiology, BMI Body Mass Index, AT anaerobic threshold, mGPS modified 
Glasgow Prognostic Score, POD postoperative day, CRP C-reactive protein 
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 Figures and Legends 
 
Figure 6-1: Scatter plot of VO2 at anaerobic threshold (ml/kg/min) and VO2 at peak exercise 
(ml/kg/min) 
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Figure 6-2: Box plots of (A) VO2 at anaerobic threshold (ml/kg/min) and (B) VO2 at peak exercise (ml/kg/min) grouped by American Society of Anesthesiology (ASA) score 
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Figure 6-3: Box plots of (A) VO2 at anaerobic threshold (ml/kg/min) and (B) VO2 at peak exercise (ml/kg/min) grouped by modified Glasgow Prognostic Score (mGPS) 
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Figure 6-4: Median postoperative C-reactive protein (CRP) concentrations (mg/L) in patients grouped by (A) VO2 at the anaerobic threshold (ml/kg/min) and (B) VO2 at 
peak exercise 
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Figure 6-5: Scatter plot of postoperative day 3 C-reactive protein (CRP) concentrations (mg/L) and (A) VO2 at the anaerobic threshold (ml/kg/min) and (B) VO2 at peak 
exercise (ml/kg/min) 
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7 The relationship between systemic inflammation and 
stoma formation following anterior resection for 
rectal cancer: a cross-sectional study 
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  Introduction 
Rectal cancer is one of the most prevalent cancers diagnosed in the western world (CRUK 
2014). Anterior resection with total mesorectal excision (TME) is the preferred surgical 
technique to preserve the anal sphincter and avoid a permanent colostomy where 
abdominoperineal resection is not required (Abraham et al. 2005). However, anterior 
resection is associated with increased risk of anastomotic leakage, a major complication of 
this type of rectal surgery, when compared to resection of colorectal cancer in other 
locations (Matthiesen et al. 2004).   Furthermore, anastomotic leakage has been indicated 
to be associated with increased risk of local recurrence and decreased short and long term 
survival of patients who have undergone potentially curative resection (Mirnezami et al. 
2011, Artinyan et al. 2015). 
Recent evidence suggests that the postoperative systemic inflammatory response, measured 
by C-reactive protein (CRP), is associated with both short and long term outcomes in 
colorectal cancer patients (Adamina et al. 2015, McSorley Chapter 4). A recent 
comprehensive review has suggested that CRP concentrations exceeding 150mg/L on 
postoperative days 3 to 5 should alert clinicians to the possible development of 
postoperative complications, including anastomotic leakage, precluding early discharge 
(McDermott et al. 2015).  
Several studies have suggested that construction of a defunctioning stoma in patients who 
are undergoing anterior resection reduces the incidence of postoperative complications, 
including anastomotic leakage, and reoperation (Huser et al 2008, Tan et al. 2009, 
Montedori et al. 2010).  Although it has traditionally been thought that this reduction in 
anastomotic leak rate is due to diversion of the faecal stream, it may be that the formation 
of a stoma attenuates the magnitude of the postoperative systemic inflammatory response 
and that it is through this mechanism by which they reduce the rate of postoperative 
complications. 
Therefore, the aim of the present study was to investigate the relationship between 
defunctioning stoma formation, stoma reversal, the magnitude of the postoperative 
systemic inflammatory response, and complications in rectal cancer patients who have 
undergone anterior resection.  
  
     
 
154 
  
 Patients and Methods 
7.2.1 Patients 
Patients with histologically proven rectal cancer who underwent anterior resection, 
between February 2008 and April 2015 at a single centre were included in the study.  
Patients who underwent emergency surgery, palliative procedures, or who had existing 
inflammatory conditions were excluded.  Neoadjuvant treatment was offered to patients 
with histologically proven, locally advanced (T3-T4, borderline operable or inoperable) 
rectal tumours following discussion at a multi-disciplinary colorectal oncology meeting.   
All patients received prophylactic antibiotics and venous thromboprophylaxis prior to the 
induction of anaesthesia as per hospital policy.  All patients had a primary anastomosis 
formed and the decision to form a proximal defunctioning stoma, with temporary intent, 
was at the discretion of the operating surgeon.  Patients had routine preoperative blood 
sampling including a full blood count (FBC), serum CRP, and albumin concentration.   
On each postoperative day, patients were clinically assessed and had blood samples, 
including serum CRP, obtained routinely until discharged.  Further postoperative 
investigation and intervention was at the discretion of the patient’s surgical team, who 
were not blinded to blood results.  This study was approved by the West of Scotland 
Research Ethics Committee.     
7.2.2  Methods 
Data was collected prospectively in a database, anonymised, and subsequently analysed 
retrospectively.  Recorded information included patient demographics, clinicopathological 
data, operative data, postoperative data, and date of stoma reversal if applicable.  Data 
regarding the nature of the operation with regard to its categorisation and extent were taken 
form the operation note.  The height of the resected lesion and anastomosis was not 
routinely recorded. 
Serum concentrations of CRP (mg/L) were measured using an autoanalyzer (Architect; 
Abbot Diagnostics, Maidenhead, UK) with a lower detectable limit of 0.2 mg/L, as was 
serum albumin (normal range 35-50g/L).  The preoperative modified Glasgow Prognostic 
Score (mGPS) was calculated in patients for whom serum CRP and albumin concentrations 
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were available (McMillan 2013).  Exceeding the established postoperative CRP threshold 
of 150mg/L on postoperative days 3 or 4 was recorded (McDermott et al. 2015). 
Postoperative complications were recorded up to and including the first follow up clinic, 
usually six weeks after discharge from hospital.  Infective complications were categorised 
as described elsewhere and summarised here briefly (Platt et al. 2012). Wound (superficial 
surgical site) infection was defined as the presence of pus either spontaneously discharging 
from the wound or requiring drainage.  Deep surgical site infection was defined as surgical 
or image-guided drainage of intra-abdominal pus.  Anastomotic leak was defined as 
radiologically verified fistula to bowel anastomosis or diagnosed at laparotomy. 
Pneumonia was defined by fever above 38.5oC and consolidatory chest X-ray findings 
requiring antibiotic treatment.  Septicaemia was defined by the presence of sepsis 
combined with positive blood culture.  Urinary tract infection (UTI) was only included if 
complicated by septicaemia and confirmed with positive urine culture. Complications were 
also classified by severity using the Clavien Dindo grade (Dindo et al. 2004).   
7.2.3 Statistical Analysis 
Categorical data were compared using the Chi square test.  Continuous data were non-
normal so were displayed as medians and ranges, and were compared using the Mann-
Whitney U test.  Significant differences were found in the rate of defunctioning stoma 
formation dependent on whether a laparoscopic or open surgical approach was used, and so 
a post hoc subgroup analysis was performed in those patients who underwent open surgery.  
Binary logistic regression of factors associated with permanent stoma was performed using 
a backward conditional model with removal of terms with p>0.05 at each step.  Statistical 
analyses were performed using IBM SPSS version 22 for Windows (Chicago, IL, USA).  
Two sided p values <0.05 were considered statistically significant.  Missing data were 
excluded from analysis. 
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 Results 
7.3.1 Patients 
After exclusion of those patients who underwent emergency or palliative surgery, or with 
existing inflammatory disease, 869 resections for colorectal cancer were performed during 
the study period, with 251 patients undergoing surgery for rectal cancer, of which 167 
patients underwent anterior resection and were included in the study. The majority were 
male (102, 61%), over 65 years old (93, 56%), and underwent open surgery (109, 65%).  
36 patients (22%) underwent neoadjuvant chemoradiotherapy.  7 patients (4%) had 
metastatic disease at the time of surgery, all located in the liver, of which 4 underwent 
synchronous resection, and 3 underwent staged liver resection following anterior resection.  
79 patients (47%) developed a postoperative complication of which 73 were infective. 
There were 12 reported anastomotic leaks (7%).  There were 3 deaths (2%) within the 
immediate postoperative period. Of the 79 patients who developed a postoperative 
complication, 61 were Clavien Dindo grade 1-2 and 18 were Clavien Dindo grade 3-5. 100 
(60%) patients who underwent anterior resection had a defunctioning stoma formed. 
7.3.2 Variables associated with stoma formation 
Defunctioning stoma formation (Table 7-1) was significantly associated with male sex 
(69% vs. 50%, p=0.017), neoadjuvant chemoradiotherapy (30% vs 9%, p=0.001), and open 
surgery (71% vs. 55%, p=0.040). There was no significant association between stoma 
formation and other patient factors including age, BMI, smoking status, ASA score, or 
TNM staging. No significant association was found between stoma formation and 
preoperative mGPS.  There was no significant association between stoma formation and 
CRP on postoperative days 3 or 4.  There was no significant difference in the incidence or 
severity of postoperative complication, or in the rate of anastomotic leak between either 
group.   
7.3.3 Variables associated with stoma formation in patients undergoing 
open surgery 
Within the patients who underwent open surgery, there was significant association (Table 
7-2) between stoma formation and neoadjuvant chemoradiotherapy (34% vs 14%, 
p=0.029). There was no significant association between stoma formation and other patient 
factors including age, BMI, smoking status, ASA score, TNM staging, or operation type. 
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There was no significant difference in CRP between the patient groups with and without 
stoma on postoperative days 3 or 4 (Figure 7-1). There was no significant association 
between stoma formation and the incidence or severity of postoperative complications.  
7.3.4 Variables associated with permanent stoma in patients undergoing 
open surgery 
Of the 71 patients who had open surgery and a defunctioning stoma formed, 53 (75%) had 
their stoma reversed (Table 7-3).  The median time from anterior resection to stoma 
reversal was 8 months (range 1-23).  Permanent stoma was significantly associated with 
increasing age (p=0.011), higher CRP on postoperative days 3 (212mg/L vs 144mg/L, 
p=0.048) and 4 (179mg/L vs 128mg/L, p=0.044), the proportion of patients exceeding the 
established CRP threshold of 150mg/L on postoperative day 4 (67% vs 37%, p=0.039), a 
higher incidence of postoperative complications (76% vs 47%, p=0.035), anastomotic 
leakage (24% vs 2%, p=0.003), and higher Clavien Dindo grade (p=0.036).  However, 
there was no significant association between permanent stoma and BMI, smoking status, 
ASA score, TNM staging, or neoadjuvant chemoradiotherapy.  At binary logistic 
regression of those factors found to be significantly associated with permanent stoma, 
increasing age (OR 3.46, 95% CI 1.46-8.12, p=0.005), and Clavien Dindo grade (OR 3.00, 
95% CI 1.14-7.84, p=0.025) remained significantly independently associated.  
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 Discussion 
The results of the present study suggest that temporary defunctioning stoma formation is 
not associated with the magnitude of the postoperative systemic inflammatory response, or 
complications in patients who have undergone anterior resection for rectal cancer.  
However, they do suggest that increasing age, inflammation, and a complicated 
postoperative course increases the likelihood of having a permanent stoma. 
In keeping with some earlier published reports, the present study reports that males and 
patients who have undergone neoadjuvant chemoradiotherapy are more likely to have a 
defunctioning stoma at anterior resection (Marusch et al. 2002, Gastinger et al. 2005). In 
addition, the present study is also in agreement with a single study which demonstrated 
that stoma formation is not associated with body mass index (Karahasanoglu et al. 2011). 
The present study also reports that stoma formation is not associated with ASA score, 
TNM staging and age group which is in keeping with other published work (Gastinger et 
al. 2005).  
To the author’s knowledge, there has been no prior study examining the association 
between stoma formation and preoperative systemic inflammatory status. There is limited 
evidence which examines the association between stoma formation the postoperative 
systemic inflammatory response: a single study, which investigated CRP on the first and 
third postoperative day which reported a significant difference in CRP on postoperative 
day 3 (Ma et al. 2013). In contrast, the present study reported no association between CRP 
levels on postoperative days 3 or 4 between patient groups with and without stoma.  The 
anastomotic leak rate in the present study was around half that (8%) of Ma and colleagues’ 
study (16%) which may in part explain this difference.    
The present study demonstrates no association between stoma formation and postoperative 
complications when all included patients were considered. However, the present study 
reports a trend towards reduced incidence of anastomotic leakage in patients with stoma, 
although it did not reach statistical significance due to cohort size.  As surgical approach is 
a significant confounder with regard to the postoperative systemic inflammatory response, 
and was associated with the incidence of stoma formation in the present study, subgroup 
analysis was performed.   
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It was of interest that there was no significant association between stoma formation and 
patient factors such as BMI, ASA score, or smoking status.  There was, however, a 
significant association between stoma formation and neoadjuvant treatment, although 
recent evidence suggests no reduction in postoperative complication, unplanned 
reoperation, or mortality in patients who have a stoma formed following neoadjuvant 
treatment (Messaris et al. 2015).  It may be that perceived differences in rectal dissection in 
patients who have had neoadjuvant treatment prompts some surgeons to create more 
temporary defunctioning stomas in this patient group. 
The present study is in line with a few published studies, reporting that permanent stoma is 
associated with older patients (age<65) (Lee et al. 2015) and higher incidence of 
postoperative complications, including anastomotic leakage (Dulk et al. 2007, Floodeen et 
al. 2013, Kim et al. 2016). The present study also reports that permanent stoma is 
associated with higher CRP on postoperative days 3 and 4, and a higher proportion of 
patients who breached the CRP threshold on postoperative day 4.  Given the greater 
anastomotic leak rate and higher Clavien Dindo grade, this may simply reflect that patients 
experiencing significant complications are less likely to have subsequent stoma reversal, 
which would be in keeping with the result of the binary logistic regression analysis. 
However, to the author’s knowledge, there have not been any previous studies that have 
examined the relationship between postoperative systemic inflammatory response and 
permanent stoma.   
The main limitation of the present study is the relatively small number of patients 
undergoing anterior resection as a proportion of all patients operated on for colorectal 
cancer during the period.  However, this group was chosen, rather than the inclusion of 
resections at other locations, due the relatively high rate of stoma formation and to allow 
direct comparison.  The fact that data regarding lesion and anastomosis height was not 
recorded and that such a low proportion of patients had minimally invasive surgery 
following nCRT may lead to selection bias.  Furthermore, the retrospective nature of the 
study means that not all patients had CRP measured in the pre- and postoperative periods 
studied.  Finally, the high rate of both temporary stoma (60%), and of subsequent 
permanent stoma in that subgroup (25%), might suggest that more of the included patients 
should have been considered for permanent colostomy following an elective low 
Hartmann’s procedure from the outset.  The risk factors for permanent stoma; age and co-
morbidity, were those which might prompt the surgical team to pursue such a course of 
action at the outset.  
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In conclusion, the present study reports a lack of association between stoma formation and 
postoperative systemic inflammatory response in patients who have undergone anterior 
resection for rectal cancer.  However, both the systemic inflammatory response and 
postoperative complications were associated with permanent stoma.  
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 Tables and Footnotes 
Table 7-1: Relationship between temporary defunctioning stoma formation and clinicopathological 
variables in patients undergoing elective anterior resection of rectal cancer (n=167) 
Characteristic All Stoma P 
No Yes 
Sex (male/female) 102/65 33/34 69/31 0.017 
Age (<65/65-74/>74) 74/69/24 27/31/9 47/38/15 0.566 
BMI (<20/20-25/26-30/>30, kg/m2) 4/59/47/31 1/22/21/10 3/37/26/21 0.965 
ASA score (1/2/3/4) 44/71/40/2 13/29/19/0 31/42/21/2 0.235 
Smoking (no/ex/current) 277/66/23 32/27/8 45/39/15 0.839 
Preoperative mGPS (0/1/2) 135/14/9 51/8/4 84/6/5 0.356 
Neoadjuvant chemoradiotherapy (yes/no) 36/131 6/61 30/70 0.001 
Operative (laparoscopic/open) 58/107 29/36 29/71 0.040 
TNM stage (0/1/2/3/4) 4/40/56/58/7 0/19/26/18/2 4/21/30/40/5 0.141 
     
     
POD 3 CRP (median,range,mg/L) 147 (2-386) 143(21-354) 149(2-386) 0.464 
POD 4 CRP (median,range,mg/L) 128 (2-425) 133(20-425) 124(2-408) 0.495 
POD 3 CRP >150mg/L (yes/no) 70/80 25/34 45/46 0.396 
POD 4 CRP >150mg/L (yes/no) 55/84 19/31 36/53 0.777 
     
Any postoperative complication (yes/no) 79/82 29/35 50/47 0.439 
Anastomotic leakage (yes/no) 12/149 7/57 5/92 0.172 
Clavien Dindo Classification (0/1-2/3-5) 
82/61/18 
35/21/8 47/40/10 0.784 
     
Adjuvant therapy (yes/no) 41/126 16/51 25/75 0.704 
ASA American Society of Anaesthesiology, BMI Body Mass Index, CRP C-reactive protein, mGPS modified 
Glasgow Prognostic Score 
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Table 7-2: Relationship between temporary defunctioning stoma formation and clinicopathological 
variables in patients undergoing elective, open anterior resection for rectal cancer (n=107) 
Characteristic All Stoma P 
No Yes 
Sex (male/female) 63/44 18/18 45/26 0.184 
Age (<65/65-74/>74) 47/44/16 15/17/4 32/27/12 0.580 
BMI (<20/20-25/26-30/>30, kg/m2) 3/36/26/25 0/11/11/7 3/25/15/18 0.707 
ASA score (1/2/3/4) 29/46/26/1 6/18/10/0 23/28/16/1 0.309 
Smoking (no/ex/current) 49/42/15 19/13/4 30/29/11 0.597 
Preoperative mGPS (0/1/2) 89/7/8 26/4/4 63/3/4 0.175 
Neoadjuvant chemoradiotherapy (yes/no) 29/78 5/31 24/47 0.029 
TNM stage (0/1/2/3/4) 3/23/31/43/6 0/7/13/13/2 3/16/18/30/4 0.589 
     
POD 3 CRP (median,range,mg/L) 152 (37-386) 148(37-354) 153(40-386) 0.829 
POD 4 CRP (median,range,mg/L) 134 (2-408) 136(20-369) 133(2-408) 0.752 
POD 3 CRP >150mg/L (yes/no) 51/47 16/18 35/29 0.472 
POD 4 CRP >150mg/L (yes/no) 39/57 10/20 29/37 0.327 
     
Any postoperative complication (yes/no) 57/49 19/17 38/32 0.883 
Anastomotic leakage (yes/no) 8/98 3/33 5/65 0.826 
Clavien Dindo Classification (0/1-2/3-5) 49/45/12 17/15/4 32/30/8 0.785 
     
Adjuvant therapy (yes/no) 27/80 10/26 17/54 0.813 
ASA American Society of Anaesthesiology, BMI Body Mass Index, CRP C-reactive protein, mGPS modified 
Glasgow Prognostic Score 
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Table 7-3: Relationship between permanent stoma and clinicopathological variables in patients 
following stoma formation during elective, open anterior resection for rectal cancer (n=71) 
Characteristic All Permanent Stoma P 
No Yes  
Sex (male/female) 45/26 34/19 11/7 0.817 
Age (<65/65-74/>74) 32/27/12 29/18/6 3/9/6 0.011 
BMI (<20/20-25/26-30/>30, kg/m2) 3/26/16/19 2/19/12/15 1/7/4/4 0.606 
ASA score (1/2/3/4) 23/28/16/1 18/20/12/1 5/8/4/0 0.884 
Smoking (no/ex/current) 30/29/11 23/19/10 7/10/1 0.241 
Preoperative mGPS (0/1/2) 63/3/4 46/3/3 17/0/1 0.579 
Neoadjuvant chemoradiotherapy (yes/no) 24/47 19/34 5/13 0.532 
TNM stage (0/1/2/3/4) 3/16/17/30/4 2/13/13/22/3 1/3/4/8/1 0.974 
     
POD 3 CRP (median,range,mg/L) 152(37-386) 144(40-386) 212(55-333) 0.048 
POD 4 CRP (median,range,mg/L) 134(2-408) 128(2-388) 179(33-408) 0.039 
POD 3 CRP >150mg/L (yes/no) 35/29 24/25 11/4 0.097 
POD 4 CRP >150mg/L (yes/no) 29/37 19/32 10/5 0.044 
     
Any postoperative complication (yes/no) 38/32 25/28 13/4 0.035 
Anastomotic leakage (yes/no) 5/65 1/52 4/13 0.003 
Clavien Dindo Classification (0/1-2/3-5) 32/30/8 28/22/3 4/8/5 0.036 
     
Adjuvant therapy (yes/no) 17/54 14/39 3/15 0.510 
ASA American Society of Anaesthesiology, BMI Body Mass Index, CRP C-reactive protein, mGPS modified 
Glasgow Prognostic Score 
  
     
 
164 
  
 Figures and Legends 
 
Figure 7-1: Impact of stoma formation on the postoperative systemic inflammatory response following 
elective, open anterior resection for rectal cancer 
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8 The impact of operation duration on postoperative 
complications and the systemic inflammatory 
response following surgery for colorectal cancer 
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 Introduction 
As discussed in earlier chapters, postoperative serum C-reactive protein (CRP) has been 
found to be an objective marker of the magnitude of surgical injury and the postoperative 
systemic inflammatory, or “stress”, response (Watt et al. 2015c).  In the context of surgery 
for colorectal cancer, established threshold postoperative CRP concentrations are 
associated with the development of postoperative complications (McDermott et al. 2015).  
Furthermore, laparoscopic colorectal surgery has been found to be associated with lower 
postoperative serum CRP concentrations when compared to open surgery, suggesting a 
lesser degree of surgical trauma (Veenhoff et al. 2012, Ramanathan et al. 2015b, Watt et al. 
2015c).   
Several recent studies have reported that increasing operative duration has a negative 
impact on short term outcomes following both laparoscopic and open colorectal surgery in 
terms of increasing postoperative complication rates (Evans et al. 2012, Owen et al. 2013, 
Bailey et al. 2014), readmission rates (Kelly et al. 2013), and length of stay (Harrison et al. 
2014).  Studies, in patients undergoing aortic and spinal surgery, report that increasing 
operative time is associated with a greater postoperative systemic inflammatory response, 
and in particular, higher postoperative serum concentrations of CRP and IL 6 (Norman et 
al. 1997, Chung et al. 2011).  This finding suggests that longer operations lead to greater 
surgical trauma and/or complications which increase the postoperative systemic 
inflammatory response.  This is of interest given the observed associations between the 
magnitude of the postoperative systemic inflammatory response and postoperative 
complications, and with long term outcomes following surgery for colorectal cancer.   
To the authors’ knowledge no similar studies have examined the impact of operation 
duration on the postoperative systemic inflammatory response following surgery for 
colorectal cancer.  Therefore, the aim of the present observational study was to examine 
the impact of operative time on postoperative complications and the systemic 
inflammatory response following both open and laparoscopic surgery for colorectal cancer. 
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 Patients and Methods 
8.2.1 Patients 
This observational study included patients who underwent elective, potentially curative 
resection for histologically confirmed colorectal cancer at two centres between March 
2010 and May 2013.  Patients who underwent emergency surgery, with metastatic disease, 
or who had existing inflammatory conditions, e.g. inflammatory bowel disease and the 
systemic vasculitides, were excluded.  All patients received prophylactic antibiotics and 
venous thromboprophylaxis prior to the induction of anaesthesia as per hospital policy.  On 
each postoperative day patients were clinically assessed and had blood samples, including 
serum CRP, obtained as standard until discharged.  Further postoperative investigation and 
intervention was at the discretion of the patient’s surgical team. 
8.2.2 Methods 
Data was collected prospectively in a database, anonymised, and was subsequently 
analysed.  Recorded information included patient demographics, tumour site, TNM stage 
(TNM, AJCC), surgical approach, complications, and postoperative serum CRP 
measurements.  Data regarding the nature, severity, and management of complications was 
categorised using the Clavien Dindo scale (Dindo et al. 2004).  Data regarding operation 
duration was collected retrospectively from the operating room management software 
(Opera, v4.0, CHCA, Canada).  The duration of the operation in minutes was defined as 
the time from first incision to placement of the wound dressing.  Time in the anaesthetic 
room and/or theatre recovery was not included.  Serum concentrations of CRP (mg/L) were 
measured using an autoanalyzer (Architect; Abbot Diagnostics, Maidenhead, UK) with a 
lower detectable limit of 0.2 mg/L.  Any uncertainties were addressed by review of 
electronic and/or physical case notes. This study was approved by the West of Scotland 
Research Ethics Committee as part of surgical audit.    
8.2.3 Statistical Analysis 
Categorical data regarding patient characteristics were compared using the Chi square test.  
Data regarding postoperative CRP were not normally distributed and are presented as 
medians and ranges.  Medians of continuous variables were compared using the Mann-
Whitney U test.  Correlation between operation duration and CRP concentrations on 
postoperative days 3 and 4 were assessed using Spearman’s correlation coefficients and 
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scatter plots with CRP measured on a logarithmic scale.  In all tests, a two sided p value 
<0.05 was considered statistically significant.  Statistical analyses were performed using 
IBM SPSS version 22 for Windows (Chicago, IL, USA). 
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 Results 
In total, 341 patients were included in the study.  The majority were male (185, 54%), over 
65 years old (231, 68%), with colonic (241, 71%) and node negative disease (230, 67%).  
188 patients (55%) underwent open surgery and 153 (45%) underwent laparoscopic 
surgery.  Patients who underwent laparoscopic surgery had a longer median operation 
duration (220 mins vs. 150 mins, p<0.001) and lower median serum CRP on the second 
(124 mg/L vs. 174 mg/L, p<0.001), third (122 mg/L vs. 171 mg/L, p<0.001), and fourth 
(101 mg/L vs. 138 mg/L, p=0.013) postoperative days when compared to those who 
underwent open surgery.    
Of the total 341 patients (Table 8-1), the median operation duration was 180 mins (range 
42-500).  There was a significant association between surgery lasting longer than 180 mins 
and increasing age (p=0.016), male sex (p=0.041), rectal cancer (p<0.001), ASA score 
(p=0.011), preoperative mGPS (p=0.001), and neoadjuvant chemoradiotherapy (p=0.001).  
Surgery lasting longer than 180 mins was significantly associated with stoma formation 
(36% vs. 22%, p=0.024) and Clavien Dindo grade 3-5 complications (16% vs. 5%, 
p=0.001).  There was no significant correlation (Figure 8-1) between the operation duration 
and CRP on postoperative day 3 (rs=0.009), or 4 (rs=-0.040).  Furthermore, there was no 
significant association between operation duration and the established thresholds for 
postoperative CRP. 
Of the 188 patients who underwent open surgery (Table 8-2), the median operation 
duration was 150 mins (range 42-500).  100 (53%) experienced a complication, of which 
71 (38%) were infective type and 21 (11%) were Clavien Dindo grade 3-5 severity.  There 
was a significant association between surgery lasting longer than 150 mins and surgery for 
rectal cancer (p<0.001) and neoadjuvant chemoradiotherapy (p=0.005).  Surgery lasting 
longer than 150 mins was significantly associated with stoma formation (43% vs. 24%, 
p=0.022) and any postoperative complication (61% vs. 44%, p=0.001).  There was no 
significant correlation (Figure 8-2) between the operation duration and CRP on 
postoperative day 3 (rs=0.121), or 4 (rs=0.043).  Furthermore, there was no significant 
association between operation duration and the established thresholds for postoperative 
CRP. 
Of the 122 patients who underwent open surgery for colonic cancer (Table 8-3), the 
median operation duration was 140 mins (range 42-476).  63 (52%) experienced a 
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complication, of which 44 (36%) were infective type and 14 (11%) were Clavien Dindo 
grade 3-5 severity.  There were no significant associations between surgery lasting longer 
than 140 mins and any preoperative clinicopathological characteristics.  Surgery lasting 
longer than 140 mins was not significantly associated with stoma formation or 
postoperative complications.  There was no significant correlation (Figure 8-3) between the 
operation duration and CRP on postoperative day 3 (rs=0.192), or 4 (rs=0.054).  
Furthermore, there was no significant association between operation duration and the 
established thresholds for postoperative CRP. 
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 Discussion 
The results of the present study report no association between operative time and 
postoperative CRP, suggesting that the duration of an operation does not necessarily 
correlate with the degree of the surgical injury.  Furthermore, after adjusting for variables 
associated with the postoperative systemic inflammatory response and complications, 
including surgical approach and tumour location, there was no association with 
postoperative complications. 
In keeping with earlier published reports, the present study found that those who 
underwent laparoscopic surgery for colorectal cancer had a longer operation (Grailey et al. 
2012) and lower postoperative serum CRP (Karanika et al. 2013) when compared to those 
undergoing open surgery.  In the present study, surgery for a rectal cancer, and 
neoadjuvant treatment, were associated with longer operative time in both the open and 
laparoscopic groups.  Previous studies have reported longer operative duration in patients 
who have undergone surgery for rectal cancer following neoadjuvant therapy (Cheung et 
al. 2009), but this has not been universally replicated (Rosati et al. 2007, Akiyoshi et al. 
2009).   
Both IL6 and CRP concentrations in the postoperative period are thought to accurately 
represent the magnitude of the postoperative systemic inflammatory response and reflect 
the degree of surgical trauma (Watt et al. 2015c).  The use of laparoscopic surgical 
techniques is well recognised to be associated with less surgical trauma and attenuation of 
the postoperative systemic inflammatory response when compared to more traditional open 
surgical techniques (Watt et al. 2015c).  However, the reasons for this remain poorly 
understood.  Some suggestions include the smaller overall abdominal wound size, the use 
of warm CO2 insufflation, and the no-touch techniques employed during most minimally 
invasive surgery (Krikri et al. 2013).  Alternatively, it may be that selection of patients 
suitable for laparoscopic surgery in such clinical studies leads to biased reporting.    
This is of clinical interest due to the association between the magnitude of the 
postoperative systemic inflammatory response and outcomes following surgery for 
colorectal cancer (Adamina et al. 2015).  Exceeding established postoperative CRP 
thresholds has been shown to be associated with both postoperative complication severity 
(McSorley Chapter 3) and cancer specific survival (McSorley Chapter 4).  The results of 
the present study suggest that a longer operation does not necessarily reflect a greater 
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degree of surgical trauma, and that the surgical approach is of far more importance with 
regard to the postoperative systemic inflammatory response. 
The main limitation of the present study was the relatively small number of patients 
included, especially following subgroup analysis to control for the most significant 
cofounders: surgical approach and rectal disease.  This, however, was based on previous 
evidence demonstrating that laparoscopic procedures have a significantly longer operative 
time (Grailey et al. 2012) but lower postoperative serum CRP than open procedures 
(Veenhof et al. 2012, Ramanathan et al. 2015b, Watt et al. 2015c).  In addition, due to the 
retrospective nature of the study, there was a high proportion of missing data (almost 40%) 
with regard to BMI and stoma formation recording.  Given that BMI in particular is 
thought to relate to postoperative systemic inflammation this may well lead to significant 
bias.  Furthermore, although the use of the Opera theatre management software allowed for 
relatively straightforward data collection, the time recording for the start and end of each 
operation is user dependent and therefore prone to error. 
The present study demonstrates minimal impact of operation duration on the postoperative 
systemic inflammatory response following either open or laparoscopic surgery for 
colorectal cancer.  This suggests that the duration of the operation itself is not associated 
with the degree of surgical trauma, especially in comparison to the surgical approach used.  
Given the lower postoperative CRP concentrations in those undergoing laparoscopic 
procedures, it may be that open surgery, along with other, as yet unidentified, 
intraoperative variables, may contribute to the postoperative systemic inflammatory 
response more significantly. 
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 Tables and Footnotes 
Table 8-1: Impact of operation duration on postoperative complications and systemic inflammation 
after elective surgery for colorectal cancer 
Characteristic All  Operation duration (mins) 
<180 >180 P 
Age (<65/65-74/>74) 110/119/112 50/53/69 60/66/43 0.016 
Sex (male/female) 193/148 88/84 105/64 0.041 
TNM Stage (0/I/II/III) 7/80/143/111 1/35/82/54 6/45/61/57 0.255 
Site (colon/rectum) 241/100 142/30 99/70 <0.001 
ASA score (1/2/3/4) 38/136/119/11 14/63/68/7 24/73/51/4 0.011 
BMI (<20/20-25/25-30/>30) kg/m2 11/61/81/77 3/34/34/37 8/27/47/40 0.978 
mGPS (0/1/2) 241/25/57 110/10/41 131/15/16 0.001 
Neoadjuvant treatment (yes/no) 40/289 10/158 30/131 0.001 
     
Approach (open/laparoscopic) 188/153 122/50 66/103 <0.001 
Stoma (yes/no) 71/171 25/88 46/83 0.024 
Any complication (yes/no) 153/188 73/99 80/89 0.385 
Infective complication (yes/no) 111/230 52/120 59/110 0.419 
Clavien Dindo ≥3 complication 
(yes/no) 
36/305 9/163 27/142 0.001 
     
POD3 CRP >150 mg/L (yes/no) 156/157 74/79 82/78   0.652 
POD4 CRP >150 mg/L (yes/no) 118/162 56/81 62/81 0.717 
POD: postoperative day, CRP: c-reactive protein, ASA American Society of Anesthesiology, BMI body mass 
index, mGPS modified Glasgow Prognostic Score 
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Table 8-2: Impact of operation duration on postoperative complications and systemic inflammation 
after elective open surgery for colorectal cancer 
Characteristic All  Operation duration (mins) 
<150 >150 P 
Age (<65/65-74/>74) 59/62/67 29/26/34 30/36/33 0.829 
Sex (male/female) 103/85 48/41 55/44 0.884 
TNM Stage (0/I/II/III) 3/37/84/64 1/16/41/31 2/21/43/33 0.561 
Site (colon/rectum) 122/66 72/17 50/49 <0.001 
ASA score (1/2/3/4) 19/65/74/10 9/27/37/5 10/38/37/5 0.524 
BMI (<20/20-25/25-30/>30) kg/m2 7/41/44/43 2/19/13/23 5/22/31/20 0.332 
mGPS (0/1/2) 126/12/45 54/5/26 72/7/19 0.214 
Neoadjuvant treatment (yes/no) 30/152 7/80 23/72 0.005 
     
Stoma (yes/no) 51/94 15/47 36/47 0.022 
Any complication (yes/no) 100/88 39/50 61/38 0.019 
Infective complication (yes/no) 71/117 29/60 42/57 0.178 
Clavien Dindo ≥3 complication 
(yes/no) 
21/167 6/83 15/84 0.068 
     
POD3 CRP >150 mg/L (yes/no) 105/76 44/40 61/36   0.153 
POD4 CRP >150 mg/L (yes/no) 75/95 31/44 44/51 0.537 
POD: postoperative day, CRP: c-reactive protein, ASA American Society of Anesthesiology, BMI body mass 
index, mGPS modified Glasgow Prognostic Score  
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Table 8-3: Impact of operation duration on postoperative complications and systemic inflammation 
following elective, open surgery for colonic cancer 
Characteristic All  Operation duration (mins) 
<140 >140 P 
Age (<65/65-74/>74) 36/35/51 21/17/23 15/18/28 0.235 
Sex (male/female) 63/59 31/30 32/29 1.000 
TNM Stage (I/II/III) 24/60/38 11/33/17 13/27/21 0.798 
ASA score (1/2/3/4) 10/39/49/8 6/17/26/3 4/22/23/5 0.805 
BMI (<20/20-25/25-30/>30) kg/m2 6/22/23/24 1/10/10/14 5/12/13/10 0.109 
mGPS (0/1/2) 72/10/35 32/5/20 40/5/15 0.219 
     
Stoma (yes/no) 8/77 3/36 5/41 0.721 
Any complication (yes/no) 63/59 29/32 34/27 0.469 
Infective complication (yes/no) 44/78 20/41 24/37 0.572 
Clavien Dindo ≥3 complication (yes/no) 14/108 5/56 9/52 0.395 
     
POD3 CRP >150 mg/L (yes/no) 73/42 32/25 41/17   0.124 
POD4 CRP >150 mg/L (yes/no) 51/56 20/29 31/27 0.244 
POD: postoperative day, CRP: c-reactive protein, ASA American Society of Anesthesiology, BMI body mass 
index, mGPS modified Glasgow Prognostic Score  
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 Figures and Legends 
 
Figure 8-1: Scatter plots of operation duration (mins) and postoperative C-reactive protein concentration (mg/L) on (A) postoperative day 3 and (B) day 4, following elective 
surgery for colorectal cancer  
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Figure 8-2: Scatter plots of operation duration (mins) and postoperative CRP concentrations (mg/L) on (A) postoperative day 3 and (B) day 4, following elective open surgery 
for colorectal cancer 
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Figure 8-3: Scatter plots of operation duration (mins) and postoperative CRP concentrations (mg/L) on (A) postoperative day 3 and (B) day 4, following elective open surgery 
for colonic cancer 
 
     
 
179 
  
9 Anaemia and preoperative systemic inflammation are 
independently associated with perioperative blood 
transfusion in patients undergoing surgery for 
colorectal cancer 
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 Introduction 
A significant proportion of patients undergoing surgery for colorectal cancer will require 
allogeneic blood transfusion in the perioperative period, most due to iron deficiency 
anaemia (Acheson et al. 2012).  Blood products are a scarce healthcare resource.  In 
addition, perioperative blood transfusion has been reported to be associated with the 
development of infective postoperative complications and anastomotic leak following 
surgery for colorectal cancer (McDermott et al. 2015).  Furthermore, there is some 
evidence that perioperative blood transfusion is associated with disease recurrence 
following surgery for colorectal cancer, and that this effect is even greater in the presence 
of infective complications (Mynster et al. 2000, Amato et al. 2006).  Although the 
preoperative anaemia associated with colorectal cancers has traditionally been attributed to 
frank or occult gastrointestinal blood loss, there is increasing concern that other 
mechanisms may be additionally responsible.  One of these is the host systemic 
inflammatory response to cancer. 
The presence of a preoperative systemic inflammatory response, as measured by the 
modified Glasgow Prognostic Score, has been widely reported to be associated with both 
postoperative complications (Moyes et al. 2009) and poorer long term oncologic outcomes 
independent of stage, following surgery for colorectal cancer (McMillan et al. 2013, Park 
et al 2016).  It is therefore of interest that the presence of systemic inflammation, as 
measured by serum C-reactive protein (CRP) and albumin, is also associated with 
significant perturbation of common serum measures of iron status (McSorley et al. 2016a).  
Indeed, this state of functional iron deficiency, or anaemia of chronic inflammation, is of 
particular importance in the context of colorectal cancer surgery.  Whereas true iron 
deficient anaemia secondary to blood loss is likely to respond to preoperative iron 
replacement therapy, functional iron deficiency secondary to systemic inflammation will 
not (Kelly et al. 2017).  Although there have been recent calls to examine the impact of 
systemic inflammation on the treatment of preoperative anaemia (McSorley et al. 2016b), 
little data exists as to the prevalence of this kind of anaemia and its effect on the need for 
blood transfusion within the colorectal cancer surgery patient population.    
The hypothesis of the present study is that preoperative systemic inflammation has a 
significant impact on both preoperative anaemia and rates of perioperative blood 
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transfusion in patients undergoing surgery for colorectal cancer.  Therefore, the aim of the 
present study was to explore these relationships in this cohort of patients. 
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 Patients and Methods 
9.2.1 Patients 
Patients with histologically proven colorectal cancer, who underwent elective open surgery 
with curative intent between December 1998 and November 2007 at a single centre were 
included in the study.  Patients who underwent emergency surgery, palliative procedures, 
with metastatic disease or who had existing inflammatory conditions were excluded.  All 
patients received prophylactic antibiotics and venous thromboprophylaxis prior to the 
induction of anaesthesia as per hospital policy.  Patients had routine preoperative blood 
sampling and measurement of haemoglobin concentration, serum CRP, and albumin.  This 
study was approved as part of surgical audit by the West of Scotland Research Ethics 
Committee.    
9.2.2 Methods 
Data was collected prospectively in a database, anonymised, and subsequently analysed.  
Recorded information included patient demographics, tumour site, TNM stage (TNM, 
AJCC), American Society of Anaesthesiologists score (ASA), preoperative haemoglobin 
concentration (Hb g/dL), and postoperative complications.  The proportion of patients 
exceeding the established CRP threshold 150mg/L on postoperative days 3 and 4 was 
recorded (McDermott et al. 2015). 
Serum concentrations of CRP (mg/L) were measured using an autoanalyzer (Architect; 
Abbot Diagnostics, Maidenhead, UK) with a lower detectable limit of 0.2 mg/L as was 
serum albumin (normal range 35-50g/L).   The preoperative modified Glasgow Prognostic 
Score (mGPS), which was associated with cancer specific survival independent of disease 
stage was calculated in patients for whom preoperative serum CRP and albumin were 
available (McMillan 2013).  Using local laboratory reference ranges, anaemia was defined 
as Hb <13.0g/dl in males and <11.5g/dl in females.  Severe anaemia was defined as Hb 
<11.0g/dl in males and <10.0g/dl in females.  
Information concerning transfusion history and the number of units of packed red cells 
(PRCs) transfused was acquired retrospectively from a prospective haematology computer 
database at Glasgow Royal Infirmary. Perioperative transfusion was defined as a blood 
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transfusion occurring within 30 days before or after surgery. The indication for the blood 
transfusion, its timing within the perioperative window, and the haemoglobin threshold 
used to decide on transfusing were not documented.  There was no perioperative blood 
transfusion protocol in place during the study period.  
Infective complications were categorised as described elsewhere and summarised here 
briefly (Platt et al. 2012).  Superficial surgical site infection was defined as the presence of 
pus either spontaneously discharging from the wound or requiring drainage.  Deep surgical 
site infection was defined as surgical or image-guided drainage of intra-abdominal pus.  
Anastomotic leak was defined as radiologically verified fistula to bowel anastomosis or 
diagnosed at laparotomy.  Pneumonia was defined by fever above 38.5oC and 
consolidatory chest X-ray findings requiring antibiotic treatment.  Septicaemia was defined 
by the presence of sepsis combined with positive blood culture.  Urinary tract infection 
was only included if complicated by septicaemia and confirmed with positive urine culture.   
9.2.3 Statistical Analysis 
Categorical data regarding patient characteristics were compared using the Chi square test.  
Continuous data relating to preoperative Hb and postoperative CRP were non-normal and 
displayed as medians and ranges.  These continuous data were compared using the Mann-
Whitney U test.  Missing data were not included in analysis.  Binary logistic regression of 
variables associated with perioperative blood transfusion was performed.  Those variables 
associated with perioperative blood transfusion at a significance level of p <0.1 at 
univariate analysis were included in multivariate binary logistic regression using a 
backward conditional model.  Statistical analyses were performed using IBM SPSS version 
22 for Windows (Chicago, IL, USA).  Two sided p values <0.05 were considered 
statistically significant. 
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 Results 
9.3.1 Patients 
In total, 371 patients were included in the study (Table 9-1).  All patients underwent 
elective, open surgery.  The majority were male (195, 53%), over 65 years old (249, 67%), 
with colonic (229, 62%) and node negative disease (219, 59%). After correcting for sex, 
179 patients (48%) had no evidence of preoperative anaemia, 110 (30%) had mild 
preoperative anaemia, and 73 (20%) had severe preoperative anaemia.  85 patients (23%) 
developed a postoperative complication, of which 71 (19%) were infective complications.  
18 patients (5%) developed a postoperative anastomotic leak.  There were 7 (2%) deaths in 
the postoperative period.   
9.3.2 Perioperative blood transfusion 
115 patients (31%) required a blood transfusion in the perioperative period, of which 51 
were preoperative.  There was a significant association between preoperative median Hb in 
males (11.3 vs 13.1 g/dL, p<0.001) and females (10.5 vs. 12.3 g/dL, p<0.001) and the need 
for perioperative blood transfusion.  After correcting for sex, there was a significant 
association between any perioperative blood transfusion and the severity of preoperative 
anaemia (p<0.001).  There was a significant association between any perioperative blood 
transfusion and preoperative mGPS (p<0.001).  Of those receiving a blood transfusion in 
the perioperative period, 75 (20%) received 1-2 units of packed red cells (PRCs), 25 (7%) 
received 3-4 units, and 15 (4%) received more than 4 units.  There was a significant 
association between the number of units of PRCs transfused and both the degree of the 
preoperative anaemia (p<0.001) and the preoperative mGPS (p<0.001).   
9.3.3 Preoperative and intraoperative factors associated with 
perioperative blood transfusion 
At univariate analysis, age (p=0.066), ASA score (p=0.065), preoperative anaemia 
(p<0.001), and preoperative mGPS (p<0.001) were associated with perioperative blood 
transfusion at a significance level of p<0.1 (Table 9-1).  At multivariate analysis, 
preoperative anaemia (OR 2.65, 95% CI 1.87-3.75, p<0.001) and preoperative mGPS (OR 
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1.88, 95% CI 1.29-2.73, p<0.001) remained independently associated with perioperative 
blood transfusion. 
When patients were grouped by preoperative mGPS 0, or mGPS 1-2 (Table 9-2), only the 
degree of preoperative anaemia, corrected for sex, was associated with perioperative blood 
transfusion (both p<0.001).   
When the same analysis was carried out in patients who underwent surgery for colonic 
cancer (Table 9-3), the degree of preoperative anaemia was significantly associated with 
perioperative blood transfusion in those patients with preoperative mGPS 1-2 (p<0.001), 
but not mGPS 0 (p=0.125) 
9.3.4 Postoperative outcomes associated with perioperative blood 
transfusion 
At univariate analysis, anastomotic leak (p=0.027), and 30 day mortality (p=0.039) were 
significantly associated with perioperative blood transfusion (p=0.065), (Table 9-1).  At 
multivariate analysis, both anastomotic leak (OR 2.82, 95% CI 1.07-7.42, p=0.036), and 30 
day mortality (OR 5.39, 95% CI 1.01-28.63, p=0.048) remained independently associated 
with perioperative blood transfusion.   
When patients were grouped by preoperative mGPS 0 or mGPS 1-2 (Table 9-2), 
anastomotic leak was significantly associated with perioperative blood transfusion in 
patients with mGPS 0 (p=0.039), but not mGPS 1-2 (p=0.719).  In addition, median length 
of stay was significantly longer in patients receiving a perioperative blood transfusion in 
both those with mGPS 0 (12 vs 10 days, p=0.004) and mGPS 1-2 (13 vs 11 days, p=0.020). 
Similar results were found when the same analysis was performed in patients who 
underwent surgery for colonic cancer (Table 9-3).  Anastomotic leak was significantly 
associated with perioperative blood transfusion in patients with mGPS 0 (p=0.034), but not 
mGPS 1-2 (p=0.322).  Median length of stay was significantly longer in patients receiving 
a perioperative blood transfusion in both those with mGPS 0 (11 vs 9 days, p=0.014) and 
mGPS 1-2 (13 vs 10 days, p=0.015). 
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There was no association between the postoperative systemic inflammatory response and 
blood transfusion in the whole cohort, or at subgroup analysis of those patients without 
preoperative systemic inflammation, or colonic cancer only. 
9.3.5 Preoperative anaemia, systemic inflammation and perioperative 
blood transfusion 
Rates of perioperative blood transfusion (Table 9-4) varied from 17% in patients without 
anaemia to 62% in those with severe anaemia (p<0.001), and from 24% in patients with 
mGPS 0 to 42% in patients with mGPS 1-2 (p<0.001).  When combined, rates of 
perioperative blood transfusion varied from 16% in patients without anaemia and mGPS 0, 
to 78% in patients with severe anaemia and mGPS 1-2 (p<0.001). 
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 Discussion 
The results of the present study report associations between preoperative anaemia, 
systemic inflammation, and perioperative blood transfusion in patients undergoing elective 
surgery for stage I-III colorectal cancer. Therefore, the apparent requirement for 
perioperative blood transfusion, based primarily on preoperative anaemia, may be 
exacerbated by the presence of a preoperative systemic inflammatory response.  There was 
no significant association between perioperative blood transfusion and the magnitude of 
the postoperative systemic inflammatory response.  However, in keeping with prior 
studies, perioperative blood transfusion was associated with anastomotic leak, although 
this relationship was strongest in patients without preoperative systemic inflammation.   
The aetiology of preoperative anaemia, and thus the likelihood of receiving a blood 
transfusion in surgery for colorectal cancer, is increasingly complex (Edgren et al. 2009).  
There has been ongoing assumption that anaemia in patients with colorectal cancer relates 
primarily to occult gastrointestinal blood loss, and treatment with preoperative oral or 
parenteral administration of iron preparations has been proposed (Beale et al. 2005).  
However, the recognition that the presence of systemic inflammation can lead to a state of 
functional iron deficiency (also known as the anaemia of chronic disease or anaemia of 
inflammation) questions the above assumption (Thomas et al. 2013).  In the systemic 
inflammatory state, iron stores are sufficient but iron is sequestered by the 
reticuloendothelial system, a process driven by the effect of circulating interleukin 6 on the 
hepcidin mediated iron transport protein ferroportin (vonDrygalski et al. 2013).   
This perturbation has long been recognised (Fraser et al. 1989, Galloway et al. 2000).  
However, it is only recently that the magnitude of the effect has been well described in 
large numbers of patient observations (Duncan et al. 2012).  There have been two main 
approaches to the confounding effect of the systemic inflammatory response on the 
measurement of iron status.  The first is to develop other measurements of iron status that 
are not affected by systemic inflammation.  The second is to adjust measurement of iron 
status and anaemia using measures of systemic inflammation (Thurnham et al. 2011).   
In the Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia 
(BRINDA) publications, this second approach has been carried out using C-reactive 
protein (CRP) and α-1-acid glycoprotein (AGP), two positive acute phase proteins of 
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varying half-life (Namaste et al. 2017, Rohner et al. 2017, Mei et al. 2017).  They reported 
significant differences in the prevalence of depleted iron stores based on serum ferritin 
criteria (Namaste et al. 2017).  When serum ferritin was examined in women of 
reproductive age there was a significant difference in the proportion of patients meeting 
criteria for iron deficiency (<15 μg/L) in the lowest and highest decile of both CRP (29% 
and 6% respectively) and AGP (26% and 8% respectively).  In addition, when women of 
reproductive age were grouped by phase of inflammation using the combination of CRP 
and AGP, there was as significant difference in the mean lowest (34.9 μg/L, 95% CI 25.7-
47.4, in “reference” group [CRP ≤5mg/L and AGP ≤1g/L]) and highest ferritin 
concentration (59.2 μg/L, 95% CI 48.5-72.2 in “early convalescence” group [CRP >5mg/L 
and AGP >1g/L]).  Furthermore, the authors show that measures of iron status are altered 
below currently clinically relevant threshold values for both CRP and AGP and so propose 
that the use of a regression based correction factor should provide a more accurate 
assessment of true iron status in the context of systemic inflammation (Namaste et al. 
2017).  However, AGP is not routinely available as a measure of systemic inflammation in 
the clinical setting.    In the BRINDA project paper, the authors propose the continued and 
expanded use of AGP as a measure of the phase and magnitude of systemic inflammation.  
However, as they themselves note, “…CRP is the more routinely measured and should 
continue to be measured along with AGP…”, in part as it is not routinely used in clinical 
practice (Namaste et al. 2017).  In addition, the authors also discuss, in an earlier 
publication, the problem associated with the calculation of regression based correction 
factors caused by serum micronutrient concentrations that do not necessarily “move in 
synchrony” with the CRP and AGP defined phases of inflammation (Thurnham et al. 
2016). 
Perhaps a better approach would be to use the combination of CRP and albumin, since both 
are independently associated with measures of iron status and are routinely available.  
Clinically, this has recently been confirmed in a recent observational study in a large 
patient cohort (n=16,552), whereby the presence of systemic inflammation, as measured by 
CRP and albumin, had a profound association with all commonly used serum measures of 
iron status (McSorley et al. 2016a).  Patients were stratified by the magnitude of the 
systemic inflammatory response using both CRP and albumin as follows: group 1: CRP 
<10mg/L and albumin >35g/L, group 2: CRP11-80mg/L and albumin 25-35mg/L, and 
group 3:  CRP >80mg/L and albumin <25g/L.  When serum ferritin was compared 
amongst the three groups the median concentration was 77, 173, and 445 μg/L respectively 
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(p<0.001).  Furthermore, there was a significant difference in the proportion of patients 
meeting criteria for iron deficiency (<15 μg/L, 13%, 3% and 0% respectively, p=0.001) or 
iron excess (M>300 μg/L F>50 μg/L, 21%, 38% and 75% respectively, p<0.001). When 
transferrin saturation was compared amongst the three groups there was a significant 
difference in the proportion of patients meeting criteria for iron deficiency (TSAT <10%, 
15%, 39% and 53% respectively, p<0.001) or iron excess (TSAT M>55% F>50%, 7%, 5% 
and 5% respectively, p<0.001). 
Therefore, it may be speculated that only those patients with preoperative anaemia in the 
absence of systemic inflammation, around 24% of patients in the present study, will derive 
benefit from preoperative iron supplementation.  Those patients who are both anaemic and 
systemically inflamed in the preoperative period, around 26% of patients in the present 
study, are unlikely to respond to preoperative iron supplementation and are more likely to 
require perioperative blood transfusion.  Furthermore, in this significant proportion of 
patients who have functional rather than true iron deficiency, iron supplementation may be 
harmful by promoting infective complications. If this were to prove to be the case it may 
be further speculated that anaemia in the presence of systemic inflammation may be 
corrected by the use of effective anti-inflammatory medication prior to surgery.  These 
speculations remain to be tested in the context of a randomised clinical trial (McSorley et 
al. 2016b).  However, it is clear that such work is of considerable importance as it has the 
potential to profoundly change clinical practice. 
Indeed, the present work is consistent with a series of observations in the literature.  For 
example, a meta-analysis of previously published studies investigating the use of 
preoperative parenteral iron supplementation in patients with iron deficiency anaemia, 
across a variety of surgical specialities, reported a significant increase in preoperative 
haemoglobin and a reduction in the requirement for perioperative blood transfusion (Litton 
et al. 2013).  Somewhat concerningly, they also reported that those patients given 
parenteral iron preoperatively were more likely to have an infective complication 
following surgery.  Furthermore, a recent randomised controlled trial of preoperative 
parenteral iron supplementation in patients with apparent iron deficiency anaemia 
undergoing major abdominal surgery reported similar results in terms of both a reduction 
in the requirement for perioperative blood transfusion, and an increase in risk of 
postoperative infective complications in the treatment arm (Froessler et al. 2016).   
Froessler and colleagues reported no significant difference in median CRP concentration 
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between the intervention and control group either preoperatively (7.2 mg/L vs. 7.7 mg/L, 
p=0.99) or 4 weeks postoperative (5.8 mg/L vs. 11.0 mg/L, p=0.18).  However, the upper 
ranges of measured CRP concentration in both groups at both time points was above 10 
mg/L, a value above which the measures of iron status reported by Froessler and 
colleagues, ferritin and transferrin saturation, have been reported to be significantly 
affected by the systemic inflammatory response (McSorley et al. 2016b).  Furthermore, 
Froessler and colleagues did not describe the proportion of patients in each group with 
CRP >10mg/L at each time point, making interpretation of the difference in the degree of 
systemic inflammation between the two groups difficult.  Indeed, this may in part explain 
the significant differences in serum ferritin and transferrin saturation between the two 
groups prior to randomization and may introduce bias in terms of the difference in 
haemoglobin concentration between the two time points. 
Further trials of the use of perioperative parenteral iron therapy with the aim of reducing 
perioperative blood transfusion requirement should clearly define the preoperative 
systemic inflammatory status of participants.  In fact, we should go further, and it is the 
authors’ opinion that further trials should use preoperative CRP as an exclusion criteria, 
given that iron replacement therapy is unlikely to be as efficacious in this group of patients, 
and that their inclusion may introduce bias as well as being ethically dubious.  Patients 
undergoing surgery who have a preoperative systemic inflammatory response, whether due 
to cancer or other reasons, can perhaps be offered alternative interventions.  In addition, it 
is of interest that the current study also suggests that preoperative systemic inflammation 
may be associated with perioperative blood transfusion independent of preoperative 
anaemia.  This may be due to greater intraoperative blood loss, slower recovery from 
surgery, suppression of erythropoiesis in the postoperative period, or indeed it may be 
multifactorial in nature.  Although the reasons for such a finding remain unclear, if 
confirmed, it would add to the importance of targeting the preoperative systemic 
inflammatory response in these patients. 
The main limitation of the present study was that it was conducted in a historic cohort of 
patients.  This was due to the lack of availability of transfusion data in more recent cohorts 
at the time of writing.  The retrospective nature of the analysis lead to missing data.  A 
significant proportion of patients with no evidence of preoperative anaemia underwent 
perioperative blood transfusion.  Moreover, the present study was not able to determine 
what the indications for blood transfusion were, other than preoperative anaemia, since 
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they were not reliably recorded.  In addition, a high proportion of patients were anaemic 
(50%), and required blood transfusion (30%), which is higher than in more modern 
practice although some recent data from the same centre finds rates of anaemia to be 40% 
and perioperative blood transfusion rates to remain high at 20% (McSorley unpublished 
data).  Finally, that all included patients underwent open surgery may be considered a 
limitation given the current move toward minimally invasive surgery.  However, open 
surgery continues to form a major part of UK surgical practice in patients undergoing 
resection for colorectal cancer, and reduces the potential for confounding with regard to 
blood loss and blood transfusion introduced with other less invasive surgical modalities.   
In conclusion, the present study reports a significant association between preoperative 
systemic inflammation and perioperative blood transfusion in patients undergoing elective 
surgery for colorectal cancer.  It may be that systemic inflammation has this effect through 
both anaemia and through other, as yet, unidentified mechanisms.  Studies investigating 
the preoperative treatment of anaemia with iron should consider preoperative systemic 
inflammation as a limiting factor in treatment efficacy. 
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 Tables and Footnotes 
Table 9-1: Univariate and multivariate binary logistic regression of factors associated with any 
perioperative blood transfusion 
Characteristic Univariate (OR, 
95% CI) 
P 
Multivariate (OR, 
95% CI) 
P 
Factors affecting transfusion     
Age 1.29 (0.98-1.69) 0.066 - 0.164 
Sex 0.84 (0.54-1.31) 0.439 - - 
ASA score 1.36 (0.98-1.88) 0.065 - 0.945 
Tumour site 0.72 (0.46-1.15) 0.165 - - 
TNM stage 1.15 (0.84-1.58) 0.377 - - 
Venous invasion 0.87 (0.56-1.36) 0.550 - - 
Neoadjuvant treatment 1.8 (0.36-3.25) 0.891 - - 
<12 lymph nodes sampled 0.92 (0.58-1.46) 0.920 - - 
Preop Anaemia 2.69 (1.99-3.63) <0.001 2.65 (1.87-3.75) <0.001 
Preop mGPS 1.98 (1.45-2.71) <0.001 1.88 (1.29-2.73) <0.001 
     
Outcomes affected by transfusion     
POD 3 CRP >150mg/L 1.03 (0.65-1.65) 0.892 - - 
POD 4 CRP >150mg/L 0.99 (0.52-1.87) 0.967 - - 
Any complication 1.20 (0.72-2.02) 0.479 - - 
Infective complication 1.48 (0.86-2.54) 0.156 - - 
Anastomotic leak 2.95 (1.13-7.69) 0.027 2.82 (1.07-7.42) 0.036 
Thirty day mortality 5.73 (1.10-30.01) 0.039 5.39 (1.01-28.63) 0.048 
mGPS modified Glasgow Prognostic score, POD postoperative day, CRP C-reactive protein, Anaemia 
(none/mild/severe): males (>13/<13/<11, g/dL), females (>11.5/<11.5/<10, g/dL).   
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Table 9-2: Clinicopathological characteristics of patients undergoing elective open surgery for 
colorectal cancer receiving any perioperative blood transfusion 
Characteristics mGPS 0 p  mGPS 1-2 p 
 
No 
transfusion 
(n=170) 
Transfused 
(n=54) 
  
No 
transfusion 
(n=84) 
Transfused 
(n=60) 
 
Clinicopathological        
Age (<65 / 65-74 / ≥75) 59/62/49 18/16/20 0.448  31/23/30 14/20/26 0.134 
Sex (male / female) 99/71 29/25 0.558  37/47 27/33 0.910 
ASA score (1/2/3/4) 20/65/47/7 2/17/19/1 0.158  11/23/31/4 3/22/26/3 0.349 
Tumour Site (colon / rectum) 89/81 28/26 0.949  61/23 49/11 0.208 
TNM stage (I/II/III) 36/66/68 9/21/24 0.4487  10/37/37 2/36/22 0.910 
Venous invasion (yes/no) 76/90 28/25 0.371  43/41 22/38 0.084 
<12 lymph nodes sampled (yes/no) 67/99 16/37 0.184  22/62 23/37 0.121 
Margin involved (yes/no) 13/153 6/47 0.432  10/74 6/54 0.720 
Neoadjuvant treatment (yes/no) 6/137 2/42 0.920  4/65 3/52 1.000 
        
Haematological        
Preop anaemia (none/mild/severe)£ 107/37/19 21/19/14 <0.00
1 
 40/34/9 10/18/31 <0.001 
        
Postoperative SIR        
POD 3 CRP >150mg/L (yes/no) 65/92 21/29 0.940  37/36 25/27 0.774 
POD 4 CRP >150mg/L (yes/no) 21/111 5/38 0.625  15/51 11/40 0.881 
        
Short term outcomes        
Any complication (yes/no) 34/136 12/42 0.725  22/62 16/44 0.949 
Infective complication (yes/no) 25/145 12/42 0.195  19/65 14/46 0.920 
Anastomotic leak (yes/no) 4/166 5/49 0.039  4/80 4/56 0.719 
Thirty day mortality (yes/no) 2/164 1/52 0.566  0/84 3/57 0.070 
Length of stay (median, days) 10 12 0.004  11 13 0.020 
Adjuvant treatment (yes/no) 34/131 15/39 0.272  19/65 12/48 0.838 
ASA American Society of Anesthesiology.  Hb Haemoglobin.  CRP C-reactive protein.  PRCs Packed red 
cells. POD postoperative day. mGPS modified Glasgow Prognostic score, poGPS postoperative Glasgow 
Prognostic Score, SIR systemic inflammatory response,  £ Preoperative anaemia (none/mild/severe): males 
(>13/<13/<11, g/dL), females (>11.5/<11.5/<10, g/dL).   
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Table 9-3: Clinicopathological characteristics of patients undergoing elective open surgery for colonic 
cancer receiving any perioperative blood transfusion 
Characteristics mGPS 0 p  mGPS 1-2 p 
 
No 
transfusion 
(n=89) 
Transfused 
(n=28) 
  
No 
transfusion 
(n=61) 
Transfused 
(n=49) 
 
Clinicopathological        
Age (<65 / 65-74 / ≥75) 29/33/27 8/10/10 0.587  23/18/20 9/17/23 0.034 
Sex (male / female) 51/38 11/17 0.096  28/33 20/29 0.593 
ASA score (1/2/3/4) 9/32/26/6 1/10/11/0 0.758  11/16/24/1 3/18/22/3 0.108 
TNM stage (I/II/III) 20/37/32 4/13/11 0.474  5/29/27 2/28/19 0.905 
Venous invasion (yes/no) 34/52 14/13 0.274  35/26 16/33 0.010 
<12 lymph nodes sampled (yes/no) 34/52 8/19 0.493  16/45 18/31 0.300 
Margin involved (yes/no) 9/77 2/25 1.000  8/53 3/46 0.340 
        
Haematological        
Preop anaemia (none/mild/severe)£ 53/21/11 12/11/5 0.125  24/29/8 8/15/25 <0.001 
        
Postoperative SIR        
POD 3 CRP >150mg/L (yes/no) 35/48 15/9 0.104  23/28 19/23 0.989 
POD 4 CRP >150mg/L (yes/no) 8/59 4/16 0.460  10/37 9/33 0.986 
        
Short term outcomes        
Any complication (yes/no) 18/71 7/21 0.603  15/46 12/37 0.990 
Infective complication (yes/no) 13/76 7/21 0.250  12/49 10/39 0.924 
Anastomotic leak (yes/no) 3/86 4/24 0.034  1/60 3/46 0.322 
Thirty day mortality (yes/no) 2/84 0/27 1.000  0/61 2/47 0.196 
Length of stay (median, days) 9 11 0.014  10 13 0.015 
Adjuvant treatment (yes/no) 18/68 5/23 1.000  14/47 8/41 0.475 
ASA American Society of Anesthesiology.  Hb Haemoglobin.  CRP C-reactive protein.  PRCs Packed red 
cells. POD postoperative day. mGPS modified Glasgow Prognostic score, poGPS postoperative Glasgow 
Prognostic Score, SIR systemic inflammatory response,  £ Preoperative anaemia (none/mild/severe): males 
(>13/<13/<11, g/dL), females (>11.5/<11.5/<10, g/dL).  
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Table 9-4: The relationship between preoperative anaemia, modified Glasgow Prognostic Score, and 
any perioperative blood transfusion in patients undergoing elective surgery for colorectal cancer 
Anaemia  All  mGPS=0  mGPS=1-2    P 
 n Transfused 
n(%) 
 n Transfused 
n(%) 
 n Transfused 
n(%) 
   
All  368 114 (31)  224 54 (24)  144 60 (42)    <0.001 
              
None  178 31 (17)  128 21 (16)  50 10 (20)    0.570 
Moderate  108 37 (34)  56 19 (34)  52 18 (35)    0.940 
Severe  73 45 (62)  33 14 (42)  40 31 (78)    0.002 
            
P  <0.001  <0.001  <0.001    <0.001 
Anaemia (none/mild/severe): males (>13/<13/<11, g/dL), females (>11.5/<11.5/<10, g/dL), mGPS modified 
Glasgow Prognostic Score 
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10 The relationship between neoadjuvant 
chemoradiotherapy, the postoperative systemic 
inflammatory response, and adverse outcomes 
following surgery for rectal cancer:  a propensity 
score matched analysis 
  
     
 
197 
  
  Introduction 
Neoadjuvant chemoradiotherapy (nCRT) prior to surgical resection has become a standard 
of care for management of locally advanced rectal cancer (Sauer et al. 2004).  nCRT 
confers oncological benefits, such as downstaging of the tumour to allow clear 
circumferential margins at resection (Kim et al. 2006), and reduction of local recurrence 
(Bosset et al. 2006).  
Although nCRT has been shown to improve outcomes in rectal cancer, there is significant 
variability in the degree of response to treatment (Kim et al. 2014).  It is now evident that 
the presence of a systemic inflammatory response, evaluated using the modified Glasgow 
Prognostic Score (mGPS), is associated with poor long-term outcomes in resectable 
colorectal cancer (McMillan et al. 2013).  The presence of systemic inflammation prior to 
nCRT has been reported to be associated with poorer overall, and disease free, survival in 
patients with locally advanced rectal cancer (Carruthers et al. 2012).  Furthermore, a recent 
study of patients receiving nCRT prior to surgical resection of rectal cancer in the West of 
Scotland reported that the presence of a pre-treatment systemic inflammatory response was 
associated with a lower likelihood of complete pathological response (Dreyer et al. 2017).   
It is now well established that the magnitude of the postoperative systemic inflammatory 
response, measured by C-reactive protein (CRP), is associated with short-term outcomes 
following colorectal surgery (Singh et al. 2014, Adamina et al. 2015).  These postoperative 
complications (e.g. anastomotic leakage) have been indicated to be associated with 
increased local recurrence and reduced long term survival following surgery for colorectal 
cancer (Artinyan et al. 2014).  A recent comprehensive review suggested that exceeding 
CRP concentrations of 150mg/L on postoperative days 3 to 5 following colorectal surgery 
should alert clinicians to the possible development of complications (McDermott et al. 
2015).  Furthermore, there is some evidence to suggest that the postoperative systemic 
inflammatory response is associated with long-term oncologic outcomes following surgery 
for colorectal cancer, independent of complications (McSorley Chapter 4). 
Although there is evidence linking the pretreatment systemic inflammatory response to 
oncologic outcomes following nCRT for rectal cancer, to the authors’ knowledge, no 
studies have examined the impact of nCRT on the magnitude of the postoperative systemic 
inflammatory response.  Therefore, the aim of the present study was to investigate the 
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relationship between nCRT, the postoperative systemic inflammatory response, and 
postoperative outcomes in patients undergoing elective surgery for rectal cancer.  
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 Patients and Methods 
10.2.1 Patients 
Patients with histologically proven rectal cancer who underwent elective surgery between 
February 2008 and April 2015 at a single centre were included in the study.  Patients who 
underwent emergency surgery, palliative procedures, or who had existing inflammatory 
conditions were excluded.   
Preoperative nCRT was offered to patients with histologically proven, locally advanced, 
circumferential margin (CRM) threatening rectal tumours following discussion at a multi-
disciplinary colorectal oncology meeting.  The nCRT protocol was of 45Gy given over 5 
weeks in 25 daily fractions alongside oral fluorouracil (5-FU) and the addition of folinic 
acid on days 1 to 5 and 29 to 33.   
All patients received prophylactic antibiotics and venous thromboprophylaxis prior to the 
induction of anaesthesia as per hospital policy.  Patients had routine preoperative and daily 
postoperative blood sampling including a full blood count (FBC), serum CRP and albumin 
concentration.  Further postoperative investigation and intervention was at the discretion of 
the patient’s surgical team who were not blinded to blood test results.  This study was 
approved as part of surgical audit by the West of Scotland Research Ethics Committee.     
10.2.2 Methods 
Data was collected prospectively in a database, anonymised, and subsequently analysed.  
Prospectively recorded information included patient demographics including operation, 
body mass index (BMI), American Society of Anesthesiology (ASA) score, smoking 
status, and pathological data including TNM stage (TNM, AJCC), CRM status, 
differentiation, and venous invasion.   
Serum concentrations of CRP (mg/L) were measured using an autoanalyzer (Architect; 
Abbot Diagnostics, Maidenhead, UK) with a lower detectable limit of 0.2 mg/L, as was 
serum albumin (normal range 35-50g/L).  The preoperative modified Glasgow Prognostic 
Score (mGPS) was calculated in patients for whom serum CRP and albumin concentrations 
were available (McMillan 2013).  Exceeding the established CRP threshold of 150 mg/L 
on postoperative days 3 or 4 was recorded (McDermott et al. 2015). 
     
 
200 
  
Infective complications were categorised as described elsewhere and summarised here 
briefly (Platt et al. 2012). Superficial surgical site infection was defined as the presence of 
pus either spontaneously discharging from the wound or requiring drainage.  Deep surgical 
site infection was defined as surgical or image-guided drainage of intra-abdominal pus.  
Anastomotic leak was defined as radiologically verified fistula to bowel anastomosis or 
diagnosed at laparotomy.  Pneumonia was defined by fever above 38.5oC and 
consolidatory chest X-ray findings requiring antibiotic treatment.  Septicaemia was defined 
by the presence of sepsis combined with positive blood culture.  Urinary tract infection 
(UTI) was only included if complicated by septicaemia and confirmed with positive urine 
culture.  Additionally, postoperative complications were categorised by their severity using 
the Clavien Dindo scale (Dindo et al. 2004).   
10.2.3 Statistical Analysis 
Categorical data were compared using the Chi square test or Fisher’s exact test in analyses 
with small numbers.  Continuous data were non-normal so were displayed as medians and 
ranges. These continuous data were compared using the Mann-Whitney U test.   
Multivariate logistic regression was used to generate a propensity score for each patient, 
predicting the probability of having received nCRT or not, based on the following 
variables thought to be associated with the postoperative systemic inflammatory response 
or complications: age, sex, BMI, smoking status, ASA score, mGPS, TNM stage, surgical 
approach (open or laparoscopic), operation type (anterior or abdominoperineal resection), 
stoma formation, and the use of epidural anaesthesia.  Patients who received preoperative 
nCRT were then matched 1:1 with a patient who did not, using the closest propensity score 
on the logit scale (calliper <0.05, order of match selection randomised, without 
replacement).  Categorical data were compared using McNemar’s test.  The 
appropriateness of the propensity score matching was assessed visually by frequency of 
propensity scores in each group before and after matching.  In addition, the propensity 
scores were included as a linear covariate alongside preoperative nCRT in multivariate 
binary logistic regression models for exceeding the postoperative day 3 CRP threshold and 
postoperative complications.  Finally, the propensity scores were used to stratify the 
patients by quintiles from which an average treatment effect was calculated for both the 
postoperative day 3 CRP threshold and postoperative complications as an OR and 95% CI.  
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In all tests, a two sided p value <0.05 was considered statistically significant.  Propensity 
scoring, matching, and all statistical analyses were performed using IBM SPSS version 21 
for Windows (Chicago, IL, USA).       
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 Results 
10.3.1 Patients 
In total, 251 patients were included in the study (Table 10-1). The majority were male 
(155, 62%), over 65 years old (142, 57%), and had node negative disease (165, 66%).  85 
patients (33%) underwent preoperative nCRT.  163 patients (65%) underwent open 
surgery, 75 patients (30%) underwent laparoscopic surgery, and 13 patients (5%) 
underwent transanal surgery.  173 patients (69%) underwent anterior resection (AR) and 
62 patients (25%) underwent abdominoperineal resection (APR).  111 patients (44%) 
developed a postoperative complication of which 75 (30%) were infective and 24 (10%) 
were Clavien Dindo grade 3-5.  There were 5 deaths (2%) within the immediate 
postoperative period.  
10.3.2 The relationship between nCRT and perioperative factors in the 
unmatched cohort 
A significantly higher proportion of patients who underwent nCRT (Table 10-1) went on to 
APR (51% vs. 12%, p<0.001) and had open surgery (80% vs. 63%, p=0.004).  Of the 
patients who underwent nCRT, 11 (13%) achieved complete pathological response.  A 
significantly higher proportion of those who underwent nCRT subsequently had 
macroscopically involved circumferential margins (9% vs. 0.6%, p=0.003).  A 
significantly lower proportion of patients who underwent nCRT had histopathologically 
detectable venous invasion (45% vs. 61%, p=0.027).  A significantly higher proportion of 
those patients who underwent nCRT had a NLR >5 (39% vs. 12%, p<0.001) and a mGPS 
of 2 (14% vs. 6%, p=0.035) prior to surgery.  There was no significant association between 
nCRT and the postoperative systemic inflammatory response or postoperative 
complications. 
10.3.3 The relationship between nCRT and perioperative factors in the 
propensity score matched cohort 
Propensity scores could not be assigned to 124 patients due to missing covariate data, 
leaving 127 patients with propensity scores, of which 75 had received nCRT and 52 had 
not.  104 patients (52 from each group) were matched based on their propensity score, with 
a subsequent improvement in the balance of the distribution of propensity scores in each 
group (Figure 10-1).  In the propensity score matched cohort, there was no significant 
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association between nCRT and either the postoperative systemic inflammatory response 
(Figure 10-2) or complications following surgery for rectal cancer (Table 10-2). 
10.3.4 Sensitivity analyses using propensity scores 
A similarly non-significant association was found when the impact of nCRT on exceeding 
the postoperative day 3 CRP threshold (Table 10-3), was analysed in the unadjusted cohort 
(OR 0.90, 95% CI 0.51-1.58), in the propensity score matched cohort (OR 0.64, 95% CI 
0.28-1.45), through propensity score regression (OR 0.80, 95% CI 0.38-1.71), and 
propensity score stratification (OR 0.80, 95% CI 0.38-1.72).  The same analysis of the 
impact of nCRT on postoperative complications (Table 10-3) found a similarly non-
significant relationship in the unmatched cohort (OR 0.84, 95% CI 0.49-1.44), the 
propensity score matched cohort (OR 0.85, 95% CI 0.39-1.86), through propensity 
regression (OR 0.86, 95% CI 0.41-1.81), and propensity stratification (OR 0.86, 95% CI 
0.41-1.81). 
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 Discussion 
The present study reports no significant association between nCRT and either the 
magnitude of the postoperative systemic inflammatory response, or short term 
postoperative outcomes, following surgery for rectal cancer. 
Although the present paper reports that a higher proportion of patients who underwent 
nCRT were found to have a preoperative systemic inflammatory response, had undergone 
an abdominoperineal resection, using open surgical techniques, this did not impact on 
either the postoperative systemic inflammatory response, or short term postoperative 
outcomes, when compared to patients who did not undergo nCRT.  In addition, this 
remained the case after accounting for confounding variables related to the postoperative 
systemic inflammatory response and complications, using propensity score matching.   
Previous studies in patients undergoing nCRT prior to surgery for rectal cancer have 
reported that the presence of a systemic inflammatory response prior to treatment is 
associated with poorer tumour response to chemoradiotherapy and poorer oncologic 
outcome (Shen et al. 2014).  Higher baseline NLR has been reported to be a negative 
predictor of pathological response and disease free survival (Carruthers et al. 2012, 
Krauthamer et al. 2013).  Both CRP, and subsequently mGPS, have been reported to be 
significantly associated with poorer pathological response and poorer survival following 
nCRT for rectal cancer (Toiyama et al. 2013, Kim et al. 2014, Dreyer et al. 2017).  Other 
characteristics such as age, gender, tumour site and body mass index (BMI) have been 
shown to have limited influence (Mikaela et al. 2014, Kim et al. 2014). 
The main limitation of the present study was the small number of patients included, in 
particular the number of patients who underwent nCRT.  In addition, the retrospective 
nature of the study lead to some missing data, particularly with regard to the administration 
of perioperative dexamethasone, and the proportion of patients having CRP measured on 
postoperative day 4.  Significant differences between the groups in terms of variables 
associated with the postoperative systemic inflammatory response, and complications, lead 
to propensity score matching being used.  This achieved improved balance in terms of 
demographic and operative confounders but resulted in the exclusion of a significant 
proportion of patients.  Additional models were trialled as some imbalance remained, for 
example in the proportion of patients receiving preoperative dexamethasone in each group, 
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however additional variables, and missing covariate data reduced the sample size such that 
type II error would have become very likely.  However, it was reassuring that the overall 
treatment effect and its magnitude were similar amongst the unmatched cohort, the 
matched cohort, and when other propensity analyses were used.   
In conclusion, the present study reports that nCRT is significantly associated with the 
presence of a preoperative systemic inflammatory response prior to surgery for rectal 
cancer.  However, this finding did not extend to a significant association between nCRT 
and either the postoperative systemic inflammatory response or complications. 
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 Tables and Footnotes 
Table 10-1: Relationship between clinicopathological characteristics and neoadjuvant therapy in 
patients undergoing elective surgery for rectal cancer 
Characteristic All rectal 
(n=251) 
Neoadjuvant P  
No (n=166) Yes (n=85) 
Demographics     
Sex (male/female) 155/96 105/61 50/35 0.496 
Age (<65/65-74/>74) 107/106/37 68/67/31 39/39/6 0.057 
BMI (<20/20-25/26-30/>30, kg/m2) 7/88/70/41 4/51/48/33 3/37/22/8 0.078 
Smoking (never/ex/current) 110/94/33 78/56/20 32/38/13 0.125 
ASA score (1/2/3/4) 64/103/62/4 40/66/42/3 24/37/20/1 0.471 
     
Operative variables     
Preoperative dexamethasone (yes/no) 97/78 59/50 38/28 0.754 
Operation (AR/APR/Transanal) 173/62/13 134/20/11 39/42/1 <0.001 
Approach (laparoscopic/open) 75/163 58/97 17/66 0.004 
Operation >4h (yes/no) 117/90 72/58 45/32 0.772 
Intraoperative transfusion (yes/no) 9/161 4/102 5/59 0.299 
Stoma (yes/no)  156/71 84/64 72/7 <0.001 
     
Postoperative pathology     
TNM stage (0/ I/ II/III/IV) 11/67/84/75/11 0/56/52/50/7 11/11/32/25/4 <0.001 
CRM (R0/R1/R2) 200/28/8 134/21/1 68/7/7 0.003 
Differentiation (well-mod/poor) 210/16 143/8 67/8 0.170 
Venous invasion (yes/no) 130/105 94/61 36/44 0.027 
Tumour perforation (yes/no) 2/228 1/149 1/79 1.000 
     
Systemic inflammation     
Pre-operative mGPS (0/1/2) 198/19/20 131/16/9 67/3/11 0.033 
     
POD 3 CRP >150mg/L (yes/no) 103/110 69/71 34/39 0.773 
POD 4 CRP >150mg/L (yes/no) 76/126 53/74 23/52 0.134 
     
Postoperative outcomes     
Any postoperative complication (yes/no) 111/130 75/85 36/45 0.721 
Infective complication (yes/no) 75/166 51/109 24/57 0.722 
Clavien Dindo 3-5 complication (yes/no) 24/217 18/142 6/75 0.347 
AR anterior resection, APR abdominoperineal excision, BMI Body Mass Index, CRM circumferential margin, 
CRP C-reactive protein, mGPS modified Glasgow Prognostic Score, POD postoperative day, nCRT 
neoadjuvant chemoradiotherapy, ASA American Society of Anesthesiology 
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Table 10-2: Relationship between clinicopathological characteristics and neoadjuvant therapy in 
propensity score matched patients undergoing elective surgery for rectal cancer 
Characteristic All (n=104) Neoadjuvant P  
No (n=52) Yes (n=52) 
Demographics     
Sex (male/female) 62/42 33/19 29/23 - 
Age (<65/65-74/>74) 62/33/9 34/13/5 28/20/4 - 
BMI (<20/20-25/26-30/>30, kg/m2) 8/45/30/21 4/22/13/13 4/23/17/8 - 
Smoking (never/ex/current) 45/41/18 24/18/10 21/23/8 - 
ASA score (1/2/3/4) 34/42/27/1 17/21/13/1 17/21/14/0 - 
     
Operative variables     
Preoperative dexamethasone (yes/no) 51/39 21/22 30/17 - 
Operation (AR/APR) 69/35 35/17 34/18 - 
Approach (laparoscopic/open) 25/79 11/41 14/38 - 
Operation >4h (yes/no) 57/46 25/26 32/20 - 
Intraoperative transfusion (yes/no) 5/83 1/41 4/42 - 
Stoma (yes/no) 81/23 35/17 46/6 - 
     
Postoperative pathology     
TNM stage (0/ I/ II/III/IV) 6/20/43/31/4 0/15/20/16/1 6/5/23/15/3 - 
CRM (R0/R1/R2) 92/8/1 46/4/0 46/4/1 - 
Differentiation (well-mod/poor) 11/88 3/48 8/40 - 
Venous invasion (yes/no) 58/45 33/19 25/26 - 
Tumour perforation (yes/no) 1/103 1/51 0/52 - 
     
Systemic inflammation     
Pre-operative mGPS (0/1/2) 91/8/5 44/6/2 47/2/3 - 
     
POD 3 CRP >150mg/L (yes/no) 43/51 25/24 18/27 0.523 
POD 4 CRP >150mg/L (yes/no) 34/57 20/25 14/32 0.774 
     
Postoperative outcomes     
Any postoperative complication (yes/no) 48/56 25/27 23/29 1.000 
Infective complication (yes/no) 30/74 14/38 16/36 0.815 
Clavien Dindo 3-5 complication (yes/no) 12/92 6/46 6/46 1.000 
AR anterior resection, APR abdominoperineal excision, BMI Body Mass Index, CRM circumferential margin, 
CRP C-reactive protein, mGPS modified Glasgow Prognostic Score, POD postoperative day, nCRT 
neoadjuvant chemoradiotherapy, ASA American Society of Anesthesiology 
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Table 10-3: Odds ratios for exceeding the C-reactive protein threshold of 150mg/L on postoperative 
day 3, and postoperative complications, with respect to neoadjuvant therapy across the propensity 
score methods 
Propensity Score Model n POD 3 CRP >150mg/L 
OR (95%CI) 
Complication  
OR (95% CI) 
Unadjusted 251 0.90 (0.51-1.58) 0.84 (0.49-1.44) 
Regression adjustment 127 0.80 (0.38-1.71) 0.86 (0.41-1.81) 
Stratification by quintiles (ATE) 127 0.80 (0.38-1.72) 0.86 (0.41-1.81) 
Matched 1:1 104 0.64 (0.28-1.45) 0.85 (0.39-1.86) 
POD postoperative day, CRP C-reactive protein, OR odds ratio, CI confidence interval, ATE average 
treatment effect 
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 Figures and Legends
A B 
Figure 10-1: Distribution of propensity scores (A) before, and (B) after matching 
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Figure 10-2: Postoperative C-reactive protein (CRP) concentrations grouped by neoadjuvant therapy 
(nCRT) following surgery for rectal cancer after propensity score matching (n=104) 
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11 Comparison of the magnitude of the postoperative 
systemic inflammatory response following elective 
surgery for colorectal cancer in the UK and Japan 
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 Introduction 
Despite continuing advances in care, colorectal cancer remains one of the leading causes of 
cancer death worldwide (Ferlay et al. 2013).  Resection at surgery remains the primary 
treatment modality for cure, however it is associated with significant rates of postoperative 
complications (Ghaferi et al. 2011).  It is now well appreciated that postoperative infective 
complications (Aritnyan et al. 2014) and anastomotic leak (Mirnezami et al. 2011) may 
lead to increased recurrence and poorer survival following surgery with curative intent, 
although the mechanism remains unclear (McSorley Introduction).   
One hypothesis is that the innate immune response to surgery itself increases the risk of 
postoperative complication, and also of disease recurrence (Roxburgh et al. 2013).  Indeed, 
the association between serum concentrations of C-reactive protein (CRP), a marker of the 
magnitude of the postoperative systemic inflammatory response (Watt et al. 2015), and 
postoperative complications is now well described (Adamina et al. 2015).  A recent 
systematic review examining factors associated with anastomotic leak following colorectal 
surgery suggested that CRP concentrations of greater than 150mg/L on postoperative days 
3 to 5 warrant at least delaying early discharge, and most likely further investigation 
(McDermott et al. 2015).   
Several factors including laparoscopic surgery (Watt et al. 2015), BMI, and preoperative 
systemic inflammation (Watt et al. 2017a) have been reported to influence the magnitude 
of the postoperative systemic inflammatory response.  One factor which may influence the 
magnitude of the postoperative systemic inflammatory response which has not been 
investigated thus far is ethnicity.    Indeed, there is some evidence to suggest that, when 
compared to those from Europe, fewer patients with cancer from Japan are found to have 
preoperative systemic inflammation, although the negative prognostic impact is consistent 
across these ethnic groups (Park et al. 2017).   
Therefore, the aim of the present study was to examine the relationship between the 
magnitude of the postoperative systemic inflammatory response and perioperative 
variables in patients undergoing elective surgery, with curative intent, in the UK and Japan. 
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 Methods 
11.2.1 Patients 
Patients from two surgical units, at Glasgow Royal Infirmary (United Kingdom) and 
Dokkyo Medical University (Japan) were identified from prospectively collected and 
maintained databases of elective and emergency colorectal cancer resections.  Consecutive 
patients who, on the basis of preoperative abdominal computed tomography and 
laparotomy findings were considered to have undergone potentially curative resection for 
colorectal adenocarcinoma between February 2008 and November 2015 at both centres 
were considered for inclusion.  Patients with pre-existing inflammatory disease, metastatic 
disease, who underwent resection with palliative intent or local resection only, who 
underwent multivisceral resection, or had emergency surgery were excluded.  The 
prospective databases contained demographic, clinicopathological, perioperative, systemic 
inflammation, and outcome variables. 
11.2.2 Glasgow Royal Infirmary 
Tumours were staged using the fifth edition of the TNM classification, with additional data 
taken from pathological reports issued following resection.  All patients were discussed at 
a colorectal multi-disciplinary meeting involving surgeons, oncologists, radiologists, and 
pathologists with a colorectal cancer special interest before and after surgery.  Neoadjuvant 
treatment (nCRT) was offered to patients with histologically proven, locally advanced (T3-
T4, borderline operable or inoperable) rectal tumours following discussion at a multi-
disciplinary colorectal oncology meeting.  Complications were recorded at discharge and at 
first outpatient clinic follow up. 
All patients received prophylactic antibiotics and venous thromboprophylaxis prior to the 
induction of anaesthesia as per hospital policy.  All patients were cared for in line with a 
unit standardised perioperative care policy which included early postoperative 
mobilisation, early enteral nutrition, and the avoidance of routine nasogastric or peritoneal 
drainage. 
11.2.3 Dokkyo Medical University 
Patients were staged according to the seventh edition of the TNM classification with 
additional data taken from pathological reports issued following resection.  Patients with 
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rectal disease were offered nCRT at the discretion of the treating surgical and oncology 
teams. 
All patients received prophylactic antibiotics and venous thromboprophylaxis prior to the 
induction of anaesthesia.  Postoperative care included the selective use of peritoneal 
drainage in patients with rectal disease, and selective use of parenteral nutrition 
11.2.4 Methods 
Patients had serum CRP and albumin measured preoperatively and on postoperative day 3.  
Serum concentrations of CRP (mg/L) were measured using an autoanalyzer, as was serum 
albumin (normal range 35-50g/L). Exceeding the established CRP threshold of 150 mg/L 
on postoperative day 3 was recorded (McDermott et al. 2015).  The preoperative modified 
Glasgow Prognostic Score (mGPS) was calculated in patients for whom preoperative 
serum CRP and albumin were available (McMillan 2013).  The study was approved by the 
West of Scotland Research Ethics Committee, Glasgow (UK cohort) and the local 
institutional review board (Japan cohort). 
11.2.5 Statistical analysis 
Categorical data were compared using the Chi square test.  Continuous data were non-
normal so were displayed as medians and ranges. These continuous data were compared 
using the Mann-Whitney U test. 
Multivariate logistic regression was used to generate a propensity score for each patient, 
predicting the probability of having received surgery in either the UK or Japan, based on 
the following variables, age sex, TNM stage, along with variables thought to be associated 
with the postoperative systemic inflammatory response: BMI, ASA score, mGPS, tumour 
site, and surgical approach (open or laparoscopic).  Patients who underwent surgery in the 
UK were then matched 1:1 with a patient who underwent surgery in Japan, using the 
closest propensity score on the logit scale (calliper <0.05, order of match selection 
randomised, without replacement).  Categorical data were compared using McNemar’s 
test.  Medians of continuous data were compared using the related samples Wilcoxon sign 
rank test.  The appropriateness of the propensity score matching was assessed visually by 
frequency of propensity scores in each group before and after matching.  In addition, the 
propensity scores were included as a linear covariate alongside preoperative nCRT in 
multivariate binary logistic regression models for exceeding the postoperative day 3 CRP 
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threshold and postoperative complications.  Finally, the propensity scores were used to 
stratify the patients by quintiles from which an average treatment effect was calculated for 
both the postoperative day 3 CRP threshold and postoperative complications as an OR and 
95% CI.  
In all tests, a two sided p value <0.05 was considered statistically significant.  Propensity 
scoring, matching, and all statistical analyses were performed using IBM SPSS version 22 
for Windows (Chicago, IL, USA). 
11.2.6 Literature review 
The results obtained stimulated a post hoc systematic literature review that examined 
reported values of CRP following open and laparoscopic surgery in Europe compared to 
China and Japan.  A search was performed of PubMed from inception to 1st October 2016 
using the search terms “c-reactive protein”, “postoperative”, “colorectal surgery”.  
Abstracts were screened for relevance after which relevant full texts were appraised.  
Those studies which were pre-clinical, reviews, not in colorectal surgery, or did not report 
an average serum CRP value for patients undergoing laparoscopic or open surgery on 
postoperative days 2 or 3 were excluded. Weighted mean averages of CRP concentrations 
reported in studies comparing laparoscopic and open surgery in Europe and Asia were 
calculated.  The statistical significance of the mean difference between groups was 
assessed using the Z test.   
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 Results 
11.3.1 Patients 
In total 1,194 patients were included in the study (Figure 11-1), of which 636 underwent 
surgery in the UK centre and 558 underwent surgery in the Japanese centre (Table 11-1).  
A lower proportion of patients who underwent surgery in the UK were over 74 years old 
(27% vs. 32%, p=0.034), and male (57% vs. 63%, p=0.038), while a higher proportion 
were overweight or obese (57% vs. 22%, p<0.001) and had an ASA score of 3 or 4 (33% 
vs. 13%, p<0.001) when compared to those who underwent surgery in Japan.  A 
significantly higher proportion of patients who underwent surgery in the UK had 
undergone preoperative nCRT (15% vs. 0.01%, p<0.001).  Although there was no 
significant difference in TNM stage or tumour site, a higher proportion of those patients 
who underwent surgery in the UK had poorly differentiated tumours (8% vs. 3%, 
p<0.001), but lower rates of venous invasion (57% vs. 66%, p<0.001) and tumour 
perforation (1% vs. 4%, p=0.001), at histopathological examination when compared to 
those who underwent surgery in Japan.  A significantly higher proportion of patients who 
underwent surgery in the UK had a preoperative mGPS greater than 0 (22% vs. 15%, 
p=0.009), and a NLR greater than 3 (43% vs. 35%, p=0.004) when compared to those who 
underwent surgery in Japan. 
11.3.2 Operative and postoperative characteristics in the unmatched 
cohort 
A significantly lower proportion of patients who underwent surgery in the UK (Table 11-1) 
had a laparoscopic resection when compared to those who underwent surgery in Japan 
(35% vs. 44%, p=0.002).  There was a significant difference in the mix of surgical 
procedures performed when the two groups were compared (p=0.019).  A significantly 
higher proportion of patients who underwent surgery in the UK had 12 or more lymph 
nodes sampled and reported at histopathological examination when compared to those who 
underwent surgery in Japan (27% vs. 19%, p<0.001).  A significantly higher proportion of 
patients who underwent surgery in the UK exceeded the established serum CRP threshold 
of 150mg/L on postoperative day 3 when compared to those who underwent surgery in 
Japan (46% vs. 7%, p<0.001).  A significantly higher proportion of patients who 
underwent surgery in the UK had serum albumin concentration of less than 25g/L on 
postoperative day 3 when compared to those who underwent surgery in Japan (40% vs. 
29%, p<0.001).  Patients who underwent surgery in the UK had a significantly shorter 
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median length of postoperative stay when compared to those who underwent surgery in 
Japan (9 days vs. 13 days, p<0.001).  There were no significant differences in operation 
duration, rate of margin involvement, 30 day postoperative mortality, or the proportion of 
patients referred for adjuvant treatment when the two centres were compared. 
11.3.3 Operative and postoperative characteristics in the propensity score 
matched cohort 
Propensity scores could not be assigned to 401 patients due to missing covariate data, 
leaving 793 patients with propensity scores, of which 306 underwent surgery in the UK 
and 487 underwent surgery in Japan.  612 patients (306 from each group) were matched 
based on their propensity score, with a subsequent improvement in the balance of 
distribution of propensity scores in each group (Figure 11-2).  
In the propensity score matched cohort (Table 11-2), a significantly higher proportion of 
patients who underwent surgery in the UK exceeded the postoperative day 3 CRP 
threshold of 150mg/L when compared to those who underwent surgery in Japan (43% vs. 
8%, p<0.001).  A significantly higher proportion of patients who underwent surgery in the 
UK had a postoperative day 3 serum albumin concentration of <25g/L when compared to 
those who underwent surgery in Japan (38% vs. 27%, p=0.005).  There was a significant 
difference in median length of stay when those patients who underwent surgery in the UK 
were compared to those who underwent surgery in Japan (8 vs. 13 days, p<0.001).  There 
was no significant difference in 30 day mortality or the proportion of patients going on to 
adjuvant therapy.     
11.3.4 Sensitivity analyses using other propensity score methods 
Analysis of the impact of the country of surgery on exceeding the postoperative day 3 CRP 
threshold of 150mg/L (Table 11-3) found a similarly statistically significant probability of 
reduction in the unmatched cohort (OR 0.08, 95% CI 0.05-0.11) when using regression 
adjustment (OR 0.13, 95% CI 0.08-0.19), propensity score stratification (OR 0.12, 95% 
0.08-0.19, and propensity score matching (OR 0.12, 95% CI 0.08-0.20).   
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11.3.5 Comparison of the reported literature of the magnitude of the 
postoperative systemic inflammatory response in Asia and Europe 
The search strategy returned 197 abstracts of which 9 were reviews and 5 were pre-clinical 
animal studies.  169 studies were excluded due to either being outside colorectal surgery or 
not reporting an average serum CRP value for patients undergoing laparoscopic or open 
surgery on postoperative day 3.  14 studies, with 2,456 patients, were included, of which 9 
were from Europe and 5 were from Asia (all from China and Japan), with no studies from 
North America or Australasia (Table 11-4).    
When compared to the studies of open colorectal surgery in Europe (Table 11-5), the 
studies from Asia reported a statistically significantly lower CRP on postoperative day 3 
(mean difference -30 mg/L, 95% CI -60 to -1 mg/L, p=0.049).  When compared to the 
studies of laparoscopic colorectal surgery in Europe, the studies from Asia reported a 
statistically significantly lower CRP on postoperative day 3 (mean difference -45 mg/L, 
95% CI -70 to -20 mg/L, p<0.001). 
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 Discussion 
The results of the present study indicate that even after adjustment for confounding factors, 
the magnitude of the postoperative systemic inflammatory response was lower in Japan 
when compared to the UK.   
A large body of evidence now links the postoperative systemic inflammatory response and 
postoperative complications, (Adamina et al. 2015) which are associated with poorer 
oncologic outcome following surgery for colorectal cancer (Artinyan et al. 2014).  In 
addition, there is some evidence that the postoperative systemic inflammatory response is 
itself associated with poorer long-term outcome independent of complications (McSorley, 
Chapter 4).  Therefore, factors which modulate or attenuate the magnitude of the 
postoperative systemic inflammatory response are of interest.  Indeed, it is already 
recognised that laparoscopic surgery is associated with a lower postoperative systemic 
inflammatory response and lower complication rate following surgery for colorectal cancer 
(McSorley Chapter 3).  Furthermore, the use of corticosteroids in the perioperative period 
has been reported to be associated with both attenuation of the postoperative systemic 
inflammatory response and fewer complications following major abdominal surgery 
(Srinivasa et al. 2011).  However, it remains to be determined whether specific CRP 
thresholds determined in European studies have similar associations with postoperative 
complications and long-term outcomes in patients undergoing surgery in Asia.   
Indeed, the results of the present study are in keeping with previous reports suggesting a 
differential systemic inflammatory response to cancer dependent on nationality.  The 
presence of systemic inflammation at diagnosis, as defined by the modified Glasgow 
Prognostic Score (mGPS), has been shown to have a negative prognostic impact across a 
variety of solid tumours, in both resectable and unresectable disease, across Europe, the 
USA, Australasia, South Korea, Japan, and China (McMillan 2013).  Some prior reports 
suggest that a lower proportion of patients are systemically inflamed in Japanese cohorts 
when compared to Western cohorts (Ishizuka et al. 2009, Kobayashi et al. 2010, Jiang et al. 
2012).  This finding has recently been confirmed in a large observational study comparing 
cohorts undergoing surgery for stage I-III colorectal cancer in the UK and Japan (Park et 
al. 2017).  A lower proportion of patients in the Japanese cohort were found to be 
systemically inflamed prior to surgery, however, the negative prognostic impact of a raised 
mGPS remained.  Furthermore, the review of the existing literature reported in the present 
study suggests that patients who have undergone both open and laparoscopic surgery for 
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colorectal cancer in Asia have a lesser postoperative systemic inflammatory response when 
compared to those who have undergone the same surgery in Europe.  Taken together this 
evidence suggests that differential innate inflammatory responses exist in these two groups 
of patients, which may be underpinned by differential expression or genetic 
polymorphisms in pro-inflammatory cytokines and acute phase reactants.   
A further alternative explanation for the variation in the magnitude of the postoperative 
systemic inflammatory response found between the two centres in the present study is in 
variation amongst surgical and anaesthetic teams.  Indeed, the results of the present study 
report significant differences in operative factors between the patients who underwent 
surgery in the UK and Japan, including the proportion of patients undergoing laparoscopic 
surgery, the type of procedure performed, and the number of lymph nodes excised and 
sampled.  Although variation in outcomes dependent on surgeon and/or centre have been 
reported in the past (Burns et al. 2011, Oliphant et al. 2013), there have been no such 
reports focussing on the postoperative systemic inflammatory response.  Indeed, the 
significant differences in case mix and length of stay reported by the present study imply 
variation in surgical technique and perioperative care between the two centres.  However, 
although the magnitude of the postoperative systemic inflammatory response was 
significantly different between the two centres, other outcomes that would be expected to 
be affected by variation in care: the rates of postoperative mortality, and the proportion of 
patients going on to adjuvant therapy, were not. 
The most significant limitation of the present study was the variation in surgical practice 
and perioperative care between the sites in the UK and Japan, as evidenced by the 
significant difference in postoperative length of stay.  Around half of patients in the UK 
cohort received intraoperative dexamethasone to prevent postoperative nausea and 
vomiting whilst no patients in the Japanese cohort received perioperative steroids, a factor 
thought to influence the postoperative systemic inflammatory response.  Very few 
Japanese patients received nCRT prior to surgery, again suggesting very different 
management not just around surgery, but of patients with colorectal cancer in general 
between the two centres.  In addition, different histopathological techniques, reporting 
requirements, and TNM staging editions between centres may have introduced systematic 
differences in pathological variables.  Furthermore, differences in the recording of 
postoperative complications between the two centres prevented meaningful comparison.   
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Finally, the differences in the patients themselves might be seen as a limitation.  UK 
patients had greater obesity (BMI), comorbidity (ASA score), and existing evidence would 
suggest that these factors enhance the postoperative systemic inflammatory response.  
However, following adjustment for surgical approach, obesity and comorbidity through 
propensity score matching, there remained a difference in the postoperative systemic 
inflammatory response.  Although propensity score matching can be used in attempt to 
improve balance between groups in observational studies, it only allows us to control for 
known confounders and a possible risk of the method is the introduction of unknown and 
unrecognised systematic bias.  In the present study even after the matching process, the 
balance between groups was less than perfect.   
The basis of the differential postoperative systemic inflammatory response between the 
cohorts is not clear. It may be that ethnicity and underlying differential gene expression 
might have a role in the magnitude of the postoperative systemic inflammatory response.  
However, it may be that differences in operative and anaesthetic techniques, along with 
variation in perioperative care, have an important role to play.  These findings have 
implications for the comparison of postoperative outcomes across the globe.  For example, 
in the application of established postoperative CRP thresholds and in the design of any 
prospective studies designed to investigate attenuation of the postoperative systemic 
inflammatory response outwith Europe.   
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 Tables and Footnotes 
Table 11-1: Characteristics of patients undergoing elective resection of stage I-III colorectal cancer in 
UK and Japan (n=1194) 
Characteristic All 
Country P 
UK Japan 
N  1194 636 558 - 
Age (<65/65-74/>74) 418/431/345 217/250/169 201/181/176 0.034 
Sex (male/female) 713/481 362/274 351/207 0.038 
BMI (<20/20-25/26-30/>30) 165/494/289/196 26/214/184/180 139/280/105/16 <0.001 
ASA score (1/2/3/4) 239/632/256/23 147/280/186/22 92/352/70/1 <0.001 
Site (colon/rectum) 759/429 413/222 346/207 0.397 
TNM stage (0/I/II/III) 40/268/449/404 15/138/267/211 25/130/182/193 0.381 
Neoadjuvant treatment (yes/no) 99/1078 96/523 3/555 <0.001 
Preop mGPS (0/1/2) 939/84/144 484/56/86 455/28/58 0.009 
Preop NLR >3 (yes/no) 470/704 273/348 197/356 0.004 
Approach (open/laparoscopic) 709/465 403/221 306/244 0.002 
Procedure (RH/LH/AR/APR/TC) 434/305/318/85/29 232/172/156/55/21 202/133/162/30/8 0.019 
Surgery >4h (yes/no) 367/772 197/391 170/381 0.342 
≥12 lymph nodes sampled (yes/no) 891/270 511/120 380/150 <0.001 
Margin positive (yes/no) 55/1125 30/600 25/525 0.891 
POD 3 CRP (median,IQR,mg/L) 96 (52-163) 147 (94-213) 60 (35-96) <0.001 
POD 3 CRP >150mg/L (yes/no) 329/806 292/307 37/499 <0.001 
POD 3 albumin (median,IQR,g/L) 26 (23-29) 26 (23-29) 27 (24-30) <0.001 
POD 3 albumin <25g/L (yes/no) 386/707 237/349 149/358 <0.001 
Complication (yes/no) 498/688 261/375 237/313 0.480 
Anastomotic leak (yes/no) 71/1115 31/605 40/510 0.087 
Length of stay (median,IQR,days) 11 (8-16) 9 (6-13) 13 (10-21) <0.001 
Thirty day mortality (yes/no) 14/1180 11/625 3/555 0.063 
Adjuvant treatment (yes/no) 333/753 158/390 175/363 0.189 
UK United Kingdom, BMI Body Mass Index, ASA American Society of Anesthesiology, mGPS modified 
Glasgow Prognostic Score, NPS neutrophil platelet score, NLR neutrophil lymphocyte ratio, LMR 
lymphocyte monocyte ratio, POD postoperative day, CRP C-reactive protein, IQR interquartile range, RH 
right and extended right hemicolectomy, LH left and sigmoid colectomy, AR anterior resection, APR 
abdominoperineal resection, TC total colectomy  
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Table 11-2: Characteristics of propensity score matched patients undergoing elective resection of stage 
I-III colorectal cancer in the UK and Japan (n=612) 
Characteristic All 
Country P 
UK Japan 
N  612 306 306 - 
Age (<65/65-74/>74) 208/209/195 101/113/92 107/96/103 - 
Sex (male/female) 362/250 175/131 187/119 - 
BMI (<20/20-25/36-30/>30) 48/340/195/29 24/170/97/15 24/170/98/14 - 
ASA score (1/2/3/4) 131/353/119/9 84/139/75/8 47/214/44/1 - 
Site (colon/rectum) 396/216 203/103 193/113 - 
TNM stage (0/I/II/III) 21/142/247/202 6/68/140/92 15/74/107/110 - 
Neoadjuvant treatment (yes/no) 49/555 47/251 2/304 - 
Preop mGPS (0/1/2) 503/42/67 251/21/34 252/21/33 - 
Preop NLR (<3/>3) 366/240 165/135 201/105 - 
Approach (open/laparoscopic) 370/242 188/118 182/124 - 
Procedure (RH/LH/AR/APR/TC) 232/161/163/40/11 110/92/74/23/7 122/69/89/17/4 - 
Surgery >4h (yes/no) 191/404 89/200 102/204 - 
≥12 lymph nodes sampled (yes/no) 464/147 245/61 219/86 - 
Margin positive (yes/no) 22/590 13/293 9/297 - 
POD 3 CRP (median,IQR,mg/L) 92 (52-153) 129 (82-200) 64 (40-99) <0.001 
POD 3 CRP >150mg/L (yes/no) 146/433 121/161 25/272 <0.001 
POD 3 albumin (median,IQR,g/L) 26 (24-29) 26 (23-20) 27 (24-30) 0.001 
POD 3 albumin <25g/L (yes/no) 181/373 105/172 76/201 0.005 
Length of stay (median,IQR,days) 11 (7-16) 8 (6-12) 13 (10-21) <0.001 
Thirty day mortality (yes/no) 5/607 3/303 2/304 1.000 
Adjuvant treatment (yes/no) 168/396 68/196 100/200 0.067 
UK United Kingdom, BMI Body Mass Index, ASA American Society of Anesthesiology, mGPS modified 
Glasgow Prognostic Score, NPS neutrophil platelet score, NLR neutrophil lymphocyte ratio, LMR 
lymphocyte monocyte ratio, POD postoperative day, CRP C-reactive protein, IQR interquartile range, RH 
right and extended right hemicolectomy, LH left and sigmoid colectomy, AR anterior resection, APR 
abdominoperineal resection, TC total colectomy  
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Table 11-3: Odds ratios for exceeding the postoperative day 3 C-reactive protein threshold of 150mg/L 
with respect to country of surgery across the propensity score methods 
Propensity Score Model n POD 3 CRP >150mg/L 
OR (95%CI) 
Unadjusted 1194 0.08 (0.05-0.11) 
Regression adjustment 793 0.13 (0.08-0.19) 
Stratification by quintiles (ATE) 793 0.12 (0.08-0.19) 
Matched 1:1 612 0.12 (0.08-0.20) 
POD postoperative day, CRP C-reactive protein, OR odds ratio, CI confidence interval, ATE average 
treatment effect 
 
     
 
225 
  
Table 11-4: Studies reporting postoperative day 3 C-reactive protein concentrations following open and 
laparoscopic surgery for colorectal cancer in Asia and Europe 
Country Type Author Year Journal Patients (n) mean POD 3 
CRP (mg/L) 
Europe       
Denmark Prospective Stage et al. 1997 Br J Surg open = 14 
laparoscopic = 15 
open = 95 
laparoscopic = 126 
Spain Retrospective Delgado et al. 2001 Dis Colon Rectum open = 58 
laparoscopic = 39 
open = 91 
laparoscopic = 69 
Germany Prospective Wichmann et al. 2005 Arch Surg open = 35 
laparoscopic = 35 
open = 145  
laparoscopic = 90  
UK Retrospective Crozier et al. 2007 Br J Surg open = 180 open = 145 
Italy Prospective Vignali et al.  2009 Dis Colon Rectum open = 13 
laparoscopic = 13 
(only control group included) 
open = 82 
laparoscopic = 74 
Switzerland Retrospective Warschkow et al. 2011 Int J Colorectal 
Dis 
open =1,238 open = 141 
Denmark Retrospective Helvind et al. 2013 Surg Endoscp lap = 162 laparoscopic = 68 
UK Retrospective Selby et al. 2014 Int J Colorectal 
Dis 
open = 127 open = 168  
UK Retrospective Ramanathan et 
al.  
2015 Ann Surg Oncol open = 191 
laparoscopic = 153 
open = 169  
laparoscopic = 122 
Asia       
Hong Kong Prospective Leung et al. 2000 Ann Surg open = 17 
laparoscopic = 17 
open = 78 
laparoscopic = 58  
Japan Prospective Hatada et al. 2000 Cytokine open =100 open = 130 
Japan Prospective Nishiguchi et al. 2001 Dis Colon Rectum open = 12 
laparoscopic = 15 
open = 85  
laparoscopic = 75 
China Prospective Wang et al. 2012 J Gastrointest Surg open = 41 
laparoscopic = 40 
(only fast track groups 
included) 
open = 99  
laparoscopic = 84 
Japan Prospective Shibata et al. 2015 Tech Coloproctol open = 8 
laparoscopic = 23 
open = 102 
laparoscopic = 54  
POD postoperative day, CRP C-reactive protein, UK United Kingdom 
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Table 11-5: Weighted average postoperative day 3 C-reactive protein concentrations in Asia and 
Europe following elective surgery for colorectal cancer 
Postoperative day Approach 
Europe Asia P 
  mean (SD) mean (SD)  
POD 3 CRP (mg/L) Open 144 (35) 114 (20) 0.049 
Laparoscopic 106 (26) 61 (14) <0.001 
POD postoperative day, CRP C-reactive protein, SD standard deviation 
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 Figures and Legends 
 
Figure 11-1: Flow chart of patients undergoing surgery for colorectal cancer in the UK and Japan 
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Figure 11-2: Distribution of propensity scores (A) before, and (B) after propensity score matching 
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12 Examination of a CRP first approach for the detection 
of postoperative complications in patients undergoing 
surgery for colorectal cancer: a pragmatic study 
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 Introduction 
Anastomotic leak and other significant postoperative complications can present in a subtle 
manner and often only become clinically evident relatively late in the postoperative course, 
which is likely to contribute to their impact on outcomes (Platt et al. 2012).  
It is now well understood that the magnitude of postoperative systemic inflammatory 
response, measured by C-reactive protein (CRP), is associated with postoperative 
complications (Singh et al. 2014a, Adamina et al. 2015).  Recent consensus suggests that 
CRP concentrations exceeding 150mg/L on postoperative days 3 to 5 should alert 
clinicians to possible postoperative complications, including anastomotic leak (McDermott 
et al. 2015).  Furthermore, it has been suggested that measuring the magnitude of the 
postoperative systemic inflammatory response may be useful in determining safe 
discharge, or indeed delaying it for further investigation (Mullen 2017).  
Computed Tomography (CT) is an important imaging technique commonly used, with or 
without the addition of rectal and/or oral contrast, to diagnose postoperative complications 
including anastomotic leak (Hyman et al. 2007, Kauv et al. 2015).  Studies have shown CT 
to be both sensitive and specific in detection of these postoperative complications 
(Eckmann et al. 2004, Straatman et al. 2014).  However, compared to most routine blood 
tests such as CRP, CT is resource intensive, requires patient exposure to ionising radiation, 
and is usually carried out upon the surgical team’s suspicion.  As a consequence, CT is 
often not requested until late in the postoperative course (Kornmann et al. 2014). 
Due to this strong association with the development of postoperative complications, CRP 
may be a useful biomarker to identify those patients who would benefit from early CT.  
However, at present there is no data to inform as to whether a CRP first approach would 
result in the earlier detection of postoperative complications.  The currently recruiting 
PRECious trial aims to test this hypothesis prospectively by allocating patients to standard 
care or to a postoperative care arm in which patients will undergo contrast CT if they 
exceed a CRP threshold of 140mg/L on postoperative day 3, 4, or 5 (Straatman et al. 
2015).  The investigators plan to use a stepped wedge design and will not blind clinicians 
in the control arm to postoperative CRP concentrations.  Given that the current evidence 
for the association between CRP and postoperative complications is robust, this raises the 
possibility of selection bias and crossover of patients allocated to the control arm to early 
      
 
231 
   
CT dependent on their CRP concentrations.  Another approach would be to audit surgical 
practice prior to the introduction of a CRP first postoperative protocol. 
Therefore, the aim of the present study, in a prospective cohort, was to examine the 
relationship between the magnitude of the postoperative systemic inflammatory response, 
postoperative CT, and complications in patients who underwent surgery for colorectal 
cancer. 
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 Patients and Methods 
12.2.1 Patients 
Patients with histologically confirmed colorectal cancer who underwent elective surgery 
with curative intent, between February 2008 and April 2015 at a single centre were 
included in the study.  Patients who underwent emergency surgery, palliative procedures, 
with metastatic disease, or who had existing inflammatory conditions were excluded.   
All patients received prophylactic antibiotics and venous thromboprophylaxis prior to the 
induction of anaesthesia as per hospital policy.  Patients had routine preoperative blood 
sampling including a full blood count (FBC), serum CRP, and albumin concentration.   
On each postoperative day patients were clinically assessed and had blood samples, 
including serum CRP, obtained routinely until discharged.  Further postoperative 
investigation and intervention was at the discretion of the patient’s surgical team, who 
were not blinded to blood results. All CT scans performed in the postoperative period were 
reported by a consultant radiologist at the request of the referring surgical team.  The use 
of rectal, oral, and intravenous contrast was at the discretion of the supervising radiologist.  
There was no CRP first postoperative protocol in place during the study period.  This study 
was approved as part of surgical audit by the West of Scotland Research Ethics 
Committee.  
12.2.2 Methods 
Data was collected prospectively in a database, anonymised, and subsequently analysed.  
Recorded information included patient demographics, clinicopathological, operative, and 
radiological (CT) data.  As CRP on postoperative day 4 was the measurement analysed, 
only CT scans performed between postoperative days 4 and 14 were included.  Earlier CT 
scans were not included as a resultant early intervention may have confounded the 
subsequent postoperative day 4 CRP value.  Where multiple CT scans were performed 
during this period, only the result of the first scan in the postoperative period was included.    
Serum concentrations of CRP (mg/L) were measured using an autoanalyzer (Architect; 
Abbot Diagnostics, Maidenhead, UK) with a lower detectable limit of 0.2 mg/L, as was 
serum albumin (normal range 35-50g/L).  The preoperative modified Glasgow Prognostic 
Score (mGPS) was calculated in patients for whom serum CRP and albumin concentrations 
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were available (McMillan 2013).  Breaching the established CRP threshold of 150mg/L on 
postoperative day 4 was recorded (McDermott et al. 2015). 
Infective complications were categorised as described previously and are briefly 
summarised here (Platt et al. 2012).  Wound (superficial surgical site) infection was 
defined as the presence of pus either spontaneously discharging from the wound or 
requiring drainage.  Deep surgical site infection was defined as surgical or image-guided 
drainage of intra-abdominal pus.  Anastomotic leak was defined as radiologically verified 
fistula to bowel anastomosis or diagnosed at laparotomy. Pneumonia was defined by fever 
above 38.5oC and consolidatory chest X-ray findings requiring antibiotic treatment.  
Septicaemia was defined by the presence of sepsis combined with positive blood culture.  
Urinary tract infection (UTI) was only included if complicated by septicaemia and 
confirmed with positive urine culture.  Complications were also classified by severity 
using the Clavien Dindo grade (Dindo et al. 2004).   
12.2.3 Statistical Analysis 
Categorical data were compared using the Chi square test and Chi square for linear 
association where appropriate.  Continuous data were displayed as medians and ranges. 
These continuous data were compared using the Mann-Whitney U test.  Missing data were 
excluded from analysis.  Statistical analyses were performed using IBM SPSS version 22 
for Windows (Chicago, IL, USA).  Two sided p values <0.05 were considered statistically 
significant. 
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 Results 
12.3.1 Patients 
In total, 495 patients were included in the study (Figure 12-1).  The majority were male 
(286, 58%), over 65 years old (335, 68%), with node negative disease (328, 66%) and 
underwent open surgery (349, 70%) (Table 12-1).  170 (34%) patients exceeded the 
postoperative day 4 CRP threshold of 150mg/L.  93 (19%) patients underwent CT scan 
between postoperative days 4 and 14 following surgery, of which the majority received 
intravenous contrast (90, 97%) while 3 (3%) patients received additional rectal contrast. 
The median duration between surgery and CT scan was 7 days (range 4-14).  218 patients 
(44%) developed a postoperative complication, of which 146 (29%) were infective and 51 
(10%) were Clavien Dindo grade 3-5.  There were 22 anastomotic leaks (4%).   
When those patients who underwent surgery for colonic and rectal cancers were compared, 
there was no significant difference in the proportion of patients exceeding the established 
postoperative day 4 CRP threshold of 150mg/L (p=0.923), undergoing a postoperative CT 
scan (p=0.239), having a postoperative complication (p=0.052), anastomotic leak 
(p=1.000), or the need for reoperation (p=0.402).  Therefore, the two groups were 
subsequently analysed together. 
12.3.2 Association between postoperative CT, CRP, and complications 
Patients who underwent a CT scan (n=93), compared with those who did not (n=402, 
Figure 12-1, Table 12-2), were more likely to have a postoperative complication of any 
kind (84% vs. 35%, p<0.001), infective complication (67% vs. 21%, p<0.001), 
anastomotic leak (17% vs. 2 %, p<0.001), and have a higher Clavien Dindo grade 
(p<0.001).  They were also significantly more likely to require postoperative percutaneous 
intervention or reoperation (25% vs. 4%, p<0.001), although there was no significant 
association with time between initial surgery and intervention. 
In those patients who did not undergo a CT scan (n=402), exceeding CRP concentration of 
150mg/L (n=117) on postoperative day 4 (Figure 12-1 and Table 12-3) was associated with 
a higher rate of any kind of postoperative complication (50% vs. 29%, p<0.001), infective 
complications (36% vs. 15%, p<0.001), anastomotic leak (4% vs. 0.5%, p=0.009), and 
higher Clavien Dindo grade (p<0.001).  There was a trend toward greater need for 
postoperative intervention (7% vs. 3%, p=0.089).  Those patients who required reoperation 
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but did not undergo CT did so for reasons including haemorrhage, wound dehiscence, 
stoma complications, and discharge of enteric content from abdominal wound. 
In those patients who did undergo a CT scan (n=93), exceeding a CRP concentration of 
150mg/L (n=53) on postoperative day 4 (Figure 12-1 and Table 12-4) was not associated 
with any clinicopathological variables, or postoperative complication rates.  There was a 
significant association with earlier CT in those patients who exceeded the established CRP 
threshold of 150mg/L on postoperative day 4 (median postoperative day 6 vs. 8, p=0.001) 
and a trend toward earlier intervention (p=0.140). 
12.3.3 CRP before CT, and the association with complications and 
reoperation 
Patients who exceeded the postoperative day 4 CRP threshold of 150mg/L (n=170), 
compared with those who did not (n=325), were more likely to undergo a CT scan (30% 
vs. 12%, p<0.001) and at an earlier time (median postoperative day 6 vs. 8, p=0.001).  
They were more likely to have any kind of postoperative complication (61% vs. 36%, 
p<0.001), infective complications (47% vs. 21%, p<0.001), anastomotic leak (10% vs. 2%, 
p<0.001), and have a higher Clavien Dindo grade (p<0.001).  They were also more likely 
to require postoperative percutaneous intervention or reoperation (14% vs. 5%, p=0.003).  
In those patients who exceeded the postoperative day 4 CRP threshold of 150mg/L 
(n=170), a subsequent CT scan (n=53) compared to those without a CT scan was 
associated with a higher rate of any kind of complication (87% vs. 50%, p<0.001), 
infective complications (72% vs. 36%, p<0.001), anastomotic leak (23% vs. 4%, p=0.001), 
and a greater requirement for postoperative percutaneous intervention or reoperation (28% 
vs. 7%, p<0.001).   
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 Discussion 
The results of the present study report that the combination of high CRP on postoperative 
day 4 followed by CT is associated with higher rates of postoperative complication and re-
intervention in patients undergoing surgery for colorectal cancer. 
In keeping with prior studies, the magnitude of the postoperative systemic inflammatory 
response was associated with complications and their severity (Adamina et al. 2015, 
McSorley Chapter 3).  Furthermore, it was of interest that there was a significant rate of 
clinically important (i.e. Clavien Dindo grade ≥3) morbidity and mortality in those patients 
who exceeded the CRP thresholds on postoperative day 4 but did not undergo CT 
scanning.  This may represent a group of patients who were “failed to rescue”.   
In contrast to the widely used measurement of CRP on postoperative day 4, postoperative 
CT scanning was only carried out in approximately 1 in 5 patients.  In those patients who 
exceeded the CRP threshold on postoperative day 4, the use of CT scan was associated 
with a higher rate of all complications, infective complications, and anastomotic leak.  In 
addition, the combination of postoperative day 4 CRP and subsequent CT scan was 
associated with a significantly higher rate of postoperative intervention.  
A prior observational study by Straatman and colleagues reported a similar relationship 
between CRP and Clavien Dindo grade 3-5 complications, and a sensitivity and specificity 
of 92% and 100% respectively for contrast enhanced CT in the detection of these major 
complications in abdominal surgery (Straatman et al. 2014).  Furthermore, a recent 
observational study reported earlier diagnosis of postoperative complications, including by 
CT, and earlier intervention following surgery for colorectal cancer after the adoption of 
routine postoperative CRP measurement (Mik et al. 2016).  However, the accuracy of CT 
was not further stratified by CRP in either study.   
In those patients who did not exceed the CRP threshold on postoperative day 4, the use of 
CT scan also increased the detection rate of complications and of anastomotic leak.  Taken 
together with the above results it is clear that patients who underwent CT between 
postoperative days 4 and 14 and did not exceed the CRP thresholds on postoperative day 4, 
did so for reasons other than a raised CRP.  Also, a small number of patients required 
reoperation without having undergone postoperative CT, primarily for complications 
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which would not necessarily require a CT in their diagnosis, e.g. wound and stoma 
complications, haemorrhage, and fistulation.  
Even serious complications, such as anastomotic leak and those with a Clavien Dindo 
grade of 3 or more, are often not diagnosed until late in the postoperative course, in some 
cases as long as 12 days after surgery (Khan et al. 2008, Platt et al. 2012).  In keeping with 
this, half of all CT scans were performed 7 days or more after surgery in the present study.  
However, there was no significant difference in time to CT or intervention between the CT 
and no-CT groups in the present study.  Despite this, current evidence suggests that CT 
imaging can accurately diagnose significant intra-abdominal complications much earlier in 
the postoperative period (Kornmann et al. 2014). The currently recruiting PRECious trial 
aims to determine whether this is the case based on a CRP first approach. 
The present study has several limitations.  Due to the observational nature of the study, 
there were missing clinicopathological data.  The analysis was retrospective, however the 
process of postoperative care, investigation, and re-intervention is a dynamic one and so 
difficult to model in this way.  Only a small number of patients received rectal contrast, 
and a small number received no contrast via any route due to renal failure, which may have 
reduced the diagnostic accuracy of CT.  In many cases in which patients did not go on to 
reoperation the diagnosis of any complication relied directly on the CT scan report, 
although the use of Clavien Dindo grading has hopefully increased the objectivity of 
complication recording.  Furthermore, although the present study investigated CRP 
thresholds on day 4, the median time to CT imaging was 7 days.  Therefore, the results 
may not reflect the accuracy of CT performed earlier in the postoperative course.   
The present study suggests that current clinical postoperative management with CT 
imaging based on a combination of clinical suspicion, physiological parameters and blood 
tests is relatively successful in terms of detection and intervention in postoperative 
complications.  However, a CRP of >150mg/L on postoperative day 4 should alert the 
clinical team that a postoperative complication may be present, or developing.  Future 
prospective work should attempt to determine whether a CRP first approach to the 
diagnosis of major complications may result in earlier and improved diagnosis of major 
postoperative complications by CT imaging.  This approach may result in improved 
postoperative morbidity and mortality following surgery for colorectal cancer. 
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 Tables and Footnotes 
Table 12-1: Clinicopathological and perioperative variables of patients undergoing elective surgery for 
colorectal cancer (n=495) 
Characteristic All 
N 495 
  
Demographic characteristics  
Age (<65/65-74/>74) 160/195/137 
Sex (male/female) 286/206 
BMI (<20/20-25/26-30/>30) kg/m2 23/155/147/140 
Smoking (never/ex/current) 209/197/75 
ASA score (1/2/3/4) 96/222/153/20 
  
Pathological characteristics  
Site (colon/rectum) 298/194 
TNM stage (0/1/2/3) 13/105/207/167 
Preoperative mGPS (0/1/2) 369/44/70 
Neoadjuvant chemoradiotherapy (yes/no) 88/395 
  
Operative characteristics  
Operative approach (open/laparoscopic) 349/136 
Stoma (yes/no) 172/319 
Surgery >4h (yes/no) 153/295 
Intraop transfusion (yes/no) 26/368 
  
Postoperative outcomes  
POD4 >150mg/L (yes/no) 170/322 
CT scan during POD 4-14 (yes/no) 93/402 
Time to CT scan (median,range,days) 7 (4-14) 
Any postoperative complication (yes/no) 218/277 
Anastomotic leak (yes/no) 22/473 
Infective complication (yes/no) 146/349 
Clavien Dindo grade (0/1-2/3-4/5) 277/167/47/4 
Intervention (yes/no) 39/456 
Time to intervention (median,range,days) 7 (0-29) 
ASA American Society of Anaesthesiology, BMI Body Mass Index, CRP C-reactive protein, mGPS modified 
Glasgow Prognostic Score, POD postoperative day 
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Table 12-2: Relationship between postoperative outcomes and CT between postoperative days 4 and 14 
in patients undergoing elective surgery for stage I-III colorectal cancer (n=495) 
Characteristic CT POD 4-14 P  
No Yes 
N 402 93 - 
    
Demographic characteristics    
Age (<65/65-74/>74) 130/153/116 30/42/21 0.490 
Sex (male/female) 236/163 50/43 0.353 
BMI (<20/20-25/26-30/>30) kg/m2 18/129/122/105 5/26/25/35 0.157 
Smoking (never/ex/current) 171/158/62 38/39/13 0.867 
ASA score (1/2/3/4) 77/179/124/18 19/43/29/2 0.527 
    
Pathological characteristics    
Site (colon/rectum) 247/152 51/42 0.239 
TNM stage (0/1/2/3) 10/87/168/134 3/18/39/33 0.755 
Preoperative mGPS (0/1/2) 302/33/55 67/11/15 0.376 
Neoadjuvant chemoradiotherapy (yes/no) 71/321 17/74 0.881 
    
Operative characteristics    
Operative approach (open/laparoscopic) 286/108 63/28 0.520 
Stoma (yes/no) 131/267 41/52 0.053 
Surgery >4h (yes/no) 111/247 42/48 0.006 
Intraop transfusion (yes/no) 20/302) 6/64 0.472 
    
Postoperative outcomes    
POD4 CRP >150mg/L (yes/no) 117/282 53/40 <0.001 
Any postoperative complication (yes/no) 140/262 78/15 <0.001 
Infective complication (yes/no) 84/318 62/31 <0.001 
Anastomotic leak (yes/no) 6/396 16/77 <0.001 
Clavien Dindo grade (0/1-2/3-4/5) 262/118/21/1 15/49/26/3 <0.001 
Intervention (yes/no) 16/386 23/70 <0.001 
Time to intervention (median,range,days) 6 (0-28) 9 (4-29) 0.117 
ASA American Society of Anaesthesiology, BMI Body Mass Index, CRP C-reactive protein, mGPS modified 
Glasgow Prognostic Score, POD postoperative day 
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Table 12-3: Relationship between postoperative outcomes and CRP on postoperative day 4 in patients 
undergoing elective surgery for colorectal cancer who did not undergo CT between postoperative day 
4 and 14 (n=402) 
Characteristic POD 4 CRP >150mg/L P  
No Yes 
N 285 117 - 
    
Demographic characteristics    
Age (<65/65-74/>74) 89/112/81 41/41/35 0.791 
Sex (male/female) 159/123 77/40 0.093 
BMI (<20/20-25/26-30/>30) kg/m2 14/88/97/66 4/41/25/39 0.339 
Smoking (never/ex/current) 128/110/36 43/48/26 0.046 
ASA score (1/2/3/4) 64/122/84/11 13/57/40/7 0.055 
    
Pathological characteristics    
Site (colon/rectum) 175/107 72/45 1.000 
TNM stage (0/1/2/3) 10/67/110/95 0/20/58/39 0.131 
Preoperative mGPS (0/1/2) 226/21/27 76/12/28 <0.001 
Neoadjuvant chemoradiotherapy (yes/no) 54/222 17/99 0.314 
    
Operative characteristics    
Operative approach (open/laparoscopic) 197/82 89/26 0.214 
Stoma (yes/no) 90/191 41/76 0.561 
Surgery >4h (yes/no) 85/175 26/72 0.306 
Intraop transfusion (yes/no) 13/227 7/75 0.312 
    
Postoperative outcomes    
Any postoperative complication (yes/no) 82/203 58/59 <0.001 
Infective complication (yes/no) 42/243 42/75 <0.001 
Anastomotic leak (yes/no) 1/284 5/112 0.009 
Clavien Dindo grade (0/1-2/3-4/5) 203/69/13/0 59/49/8/1 <0.001 
Intervention (yes/no) 8/277 8/109 0.089 
Time to intervention (median,range,days) 4 (0-28) 8 (4-21) 0.145 
ASA American Society of Anaesthesiology, BMI Body Mass Index, CRP C-reactive protein, mGPS modified 
Glasgow Prognostic Score, POD postoperative day 
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Table 12-4: Relationship between postoperative outcomes and CRP on postoperative day 4 in patients 
undergoing elective surgery for colorectal cancer who did undergo CT between postoperative day 4 
and 14 (n=93) 
Characteristic POD 4 CRP >150mg/L P  
No Yes 
N 40 53 - 
    
Demographic characteristics    
Age (<65/65-74/>74) 11/19/10 19/23/11 0.415 
Sex (male/female) 21/19 29/24 0.837 
BMI (<20/20-25/26-30/>30) kg/m2 2/15/10/12 3/11/15/23 0.142 
Smoking (never/ex/current) 15/15/9 23/24/4 0.125 
ASA score (1/2/3/4) 9/18/12/1 10/25/17/1 0.780 
    
Pathological characteristics    
Site (colon/rectum) 19/21 32/21 0.293 
TNM stage (0/1/2/3) 2/6/19/13 1/12/20/20 0.824 
Preoperative mGPS (0/1/2) 29/3/8 38/8/7 0.706 
Neoadjuvant chemoradiotherapy (yes/no) 9/30 8/44 0.420 
    
Operative characteristics    
Operative approach (open/laparoscopic) 28/11 35/17 0.819 
Stoma (yes/no) 19/21 22/31 0.674 
Surgery >4h (yes/no) 16/24 26/24 0.293 
Intraop transfusion (yes/no) 4/29 2/35 0.316 
    
Postoperative outcomes    
Time to CT scan (median,range,days) 8 (4-12) 6 (4-14) 0.001 
Any postoperative complication (yes/no) 32/8 46/53 0.406 
Infective complication (yes/no) 24/16 38/15 0.271 
Anastomotic leak (yes/no) 4/36 12/41 0.165 
Clavien Dindo grade (0/1-2/3-4/5) 8/23/8/1 7/26/18/2 0.131 
Intervention (yes/no) 8/40 15/53 0.468 
Time to intervention (median,range,days) 13 (6-14) 8 (4-29) 0.140 
ASA American Society of Anaesthesiology, BMI Body Mass Index, CRP C-reactive protein, mGPS modified 
Glasgow Prognostic Score, POD postoperative day 
  
      
 
242 
   
 Figures and Legends 
 
Figure 12-1: Flowchart of postoperative outcomes stratified by postoperative day (POD) 4 C-reactive 
protein (CRP), and CT imaging following surgery for colorectal cancer 
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13 The impact of preoperative corticosteroids on the 
systemic inflammatory response and postoperative 
complications following surgery for gastrointestinal 
cancer: a systematic review and meta-analysis 
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  Introduction 
As discussed in earlier chapters, postoperative IL 6, and CRP concentrations in particular, 
have been found to be useful markers of the magnitude of the surgical injury (Watt et al. 
2015). The magnitude of this postoperative systemic inflammatory response, and in 
particular the routinely available CRP, is associated with the development of complications 
following colorectal surgery, oesophagectomy, and liver resection (Dutta et al. 2011, Platt 
et al. 2012, and Adamina et al. 2015).  Furthermore, in colorectal cancer surgery, an 
association has been described between postoperative systemic inflammation measured by 
CRP, and cancer specific survival (McSorley Chapter 4). 
One hypothesis which might link these observations is that the systemic inflammatory 
response is in some way a causal factor in the development of postoperative complications 
rather than just an epiphenomenon of it.  If this were the case it would be assumed that 
attenuation of this postoperative stress response would results in fewer complications. 
Preoperative corticosteroids are a logical choice of intervention given their potential 
potency and duration of effect (Sapolsky et al. 2000, Holte et al. 2002). Indeed, 
preoperative corticosteroids have been used as they have been found to reduce 
postoperative nausea and vomiting and analgesic requirements following abdominal 
surgery (Karanicolas et al. 2008, Waldron et al. 2013). A recent meta-analysis reported that 
preoperative corticosteroids significantly reduced postoperative day one IL 6, 
postoperative complications, infective complications, and length of stay following 
abdominal surgery (Srinivasa et al. 2011). Preoperative corticosteroids have also been 
reported to reduce postoperative IL 6 and complication rates following liver resection and 
oesophagectomy in meta-analyses of small numbers of studies (Richardson et al. 
2014, Raimondi et al. 2006, Gao et al. 2014).  
To our knowledge, no prior meta-analysis has investigated comprehensively the impact of 
preoperative corticosteroids on the postoperative surgical stress response following surgery 
for gastrointestinal cancer. The present meta-analysis is the first to examine their impact on 
CRP. Both IL 6 and CRP are objective measures of the magnitude of the systemic 
inflammatory response to surgery, however CRP is more readily available in the clinical 
setting (Watt et al. 2015c). Furthermore, no meta-analysis has attempted to assess the dose 
response between preoperative corticosteroids and the magnitude of the postoperative 
systemic inflammatory response and postoperative complication rate. 
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Therefore, the objective of the present systematic review and meta-analysis was to 
examine the impact of preoperative corticosteroids compared to placebo, in the context of 
randomized controlled trials, on the surgical stress response, in particular postoperative IL 
6 and CRP, and their relationship with the development of infective complications 
following surgery for gastrointestinal cancers. 
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 Methods 
The present systematic review and meta-analysis was performed and reported in 
accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) statement (Moher et al. 2010). 
13.2.1 Outcomes of interest 
The primary outcome of interest was the impact of single dose preoperative corticosteroids 
on markers of the postoperative stress response following surgery for gastrointestinal 
cancer, in particular IL 6 and CRP. Those studies reporting chronic preoperative 
corticosteroid use, or dosing at other perioperative time points, were excluded. Secondary 
outcomes included the impact of preoperative corticosteroids on postoperative 
complications, infective complications, and anastomotic leak following surgery for 
gastrointestinal cancer, including pre-specified subgroup analysis based on surgical 
speciality/site. Postoperative complications were coded as categorised by the authors of the 
included studies where possible. Where there was doubt, the authors of the present study 
categorised complications using a schemata described previously (McSorley Introduction). 
Post hoc meta-regression of the impact of corticosteroid dose on postoperative day 1 IL 6 
was performed following completion of the pre-specified analyses. Study selection and 
data extraction was performed by one author (SM) and any uncertainties resolved by 
consensus discussion with the senior authors (PH, DM). 
13.2.2 Literature search and study selection 
A systematic literature review was performed of the US National Library of Medicine 
(MEDLINE), PubMed, and the Cochrane Database of Systematic Reviews (CDSR) from 
inception to March 2015 inclusive. Subsequent to several pilot search strategies the 
following search term was used: “(cancer OR malignan* OR tumour OR tumor OR 
neoplasm*) AND (steroid OR corticosteroid OR glucocorticoid OR methylpredniso* OR 
predniso* OR dexamethasone) AND (surgery OR operati* OR perioperati* OR 
preoperati*)”, along with the Cochrane Highly Sensitive Search Strategy for RCTs 
(Higgins and Green 2011). Abstracts were screened for relevance and those studies which 
were animal and pre-clinical, those studies not published in English, and review articles 
were excluded. Relevant full text articles were then appraised. Randomized controlled 
trials of single dose preoperative corticosteroids in surgery for gastrointestinal cancer 
which reported on a marker of the postoperative systemic inflammatory response and 
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postoperative complications were included in the review. Reference lists of included 
studies were hand searched for further relevant studies. 
13.2.3 Data extraction and meta-analysis 
Data from included studies was extracted to tables and analysis was performed using 
Review Manager version 5.3 (RevMan 5.3, The Nordic Cochrane Centre, The Cochrane 
Collaboration, Copenhagen, Denmark). Meta-analysis of the impact of corticosteroids on 
postoperative IL 6 and CRP was performed by calculating the mean difference and 95% 
confidence intervals (CI), using the inverse variance method and combining study 
outcomes using a random effects model. Where data other than means and standard 
deviations were reported, an attempt was made to calculate these values using published 
confidence intervals or p values as described by Hozo and colleagues or by the Cochrane 
Handbook for Systematic Reviews of Interventions (Higgins and Green 2011, Hozo et al. 
2005). Results of the meta-analysis of the impact of corticosteroids on infective 
complications was assessed by odds ratios and 95% CIs, using the Mantel-Haenzsel 
method and combining study outcomes using a random effects model. Peto odds ratios and 
their 95% CIs were combined using a fixed effects model to determine the impact of 
preoperative corticosteroids on anastomotic leak as there were a small number of events. 
Meta-regression, using a random effects model, was performed with respect to the impact 
of corticosteroid dose on postoperative day 1 IL 6, following conversion to hydrocortisone 
equivalents using a freely available Macro (Wilson, D. B.)(Version 2005.05.23). Meta-
analysis macros for SAS, SPSS, and Stata. Retrieved, 7th May 2015 
from http://mason.gmu.edu/∼dwilsonb/ma.html) with IBM SPSS version 22 for Windows 
(Chicago, IL, USA) (Hozo et al. 2005). Two sided p values < 0.05 were considered 
statistically significant. 
13.2.4 Assessment of bias 
Assessment of the risk of bias was carried out using the Cochrane Collaboration tool 
provided by Review Manager version 5.3 (RevMan 5.3, The Nordic Cochrane Centre, The 
Cochrane Collaboration, Copenhagen, Denmark). Data was assessed for heterogeneity 
using the I2 statistic and Chi square test interpreted using the guidance from the Cochrane 
Handbook for Systematic Reviews of Interventions (Higgins and Green 2011). Assessment 
of potential publication bias was carried out by visual inspection of funnel plots.  Two 
sided p values <0.05 were considered statistically significant.  
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 Results 
13.3.1 Study selection process 
The study selection process is summarised in Figure 13-1. Using the search protocol 
described, 2,428 abstracts were identified. At screening, 2,354 abstracts were excluded, of 
which 16 were animal or pre-clinical studies, 227 were not in the English language, 328 
were review articles, 3 were duplicate publications, and 1,780 were not relevant to the 
review. Full text articles were reviewed of the remaining 74 studies. 
After assessment of full text articles, 63 studies were excluded, of which 36 were not in 
gastrointestinal surgery patients, 6 did not include patients with malignancy, 14 did not 
include the intervention of interest or included corticosteroids at timings other than 
preoperatively, 3 did not measure either postoperative IL 6 or CRP, 2 used historical 
controls, 1 was a duplicate study, and 1 a co-intervention of epidural analgesia alongside 
preoperative corticosteroids. The remaining 11 randomised controlled trials including 474 
patients were included in the review (Table 13-1) (Matsutani et al., 1998, Yamashita et al., 
2001, Sato et al., 2002, Muratore et al., 2003, Takeda et al. 2003, Yano et al. 
2005,Aldrighetti et al. 2006, Schmidt et al. 2007, Kirdak et al. 2008, Vignali et al. 
2009, Zargar-Shoshtari et al. 2009). 
Of the included studies, 3 including 139 patients, were in colorectal surgery (Kirdak et al. 
2008, Vignali et al. 2009, Zargar-Shoshtari et al. 2009), 4 including 156 patients were in 
oesophageal surgery (Matsutani et al. 1998, Sato et al. 2002, Takeda et al. 2003, Yano et 
al. 2005), and 4 including 179 patients were in hepatic surgery (Yamashita et al. 
2001, Muratore et al. 2003, Aldrighetti et al. 2006, Schmidt et al. 2007). Of the 474 
included patients, 436 (92%) had surgery for gastrointestinal cancer while 38 (8%) from 6 
studies had surgery for benign gastrointestinal disease but were included in the meta-
analysis (Yamashita et al. 2001, Aldrighetti et al. 2006, Schmidt et al. 2007, Kirdak et al. 
2008, Zargar-Shoshtari et al. 2009). All included patients underwent open surgery: no 
studies of minimally invasive surgery suitable for inclusion were returned by the search 
strategy. 
13.3.2 Validity assessment 
The risk of study bias is summarised using the RevMan 5.3 Risk of bias summary tool 
(Figure 13-8). Most studies were at low risk of bias, however 3 did not report outcomes for 
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patients who dropped out following randomisation (Muratore et al. 2003, Aldrighetti et al. 
2006, Kirdak et al. 2008) and 6 did not adequately report allocation concealment and 
blinding (Matsutani et al. 1998,Yamashita et al. 2001, Muratore et al. 2003, Takeda et al. 
2003, Yano et al. 2005, Aldrighetti et al. 2006). 
13.3.3 Impact of preoperative corticosteroids on IL 6 
Of the included studies, 10 including 422 patients, reported the impact of preoperative 
corticosteroids on postoperative IL 6 following surgery for gastrointestinal cancer and 
were included in meta-analysis (Figure 13-2) (Matsutani et al. 1998, Yamashita et al. 2001, 
Sato et al. 2002, Muratore et al. 2003, Takeda et al. 2003, Yano et al. 2005, Aldrighetti et 
al. 2006, Schmidt et al. 2007, Kirdak et al. 2008, Zargar-Shoshtari et al. 2009). 
Preoperative corticosteroids were significantly associated with lower serum concentrations 
of IL 6 following surgery for gastrointestinal cancer on postoperative day 1 (p<0.001), day 
2 (p=0.01), and day 3 (p=0.002), but not postoperative day 5 (p=0.11) or day 7 (p = 0.69). 
There was a wide variation in heterogeneity between studies, with the greatest on 
postoperative day 1 (I2=86%, p<0.001) and the least on postoperative day 7 (I2=6%, 
p=0.36). 
13.3.4 Impact of preoperative corticosteroids on C-reactive protein 
Of the included studies, 6 including 206 patients reported the impact of preoperative 
corticosteroids on postoperative CRP following surgery for gastrointestinal cancer and 
were included in meta-analysis (Figure 13-3) (Yamashita et al. 2001, Yano et al. 
2005, Schmidt et al. 2007, Kirdak et al. 2008, Vignali et al. 2009, Zargar-Shoshtari et al. 
2009). Preoperative corticosteroids were significantly associated with lower serum 
concentrations of CRP following surgery for gastrointestinal cancer on postoperative day 3 
(p<0.001) and day 7 (p=0.04), but not postoperative day 1 (p=0.09) or day 2 (p=0.11). 
There was a wide variation in heterogeneity between studies, with the greatest on 
postoperative day 2 (I2=87%, p<0.001) and the least on postoperative day 7 (I2=0%, 
p=0.44). 
13.3.5 Impact of preoperative corticosteroid dose on postoperative IL 6 
and CRP 
Within the 10 studies reporting postoperative day 1 IL 6, there was a wide variation in 
preoperative corticosteroid dose in the intervention arm (Matsutani et al. 1998,Yamashita 
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et al. 2001, Sato et al. 2002, Muratore et al. 2003, Takeda et al. 2003, Yano et al. 
2005, Aldrighetti et al. 2006, Schmidt et al. 2007, Kirdak et al. 2008, Zargar-Shoshtari et 
al. 2009). Following dose conversion to hydrocortisone equivalents (HEs) of both 
dexamethasone (1 mg = 30HEs) and methylprednisolone (1 mg = 5HEs) (Katzung 1995), 
it was found that 2 studies gave patients 240HEs (Schmidt et al., 2007 and Vignali et al., 
2009), 3 studies gave 2,500HEs (Yamashita et al. 2001, Yano et al. 2005, Aldrighetti et al. 
2006), 3 studies gave 3,500HEs (Matsutani et al. 1998, Sato et al. 2002, Takeda et al. 
2003), and 2 studies gave 10,500HEs preoperatively (Muratore et al. 2003, Schmidt et al. 
2007). Meta-regression revealed no significant relationship between the corticosteroid dose 
as measured by HEs and effect size on postoperative day 1 IL 6 (B= −0.0065, 95% CI 
−0.029 to 0.016, p=0.569). No further meta-regression of the impact of preoperative 
corticosteroid dose on postoperative IL 6 or CRP effect size was performed as the number 
of studies precluded meaningful analysis. 
13.3.6 Impact of preoperative corticosteroids on all postoperative 
complications 
Of the included studies 10, including 434 patients with 163 complications, reported the 
impact of preoperative corticosteroids on postoperative complications following surgery 
for gastrointestinal cancer and were included in meta-analysis (Figure 13-4) (Matsutani et 
al. 1998, Yamashita et al. 2001, Sato et al. 2002, Muratore et al. 2003, Takeda et al. 2003, 
Aldrighetti et al. 2006, Schmidt et al. 2007, Kirdak et al. 2008, Vignali et al. 2009, Zargar-
Shoshtari et al. 2009). Preoperative corticosteroids were significantly associated with fewer 
postoperative complications following surgery for gastrointestinal cancer (OR 0.44, 95% 
CI 0.28–0.70, p<0.001) There was minimal heterogeneity between studies (I2=2%, 
p=0.42). At subgroup analysis, preoperative corticosteroids were significantly associated 
with fewer postoperative complications following surgery for oesophageal (p=0.01) and 
liver malignancy (p=0.02) but not colorectal cancer (p=0.25). 
13.3.7 Impact of preoperative corticosteroids on postoperative infective 
complications 
Of the included studies 9, including 388 patients with 68 infective complications, reported 
the impact of preoperative corticosteroids on postoperative infective complications 
following surgery for gastrointestinal cancer and were included in meta-analysis (Figure 
13-5) (Yamashita et al. 2001, Sato et al. 2002, Takeda et al. 2003, Yano et al. 2005, 
Aldrighetti et al. 2006, Schmidt et al. 2007, Kirdak et al. 2008, Vignali et al. 2009, Zargar-
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Shoshtari et al. 2009). Preoperative corticosteroids were significantly associated with fewer 
postoperative infective complications following surgery for gastrointestinal cancer (OR 
0.47, 95% CI 0.26–0.83, p=0.01). There was minimal heterogeneity between studies 
(I2=0%, p=0.54). At subgroup analysis, preoperative corticosteroids were significantly 
associated with fewer postoperative infective complications following surgery for liver 
malignancy (p=0.02) but not colorectal (p=0.15) or oesophageal malignancy (p=0.58). 
13.3.8 Impact of preoperative corticosteroids on anastomotic leak 
Of the included studies, 7 including 295 patients and 19 events, reported the impact of 
preoperative corticosteroids on anastomotic leak following colorectal or oesophageal 
cancer surgery and were included in meta-analysis (Figure 13-6) (Matsutani et al. 1998, 
Sato et al. 2002, Takeda et al. 2003, Yano et al. 2005, Kirdak et al. 2008, Vignali et al. 
2009, Zargar-Shoshtari et al. 2009). The remaining 5 studies were in hepatic surgery thus 
did not report anastomotic leak. There was no significant association between preoperative 
corticosteroids and anastomotic leak (OR 1.13, 95% CI 0.44–2.90, p=0.79). There was 
minimal heterogeneity between studies (I2=0%, p=0.61). At subgroup analysis, there was 
no association between preoperative corticosteroids and anastomotic leak following 
surgery for either colorectal (p=0.71) or oesophageal malignancy (p=1.00). 
13.3.9 Assessment of publication bias 
Visual assessment of a funnel plot of studies reporting the impact of preoperative 
corticosteroids on postoperative CRP and all complications following surgery for 
gastrointestinal cancer (Figure 13-7) suggests that there may be evidence of publication 
bias with a positive skew amongst smaller studies  
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 Discussion 
The present systematic review and meta-analysis reports that preoperative corticosteroids 
reduce the magnitude of the systemic inflammatory response, in particular IL 6 on 
postoperative days 1 to 3 and CRP on postoperative days 3 and 7, following surgery for 
gastrointestinal cancer.  Furthermore, preoperative corticosteroids were significantly 
associated with fewer postoperative complications following oesophageal and hepatic 
surgery, and with fewer infective complications in hepatic surgery. 
The results of the present study, with regard to postoperative IL 6 are consistent with 
recent meta-analyses of randomized controlled trials of preoperative corticosteroids in 
colorectal surgery, liver surgery, and oesophagectomy (Srinivasa et al. 2011, Richardson et 
al. 2014, Raimondi et al. 2006, Gao et al. 2014, Orci et al. 2013). In addition, the present 
meta-analysis reports a significant reduction in IL 6 on postoperative days 2, 3, and 5 in 
those patients given preoperative corticosteroids. The present study reports a significant 
reduction in CRP on postoperative days 3 and 7 in those given preoperative corticosteroids, 
however found no significant impact of preoperative corticosteroids on postoperative day 1 
or 2. As CRP is usually seen to reach its peak concentration around 48 hours after the 
initial surgical insult, it may be that comparison on postoperative day 1 and 2 does not 
accurately reflect the influence of preoperative corticosteroids on the postoperative 
systemic inflammatory response (Gabay and Kushner 1999). It is of interest that even 
within the control groups of the studies included in the present meta-analysis, the mean 
data were below postoperative CRP thresholds associated with the development of 
postoperative complications. For example, it has recently been advocated that simple 
objective postoperative CRP thresholds >150 mg/L on post-operative days 3 to 5 be used 
to alert clinicians to the risk of postoperative complications before clinical signs and 
symptoms (McDermott et al. 2015). Moreover, when examined in detail by operative site, 
the mean CRP concentrations reported by the studies included in the present meta-analysis 
were significantly lower than values reported in a comprehensive systematic review of the 
timing and peak magnitude of postoperative IL 6 and CRP following elective colorectal, 
oesophageal, and liver surgery (Watt et al. 2015c). Therefore, it may be that patients 
recruited to previous randomised controlled trials of preoperative corticosteroids had a 
lower systemic inflammatory response compared with unselected patients. If this were to 
be the case then this may have implications for the randomised trials that reported efficacy 
of preoperative corticosteroids on complication rates. In particular, it may be that the 
efficacy was underestimated. 
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As with previous meta-analyses, there was a wide variation in corticosteroid dose 
equivalence and timing (Udelsman and Ciarleglio 2011). The degree of heterogeneity 
between studies within each speciality in the present meta-analysis suggests that this does 
have an impact on the degree of attenuation of the postoperative systemic inflammatory 
response. Within the present meta-analysis, no significant association was found between 
varying corticosteroid dose equivalencies and postoperative day 1 IL 6 effect size between 
studies. However, this analysis was performed on a post hoc basis in response to data 
heterogeneity. In addition, dose timing and the differing half-life of dexamethasone and 
methylprednisolone were not considered and may be implicated (Udelsman and Ciarleglio 
2011). The results of the present study do not define the ideal dose of preoperative 
corticosteroid to moderate the systemic inflammatory response or postoperative nausea and 
vomiting. For example, a recent meta-analysis of preoperative corticosteroids in the 
prevention of postoperative nausea and vomiting reported similar efficacy with lower 
doses of IV dexamethasone (4–5 mg) when compared to higher doses (8–10 mg) (De 
Oliveira et al. 2013). However, the efficacy of preoperative corticosteroids will depend on 
a number of factors, including the magnitude of the systemic inflammatory response (e.g. 
preventing patients breaching established threshold values of CRP) and the route and 
frequency of dose (e.g. large single dose or smaller multiple doses). Further work, in the 
context of randomised trials examining varying corticosteroid doses with reference to the 
magnitude of the postoperative systemic inflammatory response, is therefore required. 
Postoperative IL 6 and CRP concentrations have been reported to be markers of the 
magnitude of the postoperative stress response (Watt et al. 2015c). In relation to short-term 
postoperative morbidity, several recent meta-analyses have demonstrated the utility of 
elevated postoperative serum CRP in the early diagnosis of infective complications and 
anastomotic leak in gastrointestinal surgery (Adamina et al. 2015, Singh et al. 
2014a, Warschkow et al. 2012a). In addition, the magnitude of the postoperative CRP has 
been reported to be associated with complication severity following colorectal surgery 
(Selby et al. 2014, McSorley Chapter 3). Although this inflammatory response may 
represent an epiphenomenon rather than a cause of infective complications, given that the 
presence of a systemic inflammatory response (as evidenced by IL 6 or CRP) (Watt et al. 
2015c) is primarily an upregulated innate immune response (with consequent suppression 
of adaptive immunity), it is plausible that the magnitude of the postoperative systemic 
inflammatory response plays a role in the development of postoperative complications 
(Roxburgh et al. 2013).  However, there was no significant association between 
preoperative corticosteroids and complications following colorectal cancer surgery within 
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the present review.  The recently published DREAMS trial, which compared 8mg 
dexamethasone to placebo in patients undergoing predominantly colorectal surgery, 
reported no significant difference in postoperative infective complications, however 
patients in the treatment arm had significantly fewer anastomotic leaks (Magill et al. 2017).  
Unfortunately no measurements of the postoperative systemic inflammatory response were 
made.  Therefore, further interventional studies of preoperative corticosteroids would be 
required to prove such a relationship. 
It is known that corticosteroids alter gene transcription, and thus protein synthesis, 
following intracellular receptor binding, however the exact mechanism by which they act 
to reduce inflammation is poorly understood (Barnes 1998). Glucocorticoids act on the 
innate immune system, including myeloid tissue, inhibiting the activity of neutrophils and 
macrophages via reduced transcription of several proinflammatory cytokines, and by 
increasing the transcription of lipocortins which themselves inhibit cyclo-oxygenase 
dependent inflammation pathways (Leung and Bloom 2003). They are also recognised to 
have a downregulatory effect on adaptive immunity and lymphoid tissue, probably via 
inhibition of nuclear factor κB (NF- κB) (Rhen and Cidlowski 2005). The results of the 
present review, taken with that of previous meta-analyses, suggest that in the postoperative 
period the action of corticosteroids may at least be partly due to reduced transcription and 
production of IL 6 by innate immune cells, and consequently, reduced synthesis of CRP by 
hepatocytes (Srinivasa et al. 2011, Raimondi et al. 2006, Gao et al. 2014).  
There has long been a concern regarding the inhibitory effect of corticosteroids on collagen 
formation leading to postoperative wound dehiscence and potentially anastomotic leak. 
However, the present meta-analysis, along with prior randomised trials and meta-analyses, 
have failed to demonstrate a significant increase in either of these types of complication in 
patients given corticosteroids (Srinivasa et al. 2011, Gao et al. 2014, Schulze et al. 
1992, Schulze et al. 1997). Much of the prior evidence regarding wound healing and 
infection has arisen from literature surrounding surgery for inflammatory bowel disease, in 
those undergoing transplant surgery, or in those with diseases of the hypothalamo-
pituitary-adrenal axis (Nicholson et al. 1998). Indeed, recent meta-analysis of both 
experimental and clinical trials suggests that receiving corticosteroids at standard 
therapeutic doses for 10 days or less is unlikely to impair wound healing (Wang et al. 
2013). Lastly, as recent preliminary reports suggest that preoperative corticosteroids may 
have a detrimental impact on oncologic outcome, some consideration should be given to 
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their impact on longer term outcomes, especially in surgery for gastrointestinal cancer 
(Singh et al. 2014b, Yu et al. 2015). 
The main limitation of the present systematic review and meta-analysis is the relatively 
small number of patients included. To maximise the number of patients within the analysis, 
several gastrointestinal surgical specialities were considered together using a random 
effects model. In addition, there were a small number of patients included within the 
present meta-analysis who had undergone surgery for benign gastrointestinal disease. 
Indeed, these factors, to an extent, limit the generalisability of the results of the present 
study. However, the exclusion of the 6 studies which included a small proportion of 
patients without malignant disease would have significantly reduced the power of the 
present meta-analysis (Matsutani et al. 1998, Yano et al. 2005, Aldrighetti et al. 2006, 
Schmidt et al. 2007, Vignali et al. 2009). A significant degree of heterogeneity was 
reported in the analysis of postoperative IL 6 and CRP. This may reflect the pooling of the 
various surgical specialities. However, no study individually reported a statistically 
significant increase in either postoperative IL 6 or CRP in the corticosteroid treatment 
group. Thus, although there are likely to be differences in the studied patient groups or 
methodology, the direction of the treatment effect, at least, is very likely to be similar 
across the included studies. There was a wide variability in concentrations of IL 6 and CRP 
amongst studies within the same postoperative day. Both the biological variability of IL 6 
and CRP, alongside the variety of surgical specialties included in the present study, may 
account for this (Macy et al. 1997). Other potential confounders include the use of a 
variety of preoperative corticosteroids, their dose, and timing, although a random effects 
model was used as an attempt to minimise this, alongside meta-regression techniques. In 
addition, there may be a degree of publication bias toward positive results amongst the 
smaller studies included in the meta-analysis. In the present study, despite a broad and 
inclusive search strategy, there were no trials conducted in the USA included in the 
analysis. Therefore, it would appear that although preoperative corticosteroids are used in 
routine clinical practice in the USA, no formal RCTs have been undertaken there. Finally, 
all of those studies included in the present meta-analysis were published prior to 2009. A 
single study in liver surgery, published in 2010, was excluded due to the use of 
postoperative corticosteroids in the treatment group, however it interestingly reported 
reduced concentrations of IL 6 and CRP in the treatment group with a trend toward fewer 
complications (Hayashi et al. 2011). The lack of more recent studies may relate to the rapid 
uptake of enhanced recovery or “fast track” postoperative protocols in gastrointestinal 
surgery which often include preoperative corticosteroids for the prevention of 
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postoperative nausea and vomiting (Watt et al. 2015d). Nevertheless, the results of the 
present review with regard to the effect of preoperative corticosteroids on IL 6 and CRP 
provide important new information since they suggest that the efficacy of such 
interventions may be dependent on the magnitude of the postoperative systemic 
inflammatory response. 
The results of the present systematic review and meta-analysis suggest that preoperative 
corticosteroids are associated with a reduction in the magnitude of the postoperative stress 
response and, within some subgroups, the likelihood of postoperative complications 
following surgery for gastrointestinal cancer. Although the magnitude of this postoperative 
systemic inflammatory response, especially CRP, has been associated with the 
development of complications following surgery, relatively few studies have examined 
whether the attenuation of the systemic inflammatory response with preoperative 
corticosteroids is also associated with complication rates. Clearly, given the significant 
heterogeneity in the small number of studies included in the present meta-analysis, further 
work is warranted. 
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 Tables and Footnotes 
Table 13-1: Clinical trials investigating the impact of preoperative corticosteroids on the postoperative stress response following surgery for gastrointestinal cancer 
Author Year Journal Country n Speciality Steroid/dose/route/timin
g 
Surgical stress response  Period Significant outcomes 
Kirdak et al. 2008 Am Surg Turkey 27 Colorectal Dexamethasone 8mg IV 
at induction 
Pain, nausea, IL 6, CRP POD 1-3 None 
Zargar-
Shoshtari et al.  
2009 Br J Surg New 
Zealand 
60 Colorectal Dexamethasone 8mg 
IV, at induction 
Pain, nausea, WCC, 
Neutrophils, CRP, IL 1β, 
IL 6, IL 8, IL 10, IL 13, 
TNFα, (serum and 
peritoneal cytokines), 
fatigue 
Pain and nausea POD 
1-3, Fatigue POD 1-
60, CRP and 
cytokines POD 1 
Higher WCC, neutrophils 
and lower pain, nausea, 
serum IL 6, serum IL 8, 
peritoneal IL 6, peritoneal 
IL 13 in steroid group 
Vignali et al. 2009 Dis Colon 
Rectum 
Italy 52 Colorectal Methylprednisolone 
30mg/kg IV, 60 mins 
preop 
Pain, FVC, FEV1, CRP, 
IL 6, IL 8, TNFα  
POD 1-5 Higher FVC, FEV1 and 
lower pain, CRP, IL 6, IL 8 
in steroid group 
Matsutani et al. 1998 J Surg Res Japan 33 Oesophageal Methylprednisolone 
10mg/kg at induction 
TNFα, IL 6, PT, APTT, 
AT III 
POD 1-7 Higher AT III and lower 
TNFα, IL 6 in steroid group 
Sato et al. 2002 Ann Surg Japan 66 Oesophageal Methylprednisolone 
10mg/kg at induction 
IL 1, IL 6, IL 8, IL 10, 
cortisol, lymphocytes, 
neutrophils 
POD 1-7 Higher IL 10 and lower IL 
1, IL 6, and IL 8 in steroid 
group 
Takeda et al.  2003 J Nippon 
Med Sch 
Japan 17 Oesophageal Methylprednisolone 
10mg/kg IV at 
induction 
Serum and 
bronchioalveolar IL 6 and 
IL 8 
POD 1 Lower serum IL 6 and IL 8, 
and lower bronchioalveolar 
IL 8 in steroid group 
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Yano et al.  2005 Hepatogas
troenterol
ogy 
Japan 40 Oesophageal Methylprednisolone 
500mg IV 2hrs preop 
IL 6, IL 8, IL 10, WCC, 
rectal pHi, body weight 
POD 1-3 Lower IL 6, IL 8 and CRP 
Yamashita et al. 2001 Arch Surg Japan 33 Liver Methylprednisolone 
500mg IV 2hrs preop 
IL 6, IL 10, CRP, Bil, 
AST, ALT 
POD 1-7 Higher IL 10 and lower Bil, 
IL 6, CRP in steroid group 
Muratore et al. 2003 Br J Surg Italy 53 Liver Methylprednisolone 
30mg/kg IV at 
induction 
IL 6, Bil, AST, ALT, PT POD 1 Lower IL 6 in steroid group 
Aldrighetti et 
al. 
2006 Liver 
Transpl 
Italy 73 Liver Methylprednisolone 
500mg IV at induction 
IL 6, TNFα, Bil, AST, 
ALT, PT, platelets, AT 
III, D-dimer 
POD 1-5 Higher AT III, platelets, and 
lower IL 6, TNFα in steroid 
group 
Schmidt et al. 2007 J 
Hepatobili
ary 
Pancreat 
Surgery 
Germany 20 Liver Methylprednisolone 
30mg/kg IV 90 mins 
preop 
IL 6, IL 8, IL 10, CRP, 
TNFα, HLA-DR, Bil 
 Lower IL 6, IL 8, CRP, 
TNFα, Bil in steroid group 
POD postoperative day, IV intravenous, IL interleukin, CRP C-reactive protein, TNF tumour necrosis factor, WCC white cell count, FVC forced vital capacity, FEV forced expiratory 
volume, ADH anti-diuretic hormone, AT antithrombin, Bil bilirubin, AST aspartate transaminase, ALT alanine transaminase, PT prothrombin time, HLA human leukocyte antigen 
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 Figures and Legends 
 
Figure 13-1: PRISMA flow chart of study selection 
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Figure 13-2: Impact of preoperative corticosteroids on serum interleukin 6 following surgery for 
gastrointestinal cancer 
  
Study or Subgroup
2.1.1 Postoperative day 1
Matsutani et al. 1998
Yamashita et al. 2001
Sato et al. 2002
Takeda et al. 2003
Muratore et al. 2003
Yano et al. 2005
Aldrighetti et al. 2006
Schmidt et al. 2007
Kirdak et al. 2008
Zargar-Shoshtari et al. 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 4024.75; Chi² = 65.70, df = 9 (P < 0.00001); I² = 86%
Test for overall effect: Z = 5.18 (P < 0.00001)
2.1.2 Postoperative day 2
Yano et al. 2005
Aldrighetti et al. 2006
Schmidt et al. 2007
Kirdak et al. 2008
Subtotal (95% CI)
Heterogeneity: Tau² = 194.39; Chi² = 3.76, df = 3 (P = 0.29); I² = 20%
Test for overall effect: Z = 2.58 (P = 0.01)
2.1.3 Postoperative day 3
Matsutani et al. 1998
Yamashita et al. 2001
Sato et al. 2002
Schmidt et al. 2007
Subtotal (95% CI)
Heterogeneity: Tau² = 230.42; Chi² = 8.89, df = 3 (P = 0.03); I² = 66%
Test for overall effect: Z = 3.03 (P = 0.002)
2.1.5 Postoperative day 5
Matsutani et al. 1998
Sato et al. 2002
Subtotal (95% CI)
Heterogeneity: Tau² = 2763.02; Chi² = 4.25, df = 1 (P = 0.04); I² = 76%
Test for overall effect: Z = 1.62 (P = 0.11)
2.1.7 Postoperative day 7
Matsutani et al. 1998
Yamashita et al. 2001
Sato et al. 2002
Schmidt et al. 2007
Subtotal (95% CI)
Heterogeneity: Tau² = 8.03; Chi² = 3.21, df = 3 (P = 0.36); I² = 6%
Test for overall effect: Z = 0.40 (P = 0.69)
Mean
86
30
108
92
22
110
26
16
199
53
120
24
14
199
41
16
46
10
25
35
23
8
7
20
SD
87
14
85
77
11
226
20
14
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129
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17
13
179
65
16
50
8
48
58
58
16
40
24
Total
14
17
33
7
25
20
36
10
14
29
205
20
36
10
14
80
14
17
33
10
74
14
33
47
14
17
33
10
74
Mean
515
81
463
486
276
300
73
92
294
128
145
46
77
294
103
33
126
30
55
150
47
10
43
15
SD
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46
322
923
232
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38
86
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1,318
402
27
73
218
86
16
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24
70
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16
165
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Total
19
16
33
10
28
20
37
10
13
31
217
20
37
10
13
80
14
16
33
10
73
14
33
47
19
16
33
10
78
Weight
6.0%
19.7%
11.1%
0.9%
13.8%
1.7%
20.1%
17.1%
8.2%
1.4%
100.0%
0.9%
74.2%
22.2%
2.7%
100.0%
10.0%
40.5%
13.6%
36.0%
100.0%
54.6%
45.4%
100.0%
5.6%
60.5%
2.7%
31.3%
100.0%
IV, Random, 95% CI
-429.00 [-620.65, -237.35]
-51.00 [-74.50, -27.50]
-355.00 [-468.63, -241.37]
-394.00 [-968.91, 180.91]
-254.00 [-340.04, -167.96]
-190.00 [-599.23, 219.23]
-47.00 [-60.88, -33.12]
-76.00 [-130.00, -22.00]
-95.00 [-246.11, 56.11]
-75.00 [-541.33, 391.33]
-148.42 [-204.52, -92.31]
-25.00 [-288.47, 238.47]
-22.00 [-32.32, -11.68]
-63.00 [-108.96, -17.04]
-95.00 [-246.11, 56.11]
-33.07 [-58.24, -7.90]
-62.00 [-118.47, -5.53]
-17.00 [-27.92, -6.08]
-80.00 [-125.93, -34.07]
-20.00 [-35.68, -4.32]
-31.12 [-51.29, -10.96]
-30.00 [-74.46, 14.46]
-115.00 [-182.45, -47.55]
-68.56 [-151.50, 14.38]
-24.00 [-64.04, 16.04]
-2.00 [-12.92, 8.92]
-36.00 [-93.93, 21.93]
5.00 [-11.11, 21.11]
-1.95 [-11.48, 7.58]
Year
1998
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2005
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2007
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2005
2006
2007
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1998
2001
2002
2007
1998
2002
1998
2001
2002
2007
Steroid Control Mean Difference Mean Difference
IV, Random, 95% CI
-200 -100 0 100 200
Favours steroid Favours control
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Figure 13-3: Impact of preoperative corticosteroids on serum C-reactive protein following surgery for 
gastrointestinal cancer 
  
Study or Subgroup
2.2.1 Postoperative day 1
Yamashita et al. 2001
Yano et al. 2005
Schmidt et al. 2007
Kirdak et al. 2008
Zargar-Shoshtari et al. 2009
Vignali et al. 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 128.10; Chi² = 26.09, df = 5 (P < 0.0001); I² = 81%
Test for overall effect: Z = 1.61 (P = 0.11)
2.2.2 Postoperative day 2
Yano et al. 2005
Schmidt et al. 2007
Kirdak et al. 2008
Subtotal (95% CI)
Heterogeneity: Tau² = 328.85; Chi² = 15.20, df = 2 (P = 0.0005); I² = 87%
Test for overall effect: Z = 1.58 (P = 0.11)
2.2.3 Postoperative day 3
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Yano et al. 2005
Schmidt et al. 2007
Vignali et al. 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 452.57; Chi² = 19.87, df = 3 (P = 0.0002); I² = 85%
Test for overall effect: Z = 3.74 (P = 0.0002)
2.2.7 Postoperative day 7
Yamashita et al. 2001
Yano et al. 2005
Schmidt et al. 2007
Subtotal (95% CI)
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Figure 13-4: Impact of preoperative corticosteroids on all postoperative complications following 
surgery for gastrointestinal cancer 
  
Study or Subgroup
1.1.1 Colorectal
Kirdak et al. 2008
Vignali et al. 2009
Zargar-Shoshtari et al. 2009
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.77; Chi² = 4.80, df = 2 (P = 0.09); I² = 58%
Test for overall effect: Z = 1.15 (P = 0.25)
1.1.2 Oesophageal
Matsutani et al. 1998
Sato et al. 2002
Takeda et al. 2003
Yano et al. 2005
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.65, df = 1 (P = 0.42); I² = 0%
Test for overall effect: Z = 2.58 (P = 0.010)
1.1.3 Hepatic
Yamashita et al. 2001
Muratore et al. 2003
Aldrighetti et al. 2006
Schmidt et al. 2007
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 1.39, df = 3 (P = 0.71); I² = 0%
Test for overall effect: Z = 2.28 (P = 0.02)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.01; Chi² = 8.13, df = 8 (P = 0.42); I² = 2%
Test for overall effect: Z = 3.44 (P = 0.0006)
Test for subgroup differences: Chi² = 0.56, df = 2 (P = 0.76), I² = 0%
Events
6
8
20
34
0
11
0
0
11
2
7
5
2
16
61
Total
14
26
29
69
14
33
7
0
54
17
25
36
10
88
211
Events
13
11
22
46
5
20
0
0
25
2
12
14
3
31
102
Total
13
26
31
70
19
33
10
0
62
16
28
37
10
91
223
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Figure 13-5: Impact of preoperative corticosteroids on infective postoperative complications following 
surgery for gastrointestinal cancer 
  
Study or Subgroup
1.2.1 Colorectal
Kirdak et al. 2008
Zargar-Shoshtari et al. 2009
Vignali et al. 2009
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.05; Chi² = 2.16, df = 2 (P = 0.34); I² = 7%
Test for overall effect: Z = 1.43 (P = 0.15)
1.2.2 Oesophageal
Matsutani et al. 1998
Sato et al. 2002
Takeda et al. 2003
Yano et al. 2005
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.45; Chi² = 1.60, df = 1 (P = 0.21); I² = 37%
Test for overall effect: Z = 0.56 (P = 0.58)
1.2.3 Hepatic
Yamashita et al. 2001
Muratore et al. 2003
Aldrighetti et al. 2006
Schmidt et al. 2007
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.48, df = 2 (P = 0.78); I² = 0%
Test for overall effect: Z = 2.35 (P = 0.02)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 5.97, df = 7 (P = 0.54); I² = 0%
Test for overall effect: Z = 2.57 (P = 0.01)
Test for subgroup differences: Chi² = 1.61, df = 2 (P = 0.45), I² = 0%
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Figure 13-6: Impact of preoperative corticosteroids on anastomotic leak following surgery for 
gastrointestinal cancer 
Study or Subgroup
1.3.1 Colorectal
Kirdak et al. 2008
Zargar-Shoshtari et al. 2009
Vignali et al. 2009
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 2.14, df = 2 (P = 0.34); I² = 6%
Test for overall effect: Z = 0.37 (P = 0.71)
1.3.2 Oesophageal
Matsutani et al. 1998
Sato et al. 2002
Takeda et al. 2003
Yano et al. 2005
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 0.51, df = 1 (P = 0.47); I² = 0%
Test for overall effect: Z = 0.00 (P = 1.00)
Total (95% CI)
Total events
Heterogeneity: Chi² = 2.72, df = 4 (P = 0.61); I² = 0%
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Chi² = 0.07, df = 1 (P = 0.79), I² = 0%
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Figure 13-7: Funnel plots of studies reporting the impact of preoperative corticosteroids on (A) C-reactive protein, and (B) complications following surgery for 
gastrointestinal cancer 
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Figure 13-8: Risk of bias summary of included studies (green symbol=low risk, red symbol=high risk, 
empty=unclear risk) 
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14 The impact of preoperative dexamethasone on the 
magnitude of the postoperative systemic 
inflammatory response and complications following 
surgery for colorectal cancer 
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 Introduction 
There is good evidence that, compared with open surgery, laparoscopic surgery is 
associated with a reduction in the postoperative systemic inflammatory response (Watt et 
al. 2015c).  However, no definite causal relationship has yet been defined between 
attenuation of the postoperative systemic inflammatory response and postoperative 
complications.  Furthermore, it remains to be seen whether strategies which attenuate the 
postoperative systemic inflammatory response may also reduce postoperative complication 
rates. 
Corticosteroids, administered at the induction of anaesthesia are associated with the 
prevention of postoperative nausea and vomiting (Karanicolas et al. 2008).  Indeed, 
preoperative dexamethasone has now been integrated into many “enhanced recovery” and 
“fast track” perioperative care protocols, although the underlying mechanism remains 
unclear (Watt et al. 2015d).  Also, there is evidence that preoperative administration of 
corticosteroids is associated with a reduction in the postoperative systemic inflammatory 
response following abdominal surgery (Srinivasa et al. 2011, McSorley Chapter 13).   
The meta-analysis performed in the previous chapter reported a reduction in postoperative 
complications in patients given corticosteroids at the time of hepatic and oesophagogastric 
surgery.  However, when the same analysis was performed in a subgroup of RCTs of 
patients undergoing surgery for colorectal cancer, the association did not reach statistical 
significance (McSorley Chapter 13).  This may be due to the small number of such studies 
performed in colorectal cancer surgery. 
Therefore, the aim of the present study was to examine the impact of preoperative 
dexamethasone on the magnitude of the postoperative systemic inflammatory response and 
complications following surgery for colorectal cancer.  A propensity score analysis was 
performed due to significant imbalances in patient and operative variables potentially 
associated with both the postoperative systemic inflammatory response and complications. 
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 Patients and Methods 
14.2.1 Patients 
This retrospective observational study of a prospectively collected database included 
patients who underwent resection with curative intent for histologically confirmed 
colorectal cancer in a single centre between 2008 and 2016.  Patients without available 
anaesthetic records, receiving long term steroids, who had existing inflammatory 
conditions, who had emergency surgery, or metastatic disease were not included in the 
analysis. 
Clinical, radiological, and pathological data of all patients were reviewed by a specialist 
colorectal oncology multi-disciplinary team before and after surgery.  All patients received 
prophylactic antibiotics and venous thromboprophylaxis prior to the induction of 
anaesthesia as per hospital policy.  The use of epidural anaesthesia was at the discretion of 
the anaesthetic and surgical teams.  Patients were given dexamethasone intravenously prior 
to the induction of anaesthesia, and at the discretion of the anaesthetist, to reduce the 
likelihood of postoperative nausea and vomiting. 
On each postoperative day patients were clinically assessed and had blood samples, 
including serum CRP, obtained as standard until discharged.  Further postoperative 
investigation and intervention was at the discretion of the patient’s surgical team who were 
not blind to serum CRP results. 
14.2.2 Methods 
Clinicopathological data was collected prospectively in a database, anonymised, and were 
subsequently analysed.  Recorded information included patient demographics, tumour site, 
TNM stage (TNM, 5th ed, AJCC), surgical approach, complications, preoperative and 
postoperative serum CRP measurements.   
Serum concentrations of CRP (mg/L) were measured using an autoanalyzer (Architect; 
Abbot Diagnostics, Maidenhead, UK) with a lower detectable limit of 0.2 mg/L, as was 
serum albumin (normal range 35-50g/L). Exceeding the established CRP threshold of 150 
mg/L on postoperative days 3 or 4 was recorded (McDermott et al. 2015).  The 
preoperative modified Glasgow Prognostic Score (mGPS) was calculated in patients for 
whom preoperative serum CRP and albumin were available (McMillan 2013).   
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Data regarding the use of dexamethasone for the prevention of postoperative nausea and 
vomiting at induction of anaesthesia, the use of epidural anaesthesia, and the need for 
intraoperative blood transfusion were collected by retrospective review of anaesthetic 
notes.   
Complications were recorded and categorised by severity using the Clavien Dindo scale 
(Dindo et al. 2014).  Infective complications were categorised as described elsewhere and 
summarised here briefly (Platt et al. 2012).  Wound (superficial surgical site) infection was 
defined as the presence of pus either spontaneously discharging from the wound or 
requiring drainage.  Deep surgical site infection was defined as surgical or image-guided 
drainage of intra-abdominal pus.  Anastomotic leak was defined as radiologically verified 
fistula to bowel anastomosis or diagnosed at laparotomy.  Pneumonia was defined by fever 
above 38.5oC and consolidatory chest X-ray findings requiring antibiotic treatment.  
Septicaemia was defined by the presence of sepsis combined with positive blood culture.  
Urinary tract infection (UTI) was only included if complicated by septicaemia and 
confirmed with positive urine culture.   
The study was approved by the West of Scotland Research Ethics Committee, Glasgow, as 
part of surgical audit. 
14.2.3 Statistical Analysis 
In the initial unmatched cohort, categorical data were compared using the Chi square test.  
Data regarding postoperative CRP were non-normal and are presented as medians and 
ranges.  Medians of two groups were compared using the Mann-Whitney U test.  The 
treatment effect of preoperative dexamethasone in terms of exceeding the postoperative 
CRP threshold and complications was displayed as odds ratios (OR) and 95% confidence 
intervals (CI).  The magnitude of CRP by each postoperative day was displayed 
graphically as 95% confidence intervals of the median.   
Multivariate logistic regression was used to generate a propensity score for each patient, 
predicting the probability of having received preoperative dexamethasone or not, based on 
the following variables thought to be associated with the postoperative systemic 
inflammatory response or complications: age, sex, BMI, smoking status, ASA score, 
mGPS, tumour site, TNM stage, nCRT, surgical approach (open or laparoscopic), 
operation duration, blood transfusion, stoma formation, and the use of epidural anaesthesia.  
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Patients who received preoperative dexamethasone were then matched 1:1 with a patient 
who did not, using the closest propensity score on the logit scale (calliper <0.05, order of 
match selection randomised).  Categorical data were compared using McNemar’s test.  
Continuous data were compared using the related samples Wilcoxon sign rank test.  The 
appropriateness of the propensity score matching was assessed visually by frequency of 
propensity scores in each group before and after matching.  In addition, the propensity 
scores were included as a linear covariate alongside preoperative dexamethasone in 
multivariate binary logistic regression models for exceeding the postoperative day 3 CRP 
threshold and postoperative complications.  Finally, the propensity scores were used to 
stratify the patients by quintiles, from which an average treatment effect was calculated for 
both the postoperative day 3 CRP threshold and postoperative complications as an OR and 
95% CI.  
In all tests, a two sided p value <0.05 was considered statistically significant.  Propensity 
scoring, matching, and all statistical analyses were performed using IBM SPSS version 22 
for Windows (Chicago, IL, USA). 
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 Results 
14.3.1 Patient characteristics 
In total, 556 patients were included in the study (Table 14-1) of which 310 were male 
(56%) and 360 (65%) were over 65 years old.  Most had colonic (355, 64%) and node 
negative disease (375, 67%).  Laparoscopic resection was performed in 212 patients (38%) 
with the remainder having open surgery.  A postoperative complication occurred in 234 
cases (42%), of which 151 (27%) were infective and 47 (8%) were classified Clavien 
Dindo grade 3-5 severity.  Anastomotic leak occurred in 19 cases (3%).  There were 5 
(1%) postoperative deaths. 
14.3.2 Impact of dexamethasone in all patients 
In the unmatched cohort, exceeding the CRP threshold of 150mg/L on postoperative day 3 
was significantly associated with higher rates of any complication (60% vs 29%, OR 3.60, 
p<0.001), infective complication (42% vs. 16%, OR 3.87, p<0.001), anastomotic leak (6% 
vs. 1%, OR 4.16, p=0.011), and Clavien Dindo grade ≥3 complications (13% vs. 5%, OR 
3.10, p=0.001).   In the unmatched cohort (Table 14-1), 311 patients (56%) received 
dexamethasone at induction of anaesthesia, of which 194 received 4mg and 117 received 
8mg, while 245 (44%) did not.  There were significant differences between those patients 
who did receive preoperative dexamethasone and those who did not, in ASA score 
(p=0.003), preoperative mGPS (p=0.007), laparoscopic surgery (52% vs. 20%, p<0.001), 
surgery lasting more than 4 hours (41% vs. 23%, p<0.001), blood transfusion (3% vs. 9%, 
p=0.002), and epidural anaesthesia (28% vs. 64%, p<0.001).  A significantly lower 
proportion of those who received preoperative dexamethasone exceeded the established 
CRP threshold of 150mg/L on postoperative day 3 (33% vs. 55%, p<0.001) but not on day 
4.  Preoperative dexamethasone was significantly associated with fewer postoperative 
complications (36% vs. 50%, OR 0.40, p=0.001) and infective complications (23% vs. 
32%, OR 0.57, p=0.021) but not anastomotic leak or complication severity.  
14.3.3 Impact of dexamethasone in propensity score matched cohort 
Propensity scores could not be assigned to 156 patients due to missing covariate data, 
leaving 400 patients with propensity scores, of which 262 had received dexamethasone at 
induction of anaesthesia and 138 did not (Figure 14-1).  276 patients (138 from each 
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group) were matched based on their propensity score, with a subsequent improvement in 
the balance of the distribution of propensity scores in each group (Figure 14-2).    
In the propensity score matched cohort, exceeding the CRP threshold of 150mg/L on 
postoperative day 3 was significantly associated with higher rates of any complication 
(59% vs 28%, OR 3.58, p<0.001), infective complication (44% vs. 15%, OR 4.38, 
p<0.001), and Clavien Dindo grade ≥3 complications (13% vs. 6%, OR 2.56, p=0.032), but 
not anastomotic leak (7% vs. 2%, OR 3.29, p=0.068).  Following propensity score 
matching the distribution of patient and operative variables was balanced between the two 
groups (Table 14-2).  A significantly lower proportion of those who received preoperative 
dexamethasone exceeded the established CRP threshold of 150mg/L on postoperative day 
3 (36% vs. 56%, OR 0.42, p=0.001) but not on day 4.  Preoperative dexamethasone was 
significantly associated with fewer postoperative complications (34% vs. 49%, OR 0.53, 
p=0.001).  
14.3.4 Sensitivtiy analyses using other propensity score methods 
Analysis of the impact of preoperative dexamethasone on exceeding the postoperative day 
3 CRP threshold (Table 14-3) found a similarly statistically significant probability 
reduction using regression adjustment (OR 0.53, 95% CI 0.34-0.83), propensity score 
stratification (OR 0.41, 95% 0.25-0.57), and propensity score matching (0.42, 95% CI 
0.26-0.70).  The same analysis of the impact of preoperative dexamethasone on 
postoperative complications (Table 14-3) found a similarly statistically significant 
probability reduction using regression adjustment (OR 0.62, 95% CI 0.40-0.96), propensity 
score stratification (OR 0.62, 95% 0.29-0.95), and propensity score matching (0.53, 95% 
CI 0.33-0.86). 
14.3.5 Time dependent effect of preoperative dexamethasone 
Dexamethasone at the induction of anaesthesia had a similar time dependent effect on 
postoperative CRP in both the unmatched and matched cohorts.  There was a significant 
reduction in CRP on postoperative days 1 to 3 in those given dexamethasone, with similar 
CRP concentrations observed in both groups from postoperative day 4 onward. 
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 Discussion 
The present study reports that dexamethasone, given at the induction of anaesthesia prior to 
surgery for colorectal cancer, was associated with a reduction in the magnitude of the 
postoperative systemic inflammatory response and fewer postoperative complications.    
Currently, corticosteroids are given in the perioperative period to reduce postoperative 
nausea and vomiting (Karanicolas et al. 2008, Watt et al. 2015d).  However, when taken 
together with existing evidence (McSorley Chapter 13, Laaninen et al. 2016), the results of 
the present study also suggest an important role for reducing the complication rate 
following surgery for colorectal cancer by attenuating the postoperative stress response. 
Indeed, the use of preoperative corticosteroids represents a potentially simple and cost 
effective method of improving surgical outcomes for a large surgical population.  It was of 
interest that postoperative CRP retained its association with postoperative complications in 
those patients who had received preoperative dexamethasone.  In particular, the CRP 
threshold of 150mg/L on postoperative day 3 remained significantly associated with all 
complications, and infective complications, in this group of patients in whom the 
magnitude of the postoperative systemic inflammatory response was lower as a whole.  
Indeed, the results of the present study suggest that the measurement of postoperative CRP 
in this subgroup remains useful in the clinical setting.  For these reasons, the present study 
in colorectal cancer is timely. 
There remain long standing concerns that corticosteroids may inhibit collagen formation 
and, therefore, wound healing in the post-operative period.  However, neither the present 
study, or previous meta-analyses, have identified a significant negative association with 
either wound complications or anastomotic leak (Srinivasa et al. 2011, McSorley Chapter 
13).  Furthermore, there have been some concerns that preoperative corticosteroids may 
have a negative impact on oncologic outcome following surgery for colorectal cancer, 
however the evidence for this is limited in both numbers and length of follow up (Singh et 
al. 2014b).  
The mechanisms by which corticosteroids exert their anti-inflammatory action remain 
poorly understood.  Inhibition of nuclear factor κB (NF- κB) leads to a downregulatory 
effect on lymphoid tissue and thus adaptive immune responses (Chu et al. 2014).  In 
addition, attenuation of the innate immune response and myeloid tissues occurs as a 
consequence of reduction of the transcription of pro-inflammatory cytokines such as IL 6, 
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alongside the inhibition of cyclo-oxygenase dependent pathways by increasing 
transcription of lipocortins (Leung et al. 2003, Rhen et al. 2005).   
An important implication of the present and previous results is that postoperative 
complications are themselves recognised to have a negative impact on oncologic outcomes 
(McSorley Chapter 4).  Indeed, the generation of a pro-metastatic environment through 
systemic inflammation, as part of the surgical injury and the severity of postoperative 
complications, has been proposed to promote metastatic disease progression (McAllister et 
al. 2014).  Furthermore, it has been proposed that this host response to both the tumour and 
surgery should become a target for intervention (Roxburgh et al. 2013).  Indeed, it may be 
hypothesised that a reduction in the magnitude of the postoperative systemic inflammatory 
response with a consequent reduction in postoperative complication rates may improve 
long-term outcomes following surgery for colorectal cancer. Strategies such as the 
prospective evaluation of perioperative corticosteroids represent a logical starting point. 
The main limitation of the present study was its retrospective nature.  This lead to some 
missing data both clinicopathological and in terms of postoperative CRP measurements.  
Significant imbalance between the two groups meant that propensity score matching was 
used to obtain balanced groups for determination of the treatment effect.  However, this 
resulted in the exclusion of a significant proportion of patients and does not necessarily 
help those confounders that are either unmeasured or unknown (Austin 2011).  However, it 
was reassuring that the overall treatment effect and its magnitude were similar amongst the 
unmatched cohort, the matched cohort, and when propensity regression was applied (Shida 
et al. 2016).  Dexamethasone was used throughout the study period although was never 
“routine” or part of a formal protocol and was used at the discretion of the anaesthetist.  
The proportion of patients receiving dexamethasone changed from around 30% during the 
first half of the study period to around 50% in the second half of the study period. This 
change was in line with the increasing use of minimally invasive surgery.  This may 
represent a potential source of bias which matching cannot adjust for.  In addition, the 
nature of the analysis prevented the assessment of any dose response relationship.    
In summary, the results of the present study suggest that the use of preoperative 
corticosteroids is associated with both attenuation of the magnitude of the systemic 
inflammatory response and fewer complications, following surgery for colorectal cancer.  
This adds evidence to the hypothesis that the magnitude of the postoperative systemic 
inflammatory response and postoperative complications are causally related.  Optimal 
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doses and treatment regimens are yet to be determined.  Indeed, further prospective 
randomized trials are necessary before recommendations regarding the use of preoperative 
dexamethasone in the context of the postoperative systemic inflammatory response can be 
made. 
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 Tables and Footnotes 
Table 14-1: Association between clinicopathological characteristics, perioperative factors, and 
preoperative dexamethasone in patients undergoing surgery for colorectal cancer (n=556) 
Characteristic All Preoperative dexamethasone P 
No Yes 
N 556 245 311 - 
Age (<65/65-74/>74) 196/219/141 85/88/72 111/131/69 0.214 
Sex (male/female) 310/246 139/106 171/140 0.731 
BMI (<20/20-25/26-30/>30) 38/170/172/156 14/74/65/76 24/96/107/80 0.242 
Smoking (never/ex/current) 251/223/73 114/94/34 137/129/39 0.706 
ASA score (1/2/3/4) 136/248/155/16 50/108/74/13 86/140/81/3 0.003 
Preop mGPS (0/1/2) 429/40/48 179/21/29 250/19/19 0.007 
Site (colon/rectum) 355/201 159/86 196/115 0.658 
TNM stage (0/I/II/III) 13/127/229/181 5/47/112/80 8/80/117/101 0.261 
Neoadjuvant treatment (yes/no) 82/466 34/209 48/257 0.630 
     
Approach (open/lap) 337/212 195/49 142/163 <0.001 
Surgery >4h (yes/no) 183/370 57/187 126/183 <0.001 
Intraop transfusion (yes/no) 29/517 21/221 8/296 0.002 
Stoma (yes/no) 164/390 72/173 92/217 0.926 
Epidural (yes/no) 244/308 158/87 86/221 <0.001 
     
     
POD 3 CRP (median,range,mg/L) 138 (9601) 166 (22-601) 118 (9-430) <0.001 
POD 3 CRP >150 mg/L (yes/no) 239/292 136/101 103/191 <0.001 
POD 4 CRP (median,range,mg/L) 112 (13-528) 118 (13-528) 105 (15-415) 0.018 
POD 4 CRP >150 mg/L (yes/no) 153/308 79/142 74/166 0.277 
POD 3 albumin 
(median,range,g/L) 
26 (7-40) 25 (14-35) 27 (7-40) <0.001 
POD 3 albumin <25g/L (yes/no) 189/332 104/130 85/202 0.001 
POD 4 albumin 
(median,range,g/L) 
26 (13-35) 25 (14-35) 27 (13-35) <0.001 
POD 4 albumin <25g/L (yes/no) 170/285 97/121 73/164 0.003 
     
Any complication (yes/no) 234/321 122/123 112/198 0.001 
Infective complication (yes/no) 151/404 79/166 72/238 0.021 
Anastomotic leak (yes/no) 19/536 12/233 7/303 0.103 
Clavien Dindo (0-2/3-5) 47/508 23/222 24/286 0.540 
     
Thirty day mortality (yes/no) 5/550 3/242 2/308 0.659 
Adjuvant treatment (yes/no) 152/325 61/165 91/160 0.031 
BMI body mass index. ASA American Society of Anaesthesiologists.  POD postoperative day. CRP C-
reactive protein, mGPS preoperative modified Glasgow Prognostic score, CR-POSSUM Colorectal 
Physiologic and Operative Severity Score for the Enumeration of Mortality and Morbidity 
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Table 14-2: Association between preoperative dexamethasone and outcomes in propensity score 
matched patients undergoing surgery for colorectal cancer (n=276) 
Characteristic All Preoperative dexamethasone P 
No Yes 
N 276 138 138 - 
Age (<65/65-74/>74) 102/106/68 54/49/35 48/57/33 - 
Sex (male/female) 161/115 79/59 82/56 - 
BMI (<20/20-25/26-30/>30) 16/97/82/81 8/54/34/42 8/43/48/39 - 
Smoking (never/ex/current) 130/113/33 64/52/11 66/61/11 - 
ASA score (1/2/3/4) 72/116/80/8 36/59/37/6 36/57/43/2 - 
Preop mGPS (0/1/2) 224/26/26 107/15/16 117/11/10 - 
Site (colon/rectum) 170/106 86/52 84/54 - 
TNM stage (0/I/II/III) 7/69/109/91 4/30/60/44 3/39/49/47 - 
Neoadjuvant treatment (yes/no) 49/227 25/113 24/114 - 
     
Approach (open/lap) 184/92 93/45 91/47 - 
Surgery >4h (yes/no) 94/182 44/94 50/88 - 
Intraop transfusion (yes/no) 13/263 6/132 7/131 - 
Stoma (yes/no) 90/186 43/95 47/91 - 
Epidural (yes/no) 132/144 66/72 66/72 - 
     
POD 3 CRP (median,range,mg/L) 143 (17-430) 166 (22-382) 126 (17-430) <0.001 
POD 3 CRP >150 mg/L (yes/no) 123/145 75/58 48/87 0.001 
POD 4 CRP (median,range,mg/L) 121 (13-415) 121 (13-369) 121 (19-415 0.241 
POD 4 CRP >150 mg/L (yes/no) 80/158 46/75 34/83 0.349 
POD 3 albumin 
(median,range,g/L) 
26 (7-35) 25 (15-35) 26 (7-35) 0.058 
POD 3 albumin <25g/L (yes/no) 96/166 52/78 44/88 0.392 
POD 4 albumin 
(median,range,g/L) 
26 (14-35) 25 (14-35) 26 (16-35) 0.768 
POD 4 albumin <25g/L (yes/no) 88/150 48/72 40/78 0.749 
     
Any complication (yes/no) 115/161 68/70 47/91 0.009 
Infective complication (yes/no) 78/198 45/93 33/105 0.134 
Anastomotic leak (yes/no) 13/263 9/129 4/134 0.227 
Clavien Dindo (0-2/3-5) 26/250 17/121 9/129 0.152 
     
Thirty day mortality (yes/no) 2/274 2/136 0/138 - 
Adjuvant treatment (yes/no) 65/168 31/92 34/76 0.728 
BMI body mass index. ASA American Society of Anaesthesiologists.  POD postoperative day. CRP C-
reactive protein, mGPS preoperative modified Glasgow Prognostic score,  
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Table 14-3: Odds ratios for exceeding the C-reactive protein threshold of 150mg/L on postoperative 
day 3, and postoperative complications, with respect to preoperative dexamethasone across the 
propensity score methods 
Propensity Score Model n POD 3 CRP >150mg/L 
OR (95%CI) 
Complication  
OR (95% CI) 
Unadjusted 556 0.40 (0.28-0.57) 0.57 (0.41-0.80) 
Regression adjustment 400 0.53 (0.34-0.83) 0.62 (0.40-0.96) 
Stratification by quintiles (ATE) 400 0.41 (0.25-0.57) 0.62 (0.29-0.95) 
Matched 1:1 276 0.42 (0.26-0.70) 0.53 (0.33-0.86) 
POD postoperative day, CRP C-reactive protein, OR odds ratio, CI confidence interval, ATE average 
treatment effect 
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 Figures and Legends 
 
Figure 14-1: Patient flow chart for preoperative dexamethasone before elective surgery for colorectal 
cancer 
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Figure 14-2: Distribution of propensity scores (A) before (n=400) and (B) after matching (n=276) 
 
    
 
282 
  
15 The CORTISONE Trial: CORticosteroids To reduce 
Inflammation and improve Short-term Outcomes 
after surgery for colorectal NEoplasia  
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 Study synopsis 
Title of Study: The CORTISONE Trial:  CORticosteroids To reduce 
Inflammation and improve Short-term Outcomes after 
surgery for colorectal NEoplasia 
Study Centre: Glasgow Royal Infirmary (GRI), Queen Elizabeth 
University Hospital (QEUH), Royal Alexandra Hospital 
(RAH) 
Duration of Study: 24 Months  
Primary Objective: To determine whether there is a dose response 
relationship between perioperative dexamethasone and 
complications following surgery for colorectal cancer 
Secondary Objective: To determine whether there is a dose response 
relationship between perioperative dexamethasone and 
the magnitude of the postoperative systemic 
inflammatory response following surgery for colorectal 
cancer 
Primary Endpoint: Proportion of any postoperative complication in each 
group at first clinic follow up. 
 Rationale: The magnitude of the postoperative systemic 
inflammatory response, measured by CRP, is widely 
reported to be associated with the development of 
complications after surgery for colorectal cancer.  
However, the potentially causal nature of this relationship 
remains unclear.  Observational data suggests that 
dexamethasone given in the perioperative period to 
prevent postoperative nausea and vomiting (PONV) is 
associated with lower CRP on POD 3 and fewer 
postoperative complications.  However, the presence of a 
dose dependent effect is less clear. This requires 
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prospective study as a simple intervention, such as 
dexamethasone, may significantly improve postoperative 
morbidity through attenuation of the postoperative 
systemic inflammatory response.  
Methodology: Multi-centre, double blind, randomised controlled trial  
Sample Size: 183 
Screening: Patients will be screened for eligibility at the time of 
diagnosis with colorectal cancer by the Multi-
Disciplinary team meeting. 
Registration/Randomisation: Initial contact at preoperative assessment clinic two 
weeks prior to surgery.  Informed consent will be sought 
at the Same Day Admissions Units at GRI, QEUH and 
RAH on the morning of surgery. 
Patients will be randomised immediately prior to surgery 
by telephone using a computer generated randomisation 
key held by the CTU data manager.  Randomisation will 
be stratified by surgical approach; open or laparoscopic 
resection, and centre.   
Main Inclusion Criteria: Elective surgery for stage I-III colorectal cancer at GRI, 
QEUH or RAH  
Male or female aged >18 years 
Understand verbal and written information in English 
Main Exclusion Criteria: Emergency surgery 
Metastatic disease 
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Existing systemic inflammatory disease; e.g. rheumatoid 
arthritis (RA), vasculitis, inflammatory bowel disease 
(IBD) 
Already prescribed systemic steroids 
Intolerance or documented prior adverse reaction to 
dexamethasone/corticosteroids 
Product, Dose, Modes of 
Administration:  
Treatment Dexamethasone IV in 100ml normal saline 
Group 1: 2 x placebo at induction of anaesthesia and 
POD 1 
Group 2: 4mg x 1 at induction of anaesthesia, x1 placebo 
(normal saline) on POD 1 
Group 3: 8mg x 1 at induction of anaesthesia, and 8mg x 
1 on POD 1 
Duration of Treatment: Day of surgery and POD 1 
Statistical Analysis: Proportions of patients experiencing postoperative 
complications, in each treatment group will be compared 
using the Chi square test, and the treatment effect size 
will be estimated using odds ratios (OR) and their 95% 
confidence intervals (CI).  Statistical analysis will be 
performed using SPSS v22 (IBM, Chicago, IL, USA). 
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 Study flow chart 
 
 
Figure 15-1: Trial flow chart 
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 Introduction 
15.3.1 Background 
Colorectal cancer remains a leading cause of mortality in the UK (CRUK 2014).  Surgical 
resection is the cornerstone of curative management but is itself associated with morbidity 
and mortality (Ghaferi et al. 2011).  Long-term survival is primarily related to disease 
stage, however it is now well recognised that postoperative complications have a negative 
impact on oncologic outcome (Mirnezami et al. 2011, Artinyan et al. 2015). In addition, 
they are associated with a significant health care and societal cost due to prolonged 
hospital stay and delay in return to function. 
The routinely measured acute phase marker C-reactive protein (CRP), measured in the 
postoperative period, has been reported to be a reliable measure of the magnitude of the 
postoperative systemic inflammatory response (Watt et al. 2015a).  Furthermore, an 
association between the magnitude of this postoperative systemic inflammatory response 
and the development of postoperative infective complications has been reported following 
surgery for colorectal cancer (Platt et al. 2012, Singh et al. 2014, Adamina et al. 2015), 
independent of presentation (Straatman et al. 2016) and surgical approach (Ramanathan et 
al. 2015).  Indeed, threshold concentrations of CRP in the postoperative period have been 
established to predict the development of severe complications (Selby et al. 2014, 
McSorley Chapter 3).  A recent comprehensive review suggested that CRP concentrations 
greater than 150mg/L on postoperative days 3 to 5 should prompt investigation of potential 
postoperative complications such as anastomotic leak (McDermott et al. 2015). However, 
the nature of the relationship between the postoperative systemic inflammatory response 
and complications remains unclear.  Is high CRP in the postoperative period merely an 
epiphenomenon of the developing complication or is it causally implicated through 
immunologic dissonance? 
15.3.2 Rationale 
Corticosteroids administered at the induction of anaesthesia are associated with the 
prevention of postoperative nausea and vomiting (PONV) across a variety of surgical 
specialities (Karanicolas et al. 2008).  Indeed, preoperative dexamethasone has now been 
integrated into many “enhanced recovery” and “fast track” perioperative care protocols 
(Watt et al. 2015b). At present, dexamethasone forms part of the NHS GG&C Enhanced 
Recovery After Surgery (ERAS) protocol and, in a recent audit at GRI (unpublished data), 
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was given to around 80% of patients undergoing colorectal surgery.  Despite this, the 
underlying mechanism by which corticosteroids reduce the risk of PONV remains unclear.  
In addition, recent meta-analyses of randomized controlled trials have reported that 
preoperative administration of corticosteroids is associated with a reduction in the 
postoperative systemic inflammatory response and complications following abdominal 
surgery, and surgery for gastrointestinal cancers (Srinivasa et al. 2011, McSorley Chapter 
13, McSorley Chapter 14).  However, there is as yet no evidence of a dose response 
relationship between steroids, the postoperative systemic inflammatory response, and 
postoperative complications.  Furthermore, it may be that by reducing postoperative 
complication rate, perioperative corticosteroids can lead to improved long term outcomes.  
As dexamethasone is now routinely used for the prophylaxis of PONV, an alternative 
parenteral anti-emetic, ondansetron, will be used perioperatively in both groups.  
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 Study hypothesis 
There is a dose dependent relationship between dexamethasone given in the perioperative 
period and both complications and the magnitude of the systemic inflammatory response, 
measured by CRP, following surgery for colorectal cancer. 
15.4.1 Primary Endpoint 
• Proportion of patients experiencing any postoperative complication, classified by 
type and Clavien Dindo grade, at first clinic follow up 
15.4.2 Secondary endpoints 
• Length of hospital stay 
• Unplanned readmission within 30 days of surgery 
• Proportion of patients exceeding established CRP threshold of 150mg/L on 
postoperative day 3 
• 30 day Mortality  
• Health economic analysis 
• Postoperative quality of life measures at first clinic follow up 
• Multiplex analysis of postoperative cytokines inc IL1, IL 2, IL 6, IL 10, TNF alpha, 
TNF beta, GM-CSF 
• Flow cytometry of postoperative circulating immune cells populations 
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 Study design 
The study design is that of a multi-centre, prospective, double-blind, randomised controlled 
trial.  The three centres, GRI, QEUH and RAH, have been chosen by the investigators due 
to the similar nature of their multi-disciplinary colorectal cancer care, and perioperative 
care.  The sites each perform around 140 cancer resections per year. 
15.5.1 Study Population 
The study would aim to include patients undergoing elective colorectal surgery for stage I-
III colorectal cancer at GRI, QEUH, and RAH.  Inclusion and exclusion criteria are listed 
below.  Patients would be identified for potential inclusion through the weekly Glasgow 
Colorectal Cancer Multi-Disciplinary Team meetings.  
15.5.2 Inclusion criteria 
• Patients undergoing elective colorectal surgery for stage I-III colorectal cancer at 
GRI, QEUH or RAH 
• Male and female patients aged ≥18 years 
• Able to understand verbal and written information in English 
15.5.3 Exclusion criteria 
• Emergency surgery  
• Metastatic disease (unless planned staged metastastectomy)  
• Palliative/defunctioning surgery 
• Underlying inflammatory disease (e.g. IBD, RA, vasculitis) 
• Already prescribed systemic corticosteroids    
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15.5.4 Identification of participants and consent 
Participants will be identified from the weekly Glasgow Colorectal Cancer Multi-
Disciplinary team meetings prior to their preoperative anaesthetic assessment.  The trial 
will first be discussed, and patient information leaflets supplied at the preoperative 
assessment clinic by the preoperative assessment nurse, usually around two weeks prior to 
surgery (Appendix A).  This will provide patients with adequate time to read the 
information and contact the investigators with any questions prior to consent being sought.  
Informed consent will be sought at the Same Day Admissions Units at GRI, QEUH, and 
RAH on the morning of surgery by a member of the surgical or anaesthetic team 
(Appendix B). 
15.5.5 Withdrawal of subjects 
Withdrawal will be permitted at any time prior to, or during, enrolment in the study, at the 
patient’s request, or at the request of the surgical or anaesthetic team providing care.  There 
will be no change to the patient’s planned operative care, perioperative care, or follow up.  
Those patients who do not wish to take part, or withdraw prior to randomisation, may 
receive intravenous dexamethasone during their surgery as this forms part of the existing 
NHS GG&C Enhanced Recovery After Surgery (ERAS) protocol.  Those patients who do 
not wish to take part, or withdraw prior to randomisation, will not form part of the study 
and data-analysis.  Any patients withdrawing after randomisation will be included in the 
intention-to-treat analysis.  
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 Study Outcome Measures 
15.6.1 Primary Outcome Measure 
1. Postoperative complications recorded at first clinic return (usually postoperative week 4-
6), both by type (e.g. infective and non-infective complications) and severity (by Clavien 
Dindo grade).  The presence of complications will be assessed by the clinical trial nurse, 
using a standardised pro-forma (Appendix C), blind to the treatment allocation of the 
patients.   
15.6.2 Secondary Outcome Measure 
1. The proportion of patients exceeding the threshold serum CRP value of 150mg/L on 
postoperative day 3.  This data will be recorded from the laboratory reporting systems by 
the local research team. 
2. Length of hospital stay.  Duration measured from day of surgery to date of discharge.  
This will be recorded by the local research team. 
3. Unplanned readmission within 30 days of surgery.  This will be recorded by the local 
research team. 
4. Mortality within 30 days of surgery.  This will be recorded by the local research team. 
5.  Health economic analysis will be performed to examine the cost/benefit implications of 
routine administration of perioperative dexamethasone at the different doses in comparison 
to savings relating to postoperative complications and length of stay 
6.  Quality of life questionnaires (MSAS, FACT-G) will be administered at the first 
postoperative clinic visit 
7.  Multiplex analysis of blood samples taken and stored from the immediate postoperative 
period will be used to compare circulating cytokine profiles between treatment groups 
8. Flow cytometry of blood samples taken and stored from the immediate postoperative 
period will be used to compare circulating immune cell subsets and populations between 
treatment groups.  
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 Trial procedures 
Table 15-1: Schedule of enrolment, interventions, and assessments 
Time period Pre-surgery Surgery Post-surgery 
Visit Diagnosis/
MDT 
- 2 weeks 
to surgery 
Preassessment 
clinic 
- 1 week to 
surgery 
Operative 
day 
Postop - 
days 3+4 
Postop 
discharge 
- days 5-7 
Outpatient 
clinic 
- 6 weeks 
Identification x      
Eligibility x      
Consent  x     
Demographics  x     
Medical history  x     
Baseline bloods  x     
Randomisation   x    
Intervention 
(placebo/4mg/8
mg x 2 
dexamethasone 
IV) 
  x    
Postoperative 
bloods (CRP 
and albumin) 
   x   
Postoperative 
complication 
recording 
    x x 
  
15.7.1 Preoperative period  
Following identification of patients suitable for study inclusion at the MDT around 2 
weeks prior to surgery, patients will be invited to participate by post which includes the 
participant information sheet and consent form.   At the pre-assessment clinic, around 1 
week prior to surgery, data including demographics, comorbidities, and medication will be 
recorded, as is the usual standard of care.  The completed pre-assessment documentation 
will then be used to exclude those patients meeting the above criteria. The Clinical 
Research Fellow will meet the patient at their pre-assessment clinic visit.  The trial will be 
discussed and the patient will be invited to give informed written consent to participate.   
In addition, baseline routine blood tests will be taken at the pre-assessment clinic including 
haemoglobin, CRP, and albumin, which is the usual standard of care.  
15.7.2 Day of surgery 
Patients will attend the Same Day Admission Unit on the morning of surgery, usually 
around 2 weeks prior to surgery, as per unit standard protocol.  Written informed consent 
will be sought on the morning of the procedure if it has not already been sought at pre-
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assessment.  Written informed consent is required prior to any trial specific interventions 
being performed.  Those procedures which form part of the usual standard care can be 
carried out in advance of such consent.  The use of conventional open or laparoscopic 
surgery will be at the discretion of the consultant surgeon.  Patients who are eligible and 
consent to take part in the trial will be computer randomised in the anaesthetic room 
immediately prior to the induction of anaesthesia.  Prior to the skin incision, all patients 
will be given prophylactic intravenous antibiotics as per unit protocol.  The surgical 
technique, including formation of ostomies will be at the discretion of the consultant 
surgeon. 
15.7.3 Postoperative period 
Patients will be cared for in line with a unit standardised ERAS program including the use 
of early mobilisation, early oral nutrition, multimodal analgesia and antiemesis, and the 
avoidance of routine nasogastric and peritoneal drainage.  The use of regional anaesthetic 
techniques including spinal, epidural, and rectus sheath analgesia will be at the discretion 
of the consultant anaesthetist.  Blood tests will be taken daily as routine until discharge, 
including CRP.  The surgical team will not be blind to these blood results.  Investigation 
of, and treatment for, any postoperative complications will be at the discretion of the 
patient’s clinical team. 
15.7.4 Randomisation 
Patients will be randomised and given a participant number immediately prior to surgery 
by telephone.   The allocation will be computer generated so will not be known to the 
research team.  The computer generated randomisation key will be held by the CTU data 
manager.  Randomisation will be stratified by surgical approach; open or laparoscopic 
resection, and centre.  At the end of the trial the randomisation key will be given to the 
research team to allow patient allocation to be revealed. 
15.7.5 Blinding 
For the purposes of double blinding, all doses of dexamethasone will be prepared in 100ml 
bags of normal saline which will appear identical, be labelled with trial labelling only, and 
be administered via an intravenous cannula over 30 mins.  The first dose will be given at 
the induction of anaesthesia, with patients in group 1 administered 100ml normal saline 
placebo, group 2 administered 4mg of dexamethasone in 100ml normal saline 
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intravenously over 30 mins, and those patients in group 3 administered 8mg of 
dexamethasone in 100ml normal saline over 30 mins.  On the first postoperative day those 
patients in group 3 will receive 8mg dexamethasone intravenously prepared in 100ml 
normal saline over 30 mins and those patients in groups 1 and 2 will receive placebo of 
100ml normal saline only intravenously over 30 mins.  Both the patients and the clinical 
teams caring for the patients will be blind to treatment allocation until the data is de-
anonymised following the closure of the trial.  Clinicians will not be blind to postoperative 
CRP blood results.  Investigation and treatment of postoperative complications will be at 
the discretion of the patient’s surgical team. 
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 Assessment of safety 
15.8.1 Risk assessment 
A formal risk assessment, which acknowledges the risks associated with the conduct of the 
trial and proposals of how to mitigate them through appropriate quality control (QC) and 
quality assurance (QA) processed, will be undertaken by the CTU.  Risks will be assessed 
in terms of their impact on: the rights and safety of participants; trial design, reliability of 
results and institutional risk; and project management. 
QA is defined as all the planned and systematic actions established to ensure the trial is 
performed and data generated, documented and/or recorded and reported in compliance 
with the principles of GCP. QC is defined as the operational techniques and activities 
performed within the QA system to verify that the requirements for quality of the trial 
related activities are fulfilled.  
15.8.2 Adverse events 
The principles of Good Clinical Practice (GCP) require that investigators and sponsors 
follow specific procedures when notifying and reporting adverse events or adverse 
reactions in clinical trials.  These procedures are described below.  All AEs, ARs, and 
SAEs should be recorded in the patient’s medical notes and the case report form (CRF).  
The investigators should assess the severity of the AE using the standardised definitions 
and the nature of its cause. 
Investigators should record any SAEs related to the trial intervention occurring from the 
time of randomisation until the first postoperative follow up clinic visit or 30 days after 
surgery, whichever is first.   If the event is classified as ‘serious’ and related to the trial 
intervention then an SAE form must be completed and the CTU notified within 24 hours. If 
the event is classified as 'serious’ and assessed as not being related to exercise or reported 
as a post-operative morbidity (POM) these should still be reported to the CTU.  The 
minimum data required for reporting an SAE are the participant number and date of birth, 
name of reporting investigator and sufficient information on the event to confirm 
seriousness. Any further information regarding the event that is unavailable at the time of 
the first report should be sent as soon as it becomes available.  The Chief Investigator, or a 
co-investigator, will review all SAE forms.  If an SAE is considered to be related to the 
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trial intervention then continuation of the trial for that patient should be discussed with the 
Chief Investigator.   
Adverse events in the trial include: 
• Postoperative mortality (within 30 days of surgery) 
• Postoperative morbidity, within 30 days of surgery or up to the first follow up 
clinic visit – this should be graded according to the type and Clavien Dindo 
classification and reported on the appropriate CRF 
• Readmissions relating to post-operative morbidities within 30 days of surgery  
• A new condition that is detected after the trial intervention, prior to the first clinic 
follow up visit. 
Adverse events in this trial do not include: 
• Recurrence of primary cancer- this should be reported on the appropriate CRF 
• Death due to primary cancer- this should be reported on the appropriate CRF 
• Medical or surgical procedures; the condition that led to the procedure is the 
adverse event 
• Pre-existing disease or a condition present that was diagnosed before trial entry and 
does not worsen 
• Hospitalisation where no untoward or unintended response has occurred e.g. 
elective surgery, social admissions 
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 Statistics and data analysis 
15.9.1 Sample size  
This would be a 1:1:1 study. The maximum study size would be 183 patients, based on a 
difference in proportions of success of 20% (50% vs 70%) with 90% power and a 10% 1-
sided level of statistical significance. There would be 2 equally spaced interim analyses 
(after 1/3 and 2/3 of patients) where consideration would be given to dropping the 0mg 
arm. 
The interims would compare (4 and 16mg) vs. 0mg, i.e. any treatment vs. no treatment 
(2:1).  There would be a 13% probability of dropping 0mg at the first interim (p<0.004; 
after 60 patients {~20 per arm}) and 53% probability of dropping 0mg at the second 
interim (p<0.043; after 121 patients {~40 per arm}) If the 0mg arm was dropped at an 
interim the study would continue to recruit 1:1 to 4mg and 16mg to a maximum of 61 
patients per arm. 
The null hypothesis (H0) of the study is that the complication rate is the same for all 3 
groups (0mg, 4mg, 16mg). 
The first alternative hypothesis (H1A) is to test whether any treatment is better than no 
treatment {(4mg and 16mg ) vs 0mg}. There are 2 possible outcomes here: 
1. If having any treatment is statistically significantly superior to 0mg (a lower 
complications rate is seen) the second alternative hypothesis (H1B) of comparing the 16mg 
and 4mg would be tested at a 10% significance level. With 122 patients (61 per arm) and 
success rates of 60% and 80% for 4mg and 16mg respectively, the power of the test would 
be 88%. 
2. If having any treatment is not statistically significantly superior to 0mg the third 
alternative hypothesis (H1C) of comparing the 16mg (n = 61) and 0mg would be tested. 
With 122 patients (61 per arm) and success rates of 50% and 70%* for 0mg and 16mg 
respectively, the power of the test would be 85%. 
* A more modest success level than the original hypothesised 80% as, if that level been 
observed, the test of treatment versus no treatment would have been significant and the 
final analysis would have been to compare the 16mg and 4mg. 
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Note that, as a sequential gateway testing procedure is being employed, H1A and H1B 
operate at 10% level of statistical significance. As H1C is a fall-back analysis the overall 
significance level for this is 20%.    
15.9.2 Management and delivery 
Data will be entered by the local research team onto the case report form (CRF) of the trial 
database which will be held securely on University of Glasgow servers.  The database will 
be password protected and only available to members of the trial team.  The servers are 
protected by firewalls and patched and maintained according to University of Glasgow IT 
service practice.  The physical location of the servers, as with the terminals used to access 
them, is protected by CCTV and security door access. 
The results of the trial will be disseminated regardless of the direction of effect. Ownership 
of the data arising from the study resides with the trial team. The publication policy will be 
in line with rules of the International Committee of Medical Journal Editors. 
The trial protocol will be published and made available for public access throughout the 
trial period. 
15.9.3 Statistical analysis plan 
All statistical analyses will be performed using IBM SPSS v22 for Windows (IBM, 
Chicago, IL, USA).  Two sided p values <0.05 will be considered statistically significant. 
Initially patients will be randomized 1:1:1 to each group.  Interim analyses following 
recruitment of 1/3 and then 2/3 of patients will compare complication rates in Group 1 
(placebo) to combined Group 2 and 3 (dexamethasone, any dose), to determine whether a 
significant treatment effect exists.  If a significant difference is found then no further 
patients will be randomized to placebo, with all further recruited patients randomized 1:1 
to Group 2 or 3.  Final analysis will then determine whether a significant difference in 
complication rate is found between Groups 2 (4mg dexamethasone) and Group 3 (8mg x 2 
dexamethasone).  If no significant difference is found between placebo and any 
dexamethasone dose at interim analysis then the remaining patients with be randomized to 
Group 1 (placebo) and Group 3 (8mg x 2).  The final analysis will then determine whether 
a significant difference in complication rate is found between placebo and any dose of 
dexamethasone. 
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15.9.4 Study closure / Definition of end of trial 
The end of the trial is defined as the first clinic visit, or 30 days after the last patient’s 
randomisation to the trial, whichever occurs first.  This is anticipated to be around 24 
months after trial commencement.  
15.9.5 Data Handling 
15.9.5.1  Case Report Forms / Electronic Data Record 
Individual CRFs will be held in the trial database, held securely on University of Glasgow 
Servers as above.  These data will be anonymised and the only identifier used will be the 
participant number. The randomisation/anonymisation key will link participant number to 
a patient identifier, the CHI number, for the purposes of linkage, and will be held 
separately by the CTU data manager.  Access to these files and information will be 
restricted to trial staff.   
15.9.5.2  Record Retention 
The anonymised data, including individual enrolment and CRFs, will be held on the 
University of Glasgow server for a minimum of 10 years following trial closure.  In 
addition, a password protected copy of the randomisation key will be kept securely on the 
University server to allow linkage if required in the future. 
The patient consent form will explain that if a participant wishes to withdraw from the 
study, the data acquired prior to that point will be retained unless the patients requests 
otherwise.  Reason for withdrawal will be recorded if given, as will loss to follow up. 
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    Study monitoring/auditing 
The Sponsor (NHS GG&C) randomly selects 10% of research studies for audit per annum. 
 Protocol amendments 
Any change in the study protocol will require an amendment.  Any proposed protocol 
amendments will be initiated by the CI and submitted to the ethics committee and sponsor.  
The CI will liaise with the study sponsor to determine whether an amendment is non-
substantial or substantial.  All amended versions of the protocol will be signed by the CI 
and Sponsor representative.  Before the amended protocol can be implemented favourable 
opinion/approval must be sought from the original reviewing REC and Research and 
Development (R&D) office(s). 
 Ethical considerations 
The study will be carried out in accordance with the World Medical Association 
Declaration of Helsinki (1964) and its revisions (Tokyo [1975], Venice [1983], Hong Kong 
[1989], South Africa [1996], Edinburgh [2000], Seoul [2008] and Fortaleza [2013]). 
Favourable ethical opinion will be sought from an appropriate REC before patients are 
entered into this clinical trial. The CI will be responsible for updating the Ethics committee 
of any new information related to the study. 
The rights of the participant to refuse to participate in the trial without giving a reason must 
be respected. After the participant has entered the trial, the clinician remains free to give 
alternative treatment to that specified in the protocol, at any stage, if s/he feels it to be in 
the best interest of the participant. The reasons for doing so must be recorded. After 
randomisation, the participant must remain within the trial for the purpose of follow up and 
data analysis according to the treatment option to which they have been allocated. 
However, the participant remains free to change their mind at any time about the protocol 
treatment and follow up without giving a reason and without prejudicing their further 
treatment. 
As this is a Clinical Trial of Investigational Medicinal Product (CTIMP), as defined by EU 
directive 2001/20/EC, the trial will be registered in the European Clinical Trials Database 
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and submitted to the Medicines Healthcare Products Regulatory Agency (MHRA) for a 
Clinical Trial Authorisation (CTA).  
 Insurance and indemnity 
Trial and clinical staff with NHS and Honorary NHS contracts will be covered by their 
NHS insurance and indemnity, and as such a research passport will not be required for 
these individuals.  University of Glasgow employees will be covered by the University of 
Glasgow Clinical Trials Insurance Policy.  
The NHS has a duty of care to patients treated, whether or not the patient is taking part in a 
clinical trial, and the NHS remains liable for clinical negligence and other negligent harm 
to patients under its duty of care.
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16 Conclusions 
 Overview of work 
It is already well documented that an exaggerated postoperative systemic inflammatory 
response is associated with infective complications following surgery for colorectal cancer.  
In addition, these postoperative complications have been shown to have negative 
implications for long-term prognosis.  Serum C-reactive protein (CRP) has been 
recognised as a marker of the magnitude of the postoperative systemic inflammatory 
response, and clinically relevant threshold values have already been derived.  However, the 
nature of the relationship between the postoperative systemic inflammatory response and 
oncologic outcomes, along with factors which influence the postoperative systemic 
inflammatory response, were less well understood.  Therefore, the aims of this thesis were 
to further examine the relationship between the postoperative systemic inflammatory 
response, postoperative complications, and long term oncologic outcomes and ask whether 
attenuation of the postoperative systemic inflammatory response might result in improved 
outcomes following surgery for colorectal cancer. 
The results of Chapter 3 report that an exaggerated postoperative systemic inflammatory 
response is associated with postoperative complications regardless of our method of 
classification.  In addition, it reported the association between exceeding established 
postoperative CRP thresholds and the need for reintervention following surgery for 
colorectal cancer.  However, perhaps of more interest are the results of Chapter 4, which 
suggest that the postoperative systemic inflammatory response has a direct effect on cancer 
specific survival, independent of complications.  We hypothesise that this relates to 
downregulation of the useful anti-tumour adaptive immune response by the overwhelming 
postoperative innate response.  This would have profound implications.  Firstly, it perhaps 
suggests a mechanism by which postoperative complications, regardless of type, lead to 
disease recurrence and cancer death.  Second, by having a direct impact on survival, the 
question of whether attenuation of the postoperative systemic inflammatory response to 
improve both short and long-term outcomes becomes pressing. 
Existing evidence suggests that patient and operative factors influence the magnitude of the 
postoperative systemic inflammatory response.  Patient factors such as comorbidity, BMI, 
and the presence of preoperative systemic inflammation act to increase the magnitude of 
the postoperative systemic inflammatory response.  The use of minimally invasive 
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laparoscopic surgery, however, is well recognised to reduce the postoperative systemic 
inflammatory response.  Chapters 5 to 11 examined some other important patient and 
perioperative factors which might have an influence on the postoperative systemic 
inflammatory response.  Chapter 5 reported that female patients with higher BMI and 
visceral obesity, measured by preoperative CT, were more likely to exceed the established 
CRP thresholds on postoperative days 3 and 4, and that this was also associated with a 
higher rate of postoperative complication.  Visceral fat is well understood to be an active 
endocrine and immunological tissue and it may be that an increased quantity promotes 
postoperative systemic inflammation.  The same relationship was not found amongst male 
patients, however the reasons for this were not clear.  It may be that it relates to sex 
specific differences in fat distribution. 
Chapter 6 reported no significant association between patients with poorer exercise 
tolerance and a lower anaerobic threshold, as measured by cardiopulmonary exercise 
testing (CPEX), and the postoperative systemic inflammatory response.  However, this was 
in a small number of patients, and it may well be that a small effect is present, but that the 
sample size did not have the requisite power to detect it.  The idea that measures of 
physical fitness derived from CPEX might relate to the postoperative systemic 
inflammatory response remains plausible.  A low anaerobic threshold at CPEX might 
simply reflect the burden of comorbidity.  However, it could be hypothesised that a lower 
anaerobic threshold predisposes patients to relative hypoxia and oxygen debt in the 
perioperative period which drives systemic inflammation.  Furthermore, relative hypoxia is 
known to be an adverse prognostic factor at the tumour level, although whether a short 
period of relative whole body hypoxia at the time of surgery could have an effect on the 
tumour itself is less clear.  Further work in this area might involve the increasingly popular 
use of CPEX for “prehabilitation” in patients undergoing surgery for colorectal cancer.  In 
particular, if it could be demonstrated that prehabilitation improved patients’ anaerobic 
threshold, and in turn reduced the magnitude of the postoperative systemic inflammatory 
response, a more causal argument could be drawn.    
Several other patient and operative factors investigated were not found to influence the 
postoperative systemic inflammatory response.  Chapter 7 reported no association between 
the magnitude of the postoperative systemic inflammatory response and the formation of a 
temporary defunctioning stoma, which is often a useful technique to protect high risk 
anastomoses and lessen the consequences of subsequent leakage.  Chapter 8 reported that 
operation duration is not directly associated with the postoperative systemic inflammatory 
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response, instead suggesting that the surgical approach is more important.  Chapter 9 
reported no significant association between perioperative blood transfusion and the 
magnitude of the postoperative systemic inflammatory response, although preoperative 
systemic inflammation and anaemia were found to be strongly related.  Chapter 10 
reported no association between preoperative neoadjuvant chemoradiotherapy (nCRT) and 
the magnitude of the postoperative systemic inflammatory response in patients undergoing 
surgery for rectal cancer.  This finding is of interest given that patients who have 
undergone nCRT often have more difficult pelvic dissection due to localised post radiation 
inflammation.  In combination with Chapter 8, the results of this chapter reassure that what 
might be perceived as longer and more difficult surgery does not necessarily equate to 
greater surgical trauma.     
Chapter 11 reported that the postoperative systemic inflammatory response of patients 
undergoing surgery for colorectal cancer in the UK was much greater than that of patients 
in Japan.  This was the case even after accounting for the very dramatic differences in 
patient characteristics between the cohorts.  This is, of course, not a modifiable risk factor 
from the point of view of patient or surgeon, however it raises important issues with regard 
to the reporting of the postoperative systemic inflammatory response from cohorts around 
the world.  It may also lead to further fruitful avenues of research with regard to why some 
populations appear to have a greater propensity for systemic inflammation than others 
following trauma. 
At present, postoperative care following surgery for colorectal cancer in the UK is 
dominated by the use of Enhanced Recovery (ERAS) and “fast track” protocols.  The 
investigation of potential complications following surgery is a reactive and clinician driven 
paradigm of care, based on markers of patient physiology such as heart rate, core body 
temperature, blood pressure etc.  Chapter 12 examined the use of CRP on day 4 to prompt 
early investigation of such potential complications by computed tomography (CT) in the 
presence of an exaggerated postoperative systemic inflammatory response.  The use of 
such an objective method of “flagging” patients at high risk of postoperative complication 
may result in the earlier and more accurate diagnosis of postoperative complications.  
Given their prognostic impact, this early and thorough detection is of utmost importance.   
Although an exaggerated postoperative systemic inflammatory response is clearly 
associated with postoperative complications, it was not clear whether attenuation of it 
would result in better outcomes. Chapters 13 and 14 examined the use of single dose 
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preoperative corticosteroids for the attenuation of the postoperative systemic inflammatory 
response and whether it might improve short term outcomes following surgery for 
colorectal cancer.  These results are important for several reasons.  First, a relatively 
simple intervention was shown to reduce the magnitude of the postoperative systemic 
inflammatory response.  Second, the same intervention was also associated with lower 
rates of postoperative complications not only within the existing literature but within our 
own cohort.  Although these observations cannot definitely show that the postoperative 
systemic inflammatory response has a causal role in the development of postoperative 
complications, they add weight to this argument and should prompt prospective studies 
which aim to explore a possible dose response relationship between the postoperative 
systemic inflammatory response, methods of its attenuation, and complications following 
surgery.  In addition, the evidence with regard to the use of corticosteroids at surgery and 
long-term oncologic outcomes is lacking, and future work should also focus on this issue.  
Finally, evidence of the impact of individual components of ERAS protocols on the 
postoperative systemic inflammatory response is lacking, with the exception of minimally 
invasive surgery.  The work presented in this thesis lays the foundation for future work, 
such as the simplification of postoperative care protocols by removing components found 
to have no objective or measurable impact on the postoperative systemic inflammatory 
response.   
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 Future work 
Since the completion of this work, several relevant additions to the literature surrounding 
the postoperative systemic inflammatory response have been made which will influence 
future work.  The measurement of the magnitude of the postoperative systemic 
inflammatory response has been further refined with the postoperative Glasgow Prognostic 
score (poGPS), which combines serum CRP and albumin to further stratify the risk of 
infective complications following surgery for colorectal cancer (Watt et al. 2017b).  
Indeed, the introduction of the poGPS has validated the finding of the present thesis that 
the postoperative systemic inflammatory response is itself prognostic in this group of 
patients.  Furthermore, the clinicopathological determinants of the magnitude of the 
postoperative systemic inflammatory response, other than those considered within the 
present thesis, have been further elucidated, with confirmation that comorbidity, the 
preoperative systemic inflammatory response, obesity, and surgical approach are key (Watt 
et al. 2017a).  In addition, a recent randomised controlled trial has reported that a single 
dose of 8mg of intravenous dexamethasone, given at the induction of anaesthesia, reduces 
the incidence of postoperative nausea and vomiting (PONV) and the need for additional 
anti-emetics following gastrointestinal surgery (Magill et al. 2017). Although the overall 
rate of infective complications reported was no different between the steroid and placebo 
groups, there was a significantly lower rate of anastomotic leak in the steroid group.  The 
authors suggest that one of the possible mechanisms by which dexamethasone reduces the 
incidence of PONV is by its anti-inflammatory effects, however no measure of the 
postoperative systemic inflammatory response was included in the presented paper.  The 
lack of such a measure means that in that study no conclusions can be drawn between 
steroid, postoperative systemic inflammation, and the reported complications.  This further 
suggests that future trials of corticosteroids with postoperative outcome endpoints, such as 
complications, should take the postoperative systemic inflammatory response into account 
as a potential mechanism of action. 
With the objective definition of the postoperative systemic inflammatory response, and its 
established relationship with postoperative complications, it will be easier to define the 
likely benefits of perioperative interventions, such as robotic surgery, prehabilitation 
programmes, regional and general anaesthetic techniques, and anti-inflammatory 
medications.  In particular, it will allow the dissection of factors contributing to the 
magnitude of the postoperative systemic inflammatory response.  These include factors 
pertaining to the patient, the surgery itself, anaesthesia, and postoperative care.  
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Table 16-1: Relationship between perioperative factors and the postoperative systemic inflammatory 
response, a summary 
Category Factor Impact on 
postoperative systemic 
inflammatory response 
Comment 
Preoperative 
and patient 
Comorbidity Increases Also associated with 
complications 
 Obesity Increases Also associated with 
complications 
 Preoperative systemic 
inflammation 
Increases Also associated with 
complications 
 Neoadjuvant therapy No effect Some conflicting evidence of 
association with complications 
 Preop drugs – NSAIDS, 
statins etc. 
More data required  
 Preoperative 
counselling 
More data required  
 Prehabilitation 
programmes 
More data required Low anaerobic threshold at 
cardiopulmonary exercise testing 
associated with complications 
 Preoperative 
carbohydrate loading 
More data required Single study reporting no 
relationship with postop IL 6 and 
CRP.  Evidence relating to 
reduction in perioperative insulin 
resistance. 
 Mechanical bowel 
preparation 
More data required No association with complication 
unless combined with oral 
antibiotics 
    
Intraoperative Laparoscopic surgery Decreases Impact on complications beyond 
wound related remains uncertain 
 Perioperative steroid Decreases Associated with fewer 
complications 
 Operation duration No effect  
 Defunctioning stoma No effect Reversal associated with 
morbidity 
 Blood transfusion No effect Evidence that preoperative 
transfusion in context of systemic 
inflammation associated with 
poorer outcomes 
 Regional anaesthesia More data required  
 General anaesthetic 
techniques and drugs 
More data required  
 Goal directed fluid 
therapy 
More data required Single study reporting association 
between goal directed fluid 
therapy and lower postop IL6, not 
replicated in other studies 
    
Postoperative Pre-emptive antibiotics No effect Unpublished data 
 Early mobilisation More data required  
 Early enteral nutrition More data required  
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Figure 16-1: Schematic of factors associated with the postoperative systemic inflammatory response 
and their association with outcomes after surgery for colorectal cancer 
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Appendices 
Appendix A: Sample Patient Information Sheet 
 
                    
 
Investigators: Mr Campbell Roxburgh, Mr Stephen McSorley, Prof Paul Horgan 
Tel: 01412018676 or 01412018675 
E-mail: campbell.roxburgh@glasgow.ac.uk,stephen.mcsorley@glasgow.ac.uk 
 
Participant Information Sheet 
 
Title of study 
The CORTISONE Trial: CORticosteroids To reduce Inflammation and improve Short-
term Outcomes after surgery for colorectal NEoplasia 
 
Invitation to take part 
Thank you for reading this information sheet. You are being invited to take part in a research 
study, which is part of a doctoral thesis to be submitted at the University of Glasgow.  
Before you decide to take part in this study, it is important for you to understand why the 
research is being done and what it will involve.  Please take time to read the following 
information carefully and discuss it with others if you wish.  Please ask us if there is anything 
that is not clear or if you would like more information.  Take time to decide whether or not 
you wish to take part. 
 
What is the purpose of the study? 
Surgery is at present the main method of cure for patients diagnosed with colorectal cancer.  
However, the major surgery required is associated with complications in as many as 1 in 3 
patients.  These postoperative complications are recognised to cause lengthier postoperative 
recovery, poorer quality of life for affected patients, and an increased risk of death, both in 
the early postoperative period, and years after surgery. 
The postoperative stress response (also sometimes called the postoperative systemic 
inflammatory response) is increasingly thought to be associated with these complications.  
This stress response is the body’s natural way of dealing with the trauma of surgery, however 
in some patients it becomes inappropriately exaggerated.  This is thought to cause the 
immune system to be less effective at fighting infection, allowing complications to develop.  
The exact reason why some people develop such a large stress response after surgery is not 
yet known.  However, there may be methods to dampen it and so reduce the risk of 
postoperative complications. 
Dexamethasone is a steroid medication and it may be one of such methods.  It is already 
very commonly given, to patients having surgery for colorectal cancer because it has been 
shown to reduce nausea and vomiting after surgery.  In this situation, it is normally given 
during the anaesthetic, into a vein using a “drip”, at a low dose.  Some research also suggests 
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that it dampens the stress response after surgery, and might reduce complications, although 
how it does this, and what the best dose would be is not yet known.   
Patients entering this study will receive either placebo (no dexamethasone), or one of two 
doses of dexamethasone at the time of their surgery, either a “low” dose or a “high” dose.  
Blood tests taken as part of routine care after surgery will then be analysed and markers of 
the postoperative stress response measured to determine if the different doses have a 
different effect on the stress response.  Postoperative complications will be recorded up to 
the first clinic follow up visit after discharge, as is routine after this kind of surgery, and the 
effect of the different doses of dexamethasone will be analysed. 
This study is what is known as a “double blind, randomised controlled trial”.  This means 
that neither you, nor the surgical and anaesthetic teams looking after you, will know which 
steroid treatment you have received during surgery.  However, they will be able to see your 
postoperative blood tests, and will investigate and treat any postoperative complications as 
they normally would after this kind of surgery.           
The study is being undertaken towards obtaining the degree of Medical Doctorate (M.D.) 
 
Why have I been chosen? 
You have been chosen because you have been diagnosed with colorectal cancer, are 
attending the anaesthetic pre-assessment clinic, and will be undergoing surgery at either 
Glasgow Royal Infirmary, Queen Elizabeth University Hospital, or the Royal Alexandra 
Hospital. 
  
To take part in this study: 
 
-You should be attending for elective surgery for colorectal cancer at Glasgow Royal 
Infirmary, Queen Elizabeth University Hospital, or the Royal Alexandra Hospital. 
 
-You should be aged 18 years or over 
 
-Male or female 
 
-You should NOT have an existing illness involving the immune system, for example; 
rheumatoid arthritis, lupus, vasculitis, ulcerative colitis, Crohn’s disease 
 
-You should NOT already be taking steroid tablets or be receiving steroid injections, for 
example: prednisolone, dexamethasone, triamcinolone, hydrocortisone.  However, steroid 
creams for skin conditions, or inhalers for respiratory illness, are allowed. 
 
-You should NOT have previously had an adverse reaction to steroid medication such as 
those named above 
 
Do I have to take part? 
It is up to you whether or not to take part.  If you do decide to take part you will be asked to 
sign a consent form.  If you decide to take part you are still free to withdraw at any time and 
without giving a reason.  A decision to withdraw at any time, or a decision not to take part, 
will not affect the standard of care you receive. 
 
What will happen to me if I take part? 
You should read this information sheet.  A member of the surgical team will ask you whether 
you wish to take part in the study on the morning of your surgery.  If you agree you will be 
asked to sign a consent form.  A trial participant number will be assigned to you at random 
and this will determine what dose of dexamethasone or placebo you receive during surgery.  
This will be given via the “drip” that will be inserted by the anaesthetist routinely, and 
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through which you would normally receive anaesthetic medication.  Postoperative blood 
tests will be taken daily, as would happen normally after surgery.  When you attend your 
first clinic visit after discharge a member of the trial team will record whether you 
experienced a postoperative complication, and its nature.  Otherwise, your postoperative care 
and follow up will be entirely the same as if you were not taking part in the study. 
 
What do I have to do? 
Think about whether you would like to take part in the study.  You can then tell the surgical 
team on the morning of surgery.  If you have any questions please contact a member of the 
trial team on the above contact information.  After the study has ended, your samples will 
be stored in an anonymised fashion and after 10 years they will be destroyed. 
 
 
What are the possible disadvantages and risks of taking part? 
Steroid medications like dexamethasone have been known to cause adverse reaction such 
as poor wound healing, infections, and high blood sugars, although these are much more 
likely when the drug is used over the long term for chronic conditions. 
 
What are the possible benefits of taking part? 
Studies to date suggest that dexamethasone and other steroid medications are associated with 
fewer complications after surgery for colorectal cancer.  Complications are associated with 
longer hospital stay and recovery, poorer quality of life, and even death after surgery.  
However, very few of these have been randomised controlled trials.  Furthermore, most have 
compared a steroid to a placebo (or no steroid), and very few have compared two different 
doses of steroid medication.  Therefore, there may in fact be no benefit to receiving a higher 
dose of steroid.  This study aims to clarify this. 
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential. Your GP will not routinely be informed of your participation. However, 
should any of your blood tests show anything unexpected, or should you have an adverse 
reaction to the trial medication, we will write to your GP and inform them. Your GP will 
then decide if this requires further investigation. The GP will contact you if this is the case. 
The research team members will need to access your medical records for the study purpose 
and all information will be kept confidential. Representatives of the study Sponsor, NHS 
Greater Glasgow and Clyde, may look at your information to make sure that the study is 
being conducted properly. 
 
What will happen to the results of the research study? 
Results will be presented at meetings of learned societies and published in scientific journals. 
Results will also be included in student project reports, when applicable. We will arrange a 
meeting to discuss the results with participant volunteers if they would like that. Again, your 
data will be anonymised and you will not be identifiable.  
 
Who is organising and funding the research? 
This project is being organised by the Academic Unit of Surgery at the University of 
Glasgow and NHS Greater Glasgow and Clyde.  
Funding TBC 
 
Who has reviewed the study? 
TBC 
 
Contact for further information 
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If you require further information please contact Mr Campbell Roxburgh or Mr Stephen 
McSorley by telephone at 0141 2018675 or via e-mail at 
campbell.roxburgh@glasgow.ac.uk or stephen.mcsorley@glasgow.ac.uk. 
 
If you have any questions about colorectal cancer, or involvement in research and want to 
seek advice or support, you can contact Macmillan’s free helpline on 0808 808 00 00.  
 
Thank you for reading this information sheet. 
  
    
 
366 
  
Appendix B: Sample Consent Form 
 
Investigators: Mr Campbell Roxburgh, Mr Stephen McSorley, Prof Paul Horgan 
Tel: 01412018676 or 01412018675 
E-mail: campbell.roxburgh@glasgow.ac.uk,stephen.mcsorley@glasgow.ac.uk 
 
 
CONSENT FORM 
 
Title of Project: The CORTISONE Trial: CORticosteroids To reduce Inflammation 
and improve Short-term Outcomes after surgery for colorectal NEoplasia 
 
                                                            Please initial box 
 
1. I confirm that I have read and understand the information sheet dated....  
(version …) for the above study. 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected.  
3. I understand that sections of my medical notes and my study information may 
be looked at by the research team and representatives of the study Sponsor 
(NHS GG&C) where it is relevant to my taking part in the research. I give 
my permission for this access to my information.  
4. I agree to my samples (blood and tissue samples) being stored  
 and used for further analysis for further research as new techniques become 
available. All future work will be ethically approved. 
5. I agree for any surplus tissue from tissue to be examined in the laboratory 
for the purpose of the research study. 
6. I consent to my GP being informed of any information that arises from 
participation. 
7. I agree to take part in the above study. 
 
           
Name of subject/Participant Number      Date                Signature 
     
Name of researcher  Date  Signature 
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Appendix C: Sample Case Report Form  
      
 
Investigators: Mr Campbell Roxburgh, Mr Stephen McSorley 
Tel: 01412018676 or 01412018675 
E-mail: campbell.roxburgh@glasgow.ac.uk or stephen.mcsorley@glasgow.ac.uk 
 
CASE REPORT FORM 
 
Title of Project: The CORTISONE Trial: CORticosteroids To reduce Inflammation and 
improve Short-term Outcomes after surgery for colorectal NEoplasia 
 
 
Participant identification number________________  Date of 
birth___/___/_____ 
 
 
Date of surgery___/___/______   Date of discharge___/___/_____   Length of stay 
(days)_____ 
 
 
Surgical approach:   laparoscopic / converted  / open 
 
 
CRP concentration on postoperative day 3:  ___________mg/L 
 
 
Did the patient die during the 30 days after surgery?:  no / yes 
• If yes, what was the recorded date ___/___/_____ and cause of death: 
 
o Ia_______________________________________________ 
 
o Ib_______________________________________________ 
 
o Ic_______________________________________________ 
 
 
o Id_______________________________________________ 
 
o II_______________________________________________ 
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Did the patient have an unplanned readmission during the 30 days after surgery?: no / yes 
 
• If yes, what was the date ___/___/_____ and cause of readmission 
___________________________________________________________________
___________________________________________________________________
______________________ 
 
Did the patient have a complication during the period between randomisation and the first 
clinic follow up visit?:  no / yes 
 
• If yes, then on what date was it diagnosed?: ___/___/_____ 
 
• If yes, did it require intervention?: no / yes  
 
o If it did, was the intervention: radiological  / surgical  / endoscopic  
 
and on what date was it ___/___/______ 
 
• If yes did it require admission to ICU?: no / yes 
 
o If it did, on what date: ___/___/______ 
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If the patient had a complication during the period between randomisation and the first 
clinic follow up visit, please circle the appropriate Clavien Dindo grade based on the 
corresponding definition below.  If the patient had more than one complication then circle 
the grade of the most severe complication: 
 
Clavien Dindo 
grade 
Description 
0  No complication 
1 
 
Any deviation from the normal postoperative course without the 
need for pharmacological treatment or surgical, endoscopic and 
radiological interventions.  Acceptable therapeutic regimens are: 
drugs as antiemetics, antipyretics, analgesics, diuretics, electrolytes 
and physiotherapy.  This grade also includes wound infections 
opened at the bedside. 
2 
 
Requiring pharmacological treatment with drugs other than such 
allowed for grade 1 complications 
3  Requiring surgical, endoscopic or radiological intervention 
 3A Intervention not under general anaesthesia 
 3B Intervention under general anaesthesia 
4 
 
Life threatening complication requiring ICU management including 
CNS complications 
 4A Single organ dysfunction (including dialysis) 
 4B Multi organ dysfunction 
5  Death 
ICU: intensive care unit, CNS: central nervous system 
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If the patient had a postoperative complication, please circle the most appropriate type, 
location, and complication based on the corresponding definition below.  If the patient had 
more than one complication please circle as many as appropriate: 
Type Location Complication Definition 
Infective    
 SSI wound infection The presence of pus in the wound either discharging 
spontaneously or requiring drainage 
  anastomotic leak Anastomotic defect diagnosed radiologically, at endoscopy 
or laparotomy 
  Intra-abdominal 
collection 
Surgical or radiologically guided aspiration of pus from 
abdominal cavity 
 RSI pneumonia Fever above 38.5C, or SIRS, associated with positive chest 
x-ray findings 
  septicaemia SIRS with positive blood culture 
  UTI Lower urinary tract symptoms, or fever, with positive 
urinalysis and/or urine culture 
Non-infective    
 wound seroma Sterile superficial wound collection without fever or 
surrounding cellulitis 
  dehiscence Deep or superficial separation of the wound without fever, 
pus or surrounding cellulitis 
 surgical site haemorrhage Bleeding requiring radiological or operative intervention 
 cardiac MI Myocardial ischaemia causing ECG changes and raised 
cardiac enzymes/markers 
  arrhythmia New, resting ECG arrhythmia, requiring medical 
intervention 
 vascular VTE Deep or pulmonary venous thrombosis with clinical 
symptoms, confirmed radiologically 
  CVA Persistent focal neurological deficit with radiological 
evidence of cerebral vascular territory infarction 
 urinary renal failure Oliguria/anuria with decreasing GFR, with or without need 
for renal replacement therapy 
  acute urinary 
retention 
Painful/painless anuria with inability to void requiring 
urinary catheterisation 
 GI ileus Paralytic/non-mechanical small bowel obstruction 
SSI: surgical site infection, RSI: remote site infection, SIRS: systemic inflammatory response syndrome, 
UTI: urinary tract infection, MI: myocardial infarction, ECG: electrocardiogram, VTE: venous 
thromboembolism, CVA: cerebrovascular accident, GFR: glomerular filtration rate, GI: gastrointestinal 
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Notes:___________________________________________________________________
____ 
_________________________________________________________________________
____ 
_________________________________________________________________________
____ 
 
_________________________________________________________________________
____ 
 
 
 
 
Completed by (print) ____________________________________ 
Completed by (signature) _________________________________ 
Completion date:___/___/______ 
 
 
Entered by (print)______________________________________ 
Entered by (signature)__________________________________ 
Entry date ___/___/_____ 
 
